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The reverse transcriptase (RT) enzyme of the human immunodeficiency virus is an 
attractive target for rational drug design as it is an essential and unique enzyme in the 
viral life cycle. RT can be inhibited by non-nucleoside inhibitors acting at an allosteric 
binding pocket (NNIBP). The inherent flexibility of the enzyme has made the study of 
the mechanism(s) of its functions and inhibition by non-nucleoside inhibitors difficult 
and ambiguous. Furthermore, this flexibility in the NNIBP has made it difficult to 
characterise the binding pocket for rational drug design.
The synthesis of simple analogues of the antiviral michellamine alkaloids was 
undertaken to determine if they were active at the NNIBP, as the michellamines are 
known to inhibit RT. A Suzuki cross-coupling methodology was found to be the most 
efficient and high yielding route to substitute simple aromatic aryl and alkyl moieties in 
place of the tetrahydroisoquinoline moiety of michellamine. It was found that a weak 
base was required to form the boronate ester, but a stronger base was necessary for the 
subsequent cross coupling to proceed. The homo-coupling to synthesise the dimeric 
series of analogues was performed under essentially the same conditions, by forming 
the boronate ester of the ortho-brominated monomeric analogue and self-coupling to 
achieve dimérisation, in moderate yield. Deprotection of the synthesised monomeric 
and dimeric analogues was performed to yield the desired potential inhibitors. These 
were sent for biological testing, with results unavailable at the time of printing.
An objective, and quantitative method to analyse conformational changes of the reverse 
transcriptase enzyme induced by substrate and inhibitor binding was established. Using 
this technique, a large number of substrate and non-nucleoside inhibitor-bound x-ray 
crystallographic structures were superimposed onto an unliganded form of RT to study 
the conformational displacement and change of the polymerase and RNase H active 
sites and the primer and template grips, upon substrate and inhibitor binding. The 
binding of inhibitors to the NNIBP, in particular, induced large conformational changes, 
both proximal to and remote from the binding pocket. The residues of the polymerase 
and RNase H active sites showed small conformational displacements in substrate
V
structures, possibly to adopt catalytically active conformations to recognise the nucleic 
acid and incoming nucleotide, and prepare for polymerisation and ribonuclease 
hydrolysis. The template and primer grips in the substrate bound structures also showed 
displacements to maximise intermolecular interactions with the bound double stranded 
DNA. In the inhibitor-bound structures the active sites showed large displacements that 
affected the possible coordination complexes of the catalytic residues with the template 
and primer strands, the incoming nucleotides, and essential magnesium cations. The 
nucleic acid grips were displaced into a space occupied by the double stranded DNA in 
the substrate-bound structures, and would either prevent nucleic acid from binding to 
RT, or disrupt the normal intermolecular interactions between the enzyme and the 
nucleic acid. The results supported literature postulating that a mechanism of inhibition 
involved an opening of the hand-shaped structure of the enzyme as the structural motifs 
and active sites moved away from each other and the bound nucleic acid.
Computer aided ligand design has traditionally been segregated into the classification of 
either ligand-based or structure-based. Preliminary studies were undertaken to establish 
an integrated approach to drug design using computational tools from both strategies. 
Ligands and structures for both approaches were deliberately limited to those from x-ray 
crystallographic structures. Ligand-derived pharmacophores were generated, merged 
and analysed to determine ability to correlate ligand structure to activity and predictive 
power. A structure-derived pharmacophoric query was developed from the activity 
‘weighted’ model of the three-dimensional x-ray structures whose inhibitors were used 
in the ligand-based pharmacophore. This query, termed the ‘superligand’, represented 
all the potential binding interactions of residues of the active site to a potential ligand in 
the pocket. Database searching with this superligand identified several compounds of 
interest, which were obtained for biological testing. The superligand was converted to a 
traditional pharmacophore form and represented the first step toward the generation of 
the ‘combiphore’, an integration of ligand- and structure-based pharmacophores.
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Chapter 1 ♦
Introduction
♦
1.1 The Human Immunodeficiency Virus
The human immunodeficiency virus (HIV) is the causative agent of the acquired 
immunodeficiency syndrome (AIDS). As the etiological agent of one of the most 
socially, economically, and medically deleterious epidemics of the late twentieth 
century it has generated an unprecedented volume of detailed studies of its structure, 
replication and pathogenesis. Conclusions, conjecture and theories about HIV have not 
only helped to mitigate its damage, but are applicable to other viruses, and have 
increased the understanding of multitudinous other cellular and viral systems. A greater 
understanding of these viral adversaries is needed if a cure or preventative is to be 
found.
Viruses are biological entities whose genomes consist of nucleic acid. They can only 
replicate inside host cells using cellular metabolic machinery to form a pool of 
components which assemble into particles called virions, which serve to protect the 
genome and transfer it to other cells.1 Retroviruses, such as HIV, are those viruses 
whose genome is composed of RNA.
A member of the lentivirus subfamily (Latin lentus, slow), HIV is an exogenous, non­
oncogenic retrovirus causing chronic diseases of the immune system and the central 
nervous system. Lentiviruses comprise one of three subfamilies of retroviruses, and 
usually infect cells of the immune system causing cytopathic effects, such as syncytia, 
the formation of a large multinucleated cell, and cell death. They contain additional 
genes to other retroviruses that play a role in efficient virus replication and persistence,
tiMmfrtitWim
and are unique in their ability to infect non-dividing cells.1 Lend viral infections are not 
cleared by the immune system, leading to accumulated damage over a period of many 
years and exposing the host to opportunistic infections. '
There are two predominant strains of HIV. HIV-1, which was isolated in 1983, is found 
worldwide and is responsible for most cases of HIV infection. HIV-2, isolated in 1986; 
is endemic in western Africa and is spreading in India. The two strains share a 40-50% 
homology in their nucleotide sequence, being similar in morphology, ultrastructure, and 
genomic organisation. HIV-1 is the more virulent and progressive of the two strains, 
with both strains being typified by chronic opportunistic infections leading to diseases 
with long incubation periods.
1.1.1 HIV-1 genome and virion structure
The HIV-1 genome (Figure 1.1) consists of two homologous single (+) strands of RNA, 
9.8 kb in length.2’3 It encodes a total of three structural proteins, two envelope proteins, 
three enzymes, and six accessory proteins. The three coding regions, gag, pol, and env 
encode the capsid proteins, the viral enzymes necessary for replication, and the external 
glycoproteins respectively.
fi 1 2 3 A 5 6 7 8 9  10
vif tst vpu jsv
Figure 1.1 HIV-1 genome.
The additional proteins expressed by HIV-1 are either part of the viral particle (vif and 
vpr), directly regulate viral gene expression (tat and rev), or interact with cellular 
processes to promote virus propagation (vpu and nef). HIV-2 lacks the vpu gene, and 
instead has a vpx gene. Retroviruses such as HIV-1 have the distinguishing 
characteristic ability to regulate their own gene expression in infected cells. This allows 
them to establish a long-term association with the host, and generate chronic active 
infections.
2
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The structural biology of HIV-l has been intensively studied, and considerable details 
of its structure and the interactions of its major proteins are available.2’4 HIV-l has a 
cone-shaped capsid core particle, enveloped by a lipid bilayer derived from the 
membrane of the host cell (Figure l .2).
Figure 1.2 HIV-l structure and proteins.
Exposed surface glycoproteins (SU, gpl20) are anchored by interactions with the 
transmembrane protein (TM, gp41). A matrix shell composed of the matrix protein 
(MA, p i7) lines the inner surface of the viral membrane. At the centre of the virus is a 
conical capsid core formed by the capsid protein (CA, p24). The core encapsidates two 
copies of the unspliced viral genome, which is stabilised as a ribonucleoprotein complex 
with the nucleocapsid protein (NC, p7). The three essential virally encoded enzymes 
protease (PR), reverse transcriptase (RT), and integrase (IN) are also found in the core.
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1.1.2 HIV life cycle
HIV employs a ‘Trojan horse’ strategy to infiltrate cells of the host immune system, 
before hijacking its cellular mechanisms and resources to produce more virions."' ' In 
productively infective cells, viral infection can cause host cell destruction after 2.2
days.6-8
Figure 1.3 HIV life cycle.
HIV-1 binds specifically to cells bearing the Cp4 transmembrane glycoprotein, a 
receptor that normally functions in immune recognition and is found on a variety of 
cells of hematopoietic origin, such as T lymphocytes, monocytes, macrophages, and B 
lymphocytes (Figure 1.3). Absorption and fusion of the virus envelope with the host 
cell membrane is mediated by specific interactions between the viral envelope 
glycoprotein SU, the amino-terminal immunoglobulin domain of CD4, and additional 
cell-surface proteins. After penetration, uncoating of the virus core introduces an 
intracellular reverse transcription complex into the cytoplasm.
Within the first six hours of infection the viral RNA is converted to DNA in the 
cytoplasm of the cell by a ribonucleoprotein complex containing the genomic RNA 
together with the NC and MA proteins, and the RT and IN enzymes. The newly 
synthesised proviral DNA migrates to the nucleus as a nucleoprotein complex where it 
then integrates with high efficiency into the target DNA, mediated by IN. Integration 
appears to be random, with the viral DNA remaining permanently associated with the 
host cell genetic material. Proviral DNA appears in the cytoplasm four hours after 
infection and can undergo integration after 24 hours.5
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The proviral DNA can remain in a latent state until cellular activation of the CD4+ T 
cell by the transcription factor NF-kB binding to promoters in the cellular and viral 
DNA. Viral gene expression begins with the synthesis of spliced and unspliced 
messenger RNA (mRNA) transcripts by the cellular RNA polymerase II. The unspliced 
mRNA is required as the genomic RNA to be incorporated into the virion, and the 
spliced mRNA transcripts are required for encoding the viral proteins. These are 
transported out of the nucleus for encapsidation and translation into the proteins of the 
virus. Transcription and transportation out of the nucleus occur when cellular DNA 
binding transcriptional factors activate the HIV-1 promoter (pro) gene and suitable 
concentrations of the regulatory tat, rev and nev proteins accumulate. The viral 
quiescence of some infected primary cells is thus explained since viral activation is 
induced by cell activation of the infected cell.
The spliced transcripts are translated by endoplasmic reticulum-bound ribosomes before 
post-translational modification and folding in the endoplasmic reticulum and the Golgi 
complex. Unspliced mRNA is translated by free ribosomes. Proteolytic processing and 
mature core formation occur after the virus is released from the infected cell. These 
stages of the viral life cycle are not well studied or documented.
1.1.3 Immune response to HIV
HIV is carried in infected CD4+ T cells, dendritic cells, monocytes, and macrophages, 
and as free virus in blood, semen, vaginal fluid, and breast milk. Initial viral infection 
triggers both humoral and cellular immune responses. Macrophages and related cells 
engulf free viral particles, digesting them down to small peptides, or epitopes, that are 
displayed on their cell surface. White blood cells known as helper T lymphocytes 
(CD4+ T lymphocytes) bear receptors able to recognise a single displayed epitope. 
Once the helper T cell encounters the right epitope on a macrophage, it binds to the cell, 
divides and secretes small proteins that help to activate and promote replication of 
cytotoxic killer T lymphocytes (CD8+ T lymphocytes), B-lymphocytes, and 
macrophages.
Cytotoxic killer T lymphocytes, once activated, are able to attack and destroy virus- 
infected cells bearing that specific epitope. Activated B lymphocytes secrete antibodies 
into the blood and lymph streams that recognise specific epitopes on the viral surface.
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The antibodies mark free viral particles, not sequestered in cells, for destruction by 
other immune cells, such as macrophages.
HIV infection induces cell death, and impairs the immune systems’ ability to prime and 
regenerate its own cells.9 Cell death occurs primarily via direct viral killing, resulting 
from the disruption of the cell membrane by massive viral budding and interference 
with cellular functions by viral proteins. The elimination of infected cells by cytotoxic 
T lymphocytes that recognise viral epitopes, and the increased susceptibility of infected 
cells to the induction of apoptosis, or programmed cell death, also contribute to a 
decline in the CD4+ cell count. Infected cells are also able to fuse with as many as 500 
uninfected T cells to form a giant multinucleated cell called a syncytium. A syncytium 
is able to produce large quantities of virus for a short period of time before dying, 
within 48 hours of formation. HIV infection is also believed to damage stem cells, 
thymocyctes, thymic epithelial cells, and lymph nodes responsible for T cell production, 
proliferation and maturation.9 Significantly, the infection and depletion of dendritic 
cells and CD4+ helper T lymphocytes affects the generation, long-term responsiveness 
and protective function of CD8+ cytotoxic T lymphocytes, the cells most responsible for 
clearing the virus from the immune system.10
1.1.4 Virus reservoirs and the mutability of HIV
A normal aggressive immune response in conjunction with highly active anti-retroviral 
therapy (HAART) can reduce viral plasma loads below the limits of detection. Yet 
despite this apparent success, HIV resists complete eradication and progresses to cause 
the severe immune impairment that defines full-blown AIDS. This evasion and the 
subsequent devastation of the immune response is due to the virus’ ability to reside in 
latent reservoirs and its propensity to evolve away from any pressures exerted by the 
host’s immune system.
The existence of latent reservoirs provides a seemingly absolute strategy for viral
8 1112persistence in an infected patient despite potent anti-retroviral therapies. ’ ’ 
Sequestering of virus in these reservoirs occurs soon after infection, when there is a 
period of intense replication and widespread dissemination of virus. Highly active anti­
retroviral therapy (HAART) as early as 10 days after the onset of symptoms of primary 
infection fails to prevent formation of latent reservoirs of virus. Identified reservoirs 
include extracellular virus trapped as anti gen: antibody complexes on the surface of
. . . . . .  . %
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follicular dentritic cells and lymphoid tissue, in which infected resting memory CD4+ T 
cells, B lymphocytes, monocytes, macrophages, and dendritic cells are found.14'17 
Although they contribute to less than 1% of the plasma virus, each viral compartment 
can serve as the ‘ember’ to re-ignite a high rate of viral replication when a therapeutic 
regimen is withdrawn,8,18 or an immune response decays.
Macrophages and dendritic cells are also able to harbor replicating virus without 
necessarily being killed by it.17,19 They serve not only as an important reservoir of 
infection, but are another means of spreading the virus to other tissues such as the brain, 
testes and retina where most anti-retroviral drugs cannot penetrate. Infected resting and 
memory CD4+ cells are suspected to have life spans in the order of months, and possibly 
even years. This stable reservoir may harbour the virus as either unintegrated DNA or 
in the proviral DNA form, and only requires activation by antigen or host- 
transcriptional factors to begin production and release of infectious virions. These 
latent cells provide a long-term memory of viral genotypes no longer present in 
replicating viral populations.20 In these reservoirs HTV is active and progressive even 
when there is little evidence of disease activity in the peripheral blood, and the patient is 
experiencing clinical latency.14
HIV is considered by many to be the most variable virus known to date. The genetic 
variation, bom of remorseless cycles of viral replication, which allows it to finally 
defeat the immune system, ironically is most probably due to chronic activation of that 
very immune system.21 The minimum duration of the HIV-1 life cycle in vivo is 1.2 
days on average.8 In that time RT plays a vital role in replication of the viral RNA 
genome into dsDNA. RT is an extremely error-prone enzyme, lacking the 3’—>5* 
exonucleolytic activity required for proofreading of the growing DNA. All incorrect 
nucleotides incorporated during (-) strand DNA synthesis from the RNA template are 
definitively fixed in the viral genome.22 The mutation rate of HIV-1 RT is in the range 
of 10'3 to 10'4 misincorporations per nucleotide per site per replication cycle.21 Thus 
mutations occur along the entire length of the genome at the rate of 104 to 105 times per
day.23 Because of this low fidelity, HIV does not have a fixed genomic sequence, but
21rather exists as mutant swarms of quasi-species.
In a latent HIV infected patient the average viral production and clearance has been 
estimated at 1.03 x 1010 virions per day,8,23 with approximately one half of the
6,7
circulating virus being replaced with newly produced virions each day. In the absence
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of any response from the immune system, the viral population would on average double 
every two days. For a patient who lives with HIV for ten years the viral particles in the 
body have undergone as much genetic change as humans might experience in the course 
of millions of years.20 This enormous diversity is manifested in viral variants bearing 
fewer recognizable epitopes, making them more difficult for the immune system to 
detect, and in variants resistant to anti-viral drugs.
The relentless cycles of replication spawn an enormous diversity of viral populations 
that impair the efficiency of the immune response. Each viral population has different 
epitopes, but all virions are able to infect any cell of the immune system that bears the 
CD4 receptor. The cells of the immune system are at a distinct disadvantage as they are 
designed to accurately respond to a specific antigenic attack, recognizing only selected 
epitopes; any given immune response is effective against only some viral populations.10 
Once a certain antigenic diversity threshold is reached, the immune system is 
overwhelmed and becomes totally inefficient in its defense. When the CD4+ T cell 
count falls below 200 cells.pL’1, from a normal uninfected level of 1200 cells.pL'1; the 
immune system collapses, and a patient is said to have AIDS.
This understanding of the dynamics of the immune system and its response to the 
continuous replication and evolution of HIV provides the most simple of strategies; by 
inhibiting or retarding replication, the rate at which mutants arise can be minimised to
contain viral diversity. Reducing viral levels and curtailing diversity would help the
20natural immune system to quell the virus.
1.1.5 Nucleoside reverse transcriptase inhibitors (NRTIs)
To date no cure has been found for any viral infection. The only alternative course of 
action is the use of anti-viral drugs to inhibit the virus and bolster the natural immune 
response to contain infection. Nucleoside analogues were the first and most logical 
choice for viral inhibition as much of this drug design stratagem had already been 
studied with anti-cancer drugs. The most attractive viral target is the reverse 
transcriptase (RT) enzyme, as it is unique to the virus and has no endogenous 
counterpart in the eukaryotic cell.
Nucleoside reverse transcriptase inhibitors (NRTIs) mimic 2’-deoxynucleotide-5’- 
triphosphates (dNTPs), naturally occurring building blocks for DNA synthesis, such as 
thymidine (1) shown in its unphosphorylated form (Figure 1.4). They act as
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competitive alternative substrates to inhibit the elongation of the growing DNA chain. 
Once incorporated at the 3 ’end of the primer strand by RT, they block chain elongation 
because the 3 ’ position of the ribose is blocked or lacks the OH group necessary for 
subsequent 5’-3’ phosphodiester bonds to form.24
d4T (5) 3TC (6) Abacavir (7)
Figure 1.4 Nucleoside reverse transcriptase inhibitors.
NRTIs face several disadvantages that undermine their effectiveness as clinical drugs. 
Despite their selectivity for RT, they can also nevertheless inhibit the activity of normal 
cellular DNA polymerases a, (3, y and 5 leading to myelotoxicity and the inhibition of 
bone marrow progenitor cells.25 Their effectiveness is also reduced in metabolically 
active cells with high pools of naturally occurring dNTPs. NRTIs need to be 
phosphorylated successively to the 5’-monophosphate, 5’-diphosphate, and 5’- 
triphosphate form, which can cause problems as some inhibitors have a low affinity for 
nucleoside kinases that are responsible for the crucial initial phosphorylation. 
Furthermore the nucleoside kinase activities of some resting cells, such as monocytes 
and macrophages, may be insufficient to satisfactorily phosphorylate even those 
analogues that have a high affinity for the enzyme.24 Additionally the intracellular 
buildup of partially phosphorylated intermediates may also contribute to toxicity25
In 1987, AZT (zidovudine, Retrovir®) (2) became the first drug to be approved by the 
American Food and Drug Administration (FDA) for the treatment of AIDS. It became
9
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the mainstay in the treatment of people with HIV despite its modest and short-term 
value in slowing the progression of HIV and reducing the number of opportunistic 
infections. Its success was limited by the rapid emergence of resistant viral strains, ddl 
(didanosine, Videx®) (3) and ddC (zalcitabine, HIVID®) (4) were approved by the FDA 
1991 and 1992, respectively, for anti-retroviral use in patients with advanced HIV who 
were intolerant to or deteriorating on AZT. In 1994 d4T (stavudine, Zerit®) (5) was 
approved for use in patients with advanced HIV infection. Unlike ddl and ddC, d4T 
was found to be effective in penetrating the central nervous system, including the spinal 
cord and brain; a property which is important for patients who have experienced brain 
swelling and complications due to toxoplasmosis, or AIDS-related dementia. 3TC 
(lamivudine, Epivir®) (6) was approved for use in combination with AZT in 1995. The 
addition of 3TC to a therapeutic regimen was found to cause AZT-resistant viral strains 
to revert to AZT-sensitive strains. The most recent addition to the class of NRTIs 
approved by the FDA was Abacavir (1592U89 succinate, Ziagen®) (7) in 1998. 
Abacavir requires monophosphorylation and then deamination, before final 
phosphorylation to the activated triphosphate form. As a monotherapy abacavir appears 
to have a stronger anti-HIV effect than any of the other approved NRTIs, as well as 
being less toxic to the hemopoietic system than AZT, but is generally used in 
combination with AZT, ddl or ddC because of its synergistic anti-HIV activity.
Clinically, the treatment of HIV involves the use of combinations of two, three or even 
more anti-retroviral drugs.24 This strategy maximises additive or synergistic affects of 
different drugs, decreases toxicity by reducing the dosage of the individual compound, 
reduces the risk of drug resistance development, and can cover a greater spectrum of 
activity, while achieving potent and sustained suppression of HIV replication. 
Combination therapy can be successful provided the individual compounds do not have 
overlapping toxicity profiles, are not antagonistic, can lead to different and preferably 
mutually antagonising resistance mutations, and are targeted at different viral proteins, 
or at different active sites within the same viral protein. NRTIs are regularly used in 
combination with protease inhibitors and non-nucleoside reverse transcriptase
inhibitors.
1.1.6 Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Since the late 1980s, more than 30 structurally different classes of compounds have 
been identified as non-nucleoside reverse transcriptase inhibitors NNRTIs.26’28 These 
allosteric inhibitors are highly specific for HIV-1 RT and have secured a definitive 
place in the treatment of HIV-1 infections, with three currently approved for clinical use 
(Figure 1.5) and several others (Figure 1.6) in pre-clinical or clinical development and 
trials.
NNRTIs are reversible allosteric inhibitors acting at a site distinct from the polymerase 
active site (PAS) of the RT enzyme, as demonstrated by their non-competitive 
inhibition with respect to dNTPs and nucleic acid template-primer, and the absence of 
cross-resistance with NRTIs.24 NNRTIs have several advantages that make them more 
efficacious and beneficial than NRTIs. They do not require previous phosphorylation to 
become active and their non-competitive action with respect to substrates means their 
action is not compromised in metabolically active cells with high pool levels of dNTPs. 
Their unique allosteric activity means they do not interact with normal cellular DNA 
polymerases a, (3, y and 8. This greater specificity for RT has led to an increase in the 
valuable ratio between the cytotoxic concentration (CC50) required to reduce viability of 
host cells by 50% and the effective concentration (EC50) required to inhibit HIV-1 
induced cytopathicity by 50%, termed the selectivity index. Despite their notoriety for 
the rapid emergence of drug resistance, this can be circumvented if sufficiently high, but 
nontoxic, concentrations are used to suppress virus replication and prevent the break- 
though of resistant virus, or if used in combination therapy.24
In 1996, Nevirapine (BI-RG-587, Viramune®) (8) became the first NNRTI to be 
approved for use in combination with NRTIs for patients experiencing clinical and 
immunological deterioration. A member of the dipyridodiazepinone class of NNRTIs 
nevirapine is a potent anti-retroviral inhibitor capable of crossing the blood brain 
barrier. Delavirdine (U-90152S, Rescriptor®) (9), a bis(heteroaryl)piperazine (BHAP) 
derivative was approved for use in 1997, and Efavirenz (L-743,726, DMP-266, 
Sustiva®) (10), a benzoxazinone derivative, was approved in 1998.
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Figure 1.5 Approved NNRTIs.
Despite the qualified success of approved NNRTIs with combination therapy in 
reducing the viral load, the rapid appearance of resistance mutants and the failure of 
HAART and combination therapy to completely eradicate established HIV infection in 
patients has assured the continuing need for NNRTIs with greater spectra of inhibition. 
Those currently in pre-clinical or clinical trial represent just a small assortment of the 
various classes of NNRTIs (Figure 1.6).
O CH, Cl
MKC-442 (12) Pyridinone (13)
CtT
VI or CH3 
Loviride (14) Trovirdine (15)
H C J C C V  S<A>
h3c^ ch3 
Quinoxaline (16)
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Tivirapine (8-chloro TIBO, R86183) (11), an analogue from the
tetrahydrobenzodiazepine (TIBO) class, and MKC-442 (I-EBU) (12), a 
hydroxyethoxymethylphenylthiothymine (HEPT) derivative, are actually from those 
chemical classes first investigated as NNRTIs. Other NNRTIs in current trials include 
Pyridinone (L-697,661) (13), Loviride (a-APA, R89439) (14), an a-
anilinophenylacetamide (a-APA) derivative, Trovirdine (LY 300046) (15), a 
phenylethylthiazolylthiourea (PETT) analog, Quinoxaline (HBY 097) (16), 
Thiocarboxanilde (UC-781) (17), and Calanolide A (18), a natural product from 
Calophyllum lanigerum.
All NNRTIs are assumed to bind at the same site, a highly flexible hydrophobic pocket
o
located about 10 A from the PAS. Although distinct from the PAS, this pocket is 
spatially and functionally related insofar as the binding of NNRTIs at this pocket results 
in both short and long-range distortions that disrupt polymerase activity. Short range 
distortions include a repositioning of the three-stranded (3-sheet, in the p66 subunit, 
containing the catalytic residues required for polymerisation, locking the active catalytic 
site into an inactive conformation reminiscent of the conformation observed for those 
same residues in the p51 subunit. The precise geometry and mobility of key aspartic 
acid residues is distorted such that polymerase activity and its associated reactions no 
longer function. Longer-range distortions include a hinge movement of the thumb 
subdomain, which may affect RT activities such as nucleic acid strand transfer, strand 
displacement, and recognition of primers. These mechanisms are not necessarily 
mutually exclusive; the binding of a NNRTI may trigger a variety of concerted events 
resulting in the inactivation or retardation of RT. A greater understanding of how 
NNRTIs exert these influences would benefit the design and development of improved 
inhibitors.
Different structural classes of NNRTIs vary with regard to the exact amino acid residues 
of the pocket site with which they interact, although they all adopt similar butterfly-like 
shaped conformations.30 These roughly overlay each other in the binding pocket and 
are suspected to function as 7i-electron donors to aromatic side chain residues of the 
pocket.31 The corollary to this variation in residue interactions is that a mutation 
resistant to one inhibitor may not affect another inhibitor; mutations may overlap, only 
partially overlap, or not overlap at all, as observed with different NNRTIs which do not 
show cross-resistance to each other. Mutations that have been shown to confer
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resistance to NNRTIs cluster around the pocket where the NNRTIs bind suggesting that 
these resistance mutations lead to a direct alteration of inhibitor binding. Mutations 
conferring resistance to NNRTIs may affect the shape of the pocket so binding cannot 
occur, or cause a significant reduction in the favourable binding interactions with the 
inhibitor. Mutations might increase or decrease the bulk of side chains, leading to steric 
conflict or loss of contact with an interaction site, or change the local charge or 
electrical potential of that residue. Mutations may also affect the orientation of 
significant neighbouring residues that interact directly with the inhibitor. Resistance 
may involve one, or a combination, of these factors.
Although it was believed that NNRTIs have a high selectivity suppression of HIV-1 
replication but little or no inhibitory activity against HIV-2, recent studies have shown 
that delavirdine, MKC-442, tivirapine, loviride, nevirapine, and pyridinone L-697,661 
are able to inhibit HTV-2 strains, although at concentrations 50-fold higher than those 
required to inhibit HIV-1. Although genetic comparisons of HIV-1 and HIV-2 reveal 
significant sequence divergence, the amino acid sequence of the important pol gene, 
encoding the RT, PR and IN enzymes, has approximately 60% homology between the 
two strains.32 The RT enzyme of HIV-1 and 2 have about the same homology in the 
residues forming the non-nucleoside inhibitor binding pocket, with the mismatched 
residues presumably accounting for the differing activities.33 The similarity in overall 
structure and functionality of the two enzymes suggests that drugs and drug design 
strategies effective against HIV-1 RT could also be effective against HIV-2 RT. HIV-2 
is the predominant strain in Africa and India, and current HIV-1 specific drugs may 
require only optimization to fit perfectly the HIV-2 RT non-nucleoside inhibitor binding 
pocket.
1.1.7 Natural products as antivirals
A common theme that resonates in all areas of anti-retroviral inhibitor research is the 
incessant need for new and more potent inhibitors with greater chemical structural 
diversity, and differing mechanisms of inhibition to help delay the development of 
resistance and control HIV infection. This need can be realised from marine and 
terrestrial environments, which provide rich sources of novel bioactive compounds to 
act as lead compounds in the search for clinical anti-HIV candidates. One such example 
that has reached clinical trials is Calanolide A (18) (Figure 1.6), a natural product
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coumarin alkaloid from Calophyllum lanigerum var. austrocoriaceum, a rainforest tree 
from Sarawak in Malaysia.34
Massive natural product screening efforts from such groups as the US National Cancer 
Institute (NCI) have brought about the discovery of many new and exciting plant 
alkaloids that exhibit anti-HIV and anti-RT activity.35'38 Some of these antiviral natural 
products are attractive for study since their inhibitory activity has been observed in both 
strains of HIV, often with similar potencies in both enzyme systems.36,39,40
Natural products identified as exhibiting anti-HIV activity span numerous classes of 
phenolics, terpenoids, tannins, alkaloids, peptides, and carbohydrates. Figure 1.7 
illustrates a select few that share an assortment of structural features with Michellamine 
B (Section 1.2), a novel alkaloid of particular interest.
Gossypol (19) is a polyphenolic bissesquiterpene, isolated as a racemic mixture from 
cottonseed, which has been shown to have selective activity against HIV-1.41 It exists 
as (+) and (-) enantiomers, because of restricted rotation of the two naphthyl moieties, 
although only the (-) enantiomer possess the antiviral activity against HIV and 
biological activity as an antifertility agent in males. Initial studies appeared to indicate 
that gossypol had little or no inhibitory activity on HIV-1 RT,41 but recent testing has 
confirmed activity in RT assays.42 Although no information is available for the anti­
HIV activity of the gossypol monomer, analogues of gossypol have been synthesised 
where the dimer has shown activity in inhibiting the replication of HIV, while the 
monomeric form was ineffective.43 (-) Gomisin J (20) is a dibenzocyclooctadiene-type 
lignan, isolated from the fruits of Schisandra chinensis, found specifically to inhibit 
HIV-1 RT with an IC50 value of 45 pg.ml'1.36 A dibrominated derivative, meta to the 
biaryl axis, showed even more potent and selective RT activity (IC50 = 1 pg.m ll).
The anti-RT activity of the remainder of these natural products has not been specifically 
determined, although they all show anti-HIV activity. Theasinensin D (21) has shown 
moderate anti-HIV activity with an EC50 value of 8 pg.ml'1. Interestingly, Theasinensin 
B which differs only in stereochemistry at the biphenyl bond has no activity. ’ 
Punicalin (22) is an ellagitannin which has demonstrated relatively potent inhibitory 
activity against HIV replication.44
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Figure 1.7 Anti-HIV inhibitors from natural sources.
Peltatol A (23) and Conocurvone (24) are interesting as they were both found to inhibit 
the cytopathic effects of HIV-1 infection in their dimeric and trimeric forms 
respectively, but were inactive in their monomeric forms.45,46 Peltatol A, from the
m
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tropical shrub Pothomorphe peltata (Piperaceae), inhibited HIV-1 induced cell killing at 
subtoxic concentrations of less than 10 pg.ml"1, yet the monomeric catechol derivative 
was inactive in the anti-HIV screens.45 Conocurvone, from the endemic Australian 
shrub Conospermum sp. (Proteaceae), inhibited the cytopathic effects of HIV-1 
infection with an antiviral EC50 of less than 0.02 pM, with the monomeric unit known 
as Teretifolione B showing no activity.46
These are a few of the natural products (Figure 1.7) that form a loose collective of anti­
HIV agents of interest in this study. Although they all posses potent antiviral activity, 
their precise mechanisms and locations of action are as yet unknown. The salient 
features of this compilation become more evident after a greater study of principle 
natural product in this group, the michellamines.
1.2 The Michellamines
In the late 1980s, the National Cancer Institute launched a major initiative to identify 
novel anti-HIV agents from natural sources. From this massive screening program, the 
michellamines were discovered in the tropical liana Ancistrocladus korupensis, 
originally misidentified as A. abbreviatus, from the Korup rainforest of Cameroon.39,47 
The organic extracts of the aerial components of this liana showed equipotent antiviral 
cytopathic activity against HIV-1 and HIV-2 virus strains. This was of notable 
significance since few agents were known to be active against both strains of HIV.
More extensive testing revealed that the michellamines exhibited EC50 values 
(inhibition of viral cell killing) between 1 and 90 pM, and IC50 values (cytotoxic 
concentration) from 40 to greater than 240 pM against a remarkable diversity of strains 
of both HIV-1 and HIV-2 in a wide spectrum of cell types. Significantly the 
michellamines provided complete protection against several strains of virus resistant to 
currently used drugs such as AZT.47 In murine and canine models, therapeutically 
significant plasma levels of the michellamines were achieved by intravenous infusion as 
oral bioavailability proved to be negligible.48 The michellamines also demonstrated 
effective inhibition of cellular DNA polymerases a  and (3, possibly providing an
49explanation for their narrow in vitro therapeutic index in some cell systems.
Michellamine B is reported to exert its antiviral activity at two distinct stages of the 
HIV life cycle. It initially inhibits at the reverse transcriptase stage of the viral life 
cycle, acting as a non-competitive inhibitor with respect to deoxynucleotide
triphosphates.49 Additionally it interferes at a later stage by blocking cellular fusion and 
syncytium formation.47,49
Recently the michellamine alkaloids were found to inhibit protein kinase C50 and 
demonstrated anti-oxidant activity, as extremely effective free radical scavengers.51 In 
antioxidant assays, they were found to be as active as compounds being considered as 
chemopreventative agents. Aside from their antiviral activity, they could also be of 
benefit to HIV and cancer sufferers who experience oxidative stress from reactive 
oxygen species released during the disease process.51
1.2.1 Structure of the Michellamines and the Korupensamines
The michellamines were not only of biological and pharmaceutical significance in the 
search for novel anti-HIV agents. They also represented three new members in an 
intriguing novel class of naturally occurring dimeric naphthylisoquinoline alkaloids. 
The michellamines (Figure 1.8) have an unusual C5-C8" linkage previously only seen in 
the monomeric naphthylisoquinoline alkaloid Ancistrobrevine B,39,52,53 found in A. 
abbreviatus.
Michellamine A (25) Michellamine B (26) Ancistrobrevine B (27)
Figure 1.8 Alkaloids from A n cistrocladu s koru pen sis  and A. abbrevia tu s.
Michellamines A and B were found to be naturally occurring symmetrical coupled 
products of two atropoisomeric biaryl alkaloids.54 Atropisomerism arises from hindered 
rotation about a carbon-carbon bond; one isomer can only be converted to the other by 
overcoming a sufficiently high-energy barrier.55 The restricted rotation gives rise to 
dissymmetric planes, which makes the compound chiral.56 The rotary characteristics of 
biaryls are a form of helicity and designated P for a right-handed plus helix, when
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viewed along the axis and moving from the front to the rear, and M  for a left-handed 
minus helix. ’ Michellamine C was identified as an artefact formed under too harsh 
isolation conditions.47 Three more michellamines, Michellamines D-F, were isolated at 
a later date.58
The michellamines are composed of four aromatic systems; two naphthyl and two 
tetrahydroisoquinoline systems. They have four stereocentres and three biaryl axes; the 
6 -6” axis which is configuratively labile, and the 5-8' and 8" -5" '  axes which are 
stereogenic due to restricted rotation.59 They are highly polar with six free phenolic 
hydroxyl groups and two secondary amino groups. The absolute configuration of 
Michellamine B, the most naturally abundant alkaloid, was determined to be 1P,3P,5P 
(M), 1 R ,3 R ,5 S (P). Michellamines A and C have the absolute configurations 
1R,3R,5S (P), 1" 'R ,3 '"R ,5" 'S  (P) and 1P,3P,5P (.M), l '"R ,3 " 'R ,5 " 'R  (M) 
respectively. Conversion between Michellamines A and C can be achieved by base- 
catalysed atropisomerisation.47
The biogenetic precursors of the michellamines, the monomeric Korupensamines A-D 
(Figure 1.9) were isolated from A. korupensis at a later date.
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Korupensamine A (28) Korupensamine B (29)
Figure 1.9 Alkaloids from A n cistrocladu s korupensis.
They showed no anti-HIV activity, but were found to have antimalarial activity against 
Plasmodium falciparum  and Plasmodium berghei\ the IC50 values for Korupensamine A 
were 0.31 and 0.56 pg.mL' 1 for P. falciparum  and P. berghei respectively, and 0.18 and 
0.41 pg.mL' 1 for Korupensamine B. Conversely the michellamines showed only weak 
activity against both of the malaria parasite species, recording IC50 values of 20 to 
greater than 50 pg.m L1.60
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1.2.2 Synthesis of the michellamines
The combined biological, pharmaceutical and structural significance, as well as the 
scarcity of the natural resources of the michellamines provided a driving force for their 
total synthesis. Since their discovery, several research groups, using a range of 
synthetic strategies, have achieved four complete syntheses of the michellamines.
An obvious retrosynthetic analysis of these quadaryls would involve the dissection of 
the molecule at the three biaryl axes. This presented two obvious synthetic strategies to 
build the michellamines. The presumable biomimetic pathway would couple the 
isoquinoline with the naphthalene to form the korupensamine alkaloid, before 
dimérisation to yield the michellamines (Figure 1.10). The non-biomimetic pathway 
would involve the formation of the central inner axis in a binaphthyl unit, before 
coupling of the two outer axes with isoquinoline moieties (Figure 1.11).
The biomimetic pathway was the first synthesis of the michellamines to be realised by 
the Bringmann group (Figure 1.10).59 This began with the synthesis of Korupensamines 
A and B which was achieved by the palladium-catalysed intermolecular biaryl cross­
coupling reaction of a trialkylstannalated naphthalene unit (30) and a brominated 
tetrahydroisoquinoline moiety (31).53 A later synthesis of Korupensamine C involved a 
similar palladium-catalysed cross-coupling reaction of a naphthalene boronic acid 
moiety and an iodinated tetrahydroisoquinoline unit.61 Oxidative coupling of a 
protected derivative of Korupensamine A with silver (I) oxide constructed the central 
6',6""-binaphthalene bond before reduction and cleavage of the six protective groups 
yielded the final product (Figure 1.10).59’62
The second biomimetic synthesis was undertaken by the Ho ye group,63’64 where the later 
synthesis of Korupensamine C described previously was used to establish the 
monomeric unit. The central 6 '-6"  binaphthalene bond was formed by oxidative 
coupling using silver oxide to give the cross-ring naphthoquinones, which on reduction 
and deprotection afforded a mixture of Michellamines A-C.
(25 + 26)
Figure 1.10 Biomimetic synthesis of the michellamines
A third biomimetic synthesis was completed by the Dawson group.65 66 Similarly to the 
first two biomimetic syntheses, the korupensamine unit was established with a 
palladium-catalysed cross-coupling reaction of a naphthalene boronic acid and a 
brominated isoquinoline unit. In contrast to the previous dimérisation reactions, this 
synthesis was completed with another palladium-catalysed homo-coupling of a boronic 
acid derivative of the monomeric unit.
The Bringmann group also undertook the non-biomimetic synthesis (Figure 1.11), 
where the 6 '-6"  binaphthalene bond was constructed first by using a Pd(0)-copper 
bronze homo-coupling of a derivatised naphthoquinone (35). The bis-O-triflate form of 
the central binaphthalene fragment (36) was doubly coupled with a boronic acid 
isoquinoline building block (37), before removal of all protecting groups yielded the 
final michellamine product.67,68
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Figure 1.11 Non-biomimetic synthesis of the michellamines
Another more recent strategy involved starting with a biphenyl intermediate (39), and 
the construction of the two ‘outer’ naphthalene rings by a Wittig and then cyclisation 
reaction (Figure 1.12).69 The bromine substituents at the 4,depositions in (43) allow 
several options in coupling methodology for the isoquinoline units.
(43) (42)
Figure 1.12 Synthetic strategy for the binaphthalene building block representing the central 
structural element of the michellamines.
1.2.3 Analogues of the michellamines; antiviral and antimalarial activity
The lack of HIV activity of the korupensamines alluded to the necessity of the 
binaphthyl structure for anti-viral activity. This seemed to be confirmed by two 
structural analogues of the michellamines where the central binaphthyl core was 
modified. One analogue lacked the two methoxy and methyl groups on the central 
binaphthalene ring system, the other analogue also lacked the methoxy and methyl 
groups as well as the second tetrahydroisoquinoline aryl group, resulting in an 
asymmetric compound. These structural changes resulted in decreased HIV RT 
activity, but interestingly increased protein kinase C activity. The structural 
significance of the tetrahydroisoquinoline rings was next investigated by the synthesis 
of a series of structural analogues where those rings were replaced with simpler non­
chiral aryl and heteroaryl functional groups.71 All analogues were found to be devoid of 
anti-HIV activity up to a concentration of 100 pM, initially suggesting that the 
heterocyclic portion of the tetrahydroisoquinoline ring was crucial for biological 
activity. However only anti-HIV activity was investigated; anti-RT activity was not 
tested for specifically.71 These analogues were considerably less polar, with several
23
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hydrophobic aromatic moieties, and may have had very different transport properties to 
the michellamines.
Once it was established that the michellamines inhibited the reverse transcriptase 
enzyme, it was necessary to determine their site of action. Michellamine B was tested 
on two HIV RT mutants with single amino acid substitutions at positions Tyrl81 and 
Tyrl88. These two amino acid residues are part of a hydrophobic non-nucleoside 
inhibitor binding pocket, and are known to specifically contribute to binding of such 
inhibitors as nevirapine. Michellamine B was found to inhibit both of the variant RTs 
with approximately the same potency as that seen with the wild-type HIV-1 and HIV-2 
RT, and this was interpreted as michellamine acting at site(s) on the RT enzyme distinct 
from the other known non-nucleoside inhibitors.49 This may not necessarily be the case, 
as other NNRTIs do not always show cross-resistance to all mutations, and further 
evidence would be required before it was certain that michellamine did not bind in the 
same binding pocket. Although the size of michellamine may very well be the factor 
that precludes it from binding at this non-nucleoside site, it also allows for numerously 
additional and different functional contacts to be made with the enzyme, which may 
explain the activity retained in the two mutant enzymes.
The interesting antiviral and antimalarial activity of the michellamines and 
korupensamines is seen repeatedly in other related naphthylisoquinoline alkaloids, 
illustrated in Figure 1.13. Dioncopeltine A (44) has demonstrated antimalarial activity 
against P. falciparum and chloroquine-resistant malarial strains, as has Dioncophylline 
A (45) (IC50 1.44 pg.mr1, P. falciparum)?2 isolated from Triphyophyllum peltatum and 
several Ancistrocladus species.73 The related Dioncophylline C (46) also from T. 
peltatum (Dioncophyllaceae) is to date the most active antimalarial 
naphthylisoquinoline; with in vitro activity IC50 0.014 pg.ml'1 against Plasmodium 
falciparum, it is in the range of medically used drugs.74,75
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Dioncopeltine A (44) Dioncophylline A (45) Dioncophylline C (46)
Jozimine A (47) Jozimine C (48)
Figure 1.13 Michellamine related alkaloids with antiviral and antimalarial activity.
Jozimine A (47) was the first non-natural dimer described of a naturally occurring 
monomeric naphthylisoquinoline alkaloid, Dioncophylline A .76 The antimalarial 
activity of this dimer, IC50 0.075 pg.ml"1, is approximately 20 times higher than that of 
the monomer, a trend seen in several other naphthylisoquinoline systems.75 This 
antimalarial activity was unexpected, as the michellamines were entirely inactive 
against P. falciparum, just as unexpected was the lack of any anti-HIV activity.76 The 
dimer of Dioncophylline C, Jozimine C (48), on the other hand, has less antimalarial 
activity (IC50 0.445 pg.ml"1) than the monomer, but has a similar anti-HIV activity to 
Michellamine B (EC50 27 pg.ml' 1 compared to Michellamine B EC50 14 pg.ml’1 in the 
same test system).
1.3 Computational chemistry of biological and chemical systems
Computational chemistry has existed for half a century, and although its exact genesis 
and original implementation has been a source of ongoing debate, its definition is 
relatively simple; computational chemistry is the modelling or calculation of any aspect 
of chemistry by computational means rather than experimental. Although it derives 
much of its information from experimental sources, computational tools have become
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significant mainstays in diverse fields of chemistry, in particular for its application to 
biological systems. The fundamental rationale for computational chemistry has been a 
need to put order to observations, and then develop and refine models to explain these 
observations. This becomes an iterative process to elucidate the workings of basic 
systems of nature; how a chemical bond forms, how a receptor recognises a substrate, 
how a primary sequence of amino acid residues folds into a tertiary or quaternary 
structured protein; the list is truly endless.
Of the challenges in computational chemistry, perhaps the most demanding, promising 
and rewarding is that of the rational design of medicinal agents for the treatment of 
human disease. The most important processes that may be involved towards this goal 
are illustrated in Figure 1.14. Some are not specifically used for drug design, but rather 
are utilised as tools to model and understand the biological systems in which these 
drugs potentially may act.
Pharmacophore and 
receptor analysis
Molecular graphics 
and data visualisation
Molecular
modelling
Quantum
chemistry
Computational Chemistry
Molecular databases 
and diversity analysis
Molecular mechanics 
and dynamics
Quantitative structure 
property relationships
78Figure 1.14 Various fields of computational chemistry.
A detailed study of all of these fields of computational chemistry, and the role they play 
in rational ligand design is beyond the scope of this brief introduction, and have been 
reviewed and summarised.78 The areas of most interest in this research were molecular 
modelling, pharmacophore and receptor analysis, and to a smaller degree, quantitative 
structure property relationships. Further details of these fields of research are presented 
in the introductory sections of Chapters 3 and 4.
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The roles and contributions of these fields towards the rational design of medicinal 
agents are illustrated in Figure 1.15.77
Figure 1.15 Drug design cycles involved in the identification, and optimisation of potential 
medicinal agents. Results and information from one or more of the three coloured drug design 
cycles of ligand-based (blue), protein model-based (green), and structure-based (red) drug design 
feed the basic cycle (black) of biological testing and compound optimisation. The basic cycle 
continues until a satisfactory compound is produced which can be taken to pre-clinical studies. 
Each of the drug design cycles of this process, in turn, requires information and results from 
supporting research. Computational tools are able to manipulate this information, presenting it in
a logical and ordered manner to aid in subsequent drug design processes.
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The basic, traditional drug design cycle, seen in black, consists of iterative cycles of 
biological testing for the therapeutic use of the compounds identified by lead 
generation. This cycle is supplied with new and evolving knowledge developed from 
other cycles of drug design.
In the absence of information about the structure of the protein, receptor or active site, 
the blue ligand-based cycle utilises the physical properties of known ligands with 
biological activity, correlating these properties to their structure to determine the 
necessary chemical requirements for activity. When the three-dimensional structure of 
the biological target is known, the computational tools of the red structure-based cycle 
allow a much more effective study of the compounds considered for synthesis and 
biological testing, potentially determining the probability of success before the long and 
tedious process of chemical synthesis is initiated. The green protein-model-based cycle 
can be considered to be a medley of the blue and red cycles, providing an assortment of 
data from each, to support the iterative processes of structure determination, analysis, 
design, synthesis and biological testing.77
Beyond the drive to discover and optimise compounds with biological activity can lie 
the need to understand the interactions of the designed ligands with their receptor 
protein or active site. Molecular modelling of these biological systems can be 
invaluable towards greater insights into how these ligands affect their activity. 
Biological responses may be caused by the ligand blocking the binding site of a natural 
substrate and suppressing the activity of that enzyme or protein. The ligand may mimic 
the natural substrate, binding to the active site and inducing the protein to a biological 
response. In other cases, the ligand may bind to an allosteric site of the protein and 
influence some other aspect of the protein nature, such as its flexibility, or its ability to 
dimerise, or form quaternary structures with other proteins or subunits. These effects 
may be considerable enough to be detrimental to the function of the protein. Molecular 
modelling of these systems may help to understand how the ligand influences such 
changes to the protein. If the chemical features that induce these changes can be 
identified, further study and cycles of the drug design processes of Figure 1.15 may be 
able to optimise these features to take advantage of their affect on the biological target.
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1.4 Research aims
The aim of this research was to study strategies by which to inhibit the life cycle of 
HIV, in particular, the reverse transcriptase enzyme of the virus. It was proposed to 
synthesise a series of inhibitors of the reverse transcriptase enzyme based on the 
naturally occurring michellamine alkaloids. Computer-based modelling studies were 
designed to learn more about the mechanism by which non-nucleoside inhibitors inhibit 
the enzyme, as well as about the activation of the enzyme. The third objective of the 
research was to integrate ligand and structure based drug design techniques to fully 
utilise all available resources of information for reverse transcriptase inhibitor design.
1.4.1 Synthetic design objectives
The biological activities and structural motifs, which relate together the alkaloids of 
Figure 1.13 and the natural products of Figure 1.7, provide the basis for a 
pharmacophore, or template, of antiviral and antimalarial activity. These compounds 
are all dimeric or trimeric in nature, having some degree of symmetry. They contain a 
number of aromatic rings with hydrophobic character and they are all highly 
oxygenated. They have numerous hydroxy groups, particularly ortho to the biaryl axes. 
They all have activity against HIV-1 RT, but for quite a few of them their monomers are 
inactive compared to the dimeric compound. These monomeric compounds, however, 
demonstrate significant antimalarial activity.
The objective of the synthetic studies was to incorporate as many of those structural 
features prevalent in the naturally derived antiviral and antimalarial agents of Figures 
1.13 and 1.7 deemed significant for biological activity. The basic structural scaffold 
chosen was that of the michellamines, as it was the one antiviral with activity against 
both major strains of HIV. The strategy of Figure 1.16 was employed to design the 
targeted series of compounds as it also provided access to the corresponding monomers 
of the same series of compounds. The substituents chosen to replace the 
tetrahydroisoquinoline moiety of the michellamines varied in size and aromaticity to 
test steric considerations at this position, and included nitrogen-containing heteroaryls. 
The methyl substituent on the binaphthyl core was replaced by an ethyl ester 
functionality (Y) with the intention to progressively transform this to a carboxylic acid, 
a methyl alcohol and a methyl group to determine the structural requirements at this 
position.
ch3 oh
OH CH3 X = phenyl Y = COOEt
at- i n • /-»✓ -x naphthyl COOHMichellamine (26) H
methyl CH2OH
pyrimidine CH3
pyridine
Figure 1.16 Design strategy for the dimeric and monomeric analogues of Michellamine.
1.4.2 Molecular modelling objectives
The HIV-1 reverse transcriptase enzyme, responsible for the reverse transcription of 
single-stranded viral RNA into double stranded proviral DNA, plays an essential role in 
the life cycle of the vims, as illustrated in Figure 1.3. Non-nucleoside reverse 
transcriptase inhibitors are known to allosterically inhibit the replicative role of this 
enzyme and reduce the infectivity of the virus. The precise basis of this inhibition has 
not been definitively established, though several hypotheses have been proposed to 
clarify the mechanism, or mechanisms, of inhibition and rationalise the features of the 
NNRTIs that induce this response of the enzyme. The three dominant inhibition 
mechanisms essentially concern the flexibility of the enzyme, and the displacement of 
several significant structural motifs within the protein. These mechanisms are detailed 
further in Chapter 3.
The purpose of this research was to develop an objective, and quantitative method to 
analyse the conformational changes of two active sites, and two nucleic acid grip 
motifs, as well as the actual allosteric site of inhibition of the enzyme. Using x-ray 
crystallographic stmctures of RT in the unliganded form, complexed with double 
stranded DNA, with and without a nucleotide about to be incorporated, and a series of 
structurally diverse inhibitors, both inhibitor and substrate induced conformational 
changes of the enzyme were investigated. The results of this study were intended to 
either provide support to one or more of the proposed mechanisms of inhibition, or help
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conceive a more integrated clarification of the observed biological effect of the binding 
of substrates and NNRTIs to RT. Additionally, these studies were proposed to 
characterise flexibility of the allosteric binding pocket and investigate the structural 
changes induced by the chemical features of the bound inhibitors. The results of these 
analyses were anticipated to provide further insight into the basic prerequisites for 
biological activity, and aid in the design of new inhibitors to instigate the same desired 
inhibitory effects on the enzyme.
1.4.3 Drug design objectives
The abundance of data in the area of reverse transcriptase inhibitory agents, and 
information about the three dimensional structure of the enzyme provides a rich 
foundation upon which to base the design of new anti-viral inhibitors. As described in 
Figure 1.15, the two most established cycles of drug design, ligand-based and structure- 
based, are segregated by the sources of information used in the design principles and 
computational tools. This separation is, more often than not, due to necessity rather 
than choice, as the three-dimensional structures of many receptors and proteins are 
unavailable, and only structure-activity data is obtainable. This is, without a doubt, not 
the case with an enzyme like HIV-1 reverse transcriptase. In view of this propitious 
situation, a drug design strategy was proposed to exploit the wealth of ligand and 
enzyme structural information.
This research proposed to use ligand-based design techniques to derive pharmacophore 
models from inhibitors known to bind at the allosteric binding pocket of the enzyme. 
Furthermore, the inhibitors selected were those that had previously been crystallised 
with RT, and as such, their bioactive conformations were known. The three­
dimensional structures of RT were intended to be used to derive structure-based 
pharmacophores, describing all potential binding interactions of residues of the binding 
pocket. The objective of this research was to integrate these pharmacophores and fully 
exploit the twofold sources of information in one methodology, thereby hopefully 
combining the strengths from these two design methodologies; and compensating for 
their shortcomings and limitations.
Chapter 2 ♦
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2.1 Introduction
The antiviral activity of the michellamines against both major strains of the HIV virus, 
and their structural uniqueness as dimeric naphthylisoquinoline alkaloids with an 
uncommon C5-C8" biaryl linkage, made them attractive drug targets for synthesis.59,62' 
65,67,68 structural similarity seen between the michellamines (Figure 1.8),
michellamine-related alkaloids (Figure 1.13) and various other naturally derived anti­
HIV inhibitors (Figure 1.7), such as Gossypol (19), provided a lead for the design of 
potential reverse transcriptase inhibitors. The possibly coincidental antimalarial activity 
of the michellamine monomers, the korupensamines, and other naphthylisoquinoline 
alkaloids augmented the interest, and biological and pharmacological scope of the target 
compounds to be synthesised.
2.1.1 Inhibitor design and strategy
The binaphthyl motif of the michellamines and gossypol, seen boxed in Figure 2.1, was 
chosen as the basic structural scaffold of the targeted inhibitors, as the michellamines 
were the principal lead for the inhibitor design. The phenol substituent ortho to the 
biaryl axes was retained, as it appeared in most of the structures of Figures 1.7 and 1.13 
considered in the inhibitor design. Similarly the methoxy substituent was included in 
the target compound as it appeared in Gomisin J (20) and all of the naphthylisoquinoline 
alkaloids. The methyl substituent seen on the boxed binaphthyl core of michellamine, 
in Figure 2.1 was replaced with an ethyl ester functionality for the purpose of further 
transformation to increase the structural range of the designed inhibitors.
Michellamine (26)
Figure 2.1 Binaphthyl motifs of michellamine and gossypol.
The dashed boxed tetrahydroisoquinoline unit of the michellamines was replaced by the 
simpler substituents (R) of Figure 2.2. Methyl, phenyl, and naphthyl substituents were 
chosen to provide a succession of sterically different surrogates for the 
tetrahydroisoquinoline unit. Phenyl and naphthyl substituents were also chosen for their 
aromatic and electronic features; in the case of the naphthyl substituent, the fused ring 
system was similar in size to the tetrahydroisoquinoline ring system, but lacked the ring 
amine. The pyrimidine and pyridine substituents were also chosen for their simplicity 
and aromaticity, as well as the presence of the nitrogens in the ring system at different 
positions.
Dimeric Series Monomeric Series
Figure 2.2 Dimeric and monomeric series of designed inhibitors for synthesis.
A dimeric and monomeric series was conceived to investigate the possible requirement 
of a dimeric structure for antiviral activity, as the dimeric michellamines were active 
against HIV-1 and 2, while the monomeric korupensamines showed no antiviral 
activity.39,47,60 The converse observation that the korupensamines, and several of the
monomeric naphthylisoquinoline alkaloids of Figure 1.13, showed activity against 
malarial parasites while the michellamines lacked any antimalarial activity provided 
further motivation and support for the synthesis of the monomeric series. If the 
synthesised target compounds (Figure 2.2) were to be active as postulated by the 
inhibitor design, testing results would be expected to show antiviral activity for the 
dimeric series, and not the monomeric series, and antimalarial activity would be 
expected in the monomeric series and not in the dimers.
A single convergent synthetic strategy would enable the dimeric series to be completed 
progressively after the synthesis of the monomeric series, as illustrated in Scheme 2.1. 
Halogénation at the dimeric biaryl axis position would allow access to several different 
coupling reactions to complete the synthesis of the dimers. Deprotection of the 
isopropoxy groups in both monomeric and dimeric series would complete the targeted 
synthesis.
Scheme 2.1
The synthetic strategy adopted was based on two key reactions, comparable to the 
biomimetic synthesis of the michellamines59,63 (Section 1.2.2). The first key reaction 
was a cross-coupling to attach the R-substituent to the naphthyl ring system, and the 
second was a homo-coupling, illustrated in Scheme 2.1, to dimerise the naphthyl unit 
and form the binaphthyl target compounds. These coupling reactions to form the biaryl 
axes proved to be the crux of the synthetic studies.
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2.2 Biaryl bond formation
There exist many diverse methodologies for the formation of biaryl carbon-carbon 
bonds, and foremost among these are the coupling reactions of organometallic species 
with organic halides and related electrophiles. Scheme 2.2 summarises five of the most 
common methods for cross-coupling reactions. With the exception of the Ullman 
coupling, all of these couplings are most commonly catalysed by palladium catalysts.
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Ullman synthesis of biaryls comprises reactions in which two aryl halide molecules 
(A^X, Ar2X) are condensed in the presence of finely divided copper to form a new aryl­
aryl bond with the elimination of copper halide.80 The reaction is not possible with 
substituents that provide an alternate path for reaction of the aryl halide, such as amino, 
hydroxy, and free carboxy groups. Bulky substituents in the ortho positions may also
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inhibit the reaction by steric hindrance. Furthermore in the synthesis of unsymmetrical 
biaryls, an optimum yield is obtained only when one of the aryl halides is activated and 
the other is relatively unreactive.81
The Kharasch reaction involves the reaction of an aryl Grignard reagent (Ar]MgX) with 
an aryl halide (Ar2X) in the presence of an appropriate catalyst to yield the biaryl (Ar1- 
Ar ). The Kharasch reaction can also include other functionalised aryls, such as 
triflates, mesylates, ethers, as well as sulphides and sulphones. Its limitation arises in 
the polar nature of the Grignard reagent that precludes the use of several types of
functional groups in the coupling partner such as aldehydes, ketones, esters and nitro
80groups.
The Negishi reaction utilises arylzinc reagents (ArjZnX) and aryl halides, triflates, or 
fluorosulfonates (Ar2X, Ar2OTf, Ar20S02F), and unlike the Kharasch reaction, 
substituents such as nitrile, ester, and cyano groups can couple. ’ The reaction is 
reasonably able to tolerate substituents ortho to the biaryl axis when the coupling 
partner is an iodine.83
The Stille reaction is an extremely versatile route for biaryl synthesis, using 
arylstannanes (A^SnRs, R = Me, Bu) and aryl halides or triflates (Ar2X, Ar2OTf) as the
OA
coupling moieties. The neutral conditions of the reaction mean that many of the 
substituents not tolerated by the Kharasch and Negishi reactions are often tolerated in 
the Stille. The flexibility of the Stille reaction has allowed it to be exploited by solid 
phase synthesis, but its main detraction remains the toxicity of the organotin reagents 
and by-products.80
The most recent of the principal biaryl coupling reactions, the Suzuki reaction is 
extremely versatile as verified by its extensive use in natural product synthesis. It 
predominantly makes use of boronic acids [Ar1B(OH)2], although boronate esters and 
arylboranes are also frequently used, together with aryl halides or triflates (Ar2X, 
Ar2OTf).86,87 This reaction is especially suited to sterically crowded biaryls.80
2.2.1 Stille reaction
In the Stille reaction the biaryl Ar*-Ar2 can typically be formed by the coupling of an 
arylstannane with an electrophile, such as an aryl halide or an aryl triflate, catalysed by 
palladium84 (Scheme 2.3). The Stille reaction conditions are compatible with many
types of functional group such as carboxylic acid, ester, amide, nitro, ether, amine, 
hydroxy, ketone and even aldehyde groups.88 As reaction conditions can be very mild, 
a high degree of stereocomplexity can be tolerated in either of the coupling partners. 
This makes the Stille reaction particularly useful in natural product synthesis where 
sensitive functional groups and steroechemistry need to be considered in the synthetic
89strategy.
Scheme 2.3
Ar1SnR3 + Ar2X
Pd(0)Ln
Ar‘-Ar2 + R3SnX
The arylstannane can typically be prepared by the reaction of organolithium or 
organomagnesium derivatives with trialkyltin halides, such as tributyltin chloride or 
trimethyltin chloride (Scheme 2.4). Another common method of preparation is the 
palladium-catalysed cross-coupling of hexaalkyldistannanes, usually hexamethylditin or 
hexabutylditin, with organic electrophiles. Since organostannanes are relatively stable, 
some can be purified by distillation, and many withstand chromatography on silica
gel 84
Scheme 2.4
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The coupling partner of the arylstannane is usually an aryl halide or an aryl triflate. 
When triflates are used, an inorganic salt, generally lithium chloride, is usually 
necessary as a co-reagent.88 The Stille reaction is often improved by the addition of 
copper salts,90’91 the belief is that transmetallation of the arylstannane by the copper salt 
occurs yielding a more reactive organocopper reagent.
Common by-products in the Stille reaction include the homo-coupled stannane and the 
homo-coupled electrophile.84 By-products resulting from the transfer of methyl or butyl 
groups from the stannane to the coupling partners have been observed in the Stille 
reaction,92 although this is usually minor as the order of migration of groups is alkynyl
89> vinyl > aryl > allyl > benzyl » >  alkyl.
The Stille coupling was used in the synthesis of schumanniophytine (52), a lactone 
alkaloid isolated from Schumanniophyton magnificum 93 This representative of a rare 
tetracyclic pyranobenzopyranopyridine family of rings systems was prepared by the 
coupling of a nicotinic acid derivative (50) with a brominated chromone benzyl ether 
(49). The presence of the three ortho substituents, including two that were electron- 
donating, made the coupling difficult and accounted for the low yield.93 
Hydrogenolysis of the benzyl group was followed upon heating, by lactonisation to give 
(52)
Scheme 2.5
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2.2.2 Suzuki reaction
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In the Suzuki, reaction the biaryl Ar]-Ar2 is formed by the coupling of an arylboronic 
acid, or an arylboronate, with an electrophile, such as an aryl halide or an aryl triflate, 
catalysed by palladium94 (Scheme 2.6). In addition to its flexibility and versatility, with 
regard to conditions and tolerated substituents, sterically hindered or functionalised 
biaryls with substituents in the ortho positions can be obtained in good yield 95,96
Scheme 2.6
Ar‘B(OH)2 +  Ar2X
Pd(0)Ln
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Boronic acids do not necessarily need to be synthesised just prior to use as they are 
more air-stable than stannanes, with only minor quantities of the anhydride (Figure 2.3) 
found as contaminants after storage.97 The reaction is largely unaffected by the 
presence of water, and yields non-toxic by-products.85 The same functional groups 
tolerated in the Stille reaction are compatible in the Suzuki reaction. While the Stille 
reaction occurs in neutral conditions, the Suzuki cross-coupling occurs in basic 
conditions. The most commonly used base in the Suzuki reaction is Na2C 03, but this is 
often ineffective with sterically demanding coupling reactions, where Ba(OH)2 or 
K 3 PO 4  are used instead for good yields.85
R
0X 0
R ' V ' R
Figure 2.3 Boronic anhydride
Arylboronic acids can be synthesised by converting the 
corresponding aryl halide into its Grignard reagent, 
quenching with trimethyl or tributyl borate and aqueous
acidic workup.98,99 Similarly, metal-halide exchange can 
be achieved with a butyllithium reagent, before reacting 
with borate reagent and hydrolysis (Scheme 2.7).100 The introduction of alkoxydiboron 
reagents have made possible one-pot preparations of unsymmetrical biaryls via a 
modified in situ Suzuki cross-coupling.101 Scheme 2.7 (bottom) shows the first step in 
the in situ Suzuki cross-coupling reaction where the boronate ester is formed by heating 
at reflux the aryl halide with the diboron reagent.101,102 Alkoxydiborons have been 
shown to be useful boron nucleophiles for cross-coupling with aryl halides, or triflates,
that contain base-sensitive functionalities, such as aldehydes, nitriles and esters 103
Scheme 2.7
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Common byproducts in the Suzuki reaction include the deboronated product,95 and 
coupling with a phenyl moiety, usually derived from the catalyst.104,105 These can 
usually be minimised by changing the base, catalyst, catalyst quantity, or using 
phosphine free catalytic systems.105,106
The Suzuki coupling was used as a key reaction in the synthesis of the benzo[6]fluoren- 
11-one ring system of 0 4,9dimethylstealthin C (56), a methylated derivative of radical 
scavengers produced by Stereptomyces viridochromogenes.101 The coupled product 
(55) was synthesised in a quantitative yield from the naphthyl boronic acid (53) and the 
bromide (54).
Scheme 2.8
(53)
CHO
The fundamental mechanism of the Stille and Suzuki cross-coupling reactions occurs 
via three common steps (Scheme 2.2). Initially an oxidative addition of the aryl halide 
to the catalyst occurs to give an Ar!-Pd-X complex. This is followed by a 
transmetallation step, or steps, to give the diarylated palladium moiety, Ar*-Pd-Ar2, 
before a final reductive elimination yields the biaryl product, Ar^Ar2.80 Generally 
Pd(II) catalysts are used to promote the cross-coupling reaction, as they are air stable, 
but require reduction to the Pd(0) state before entering the catalytic cycle.87,108 The 
most common catalysts include tetrakis(triphenylphosphine)palladium(0) [Pd(PPh3)4], 
bis(triphenylphosphine) palladium(II) chloride [PdCl2(PPh3)2], dichloro[l,l'- 
bis(diphenylphosphino)ferrocene] palladium [PdCl2(dppf)], and palladium acetate 
[Pd(OAc)2].80
2.3 Synthesis of the brominated naphthyl unit (65)
The brominated naphthyl unit (65) was synthesised following methodology established 
for the synthesis of the korupensamines,53 and the subsequent biomimetic synthesis of 
the michellamines62 (Scheme 2.9).
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The ethyl ester at the 2-position served as a protecting group for the methyl substituent 
in the corresponding position in the michellamines, and allowed for other possible 
transformations, such as to a carboxylic acid or methyl alcohol. The protected hydroxy 
at the 5-position provided a directing group for the later dimérisation reaction at the 6- 
position. The bromine handle at the 8-position served as a good leaving group for the 
cross-coupling reactions to introduce the desired substituents.
The hydroxy substituent of (59) was protected by O-alkylation with 2-bromopropane to 
give the isopropoxy derivative in 90 % yield. Halogénation, para to the isopropoxy
group, with bromine gave (60) in a 96 % yield. The C4-Wittig unit (58) was prepared 
by the addition of sodium hydride to (57) followed by the addition of butyl 
bromoacetate in a 92 % yield.109 A Wadsworth-Homer-Emmons reaction of the 
phosphonate carbanion of (58) with the carbonyl of (60) yielded (61) in 56 % yield. 
Selective hydrolysis of the tertiary butyl group with aqueous trifluoroacetic acid yielded 
the carboxylic acid (62), which was not isolated. The cyclisation of (62) with acetic 
anhydride produced the acetoxy (63) and the hydroxy (64) naphthyl products, which 
were not separated. Reaction with sodium ethoxide solution hydrolysed (63) to the 
naphthol (64). The yield for the synthesis of (64) from (61) was 39 %. Méthylation of 
the free hydroxy group of (64) with iodomethane gave (65) in a 91 % yield. This was 
used instead of dimethyl sulfate, which gave (65) in a 96 % yield, due to safety 
considerations.
A M+ 1 peak at 367 was identified in the chemical ionisation (Cl) mass spectra for (65) 
and m/z at 325 (-42) was attributed to the loss of the isopropyl group. The protons of 
the methoxy group in the 4-position appeared as the singlet at ô 4.00 in the !H NMR 
spectrum, while the ethyl ester appeared as a coupled triplet and quartet at 5 1.45 and 5
4.45 respectively; J = 1.1 Hz. The isopropyl methyl groups were equivalent, appearing 
as a doublet at 5 1.40. The methine hydrogen of the isopropyl group appeared as a 
characteristic quintet at ô 4.53, instead of the expected septet, due to the smaller peaks 
being lost in the noise. The naphthyl 1-H and 3-H appeared as doublets at 5 8.56 and 6
7.46 respectively, with a coupling constant of 1.2 Hz, while the 6-H and 7-H also 
appeared as doublets at Ô 6.87 and 5 7.70 respectively, J = 8.4 Hz. Nuclear Overhauser 
effect spectroscopy (NOESY) identified an nOe between the isopropyl methyl groups 
and the naphthyl 6-H, expected to disappear after the dimérisation reaction at this 
position (see Section 2.6).
2.4 Cross-coupling
The synthesis of the monomeric and dimeric series of target compounds was made 
possible by hetero- or cross coupling reactions of the brominated naphthyl core unit 
(65). The dimeric series required an additional homo-coupling or dimérisation reaction 
as seen outlined in Scheme 2.10. The precise routes and details for the coupling 
reactions were determined in part by each targeted series or R group substituent.
Scheme 2.10
2.4.1 Stille cross-coupling reactions
The Stille coupling reaction was used in the published syntheses of the michellamines . 6 2  
This provided specific reaction conditions used as a starting point for the cross-coupling 
experimental procedures.
The bromine handle in the 8 -position of the naphthyl core unit (65) allowed for two 
possibilities in the preparation of the coupling units in the Stille reaction (Scheme 2.11). 
The bromine of (65) could be stannylated to the arylstannane and be coupled with the 
R-substituted aryl and alkyl halides of Scheme 2.10. Alternatively, bromobenzene (67) 
and other aryl halides, could be stannylated to couple with the brominated naphthyl (65) 
to yield the cross-coupled product (6 8 ). 6
Scheme 2.11
(66) (68) (65)
The cross-coupling of the stannylated naphthyl unit (66) with aryl halides was the 
preferred alternative as it had the advantage that once the methodology for the 
preparation of the naphthyl stannane (6 6 ) was established, it would not need to be
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modified for each different substituent to be coupled at the 8 -position. Numerous aryl 
and alkyl halides are easily available for the coupling reaction. Different R-substituted 
aryl and alkyl halides could require varying methodologies to prepare the corresponding 
stannanes and, although commercially available, are best used fresh. Also of note were 
previous Stille-based syntheses of the michellamines (Section 1.2.2), where the 
stannane was invariably on the naphthyl, rather than the isoquinoline, unit. The 
significance of this, and how it might pertain to the nitrogen of the isoquinoline, was 
uncertain, but may relate to the stannane being preferably placed on the more 
electronically rich of the two aryl units. As other nitrogen containing heteroaryls were 
planned to be used as substituents, the same strategy was employed.
2.4.1.1 Preparation of stannanes
Several attempts were made to prepare (6 6 ) via the most common procedure of 
lithiation of the halide followed by reaction with tributyltin chloride (Scheme 2.12). 
The reaction conditions were taken from the first biomimetic synthesis of the 
michellam ines , 6 2  where teri-butyllithium was used as the lithiation reagent. In the 
stannylations of (65), n-butyllithium was immediately available, and used instead of 
teri-butyllithium.
Scheme 2.12
Changes were made to the temperature at the addition of the tributyltin chloride and the 
solvent composition to induce the synthesis of (6 6 ) (Table 2.1). A colour change in the 
reaction solution during the dropwise addition of n-butyllithium over ten minutes 
implied that the first step in the reaction had occurred. However, the addition of 
tributyltin chloride at -7 8  °C in entry 1, due to the reagent’s potentially volatile nature, 
yielded no product. The temperature of this addition was carefully increased to 0 °C, in 
entries 2 and 3, without success. Removing diethyl ether from the solvent composition
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had no effect on the reaction result. In several attempts at entries 1-3, approximately 
50-75 % of the starting material was recovered, with extraneous polymeric material. 
Iodine development of all reaction TLCs showed neither the white or yellow stains 
typical of stannylated compounds. Mass spectra did not show a M+1 at 577 as expected 
and the lR  NMR was characteristic of (65), with no peaks shifting, or additional alkyl 
peaks. The evidence appeared to indicate that the lithiation reaction failed to displace 
the bromine atom for the subsequent stannylation reaction to occur.
Entry Conditions Result
1 (i) rc-BuLi, THF/Et20 , -78 °C (65), polymeric material
(ii) SnBu3Cl, -78 °C
2 (i) n-BuLi, THF/Et20, -78 °C (65), polymeric material
(ii) SnBu3Cl, 0 °C
3 (i) «-BuLi, THF, -78 °C (65), polymeric material
(ii) SnBu3Cl, 0 °C
Table 2.1 Conditions used in the attempted synthesis of (66). Entry 1 used 1.0 
equivalent of n-BuLi; entries 2 and 3 used 1.5 equivalents of w-BuLi.
The lack of success in this reaction may have been due to deviations from the literature 
starting material to be stannylated. The naphthyl unit used by Bringmann et al. 
contained a methyl group at the 2-position instead of the ethyl ester in (65).62 One 
equivalent of «-BuLi may have coordinated to the carbonyl oxygen, preventing the 
transmetallation with the tributyltin anion. However, this does not explain entries 2 and 
3 where 1.5 equivalents of n-BuLi were used; some displacement of the bromine by the 
lithium would have occurred for the subsequent stannylation. The lack of success in the 
stannylation of (65) could not be explained and its synthesis was deferred after the 
success of the stannylation of R-substituted aryl halide. The use of te?t-butyllithium 
could be considered in future attempts at the synthesis of (66).
The same procedure of lithiation followed by reaction with tributyltin chloride was used 
to stannylate the R-substituted aryl halides of Scheme 2.10. Bromobenzene (67) and 
bromonaphthalene (70) were used to prepare the corresponding stannanes in Scheme 
2.13.
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Scheme 2.13
(i) n-BuLi, -78 °C, THF
Ar-Br ---------------------► Ar-SnBu3
(ii) SnBu3Cl, 0 °C
Ar = phenyl (67) Ar = phenyl (69)
naphthyl (70) naphthyl (71)
Entries 1 and 2 of Table 2.2 showed that bis(tributyltin) and trimethyl tin chloride were 
not successful as stannylating agents, and only starting material was recovered. In the 
lithium mediated stannylations, arylstannane products (69) and (71) were only isolated 
when tributyltin chloride was used (entries 5 and 6). An alternative preparation of 
stannanes involving reflux with a palladium catalyst and stannylating reagent was 
attempted with some success in entry 4. The use of bis(tributyltin) and palladium 
tetrakis(triphenylphosphine) refluxing for 24 hours, in entry 3, yielded no product. The 
addition of triethyl amine, as an organic base, and the substitution of PdCl2 and PPh3 as 
the catalyst, generated in situ, resulted in a 57 % yield of (69). This was less than the 
yield of 70 % achieved by lithiation and subsequent stannylation of bromobenzene (67). 
All reactions required at least one silica column to remove the excess tin reagents. In 
retrospect, these conditions could have been used to prepare the naphthyl stannane (66), 
but the low yielding reaction would have been an unfavourable option after the multi­
step synthesis required to produce (65).
Entry Ar-Br Conditions Result
1 (67) (i) w-BuLi, THF, -78 °C (67)
(ii) (SnBu3)2, 0 °C
2 (67) (i) rc-BuLi, THF, -78 °C (67)
(ii) SnMe3Cl, 0 °C
3 (67) (SnBu3)2, Pd(PPh3)4, toluene, 115 °C (67)
4 (67) (SnBu3)2, PdCl2, PPh3, triethylamine, toluene, 115 °C (69) 57 %
5 (67) (i) n-BuLi, THF, -78 °C (69) 70 %
(ii) SnBu3Cl, 0 °C
6 (70) (i) jz-BuLi, THF, -78 °C (71) 76 %
(ii) SnBu3Cl, 0 °C
Table 2.2 Conditions used in the synthesis of (69) and (71) Scheme 2.13. 1.5 equivalents of n-BuLi 
and/or stannylating agent were used in each reaction.
The products (69) and (71) appeared as white spots after iodine development of reaction 
TLCs. Tributyltin incorporation was confirmed by M+ 1 peaks at 367 and 369 in the
mass spectra of (69), for the two major isotopes of tin, 118 and 120. The mass spectra 
of (71) showed M + 1 peaks at 417 and 419.
2.4.1.2 Coupling of naphthyl core halide and aryl stannanes
The conditions for the Stille reaction were also based on those used in the synthesis of 
the m ichellam ines . 6 2  Due to the immediate availability of the reagents, palladium 
chloride and triphenylphosphine were used as the catalyst instead of the palladium 
chloride bis(triphenylphosphine) and triphenylphosphine Bringmann et al. used. 
Triethylamine was also added to regenerate the catalyst that was formed in situ.
Scheme 2.14
(65) R = phenyl (69) R = phenyl (68) (15%)
naphthyl (71) naphthyl (72) (17%)
In a typical reaction (65) was added to palladium chloride, triphenylphosphine, 
triethylamine, lithium chloride, and copper (I) bromide in DMF, and heated at reflux, 
under nitrogen, for 24-48 hours. The reaction was monitored and quenched after TLC 
indicated no trace of (65), the rate-limiting reagent. The yields for the reactions, 15% 
and 17% for (68) and (72) respectively, were low and extreme anhydrous conditions and
the rigorous exclusion of air using freeze thaw cycles did little to increase the product
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yields. The addition of a few crystals of 2,6-di-terr-4-methylphenol as an anti-oxidant 
affected no change to the reaction yield of (68) or (75). Apart from the removal of a 
large amount of polymeric material in the purification process by silica column 
chromatography no explanation can be made for the up to 85% of starting material (65) 
unaccounted for.
The 1- and 7-H of (6 8 ) were shielded by the phenyl substituent and were shifted upfield; 
from 5 8.56 to 5 8.22 and 5 7.70 to 5 7.36, respectively, compared to (65). The 3-H 
signal was virtually unchanged, but 6 -H was notably shifted downfield from 8  6.87 to 8
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7.09 . The protons of the phenyl substituent were not resolved, and appeared as a 
multiplet. Nuclear Overhauser effect spectroscopy showed an nOe between the 1-H of 
(68) and the phenyl protons ortho to the biaryl axis. Mass spectra showed a M+1 at 
365.
Similarly the 1-, 3- and 7-H of (72) were shielded by the naphthyl substituent and 
showed upfield shifting to 8 7.74, 8 7.39, and 8 7.41 respectively, while the 6-H was 
shifted downfield to 8 7.14. 13C NMR revealed 27 carbon resonances as expected. The 
isopropyl group of (72) appeared not to be freely rotating, with the two methyl groups 
appearing as two separate doublets, in the NMR, compared to the one doublet seen 
in (68). In addition, two separate carbon signals at 8 22.16 and 8 22.22 were observed 
m the C NMR, as if the two methyl groups of the isopropyl were chemically 
nonequivalent. A temperature series of !H NMRs were run at 25, 35, and 45 °C to 
hopefully allow the isopropyl group to rotate freely, and appear as one doublet rather 
than two. The resulting spectra showed only a very slight decrease in the separation of 
the doublets.
The unacceptable yields of these Stille reactions detracted from these coupling 
reactions. The additional inability to recover starting material (65) from the reaction 
mixtures made this practically infeasible as a route to the target compounds. Concurrent 
Suzuki-coupling studies proved to be more successful, and the Stille cross-coupling 
reactions were terminated at this stage.
2.4.2 Suzuki cross-coupling reactions
Similar to the strategy employed in the Stille cross-coupling reactions (Scheme 2.11), 
Scheme 2.15 outlines the two possible synthetic routes to (68). A high yielding 
synthesis of (73) would allow access to halide or triflate substituents that could not be 
easily transformed to boronic acids themselves, and would avoid possible modifications 
for the synthesis of various aryl boronic acids from aryl halides or triflates. Readily 
available boronic acids, such as phenyl boronic acid (74), would also allow the 
synthesis of the target compounds from the brominated naphthyl (65).
Chapter 2 ^  —  — Synhmsis
§ The naphthyl shifts in the cross-coupled products were most apparent in the pyrimidine substituent, 
where the aromatic hydrogens were more clearly resolved, Figure 2.5 Section 2.4.2.3.
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Scheme 2.15
(73) (6 8 ) (65)
2.4.2.1 Preparation of boronic acids and esters
The boronate ester (73) was prepared in one step using bis(pinacolato)diboron 
(75 ) , 1 0 2 , 1 0 3  (Scheme 2.16). In a typical reaction (65) was added to 
bis(pinacolato)diboron (75), dichloro[ 1,1 '-bis(diphenylphosphino)ferrocene]palladium 
[PdCl2 (dppf)], and potassium acetate in THF, and heated at reflux for 24 hours. The 
crystalline boronate ester (73) was produced in 95 % yield, and only a short plug of 
silica was required to remove some baseline material for purification. TLC and mass 
spectral data revealed trace amounts of the debrominated starting material (76), with an 
M + 1 peak at 289. The choice of KOAc as base was essential to the acceleration of the 
reaction; too weak a base would slow down the reaction, and too strong a base would 
induce the formation of biaryl by-products . 1 0 3 , 1 0 6
Scheme 2.16
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(65) (73) (95%) (76) trace
NMR data showed that there was restricted rotation about the C-B bond, as the 
symmetry of the boronate ester was broken. The alkyl groups of the boronate ester (73), 
that were expected to appear equivalent, actually appeared as two signals, seen in both
H and C NMRs ( 8  1.416 and 1.417, and 8  24.92 and 24.99). The aromatic hydrogens 
were expected to show an upfield shift with the replacement of the bromine with the 
less electronegative boron. Instead, the hydrogens in the 1, 6  and 7 positions shifted 
notably downfield to 8  9.19, 8  6.97, and 8  7.99 respectively. The hydrogen at position 3 
showed a small upfield shift to 8  7.39 from 8  7.46 in (65). The 8 -carbon showed 
another unexpected downfield shift, from 8  134.40 to 8  140.50, with the replacement of 
the bromine, as did carbons 7 and 8 a. The 3-H signal in the NMR at 8  7.39 
unexpectedly appeared as a singlet when a doublet, with coupling constant of 1.2 Hz, as 
seen for the doublet of 1-H, was expected. This was attributed to a resolution problem 
with the spectrometer used to obtain the NMR. Mass spectra showed a M + 1 at 415 as 
the molecular ion, and a m/z at 373 (-42) was attributed to the loss of the isopropyl 
group.
Scheme 2.17 shows the proposed catalytic cycle of the cross coupling reaction of the 
pinacol ester of diboronic acid (7 5 ) . 1 0 3
Scheme 2.17
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The oxidative addition and reductive elimination sequences are well understood , 9 7  
unlike the transmetallation step, which is highly dependent on the organometallic 
species and conditions used . 8 6  The catalytic cycle begins with the oxidative addition of 
the brominated naphthyl (65), represented by Ar-X in Scheme 2.17, to a palladium(O) 
complex to yield an Ar-Pd(II)(L)2 -X adduct. Two transmetallation steps successively 
replace the halide group with the acetoxy group, and then the acetoxy group with the 
boronate ester. Cis-trans isomerisation can occur with the Ar-Pd(II)(L)2-B(OR)2 
intermediate before reductive elimination of the naphthyl boronate ester (71), from the 
cis isomer, to regenerate the palladium(O) com plex . 1 1 0
The role of the base in this mechanism is not definitively understood; it is thought to 
accelerate the transmetallation rate by displacing the palladium halide complex to give 
an acetoxopalladium(II) species in solution, which is known to transmetallate with 
organoboron compounds in neutral conditions . 1 0 3  Another possibility is that the 
coordination of the negatively charged base to the boron atom increases its 
nucleophilicity for transmetallation to the palladium halide . 1 0 3  The high reactivity of 
the oxopalladium complex, formed by the base, toward transmetallation with 
organoboron compounds can explain the high yields obtained in this reaction. This high 
reactivity may be due to the reactivity of the Pd-O bond that consists of a soft acid and a 
hard base combination, and the high oxophilicity of the boron centre . 1 0 3
Phenyl, and methyl boronic acid were purchased, while naphthyl boronic acid was 
prepared via a Grignard intermediate (Scheme 2.18).98 Bromonaphthalene (70) was 
added to magnesium shavings, and a crystal of iodine in THF, and heated at reflux for 2 
hours. The addition of tri-n-butylborate, followed by an acidic workup, and 
recrystallisation from water, resulted in 40% of (77).
Scheme 2.18
(i) Mg, THF, A
(ii) B(OBu)3, -78 °C ]  ^
THF/Et20  B(OH)2
(77)(70)
2 A .2 .2  Coupling of naphthyl halides and aryl boronic acids
In a typical Suzuki cross-coupling, the boronic acid was added to a mixture of the aryl 
halide, a palladium catalyst, and a base, and heated at reflux in a sealed tube or in 
standard reflux apparatus, under nitrogen for a minimum of 24 hours. The reaction was 
monitored by TLC until such a time it was determined that the reaction would not 
proceed further. This time scale of the reaction, on the whole, did not exceed 48 hours, 
but was dependent on reaction conditions, in particular the nature of the catalyst used.
The cross-coupling of phenyl boronic acid (74) of Scheme 2.19 revealed differences in 
reaction yields depending on the solvent and catalyst used as detailed in Table 2.3. 
Using Ba(OH ) 2  and Pd(PPh 3 )4 , the solvent in a series of phenyl boronic acid couplings 
with (65) was varied and the reaction yields monitored (entries 1-4). Compound (65) 
was spectroscopically identical to the product produced via the Stille cross coupling 
reaction (Section 2.4.1.2).
Scheme 2.19
(65) (74) (6 8 )
Entry Catalyst Solvent Temp. (°C) Time (hrs) Yield %
1 Pd(PPh 3 ) 4 DMF 160 48 78 %
2 Pd(PPh 3 ) 4 DME 90-100 48 69%
3 Pd(PPh 3 ) 4 dioxane 1 1 0 3 2 - 3 6 85 %
4 Pd(PPh 3 ) 4 THF 90 3 2 - 3 6 85 %
5 PdCl2 (dppf) THF 90 24 97 %
Table 2.3 Optimisation of the Suzuki cross-coupling of phenyl boronic acid (74) and the 
brominated naphthyl (65), Scheme 2.19. Ba(OH)2 was used as the base in all reactions. 
Temperatures reported were oil bath temperatures.
Entries 1 and 2 show that DMF and DME produced reasonable yields of (6 8 ), but 
reaction times on average approached 48 hours. The use of DMF also required a much 
higher reflux temperature (oil bath 160 °C). The reaction appeared to halt after 48 
hours, as monitored by TLC analysis, probably due to decomposition of the catalyst.
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Tetrahydrofuran proved to be the best solvent for use (entry 4 ), and although dioxane 
had comparable yields with Pd(PPh 3 ) 4  as the catalyst (entry 3 ), the lower boiling point 
and accessibility of THF made it the preferable solvent to use. The variation of 
PdCl2 (dppf) as catalyst had the dual effects of increasing the reaction yield and reducing 
the reaction tim e . 1 0 1 ’ 1 0 3 , 1 1 1  Entry 5 of Table 2.3 produced the highest yield of product 
and involved only an extractive work-up, a short celite plug, and recrystallisation to 
purify (6 8 ). As a general rule, Pd(PPh 3 ) 4  was the preferred catalyst for general use as is 
was easily and economically synthesised , 1 1 2  but PdCl2 (dppf) was most frequently found 
to be the better catalyst in the cross coupling.
The mechanism for the Pd-catalysed Suzuki reaction of phenyl boronic acid (74) with 
the brominated naphthyl (65) is most likely similar to the cross coupling reaction of the 
pinacol ester of diboronic acid (75) (Section 2.4.2.1), involving an oxidative addition of 
Pd(0) to the aryl halide, transmetallation of the A r1 -Pd(II)-X with the boronic acid and 
reductive elimination to give the cross-coupled product (A r!-Ar2) as shown in Scheme 
2 .20 .
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The base in the reaction is represented by OH' in Scheme 2.20, and its strength is 
thought to play a role in the acceleration of the coupling rate . 9 6 , 9 7 ’1 0 3 ’ 1 0 6 ’ 1 1 3 The oxidative 
addition is often thought to be the rate determining step in the catalytic cycle, with the 
bromine of (65) being more reactive than a chlorine in this position, but less reactive 
than an iodine or triflate com pound . 8 6
Transmetallation between the A r1 -Pd(II)(L)2-X adduct and the Ar2 -B(OH ) 2  reagent does 
not occur readily due to the low nucleophilicity of the organic group on the boron 
atom. However the nucleophilicity of the organic group on the boron atom can be 
enhanced by quatem ization of the boron with negatively charged bases, such as 
Ba(OH ) 2  in Scheme 2.19, allowing the transmetallation with the organopalladium(II) 
halide. The reductive elimination of the coupling partners (Ar1 and Ar2) from the A r1- 
Pd(II)(OR)B(OH)2 -Ar2  complex reproduces the palladium(O) complex. The A r1- 
Pd(II)(OR)B(OH)2 -Ar2  exists as cis and trans isomers, with the reaction taking place 
directly from the cis isomer, as shown in Scheme 2.20. The coupling of two aryl units 
is known to be more easily achieved than that of an aryl and alkyl, or two alkyl groups, 
suggesting participation of the 7i-orbital of the aryl group during the reductive 
elimination bond formation . 8 6
The optimised conditions for the Suzuki cross-coupling of (65) and (74) in Table 2.3 
were used as a basis for the synthesis of the naphthyl and methyl cross-coupled products 
(Scheme 2.21). PdCl2 (dppf), Ba(OH)2, and THF were initially used as catalyst, base 
and solvent respectively (Table 2.4).
Scheme 2.21
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(65) R = naphthyl (77) R = naphthyl (72)
methyl (78) methyl (79)
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Entry R Catalyst Base Time (hrs) Result
1 naphthyl PdCl2(dppf) Ba(OH)2 24 (72) 42 %
2 naphthyl Pd(PPh3)4 Ba(OH)2 48 (72) 87 %
3 naphthyl PdCl2(dppf) KOAc 24 (72) 91 %
4 methyl PdCl2(dppf) Ba(OH)2 24 (79) 38 %
5 methyl PdCl2(dppf) K2CO3 24 (79) 94 %
Table 2.4 Conditions used in the Suzuki cross-coupling of naphthyl and methyl boronic acid and 
the naphthyl core unit, Scheme 2.21. THF was used as the solvent in all reactions, and refluxed at 
an oil bath temperature of 90-100 °C.
The use of PdC^Cdppf) and Ba(OH)2, entries 1 and 4, in the Suzuki cross-coupling 
yielded 42% and 38% of the naphthyl (72) and methyl (79) cross-coupled product, 
respectively. The substitution of Pd(PPhs)4 as the catalyst, in entry 2, more than 
doubled the yield of (65) to 87 %, however the reaction time increased to 48 hours. In 
entry 3, PdCl2(dppf) was retained as the catalyst, with KOAc as the base, increasing the 
product yield to 91%. Similarly replacing Ba(OH)2 with K2CO3, in entry 5, increased 
the yield of the methyl cross-coupled product (79) to 94 %. The syntheses of (72) with 
K2CO3, and (79) with KOAc as the base were not attempted, though the results from 
such reactions may be interesting to determine the affect of the base on each substituted 
cross-coupled product.
The !H and 13C NMR spectroscopy of (72) from Scheme 2.21 was compared to the 
product synthesised by the Stille cross-coupling and found to be identical. The 
spectroscopy of (79) showed an additional singlet at 5 2.65 and 5 19.75 in the *11 and 
13C NMR alkyl regions respectively for the aryl methyl. The 1-H and 7-H showed 
shielding effects and signals downfield at 5 7.31, and 5 7.24 respectively to those seen 
in (65) at 5 8.56 and 5 7.70. The 3-H and 6-H were virtually unchanged at 6 7.43 and 6 
6.94 respectively.
Further investigation of the low yielding reactions where PdCl2(dppf) and Ba(OH)2 
were used, entries 1 and 4 of Table 2.4, revealed the homo-coupled product (80) of the 
brominated naphthyl unit (65), depicted in Figure 2.4. The percentage of (80) was not 
accurately determined in these reactions, but as a qualitative gauge, TLC indicated that 
it was the major product compared to the desired cross-coupled product.
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The structure of (80) was initially proposed after 
a m/z peak at 575 was identified by mass 
spectrometry, corresponding to M +l for (80). 
The symmetry of the product was reflected in the 
!H NMR, which had the same number and types 
of signals as (65), but showed different proton 
chemical shifts. The 1-, 3- and 7-H of (80) were 
shifted upfield to 5 7.68, 5 7.38, and 5 7.37 
respectively compared to 6  8.56, 5  7.46, and 6  
7.70 in (65). A downfield shift from 5 6.87 to 5 
7.13 was observed for 6 -H. The dimeric nature 
of (80) was most convincingly demonstrated by an nOe detected between 1-H and 7 ’-H, 
as seen in Figure 2.4. Similarly to the naphthyl cross-coupled product (72), the methyl 
groups of the isopropyl appeared as two doublets, instead of one doublet as expected. 
The methylene hydrogens of the ethyl ester also appeared as two quartets instead of one 
quartet, however the methyl of the ethyl ester was unaffected, and appeared as a single 
triplet. The C NMR showed two carbon signals for the methyl groups of the 
isopropyl, but no doubling of carbon signals for the methylene carbons of the ethyl 
ester. Another temperature series of !H NMRs, increasing in 10 °C increments from 20 
°C to 50 °C, showed the doublets of the isopropyl methyl beginning to come together, 
but not totally collapsing into a single doublet. The proton signals of the methylene of 
the ethyl ester showed no change through the series of temperature regulated !H NMRs.
From the observations of the results of Table 2.4 it was speculated that the choice of 
base and catalyst may have had differing effects on not only the reaction rate and yield, 
but may also determine the nature of the products. In the coupling of (65) and (74), 
Scheme 2.19 and Table 2.3, PdCl2 (dppf) had already been demonstrated to be a more 
effective catalyst than Pd(PPh 3 ) 4  in increasing the rate of reaction and the product yield. 
However in the instance of the naphthyl cross-coupled product, the use of PdCl2 (dppf) 
produced a dramatically decreased yield of (72) (42%) compared to the same reaction 
where Pd(PPh 3 ) 4  was used (87%). The choice of base was also considered to play a role 
in the rate of the reaction, with stronger bases thought to accelerate the transmetallation 
rate of the coupling reaction . 9 7 , 1 0 3  Yet when the stronger base was used, Ba(OH ) 2  
instead of KOAc in the synthesis of (72) and K 2 C 0 3 in the synthesis of (79), the product
(80)
Figure 2.4 Structure of the homo­
coupled product of the Suzuki cross­
coupling reactions.
yields were poorer; 42% compared to 91% and 38% compared to 94% for (72) and (79) 
respectively.
The results appeared to show that the cross coupling reactions produced the optimal 
yield when a certain reaction rate was achieved with the combination of catalyst and 
base. Exceedingly strong catalysts and bases, which accelerate the rate of reaction 
beyond the optimal for cross coupling, could favour the oxidative addition step of 
Scheme 2.20, over the two successive transmetallation steps necessary before the 
reductive elimination. The dominance of the oxidative addition would lead to the 
unwanted by-product, such as (80), rather than the cross-coupled product. Weaker 
catalysts and bases, could retard the rate of reaction, and although this would minimise 
the extent of (80) in the reaction, it could also see the appearance of debrominated 
starting material (76). This was similarly seen in the cross coupling reaction of the 
pinacol ester of diboronic acid of Scheme 2.16.
2.4.2.3 Coupling of naphthyl boronate esters and aryl halides
The Suzuki reactions for the methyl, pyrimidine, and pyridine cross-coupled products 
were carried out with the naphthyl boronate ester (73) and iodomethane, 5- 
bromopyrimidine, and 2-bromopyridine respectively. These substituents were most 
easily available as organic halides, consequently the synthesis of their boronic acids or 
esters was not pursued.
The cross coupling reactions of Scheme 2.22 were carried out as one-pot in situ 
reactions,101 without isolation and purification of the boronate ester (73). The formation 
of (73) was monitored by TLC and mass spectra before the addition of the aryl or alkyl 
halide substituent. In a typical reaction the brominated naphthyl (65) was added to 
bis(pinacolato)diboron, base (1), and catalyst in THF, and heated at reflux, under 
nitrogen, for 24 hours. Base (2), iodomethane or an aryl bromide, and a second 
equivalent of catalyst were added and heated at reflux, under nitrogen, for a further 24 
hours. TLC monitoring of the reaction after the initial 24 hours showed complete 
transformation of the brominated naphthyl (65) to the boronate ester (73), with 
occasional trace evidence of the corresponding debrominated starting material (76). A 
mild base is usually used for the first step of the reaction to minimise the homo-coupled 
by-product (76),101'103 before a stronger base is used to both hydrolyse the naphthyl 
boronate ester to the corresponding acid for reaction, and to participate in the cross­
coupling catalytic cycle of Scheme 2.20. Strangely, the use of a strong base in the 
second stage of the reaction did not appear to have an effect in favouring the unwanted 
homo-coupled by-product (76).
Scheme 2.22
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Entry R Base 1 Catalyst Base2 Result
1 methyl KOAc Pd(PPh3 ) 4 Ba(OH ) 2 (79) 95 %
2 methyl KOAc PdCl2 (dppf) Ba(OH ) 2 (79) 80 %
3 methyl k 2 c o 3 PdCl2 (dppf) Ba(OH ) 2 (80) 92 %
4 pyrimidine k 2 c o 3 PdCl2 (dppf) Ba(OH ) 2 (83) 40 %
5 pyrimidine KOAc PdCl2 (dppf) Ba(OH ) 2 (83) 77 %
Table 2.5 Conditions used in the one-pot Suzuki cross-coupling of (65) with iodomethane and 5- 
bromopyrimidine, Scheme 2.22. THF was the solvent in all the reactions.
Although a high yielding synthesis of the methyl cross-coupled product (79) had already 
been achieved, the differences in yield between the two basic strategies of Scheme 2.15 
were calculated to determine which was the better unit to have as the boronic acid. The 
comparison of the 94 % yield from the cross coupling of the brominated naphthyl (65) 
with methyl boronic acid (78), in Scheme 2.21 and Table 2.4, against either of the yields 
from the iodomethane reactions of Table 2.5, entries 1 and 2, do not definitively 
differentiate between which coupling partner is the better moiety to have as the boronic
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acid. Although different bases were selected because of the one-pot in situ 
requirements, the reaction where Pd(PPh3)4 was used produced a virtually identical 
yield of the cross coupled product (95 %). The slightly lower yield of 80 % when 
PdCl2(dppf) was used, the same catalyst used in the methyl boronic acid coupling, may 
be attributable to by-products, such as the homo-coupled naphthyl (80), although this 
was not confirmed by chromatography and spectroscopy. When K2C 03 was used as the 
first base with PdCl2(dppf), in entry 3, 92% of the homo-coupled naphthyl (80) was 
isolated, without any trace of the cross-coupled methyl product(79).
In the cross coupling of 5-bromopyrimidine, the use of K2C 03, as the first base, resulted 
in a 40 % yield of the cross-coupled product (83), and a 48 % yield of the homo-coupled 
product (80). Separation of the reaction mixture by silica chromatography, followed by 
NMR spectroscopy and mass spectrometry, confirmed the yields and structures of (83) 
and (80). The use of KOAc in place of K2C 03 in the pyrimidine cross-coupling 
increased the yield of cross coupled product to 77%; the yield of the unwanted by­
product was not determined in these later reactions.
The mass spectra of (83) showed a M+1 at 367, and a m/z at 325, corresponding to the 
loss of the isopropyl group. The symmetry afforded by the use of the 5-pyrimidine 
substituent made for easy identification in !H NMR, as seen in Figure 2.5. The 
expected shielding effects of the pyrimidyl ring were seen in the upfield shift of 1-H and 
7-H from 8 8.56 to 7.96 and 8 7.70 to 7.32 respectively, compared to (65). The shifts 
compared to the boronate ester (73) are also illustrated in Figure 2.5. 3-H showed 
negligible difference in signal between the pyrimidine cross-coupled product (83) and 
the brominated naphthyl (65), while a downfield shift was observed in 6-H from 8 6.87 
to 7.07. The 4’- and 6’-H appeared as a singlet of two hydrogens at 8 8.83 and the 2’-H 
appeared at 8 9.27 as expected for the pyrimidyl aryl substituent. HSQC and HMBC 
correlated the identified protons of the pyrimidine ring to one carbon signal at 8 157.41, 
that represented three carbons of the pyrimidine ring; the ipso carbon was at 8 134.34. 
NOESY experiments also confirmed an nOe between 7-H of the naphthyl ring system 
and the 4’- or 6’-H of the pyrimidine.
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Figure 2.5 The NMRs of the brominated naphthyl (65), the boronate ester (73) and the 
pyrimidine cross-coupled product (83) illustrate the shifts in the aromatic region.
In the synthesis of the pyridine cross-coupled product, the optimised conditions of entry 
5 of Table 2.4, using PdCl2 (dppf), and KOAc and Ba(OH)2 as the first and second base, 
respectively, in THF, failed to yield any cross-coupled product, and only the 
intermediate boronate ester (73) was recovered. Changing the solvent and the second 
base to DM E and K 2 CO 3 , respectively, resulted in no change to the reaction outcome 
(entry 1, Table 2.6). An increase in the time of heating at reflux after the addition of 2- 
bromopyridine, the second base, and fresh catalyst, from 24 to 48 hours showed no 
formation of the pyridine cross coupled product. However, TLC and mass spectral data
of these longer reactions began to show the appearance of (76), the debrominated, or in 
this case deboronated form of (65) and (73) respectively.
The reaction was modified by isolating and purifying the naphthyl boronate ester (73), 
before proceeding to the reactions of Scheme 2.23. The substitution of Pd(OAc ) 2  and 
PPh 3  as catalyst and coordinating ligand, instead of PdCl2 (dppf), and DME as solvent 
instead of THF, as suggested from literature Suzuki couplings of chloropyridines , 9 6 , 1 0 2  
proved to be successful, if not high yielding as seen in entries 4 and 5 of Table 2.6. As 
expected, the coupling of 2 -bromopyridine resulted in a greater yield than that of 2 - 
chloropyridine.
Scheme 2.23
Entry Base X Catalyst and Ligand Result
1 k 2 c o 3 Br PdCl2 (dppf) (73)
2 KOAc Br Pd(OAc ) 2 (73)
3 Ba(OH ) 2 Br Pd(OAc ) 2 (73)
4 k 2 c o 3 Cl Pd(OAc)2, PPh3 (84)36 %
5 k 2 c o 3 Br Pd(OAc)2, PPh 3 (84) 45 %
Table 2.6 Conditions used in the Suzuki cross-coupling of the naphthyl boronate ester 
and 2-halopyridine, Scheme 2.23. DME was used as the solvent in all reactions, and 
refluxed at 90-100 °C, under nitrogen.
The TLC analyses of entries 4 and 5 of Table 2.6 revealed the formation of a secondary 
product that had a retention time similar to that of the phenyl cross-coupled product 
(68). Mass spectra showed a M + 1 peak at 366 for (84) and a m/z of 365, that 
corresponded to a M +1 for the phenyl cross-coupled product (68). High resolution gas 
chromatography and mass spectra confirmed the elemental composition of the m/z 365 
and 366 peaks as C 2 2 H 2 4 0 4  (68) and C 2 2 H 2 3 N 0 4  (84), respectively. The yield for the 
phenyl cross-coupled product in these reactions was not calculated, but TLC analysis 
indicated that it was approximately equivalent to that of the pyridine cross-coupled
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product (84). Presumably the phenyl cross-coupled product (68) is produced when the 
reductive elimination occurs after the first transmetallation in Scheme 2.20. The phenyl 
ligand, L, from the triphenylphosphine of the catalyst is coupled with Ar1 from (73) to 
form the phenyl cross-coupled product, instead of the Ar‘-Ar2 pyridine cross-coupled 
product, shown in grey in Scheme 2.24. This ‘product scrambling’ has been previously 
noted in Suzuki, 1 0 4 , 1 0 5  and Stille reactions, 1 14 and may be minimised by reducing the 
catalyst quantity, 105or using phosphine free catalytic systems . 106
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No explanation could be given for the failure of PdCl2(dppf) to catalyse the cross 
coupling of the (73) and 2-bromopyridine. It can be speculates that the positioning of 
the nitrogen ortho to the halogen may have involved it in some coordination complex 
with the catalyst PdCl2 (dppf) that was unfavourable for coupling. Repeating the 
reaction with Pd(PPh3 ) 4  may reveal if indeed it was the 
bis(diphenylphosphino)ferrocene ligand that was the cause of the problem.
In addition to the previously mentioned mass spectral data, the signature splitting 
patterns of the pyridine aryl unit helped to establish the structure of (84). The 5’-H 
appeared as a doublet of doublets of doublets, with 7.4 Hz ortho and 0.8 Hz meta 
coupling to the 4’ and 6 ’-H, and 3’-H, respectively. The resolution was sufficient to see 
individual peaks, but possibly insufficient for accurate detection of the small meta 
coupling which was anticipated to be greater than 0.8 Hz. The splitting pattern of 3’-H 
was obscured by the peaks of the doublet of 7-H, and only resolved as a doublet of 7.6 
Hz, coupled to 4 ’-H. Another doublet of doublets of doublets, which visually appeared 
as a doublet of triplets characteristic of pyridines, correlated to 4’-H, with 7.6 Hz ortho 
and 1.6 Hz meta coupling to 3’ and 5’-H, and 6 ’-H, respectively. The 6 ’-H was not 
sufficiently resolved, and appeared as a broad doublet, with approximately 4.0 Hz 
coupling.
2.5 Ortho-directed bromination
Ortho bromination at the 6 position of the cross-coupled products was proposed to 
enable the dimeric series of targeted compounds to be synthesised from the monomeric 
cross-coupled series (Scheme 2.1). This bromine handle would allow access to the 
Stille and Suzuki homo-coupling reactions to form the binaphthyl moiety of the targeted 
dimeric compounds.
In a typical reaction, a suspension of pyridinium tribromide in glacial acetic acid was 
added dropwise to a stirred solution of the R-substituted naphthyl product, in 
chloroform at 0 °C (Scheme 2.25).65 In the case of (83) and (84), the chloroform was 
pre-acidified to compensate for the basic nature of the pyrimidine and pyridine 
substituents.
Scheme 2.25
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naphthyl
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(86) (97%)
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(88) (98%)
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R 1 -H 3 -H 7 -H
monomer ortho-Br monomer ortho-Br monomer ortho-Br
phenyl 8 .2 2 8 .1 7 7 .4 8 7 .4 3 7 .3 6 7 .6 5
naphthyl 7 .7 4 7 .7 0 7 .3 9 7 .4 3 7 .4 1 7 .4 7
methyl 7 .3 1 8 .2 6 7 .4 3 7 .4 6 7 .2 4 7 .5 4
pyrimidine 7 .9 6 7 .9 3 7 .4 4 7 .5 2 7 .3 2 7 .6 4
pyridine 8 .3 9 8 .3 1 7 .4 2 7 .4 6 7 .5 4 7 .8 0
Table 2.7 NMR shifts (5 ppm) for the 1-H, 3-H and 7-H of the R-substituted cross-coupled 
products, and their ori/zo-brominated derivatives.
The yields of all the ortho-directed brominations were in excess of 75 %, with that of 
the pyrimidine cross-coupled monomer (88) being almost quantitative. The products 
were purified by column chromatography and recrystallised from isopropanol.
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The most evident indication of bromine incorporation in lH NMR was expected to be 
the disappearance of the naphthyl 6-H, and the change of the 7-H from a doublet with 
ortho coupling, to a singlet. In (85) the 7-H appeared as a singlet, shifted downfield, at 
8 7.65 from the doublet of 8 Hz at 5 7.36 in (68). The 1-H and 3-H showed small 
upfield shifts to 8 8.17 and 8 7.43 compared to 8 8.22 and 8 7.48 in (68), respectively. 
Table 2.7 compares the 1-H, 3-H and 7-H proton shifts between the R-substituted cross­
coupled products and the corresponding ortho brominated derivatives. All of the 
brominated products with aromatic substitutions showed upfield shifts in the 1-H, and 
downfield shifting in the 7-H. The small shifting of the 3-H was downfield in all of the 
R-substitutions of Table 2.7, except for the previously mentioned phenyl cross-coupled 
product.
Figure 2.6 shows the significant downfield shifting by 0.95 ppm of the 1-H of (87). 
This was in contrast to the products with aromatic substituents which showed upfield 
shifts for 1-H.
1-H 3-H 6-H
(79)
1-H 7-H 3-H
ii 11 [I i ii | ii 11111 ii | in i [I i ii | ii 11111 ii | n 11111 ii | ii 11111 ii | ii 11 |i rn | ii 11 irrrrj
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Figure 2.6 T l NMRs of the methyl cross- coupled product (79), and its o rth o -brominated 
derivative (87) illustrating the shifts in the aromatic region.
The coupling constants between 1-H and 3-H in the methyl substituted products also 
showed a notable change from 0.8 Hz in (79) to 1.6 Hz in (87). These coupling 
constants remained fairly consistent for the compounds with aromatic substituents
before and after the ortho-directed bromination. Figure 2.6 also shows the loss of the 6- 
H and the change of the 7-H from a doublet to a singlet.
2.6 Dimérisation reactions
Dimérisation, or homo-coupling, reactions are essentially the same as cross-coupling 
reactions; and in most cases can be achieved as a one-pot reaction where the stannylated 
or boronate intermediate does not necessarily need to be isolated (Scheme 2.26). A 
dimérisation can have different demands to a cross-coupling reaction; in a hetero­
coupling reaction the choice of catalyst and base can play a major role in the yield of the 
product and the minimisation of dimerised products. However, this consideration is 
unnecessary in homo-coupling reaction, and bases and catalysts are often actually 
chosen to accelerate this process.
Scheme 2.26
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2.6.1 Stille homo-couplings
Several attempts were made to dimerise the phenyl substituted monomer (68) using the 
Stille coupling reaction (Scheme 2.27). In a typical reaction, the ortho-brominated 
derivative was added to Pd(PPh3)4 and bis(trimethyltin), in an organic solvent and 
heated at reflux, under nitrogen, for 24-48 hours.68,115 The use of toluene and THF as 
the organic solvent produced neither the dimerised product, nor the stannylated 
intermediate (90), and only approximately 50 % of the starting material (85) was 
recovered, with some polymeric material. The substitution of dioxane as the solvent in 
the reaction saw the appearance of m/z peaks at 527 and 529, corresponding to M+1 
peaks (118Sn and 120Sn respectively) for (90), but no anticipated peak at m/z 727 for the 
dimer product. The yield of this reaction was approximately 40 %. With the concurrent 
success of the Suzuki reaction at this time, and the low initial yield in this Stille 
reaction, the decision was made to conclude the Stille homo-coupling reactions.
Scheme 2.27
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2.6.2 Suzuki homo-couplings
The Suzuki dimerisations were conducted as one-pot reactions where the boronate ester 
was not isolated and purified before the addition of the second aryl halide. In the homo­
coupling of the phenyl substituted monomer (74), via its brominated derivative (85), 
different bases were used to evaluate their effect on the yield of the dimerised product 
(91) (Scheme 2.28, Table 2.8).
Scheme 2.28
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Initially CsF was used as both the first and second base in the homo-coupling (entry 
1), yielding 15 % of (91). This yield was improved by the change to KOAc as the first 
base and Ba(OH)2 as the second base. The use of these bases is similar to the strategy 
of the Suzuki cross-coupling (Section 2.4.2.3), where the first base was chosen as a 
relatively weak base to ensure the formation of only the boronate ester and to minimise
the formation of the unwanted homo-coupled product, before the second, stronger, base 
was chosen to accelerate the cross-coupling reaction
Entry Base1 Base2 Catalyst Ar^Ar1
1 CsF CsF PdCl2(dppf) 15 %
2 KOAc Ba(OH)2 PdCl2(dppf) 61 %
3 Ba(OH)2 Ba(OH)2 PdCl2(dppf) 64%
4 k 2c o 3 k 2c o 3 PdCl2(dppf) 50%
Table 2.8 Conditions used in the one-pot Suzuki dimérisation of the orth o - 
brominated phenyl substituted monomer (85), Scheme 2.28. THF was the solvent 
in all the reactions.
In entry 2 of Table 2.8, the use of KOAc and Ba(OH)2 resulted in a 61 % yield of (91); 
the percentages of the boronate ester and the dimer product before the addition of the 
second equivalent of the ortho-brominated phenyl substituted monomer (85) were not 
determined. This yield was further optimised to 64 % with the sole use of Ba(OH)2 in 
the coupling reaction. Despite this optimisation, the use of Ba(OH)2, as the sole base or 
as the second base, proved to be inconsistent and unpredictable. While in most 
reactions, the dimer product was isolated without difficulty, several reactions resulted in 
the recovery of only a small amount of the phenyl cross-coupled product, polymeric 
material, and an uncharacterised product that was more polar than the expected dimer 
(91). The use of K2C03, in entry 4, yielded only 50 % of (91), but proved to be more 
consistent in the synthesis of the dimer product.
The mass spectra of (91) showed a m/z at 727, corresponding to the M+1 of the dimer 
product, and m/z peaks at 685 and 643, which were assigned as the loss of one and both 
isopropyl groups, respectively. The l¥L NMR showed a notable upfield shifting in the 
proton signals of the isopropyl hydrogens; the methyl doublet of the isopropyl group 
was shifted from 6 1.38 in (85) to 6 1.11 in the dimer, and the methine quintet was 
shifted from 5 4.56 to 5 4.11 in (91). The naphthyl hydrogens (1, 1’, 3, 3’, 7, 7’) all 
show downfield shifts; the most pronounced of these are those of the 7 and 7’ 
hydrogens which are shifted from 6 7.65 in (85) to 6 7.96 in (91). These shifts are most 
likely due to the deshielding effects of the opposite naphthyl ring systems. The 3 and 3’ 
hydrogens appeared as a singlet rather than the expected doublet, with 1.6 Hz coupling, 
that the 1 and 1’ hydrogens displayed. The dimeric nature of (91) was further supported 
by NOESY experiments that detected nOes between the methyl groups of the isopropyl 
groups and both the 7 and 7’-H, and the phenyl substituents (Scheme 2.28). A nOe was
also detected between the isopropyl methine and the 7-H. These nOes would not be 
possible in the monomeric product (68), and are detected between the isopropyl of one 
naphthyl system and the phenyl substituent, and naphthyl aromatic hydrogens of the 
second naphthyl system, as illustrated by the dotted curves on (91) in Scheme 2.28.
The conditions of the synthesis of the phenyl dimer product (91) in entry 4 of Table 2.8, 
with K2CO3 as the base, PdCl2(dppf) as the catalyst, and THF as the solvent in the 
Suzuki homo-coupling, were used in the synthesis of the dimeric forms of the naphthyl, 
pyrimidyl and methyl cross-coupled products (Scheme 2.29). In a typical reaction, an 
ortho-brominated substituted monomer (Ar]-Br) was added to bis(pinacolato)diboron, 
K2CO3, and PdCl2(dppf) in THF, and heated at reflux, under nitrogen, for 24 hours, 
after which a second equivalent of the ori/to-brominated monomer, K2CO3 and 
PdCl2(dppf) were added and heated at reflux for a further 24 hours. After the initial 24 
hours, TLC analysis indicated the formation of both the boronate ester and the dimer 
product.
Scheme 2.29
R = phenyl (85) R = phenyl (92) R = phenyl (91)
naphthyl (86) naphthyl (93) naphthyl (96)
pyrimidine (88) pyrimidine (94) pyrimidine (97)
methyl (87) methyl (95) methyl (98)
The yields of the dimerised products, and other side products for the homo-coupling at 
the completion of the reaction, are presented in Table 2.9. Extending the reaction time 
after the addition of the second equivalent of R-substituted monomer for the phenyl, 
naphthyl and methyl products to 48 hours, had no effect on the yield of dimerised 
product; the yields of the boronate esters and monomeric products were not determined.
A longer reaction time was not attempted for the synthesis of (97). The homo-coupling 
of the ortho-brominated pyridine derivative (89) was not completed at this time.
R Yield (dimer) Yield (boronate) Yield (monomer)
phenyl (91) 50 % (92) 9 % (68) 38 %
naphthyl (96) 51 % (93) 18 % (72) 24 %
pyrimidine (97) 71 % (94) 6 % (83)18 %
methyl (98) 51 % (95) 14 % (79) 23 %
Table 2.9 Yields of the dimerised, boronate ester, and R-substituted monomeric 
naphthyl (debrominated) products after the Suzuki homo-coupling, Scheme 2.29.
It was uncertain why longer reaction times did not result in the formation of further 
dimer product if, at the end of 24 hours after the addition of the second equivalent of the 
ori/zo-brominated derivatives, there was still boronate ester that could participate in the 
coupling reaction. TLC analysis and mass spectra indicated that at the completion of 
the reaction, 24 hours after the addition of the second equivalent of all reagents except 
bis(pinacolato)diboron, there was no evidence of any ortho-brominated monomer. 
These reactions were carried out with two equivalents of the bis(pinacolato)diboron 
reagent (75). In a similar synthesis of a dimeric pyranonaphthoquinone, Brimble et al. 
used four equivalents of (75), and CsF as a base, and reported a 53 % yield of the dimer 
product, and a 19 % yield recovery of the boronate ester that could be recycled.116 
However, in this procedure a second equivalent of the brominated starting material was 
not added. These results seemed to suggest that the naphthyl bromide moiety (Ar!-Br) 
was more reactive than the naphthyl boronate ester [Ar!-B(OR)2], oxidatively entering 
the palladium catalytic cycle of Scheme 2.20 more readily than the boronate moiety. It 
is likely that the dimérisation reaction was not actually a true homo-coupling, but rather 
a hetero-coupling of A^-Br and Ar1-B(OR)2. As the boronate ester was formed in the 
first step of the reaction (Scheme 2.28), it presumably coupled with some of the 
brominated naphthyl that had entered the catalytic cycle as Ar!-Pd(II)(L)2-X, but not 
reacted with the base and bis(pinacolato)diboron (Scheme 2.17).
We hypothesise that the dimer synthesis could be conducted in a one-step reaction 
where only half an equivalent of (75) would be used, thus half of the brominated 
starting material would be transformed to the boronate ester, to react with the remaining 
half equivalent of brominated starting material. The reaction of (65) with 
bis(pinacolato)diboron to yield 95 % of (73) (Scheme 2.16) was extremely efficient, and
if a similar rate and yield of reaction could be expected for the ortho-brominated 
derivatives of Scheme 2.29, this may prove to be a more efficient route to the synthesis 
of the dimeric compounds, ensuring the total reaction of the boronate moieties. The 
choice of base may also need further consideration, as it may play a role in accelerating 
the rate of reaction. A faster rate of reaction could reduce the yields of the monomeric 
forms of the products found in the reactions, which are likely to come from some aryl­
palladium complex that does not complete the reductive elimination step of the catalytic 
cycle (Scheme 2.20) to form a coupled product.
The mass spectra of the methyl dimerised product (98) showed an M+1 peak at 603 and 
m/z peaks at 561 and 519, corresponding to the loss of one and both isopropyl groups, 
respectively. The naphthyl (96) and pyrimidyl dimer products (97) only showed M+1 
peaks at 827 and 731, respectively, and did not have peaks corresponding to fragments 
with the loss of one or both isopropyl groups. The !H NMRs showed similar patterns in 
the aromatic naphthyl hydrogen shifts (Table 2.10).
R 1-H
ortho-Br dimer
3-H
ortho-Br dimer
7-H
ortho-Br dimer
phenyl 8.17 8.22 7.43 7.43 7.65 7.96
naphthyl 7.70
$
7.74 7.43 7.40 7.47 8.04
methyl 8.26 8.34 7.46 7.48 7.54 7.84
pyrimidine 7.93 7.97 7.52 7.53 7.64 7.97
Table 2.10 NMR shifts (8 ppm) for the 1-H, 3-H and 7-H of the ortho-brominated derivatives and the 
corresponding dimeric derivatives. * denotes proton signals that did not resolve as doublets, and appeared as 
singlets.
The shifts of the 1 and 1 ’ hydrogens were consistently downfield, however small, in the 
dimerised products, compared to the ortho-brominated derivatives. The 3 and 3’ 
hydrogens were effectively the same. The 7 and 7’ hydrogens showed the greatest 
downfield shifting in the dimer compounds due to their position ortho to the biaryl axis, 
and the stronger deshielding effects of the opposite naphthyl ring system. The 1, 1’, 7 
and 7’ hydrogens appeared as one peak of 4H integration at 8 7.97 in the NMR of the 
pyrimidine dimer product (97), and were identified by HQSC showing correlation to 
two separate carbons of the C NMR.
The isopropyl hydrogens of the naphthyl, methyl and pyrimidine dimer products 
showed the same strong upfield shifting as previously described in the phenyl dimer 
product (91). The largest shifts were seen in the isopropyl methine hydrogens (Table
2.11), on average 5 0.46, while the average shift of the isopropyl methyl hydrogens was 
6 0.28. This effect is most likely due to the close proximity of the isopropyl methine to 
the methoxy in the 4 and 4’ position. The isopropyl methyl hydrogens may also be 
affected to a smaller degree, or it could be likely that their rotation brings them close 
enough to be electronically affected by the oxygen of the methoxy group.
R isopropyl methyl 
ortho-Br dimer
isopropyl methine 
ortho-Br dimer
phenyl 1.38 1.11 4.56 4.11
naphthyl 1.43 1.13 4.64 4.24
methyl 1.32 1.03 4.47 3.93
pyrimidine 1.39 1.12 4.58 4.15
Table 2.11 *H NMR shifts (8 ppm) for the isopropyl hydrogens of the ortho- 
brominated derivatives and the corresponding dimeric derivatives.
2.7 Deprotection reactions
The final reaction in the synthesis of the targeted compounds of Figure 2.2 was the
deprotection of the isopropoxy group, to yield the hydroxy groups ortho to the biaryl
axis. These hydroxy groups were a key feature of the inhibitor design of Section 2.1.1.
In a typical reaction, boron trifluoride diethyl etherate was added to a stirred solution of
the isopropoxy protected compound in DCM, at 0 °C under nitrogen (Scheme 2.30).
The reaction solution was normally stirred for two hours before the addition of
methanol to quench the reaction. Boron trifluoride was chosen preferentially over
boron trichloride to specifically cleave the isopropyl group, and not affect the methoxy
group, or the ethyl ester. However this precaution may have affected the yields of Table
2.12 that show the moderate yields for this reaction. A boron trichloride deprotection
by Bringmann et al. of a compound similar to the brominated naphthyl (65) used for the
cross-coupling reactions, but with a methyl substituent instead of the ethyl ester, was
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reacted for only 15 minutes and yielded 91 % of the deprotected product.
Synthesis
Scheme 2.30
R = phenyl (68)
naphthyl (72)
pyrimidine (83)
methyl (79)
{  \  nOe
OH OCH3n
C 02Et
R = phenyl (99)
naphthyl (100)
pyrimidine (101)
methyl (102)
R = phenyl (91)
naphthyl (96)
methyl (97)
pyrimidine (98)
R -  phenyl (103)
naphthyl (104)
methyl (105)
pyrimidine (106)
R monomer dimer
phenyl (99) 64 % (103)68 %
naphthyl (100)89 % (104)68 %
pyrimidine (101)56 % (105)65 %
methyl (102) 55% (106)71 %
Table 2.12 Yields of the deprotected monomer and dimer 
target compounds, Scheme 2.30.
The !H N M R s of the deprotected compounds typically saw the loss of the doublet of the 
isopropyl methyl groups that was usually about 8 1.44 in the monomer compounds, and 
5 1.10 in the dimer compounds. The quintet of the isopropyl methine hydrogens at 
about 5 4.59 in the monomer compounds and 8 4.17 in the dimer compounds was also 
absent in the deprotected compounds. In the deprotected phenyl substituted monomer 
(99), NOESY experiments detected an nOe between the naphthol at 8 9.49 and the 
methoxy at 8 4.45 (Scheme 2.30). In the deprotected dimerised phenyl product (103), a 
similar nOe was seen between the naphthol in one naphthyl system at 8 9.99 and the
methoxy in the same aromatic system at 5 4.14. Another nOe was seen between the 
naphthol and the 7, or 7’ hydrogen of the opposite naphthyl system at 5 7.59.
The loss of the isopropyl group, typically had a small downfield shifting affect on the 
methoxy groups of all of the deprotected compounds of Scheme 2.30, of the order of 5 
0.11. The naphthyl hydrogens of the monomeric series of products generally showed 
only very small changes in their chemical shifts, and varied in direction between the 
different R-substituents. The only notable large shift was in the deprotected methyl 
monomeric product (102), which saw a downfield shift in the 3-H from 8 7.31 in (79) to 
8 8.33 in (102). The assignment of 1-H and 3-H was confirmed by an HSQC 
experiment, and a NOESY experiment indicating an nOe between the 3-H and the 
methoxy substituent. The naphthyl hydrogens of the deprotected dimer series of 
compounds, (103) -  (106), showed consistent downfield shifts for the 1 and 1’ naphthyl 
hydrogens, and consistent upfield shifts for the 3, 3’, 7’, and 7’ hydrogens. These shifts 
were generally small, except for those of the 7 and 7’ hydrogens that shifted upfield, on 
average by 8 0.38.
2.8 Transformations of the ethyl ester
With the greater part of the synthesis of the monomeric and dimeric series of targeted 
compounds completed (Figure 2.2), preliminary studies were conducted to transform the 
ethyl ester sidechain of these compounds (Scheme 2.31). The lithium aluminum 
hydride reduction in THF transformed the ethyl ester to a primary alcohol functionality, 
yielding (107) in 91 % yield. This was comparable to the 93 % yield reported by 
Bringmann et al. for a similar reaction, in which the phenyl substituent of (107) is 
replaced by a bromine.53,62 The mass spectra of the methyl alcohol derivative (107) 
revealed an M+ 1 at 323, and an m/z at 281, which is likely to be the loss of the isopropyl 
group. The !H NMR also shows the loss of the indicative triplet and quartet at 8 1.34 
and 8 4.34 of the ethyl ester (68), and the appearance of a singlet of 2H integration at 8 
4.67, corresponding to the methylene of the primary alcohol (107). Small upfield shifts 
were seen in the naphthyl hydrogens due to the shielding effects of the primary alcohol, 
or rather due to the loss of the deshielding effects of the ethyl ester. The most notable 
of these were in the adjacent 1-H and 3-H that shifted from 8 8.22 to 8 7.34 and 8 7.48 
to 8 6.89, respectively, compared with (68). A NOESY experiment also detected nOes
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between the methylene hydrogens of the primary alcohol at 5 4.67, and the 1-H and 3-H 
hydrogens, as seen by the dotted line in (107) of Scheme 2.31.
Scheme 2.31
(68) (107) (108)
b f 3, d c m , 0 °c
(53%)
L-selectride, DCM, 0 °C 
(96%)
; \  nOe
To achieve the methyl group at the 2 position that is analogous to the substituent in the 
michellamine structure (26), the corresponding methyl bromide (108) was first needed. 
Attempts to follow the methodology of Bringmann et al. and use 1,2- 
dibromotetrachloroethane and triphenylphosphine in dichloromethane gave no product
r i  /T'j
(108) and only starting material was recovered. ’ An alternate synthesis with carbon
i i  n
tetrabromide and triphenylphosphine in ether afforded the bromide (108) in 94 % 
yield, comparable to the 93 % yield achieved by Bringmann et al. using 1,2- 
dibromotetrachloroethane. The mass spectra of (108) revealed m/z peaks at 385 and 387 
corresponding to M+1 peaks for the bromine isotopes of 79 and 81 respectively. Mass 
to charge peaks of 343 and 345 were identified as the loss of the isopropyl group and a 
m/z at 307 corresponded to the further loss of the bromine. The methylene hydrogens at 
the 2 position were shielded by the bromine and shifted upfield to 5 4.50 from 8 4.67 in 
the NMR of (107). 13C NMR and DEPT experiments also identified 8 34.64 as a 
methylene carbon, which HSQC experiment correlated to the 8 4.50 signal.
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The methodology of Bringmann et al. was used in the final reaction to realise the 2- 
methyl group. ’ Two successive aliquots of a solution of L-selectride in THF were 
added to a solution of the bromide (108) in DCM, followed by the addition of ethanol to 
quench the reaction. The resulting product (109) was isolated in 96 % yield. The mass 
spectra of (109) identified an M+1 at 307, and a m/z at 265, indicative of the loss of the 
isopropyl group. ]H NMR showed a change in the integration and shift of the two 
methylene hydrogens at 5 4.50 in (108) to a signal of three hydrogen integration at 5 
2.36 that was identified as the aryl methyl. All of the naphthyl hydrogens showed 
upfield shifts, most notably in the adjacent 1-H and 3-H that shifted from 8 7.39 to 5 
7.19 and 8 6.86 to 8 6.70, respectively compared to the methylene bromide derivative 
(108).
The primary alcohol derivative (107) was treated with boron trifluoride to remove the 
protection of the isopropyl group and yield the deprotected methyl alcohol derivative in 
53 % yield (110). The mass spectra of (110) identified an M+1 at 281. The !H NMR 
lacked the characteristic doublet of the isopropyl methyl hydrogens at 8 1.44 in the 
protected species (107), as well as the quintet of the isopropyl methine hydrogen at 8 
4.58. The naphthyl hydrogens showed varying shift changes; 1-H and 7-H were shifted 
slightly downfield, and 3-H and 6-H were shifted slightly upfield. Like the deprotected 
compounds of Scheme 2.30, the methoxy hydrogens of (110) saw a downfield shift 
from 8 3.98 to 8 4.08 compared to (107). A NOESY experiment also detected an nOe 
between the naphthol at 8 9.48 and the methoxy at 8 4.08.
The boron trifluoride deprotection of (109), and the further investigation of the 
transformations in the ethyl esters of all the R-substituted products in both the monomer 
and dimer series of targeted compounds (Figure 2.2) were not completed by the 
conclusion of this research. Their completed synthesis will play an important role in 
increasing the structural diversity of the targeted compounds, and providing more 
variations and derivatives for biological testing. The results from these compounds will 
provide further information to help form the pharmacophore for antiviral and 
antimalarial activity, and additional aid in future inhibitor design.
2.9 Antiviral and antimalarial testing
The deprotected compounds of Scheme 2.30 and Table 2.12 were screened for antiviral 
and antimalarial activity. The results of these tests were not yet available at the time of 
printing.
Antiviral testing is currently being carried out through AMRAD Operations118, using a 
standard reverse transcriptase assay (HTLV-IIIB infected H9 cell line) involving 
incorporation of labelled dTTP into a primer and then measuring incorporated 
radioactivity. Nevirapine is used as a standard in this assay.
Antimalarial testing is currently being carried out through Professor Yodhathai 
Thebtaranonth, using a W orld Health Organisation certified protocol, detailed in .119
2.10 Future synthetic targets
The completion of the synthesis of the dimeric and monomeric series of designed 
inhibitors, illustrated in Figure 2.12, remains the leading objective of this research. The 
establishment of the methodology for the Suzuki cross-coupling and homo-coupling 
reactions in this research should facilitate the completion of this initial phase of the 
inhibitor synthesis presently. Analogues with transformations of the ethyl ester 
sidechain, illustrated as the Y substituent in Figure 2.7, were also intended for synthesis 
and these should remain important synthetic targets for inhibitor design. The 
preliminary trial reactions illustrated in Scheme 2.31 (Section 2.8) have established that 
the methyl alcohol and methyl substituents can readily be synthesised from the ethyl 
ester.
X = phenyl Y = COOEt
naphthyl COOH
methyl CH2OH
pyrimidine CH3
pyridine
Figure 2.7 Dimeric and monomeric series of inhibitors for forthcoming synthesis.
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The carboxylic acid substituent could be transformed using an acid or base-catalysed 
ester hydrolysis reaction. These transformations, in each of the X-substituted inhibitors, 
for both the dimeric and monomeric series, will introduce significant and necessary 
structure-activity relationship (SAR) data once synthesised and tested for antiviral and 
antimalarial activity. In particular, inhibitors in which the Y-substituent is a methyl 
group should provide valuable SAR data, as the michellamine alkaloids, from which 
most of the inhibitor design was derived, have a methyl substituent in this position 
(Figure 2.1).
The directions for future inhibitor design will depend very much on the results of the 
antiviral and antimalarial testing. The scope for possible analogues, with different X- 
and Y-substituents is endless, and the selection of analogues for synthesis should be 
guided by rational drug design principles, based on the SAR data obtained from current 
biological testing. Another consideration that should influence future inhibitor design is 
the incorporation of features from other naturally derived antiviral agents. A hydroxy 
group, a prominent substituent of gossypol, the tetrahydroisoquinoline unit of the 
michellamines (26) (Figure 2.1), and many of the naturally derived antiviral agents of 
Figure 1.7 could also replace this methoxy group to add diversity to the designed 
inhibitors for SAR data.
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Conformational Studies of Reverse Transcriptase
♦ ♦
3.1 Reverse transcriptase
The discovery of reverse transcriptase (RT) in 1970120’121 set a new paradigm for the
flow of genetic information from RNA to DNA, and established a genetic and
biochemical basis for the identification of retroviruses. Reverse transcription flagrantly
violates the central dogma of molecular biology: that the flow of genetic information
was unidirectional, from DNA to RNA to protein.122 Reverse transcription by HIV-1 
RT converts single-stranded genomic RNA (ssRNA) into double stranded DNA 
(dsDNA) for integration into the host chromosome. The pivotal and unique role RT 
plays in the life cycle of the virus has made it a target for anti-HIV drug therapy.26,27 
Reverse transcriptase has also had a tremendous impact as a biotechnological tool for 
the synthesis and cloning of DNA from messenger RNA.123 *
3.1.1 Structure of HIV-1 reverse transcriptase
RT is a multifunctional enzyme, whose structure, function and mechanism has been 
extensively studied and reviewed.22,122,124'128 This enzyme possesses both RNA- 
dependent and DNA-dependent DNA polymerase activities, as well as a ribonucléase 
hybrid (RNase H) activity that specifically degrades the RNA strand of RNA/DNA 
hybrids. RT also has an RNA/RNA duplex-dependent ribonucléase activity termed 
RNase H*.129
In mature HIV-1 viral particles, RT exists as a highly asymmetric heterodimer 
consisting of 66 and 51 kDa subunits. The amino terminal of the two subunits is
identical. The p51 subunit is derived by proteolytic processing of the p66 subunit 
between Phe440 and Tyr441 by HIV-1 protease and lacks the RNase H domain.
The catalytically active p66 subunit is folded to form an ‘open right-hand’ 
configuration, creating a large DNA-binding cleft in the polymerase site that exposes 
the catalytic residues.130 The anatomical resemblance led to subdomains termed 
‘fingers’, ‘thumb’, and ‘palm’. A ‘connection’ subdomain lies between the palm and 
the RNase H subdomain located at the carboxy-terminal end of p66 (Figure 3.1, 
Appendix 7.1 Subdomains of reverse transcriptase). The p66 subunit also contains the 
binding pocket for non-nucleoside reverse transcriptase inhibitors.
Figure 3.1 Structure of HIV-1 reverse transcriptase heterodimer. The subdomains of the p66 
(ribbon) and p51 (lines) with their disparate folding and packing; fingers (blue), palm (green), 
thumb (yellow), connection (red), and RNase H (purple).
Although the amino-terminal sequence of both subunits is identical, p51 does not 
directly contribute to the various catalytic activities. The subdomains of p51 are more 
tightly packed and are folded very differently to those of the p66. The thumb is rotated 
away from the fingers, which are closed over the palm in a manner that buries the 
catalytic residues, and the connection is folded onto the palm between the fingers and 
the thumb subdomains. The p51 subunit is catalytically inactive, but interacts with the
RNase H domain in the heterodimer, and may have a role in altering the processivity of 
the p66 subunit, facilitating strand displacement, DNA synthesis, tRNA binding, as well 
as providing scaffolding support to the p66 subunit.131
The secondary structural classification of RT has been determined by two different 
groups: the Center for Advanced Biotechnology and Medicine (CABM) at Rutgers 
University and the Oxford Centre for Molecular Sciences (OCMS) at Oxford 
University. ’ The nomenclature for secondary structures used throughout will be 
that of the CABM research group (see Appendix 7.2 Secondary structure of reverse 
transcriptase).
3.1.2 Reverse transcription
The reverse transcription of viral RNA to pro viral DNA (Figure 3.2) is made possible 
by an elegant and complex mechanism that has been extensively studied and examined 
to better understand its workings, and ultimately prevent its completion.5,122,127,128 
Reverse transcription is a discontinuous process occurring in the viral nucleocapsid in 
the presence of an excess of enzyme with respect to template. Between 30 and 50 RTs 
are present in each particle, for the two RNA genomes. This excess of enzyme is 
attributed to the necessity to overcome the low processivity of the enzyme; excess
enzyme ensures recycling of RT on nucleic templates, enhancing the probability of
22obtaining completed reverse transcripts.
Step 1 - Initiation of reverse transcription - Binding of the tRNA primer to the 
primer binding site
All retroviruses utilise host-encoded transfer RNA (tRNA) species as primers for 
reverse transcription. HIV-1 uses tRNALys3, which anneals to the viral (+) strand RNA 
at a region, approximately 200 nucleotides downstream from the 5’-end of the RNA, 
known as the primer binding site (PBS). The host tRNA is partially unfolded from its 
native structure so that the 18 nucleotides at the 3’ -terminal end of human tRNALys3 that 
are complementary to the PBS can base pair to form a binary tRNA/RNA complex. 
This complex is recognised by RT, which then initiates reverse transcription by 
extending the 3’-end of the annealed primer.
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Figure 3.2 The process of reverse transcription. Red lines represent RNA strands, blue lines 
represent (-) strand DNA, and green lines represent (+) strand DNA. The curved orange line 
represents the tRNA primer. Arrows represent the elongating DNA strand. Uppercase letters 
indicate (+) strand regions, and lowercase letters represent (-) strand regions. Abbreviations are 
explained in the text. Adapted from Gotte et a l.127
Synthesis of (-) strand DNA is initiated at the 3’-hydroxyl end of the tRNALys3 with the 
genomic RNA serving as a template and proceeds toward the 5’-end of the RNA 
template. Concurrent with DNA synthesis, the RNA strand of the newly formed 
RNA/DNA hybrid is digested by the RNase H domain of RT. RNase H is able to 
discriminate between DNA/RNA and RNA/RNA substrates, and initially degrades the 
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RNA strand upstream, towards the 5’ end, of the PBS. The PBS sequence which 
formed an RNA/RNA homoduplex with tRNALys3 to initiate reverse transcription 
remains resistant to RNase H degradation at this stage.
Step 2 - First strand transfer
When RT reaches the 5’-end of the viral RNA template, the DNA transcribed thus far is 
referred to as minus-strand strong-stop DNA, (-)ssDNA. In order to complete the 
synthesis of the (-) strand DNA, the (-)ssDNA must be transferred to the 3’-end of the 
genomic RNA. This strand transfer is facilitated by the terminal repeat (r) region of the 
nascent (-)ssDNA, that is complementary to the R region of the 3’-end of the RNA 
template. RNase H degradation of the 5’-end of the RNA releases the (-)ssDNA, 
allowing its translocation to the R region of the 3’-end of the genomic RNA. Since viral 
particles contain two homologous copies of genomic RNA, the first strand transfer may 
occur either as an intra- or intermolecular event.
Step 3 - Synthesis of (+)-strand strong-stop DNA - Initiation by purine-rich 
primers
As synthesis of (-) strand DNA continues, specific RNase H degradation of the RNA 
template creates purine-rich fragments that function as RNA primers for (+) strand 
DNA synthesis. These regions of the RNA template that are highly resistant to RNase 
H degradation are located close to the genomic 3’-end and in the centre of the viral 
RNA, and are referred to as the polypurine tract (3’PPT) and the central PPT (cPPT) 
respectively. Before (-) strand DNA synthesis is completed, the synthesis of two (+) 
strand DNA segments will have been initiated by these primers, with the nascent (-) 
strand DNA as template. The two distinct (+) strand DNA segments initiated by the 
cPPT and the 3’PPT are called downstream (D+) and upstream (U+) segments 
respectively. As the U+ DNA synthesis encounters the tRNA sequence of the tRNALys3 
primer still attached to the 5’-end of the (-) strand DNA, the DNA transcribed is referred 
to as plus-strand strong-stop DNA, (+)ssDNA. This reverse transcription of the 3’-end 
of the tRNA regenerates the PBS sequence at the 3’-terminus of the (+)ssDNA.
(+)ssDNA synthesis continues until the first modified tRNA base, a methylated 
adenosine, is encountered 19 residues upstream from the 3’-end of the tRNALys3. 
Specific RNase H cuts then allow the removal of the tRNALys3 and PPT primers from 
the (+) and (-) strand DNA respectively.
Step 4 - Second strand transfer
The second strand transfer is necessary for (+)ssDNA and U+ DNA syntheses to 
continue, and is facilitated by the 18 nucleotide PBS. At this stage of reverse 
transcription, there are two copies of the PBS; the first is the (-) strand DNA copy that is 
formed when (-) strand DNA synthesis advances into the PBS region of the genomic 
RNA, and the second is the (+) strand DNA copy that is regenerated by using tRNA as a 
template during the synthesis of (+)ssDNA (Step 3). The PBS facilitates the second 
strand transfer in what is presumed to be an intramolecular event involving the 
formation of a circular intermediate. The signal for pausing of (-) strand DNA synthesis 
is the first RNase H cut at the tRNA-DNA junction that was formed during initiation of 
(-) strand DNA synthesis.
Step 5 -  Strand displacement and continuation of DNA synthesis
To ensure that the entire viral genome is transcribed, RT has a strand displacement 
activity that disrupts DNA/DNA duplexes. This allows continuation of the syntheses of 
(-) strand DNA and D+ DNA at the U3-R-U5 duplex. The U+ DNA segment serves as 
a template to complete the (-) strand DNA, while the u3 segment serves as a template 
for the completion of the synthesis of the D+ segment.
Step 6 - Completion of transcription and termination
Synthesis of the U+ segment continues until RT reaches the central terminal sequence 
(CTS), located at the centre of the genome. RT displaces part of the 5’-end of the D+ 
DNA segment, allowing U+ DNA synthesis to terminate 100 nucleotides downstream 
of the 5’-end of the D+ segment. The resulting double stranded DNA carries a (+) 
strand overlap at its centre. The legacy of the two strand transfer reactions is evident in 
the pro virus’ acquisition of duplicated U3-R-U5 sequences at both ends, known as long 
terminal repeats (LTR). The LTRs are critical for the integration of the viral DNA into 
the host genome. The final dsDNA product of reverse transcription, called proviral 
DNA, is longer at both ends than the original template viral RNA, and ready to be 
integrated into the host cell genome.
The unique replicative mechanism of reverse transcription has made reverse 
transcriptases one of the most targeted viral processes in the life cycle of HIV for drug 
inhibition. Its characteristic structure and multiple functions provide numerous sites and 
steps in the catalytic cycle for inhibition. While nucleoside analogues were the first
drugs developed to arrest the polymerisation reaction of DNA synthesis, it was the 
advent and evolution of non-nucleoside inhibitors that have lead efforts to find specific 
and efficacious drugs against RT.24 Virtually all of these inhibitors belong to the class 
of non-nucleoside reverse transcriptase inhibitors (NNRTIs) which bind at a site distinct 
from the polymerase active site of the enzyme, and exert their inhibitory influence on 
the polymerisation reaction by allosteric means.26'27
3.1.3 The non-nucleoside inhibitor binding pocket (NNIBP) and inhibition of RT
The inherent flexibility of HIV-1 RT is of manifest significance in the execution of its 
multiple biological functions. This flexibility accommodates the binding of the 
template-primer complex, inducing numerous conformational changes throughout the 
heterodimer. These changes are believed to provide a means of allosteric 
communication between spatially distant regions such as the polymerase and RNase H 
active sites, during the potentially coupled processes of dNTP incorporation and RNA 
template degradation.134 This flexibility is no more evidently demonstrated than in the 
gross displacement of the thumb subdomain from a position nearly touching the fingers 
subdomain to an upright configuration, upon binding of the nucleic acid substrate 
(Figure 3.3).132 135 Other notable conformational changes include displacements in 
sections of the fingers domain which ‘flex’ towards the palm, playing a possible role in 
allowing the release of pyrophosphate after a polymerisation reaction, translocation, and 
binding of the next dNTP during DNA elongation.136
Figure 3.3 Ribbon illustrations of the reverse transcriptase enzyme showing movement of the 
thumb subdomain, approximately 30 A, upon the binding of nucleic substrates or non-nucleoside 
inhibitors. The thumb in the unliganded enzyme (ldlo-green) comes almost into contact with the 
fingers in a ‘closed’ conformation. (Left) The DNA bound structures (lrtd-dark blue and 2hmi- 
light blue) show an extension of the thumb in an ‘open’ conformation. (Right) Inhibitor-bound 
structures (lhni-orange and lvru-red) have the thumb subdomain further extended in the ‘open’ 
conformation. Diagram made using superimposition techniques detailed in Section 3.2.
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Ironically, the very flexibility essential to the successful performance of the enzyme is 
also fundamental in its inhibition by non-nucleoside inhibitors. NNRTIs are known to 
bind in a hydrophobic pocket in the palm subdomain, some 10 A from the polymerase 
active site. In the absence of an inhibitor, the pockets exists as a mere surface 
depression, with the sidechains of two important tyrosine residues pointing into the 
hydrophobic core. The bulk of the inhibitor is accommodated for by a differential 
twisting of the pl2-(313-(314 sheet that results in an expansion of the pocket. This 
results in a shift of the p6-(39-(310 sheet that contains the catalytic residues of the 
polymerase active site to a conformation similar to that observed in the inactive p51 
subunit. While this conformational change may be sufficient to explain how the 
chemical step of phosphodiester bond formation is blocked, it does not account for the 
entirety of NNRTI inhibition. NNRTIs binding exerts varying effects on several RT 
features including, but not limited to, enzyme processivity, binding of different 
template-primers and sequences, recognition of different nucleic acid substrates, and 
cleavage specificity of RNase H activity.79
Several hypotheses have been proposed to give a rational interpretation of the 
mechanism, or mechanisms, of non-nucleoside inhibition. Of the three dominant 
inhibition mechanisms, the ‘active site distortion model’ proposes that conformational 
changes in the NNIBP distort the precise geometry, mobility, electrochemical 
environment, and solvent accessibility of the polymerase active site and its coordination 
geometry with divalent metal ion complexes.79,134 This distortion cripples the enzyme’s 
ability to interact with constantly changing base pairs and template primer substrates, 
distinguish different dNTP substrates, or permit translocation of the template-primer 
following nucleotide incorporation. The ‘primer grip model’ postulates that the creation 
of the NNIBP significantly displaces the primer grip, which is composed of the (312-f313 
hairpin. The displacement of the primer grip may effect the position and mobility of the 
primer terminus, or alter the stereochemical relationship between the primer terminus, a 
bound dNTP, and associated divalent metal cations at the polymerase active site. The 
final ‘molecular arthritis model’ speculates that NNRTI binding leads to a restriction in 
the mobility of the p66 thumb subdomain which, by virtue of its extensive interactions
130,137
with the template-primer, may interfere with the processivity of polymerisation. 
These models are not mutually exclusive; no model on its own is sufficient to explain
all the kinetic and biochemical evidence of non-nucleoside inhibition. Rather it is 
believed that several mechanisms are involved in the allosteric inhibition process.79
The study of these mechanisms of inhibition has, for the most part, been qualitative and 
based on general observations. Those few studies that have attempted to quantify the 
measure of inhibition have not always been impartial, considering only structures solved 
in their own laboratories, or wholly rational in their approach, considering only a few 
experimental structures at a time.133,138,139 Our research endeavored to resolve the lack 
of objective, quantitative analyses of the conformational changes of several structurally 
significant active sites and motifs of RT, and their role in the mechanisms of inhibition 
upon binding of NNRTIs. The conformational changes in the residues of the 
polymerase and RNase H active sites, along with the primer and template grips and the 
NNTBP were scrutinized to ascertain their role in inhibition.
The wealth of interest in RT has generated a large number of x-ray crystallographic 
structures that allowed both inhibitor and substrate induced conformational changes in 
RT to be investigated. RT structures were available in the unliganded form, complexed 
with a dsDNA template-primer and a Fab monoclonal antibody, a dsDNA template­
primer and a dNTP, and a wealth of structurally diverse inhibitors (Appendix 7.3 X-ray 
crystallographic structures of reverse transcriptase). These inhibitors (Figure 3.4) 
included the clinically used nevirapine (8), and tivirapine (11) and MKC-442 (12) in 
clinical trials. This study considers a total of 23 crystal structures from both of the 
major research groups operating in the field.
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Figure 3.4 Structures of non-nucleoside inhibitors from x-ray crystallographic RT-inhibitor 
complexes (see Appendix 7.3 X-ray crystallographic structures of reverse transcriptase).
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3.2 Superimposition
The dynamic nature and design of proteins have long been a source of unanswered 
questions and challenges for all fields of science, in particular the mechanics of protein 
function and how these processes can be disrupted. The structure comparison of 
different conformations of a protein can provide insight into these fields of research, and 
help in the optimisation of current drugs as well as the de novo design of structurally 
unique inhibitors.
The traditional method for the analysis of two related structures is to perform an optimal 
rigid body superimposition, giving equal weighting to all regions of the structure. The 
similarity of the two structures is customarily expressed as a root-mean-square deviation 
(RMSD) of the atomic coordinates used in the superimposition.140 The superimposition 
of the entire backbone, or all Ca atoms, of a protein runs the inherent and probable risk 
that small differences between the two proteins will be averaged out and missed.141 
This effect would be particularly pronounced in flexible protein systems such as RT. 
The use of subsets other than the backbone, or all the Ca atoms, has been contentious, 
with a number of schools of thought regarding the best regions of a biomolecule to 
choose for superimposition. One method is to select atoms directly surrounding the 
region to be examined, either by choosing a sequence of residues ’ or by creating a 
subset of residues within a given radius of the region to be examined.31,142 Other 
methods involve the use of polypeptide sections at either end of the region to be 
examined,14j or a ‘core’ region of the protein.1'33,135,138 The rationale behind the 
selection of atoms to be used for superimposition has not always been made clear, and is 
not consistent amongst different authors; in one example, two different superimposition 
techniques were used within the same research paper to accentuate different points.144 
Results from these studies are vulnerable to error and misinterpretation as a result of 
user-bias introduced in selecting those atoms to form the superimposition subset. 
Different results can be obtained depending on the atoms selected for the 
superimposition (see Section 3.2.3).
3.2.1 Difference distance matrices
In order to investigate conformational changes in flexible protein systems, we needed to 
define a superimposition strategy that provided a definitive, unambiguous and objective
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procedure for the superimposition of large molecules. To achieve this, we investigated 
the use of difference distance matrices (DDMs). DDMs allow the rapid identification of 
regions of conformational similarity and dissimilarity, and from these, suitable rigid 
regions can be selected for superimposition studies.145,146 They are generated by the 
comparison of the distance matrices (DMs) of two different molecules.
DMs are constructed by calculating the distances (r^) between the /th and / h atoms, for 
every combination of two atoms in a single molecule or protein. These distances are 
represented in an n x n square matrix (n equal to the number of atoms in the molecule), 
with the atoms i and j  along the axes. In this internally referenced matrix, pairs of 
atoms that are close to each other in three-dimensional space have small values of ry, 
while those that are distant have larger ry values. Due to the sizeable number of atoms 
in most proteins, only the Ca atoms of each residue of the protein are considered in the 
DM calculation.147
The DDM, comparing two protein conformations A and B, is constructed by first 
calculating separate DMs containing the distances ryA and ryB from conformations A and 
B respectively. One DM is subtracted from the other, by calculating the difference (Ary) 
between elements ryA and r,yB that have corresponding values of i andy.145
Ary = |ryA - ryB| for all combinations of i and j
The DDM is the representation of this data in an n x n square matrix with i and j  along 
the axes.
If two protein conformations A and B are identical, the corresponding distances ryA and 
ryB will be identical and the difference Ary equal to zero. However, if a residue x is in a 
different position in one structure, it will have different distances to every other residue 
j  in the protein, with all Ary values being nonzero where i = x. Consequently, regions of 
conformational dissimilarity between the two structures will appear as clusters of 
nonzero difference values in the DDM, with the value of Ary indicating the magnitude
147
of conformational change.
DDMs have previously been used for the direct analyses of movement or in the creation 
of subsets for subsequent studies in biological systems such as Human Cardiac 
Troponin C,148 human hemoglobin,149 and calbindin D9k.150 Jäger et a l  have previously 
used DDMs to a limited degree to assess which portions of the RT enzyme behave as
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rigid bodies in different crystal lattice environments.143 They concluded that the RT 
enzyme has a specific flexibility that allows rotation of the polymerase active site 
relative to the rest of the molecule, speculating that this swivel motion may be involved 
in the translocation of the growing duplex after incorporation of a new nucleotide.
In our studies, DDMs were used to identify polypeptide regions of RT which were 
conformationally similar in unliganded, inhibitor-bound, and substrate-bound x-ray 
crystallographic structure, in an unbiased and impartial manner. These regions were 
superimposed to allow the movement of the localised variable regions, which were not 
used in the superimposition calculation, to be readily identified with confidence, and 
accurately quantified. Thus, comparison studies of RT could be undertaken with the 
unique demands of proteins, when studying their movement and flexibility, taken into 
account.
3.2.2 Derivation of the superimposition subset
The ProFlex program was developed in our research group to calculate DMs and DDMs 
of different proteins and protein conformations.151 This was used to identify a subset of 
Ca atoms within RT that did not move upon binding of an inhibitor, a substrate, or 
compared to another unliganded x-ray crystallographic structure.147,151 Initially the 
superimposition subset was derived from the DDMs of 19 liganded and unliganded 
crystal structures compared against ldlo (all crystal structures from Appendix 7.3, 
excluding lhmv and Irt4-lrt7). The ldlo crystal structure was chosen as the unliganded 
RT crystal structure over lhmv and lrtj due to its higher resolution and data 
completeness. The structure of lrtj was ruled out because of known irregularities in the 
crystal collection method;79 its crystal structure was prepared by soaking out the non­
nucleoside inhibitor HEPT from a HEPT/RT complex.29 The resulting crystal structure 
was not significantly different from the inhibitor-bound structure, as if the enzyme had 
not been given sufficient allowance to return to a native unliganded conformation.
As the crystal structures had varying, missing or undefined polypeptide regions, the 20 
crystal structures, including ldlo, were aligned and only those amino acid residues 
present in all 20 structures were translated to DMs. This ensured that each crystal 
structure contributed equally to the calculations. Only the Ca coordinates were used in 
these calculations, as the inclusion of all the atom coordinates would have been 
logistically infeasible. From these DMs, 19 DDMs were calculated comparing all
m
crystal structures to that of ldlo. In each DDM, any residue with a calculated difference 
distance between its two conformations of less than 2.0 Â was defined as being 
conformationally invariable. 2.0 Â was chosen as smaller or larger values yielded too 
few and too many residues, respectively, for optimal superimposition and RMSD 
values.131 The final superimposition subset, listed in Table 3.1, was restricted to only 
those conformationally invariable residues that were common to all 19 crystal 
structures, ensuring that anomalies in any one structure were not included.
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subunit residues
p66 4-6, 95-107, 162-163, 180-181, 188-200, 202-205, 226, 
234-235, 237-239, 317, 319, 323, 339-345, 349-353, 365­
366, 368-402, 405-419, 428-436, 439, 493, 530
p51 6-7, 18-45, 54-64, 71-84, 97-111, 113-117, 121,123-138, 
140-174, 176-184, 186-192, 197-198, 201-202, 208, 252, 
254-264, 267, 274, 277, 280-282, 284, 296, 298-300, 
303-307, 320, 322, 329, 331, 333-355, 364-393, 397-417
total : 376 residues - 1528 atoms (backbone atoms of 376 residues)
Table 3.1 List of the residues of the DDM derived superimposition subset.
The DDMs of lhmv and Irt4-lrt7 compared to ldlo were calculated in the same manner 
at a later stage, after the public release of the coordinates for Irt4-lrt7. The 
superimposition subsets derived from these DDMs were found to be compatible with 
the original subset, further validating the invariability of the residues of the subset, and 
were used in the superimposition studies. To maintain the integrity of the 
superimposition subset and procedure, residues that were of interest to be studied for 
their role in the inhibition of RT were not removed from the superimposition subset. 
The final subset (Table 3.1) was then used as the basis for all superimpositions onto 
ldlo. All superimpositions were performed in the Insigh til® program,152 as were 
RMSD and displacement value measurements. The displacement data was graphed 
using Excel®153 (for further details see Chapter 6 Experimental).
The superimposition subset consisted predominantly of residues in the palm and 
connection subdomains of the p66 subunit, and the bulk of the p51 subunit, as 
illustrated in Figure 3.5. The subset contained a total of 376 residues; 41% of the total 
aligned residues (residues that were resolved in all the crystal structures) or 38% of all 
residues of the complete enzyme. Only 28% of the residues of the p66 were considered 
to remain static upon inhibitor or substrate binding. The fingers, thumb, and part of the
RNase H subdomains 
demonstrated conformational 
changes greater than 2 A. About 
45% of the residues of the p51 
subunit showed no conformational 
change when compared against 
the unliganded structure, 
supporting observations that the 
p51 acts as a scaffold for the 
catalytically active p66 subunit.
Although only the Ca atoms were 
used in the DDM calculations, the 
entire backbone of those residues 
deemed static was included in the superimposition subset. Considering the limited 
torsions and conformations possible of the backbone between two static Ca atoms, the 
inclusion of the backbone was deemed warranted and allowed for a justifiable increase 
in the number of atoms in the superimposition subset. This was verified by a 
comparison of the superimposition of the 376 Ca atoms versus the 1528 atoms of the 
backbone of those same residues, and by the RMSD values for the superimposition of 
all applicable structures onto the unliganded structure Idlo (Table 3.2). A deviation in 
the RMSD values of less than 0.05 was noted for the two DDM derived methods, 
unquestionably attributable to the marked difference of the size of the datasets.
Figure 3.5 Ribbon diagram of the unliganded HIV-1 
RT (ldlo) illustrating the distribution of the residues of 
the superimposition subset (red). The palm and 
connection subdomains of the p66, and most of the p51 
subunit showed little conformational variation upon 
substrate or inhibitor binding.
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PDB file RMSD (À) Research Group
lhmv 0.878 Harvard I
lrtd 0.733 Harvard II
2hmi 0.997 CABM
lbqm 1.770 CABM
lbqn 1.809 CABM
lhni 1.807 CABM
lhnv 1.823 CABM
lklm 0.967 OCMS
lrev 1.204 OCMS
lrtl 1.035 OCMS
lrt2 0.975 OCMS
lrt3 1.173 OCMS
lrt4 1.081 OCMS
lrt5 1.082 OCMS
lrt6 1.052 OCMS
lrt7 1.073 OCMS
lrth 1.142 OCMS
lrti 1.033 OCMS
ltvr 1.829 CABM
luwb 1.855 CABM
lvrt 1.304 OCMS
lvru 1.385 OCMS
ldlo CABM
Table 3.2 The RMSD of RT crystal structures 
after superimposition onto unliganded RT (ldlo) 
using the DDM derived superimposition subset 
(1528 atoms). The different research groups, and 
their associates that resolved the crystal structures 
have also been noted; CABM (Center for 
Advanced Biotechnology and Medicine, Rutgers 
University, New Jersey), OCMS (Oxford Centre 
for Molecular Sciences, Oxford), Harvard I 
(Harrison research group, Department of 
Molecular and Cellular Biology, Harvard 
University, Cambridge), Harvard II (Verdine 
research group, Department of Chemistry and 
Chemical Biology, Harvard University, 
Cambridge).
All root mean square deviation 
(RMSD) values for the 
superimposition in Table 3.2 were 
less than 2 Â, with those of the 
unliganded (lhmv) and substrate- 
bound (2hmi and lrtd) structures 
being less than 1 Â. The RMSD 
values also showed a preliminary 
trend related to the source of each 
crystal structure. Those crystal 
structures reported by the CABM 
(Center for Advanced Biotechnology 
and Medicine) research group had 
consistently higher RMSD values 
than structures reported by the 
OCMS (Oxford Centre for Molecular 
Sciences) group for the 
superimposition onto the unliganded 
structure, despite the fact that ldlo 
was reported by the CABM group. 
The difference in the inhibitor-bound 
structures between the two research
o .
groups was on average 0.7 A. This 
disparity between the groups of 
crystal structures was also evident in 
later aspects of the superimposition 
studies.
The resolution of the crystal structures used in our studies ranged between 2.2 A and 3.8 
A, with an average of 2.8 A. Although a difference distance of 2.0 A was defined as 
being conformationally invariable, a value less than the lowest resolution of the studied 
structures, this was justified by the large number of crystal structures used and the 
consistency of results obtained in comparing the structures.
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3.2.3 Comparison of superimposition techniques
The objectivity and validity of the DDM  based superimposition was demonstrated by 
directly comparing the outcomes of superimposition using different reported techniques. 
In the first example, an unliganded (ld lo ) and an inhibitor-bound (lvru) structure were 
superimposed onto a DNA-bound RT conformation (2hmi). The displacement of 
corresponding Ca atoms, in the region of the polymerase active site (residues 177-192), 
between the 2hmi structure, and ld lo  and lvru  were measured and plotted (Figure 3.6, 
the RMSD values and displacement data for these superimpositions are tabulated in 
Appendix 7.4).lj9 The DDM  based method used the 1528 backbone atoms of 376 static 
residues, while the Ding et al. technique used 16 Ca atoms of the (39-(310 hairpin 
(residues 177-192).
Comparison of Superimposition Techniques (Unliganded and Liganded Structures)
- unliganded
- a-APA
• - O - -unliganded 
- - D - - a-APA
Figure 3.6 Displacement of Ca atoms of residues in the region of the polymerase active site upon 
superimposition of ld lo (circle icons) and lvru (square icons) onto 2hmi using different techniques. 
Solid icons represent the data from the DDM derived superimposition; while outlined icons 
represent the superimposition data using residues 177-192.
The RMSD values of the different superimpositions of the unliganded structure onto the 
DNA-bound structure differed by only 0.2 Â, while the inhibitor-bound structure 
superimpositions differed by a much greater 1.3 Â. As clearly seen in Figure 3.6, 
superimposition by the Ding et a l  technique, that used the very residues to be
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investigated, suppressed any conformational displacements that may have been induced 
by binding of DNA or a-APA. The average displacement of both structures using this 
technique was only 0.67 A, with only two values greater than 1.0 A. The DDM based 
superimposition conversely allowed residues demonstrating DNA or inhibitor induced 
conformational change to present themselves, despite the fact that some of these 
residues were also included in the superimposition subset (180-181 and 188-200). Most 
significantly were the polypeptide sections 184-186 and 188-192. Residues 184-186 
form part of the catalytically significant polymerase active site. Using the Ding et al. 
technique, a slight propensity towards conformational change was seen in these 
residues, but was averaged out. The DDM based technique however allowed this 
propensity to be seen and impartially quantified. Also of significance were the residues 
188-192, which showed no noticeable displacement trends using the Ding et al. 
superimposition. Even though these residues were included in the DDM derived subset, 
calculated from 19 different crystal structures, they demonstrated significant 
displacements, greater than the 2 A defined as conformational invariability, in the 
inhibitor-bound structure which may merit further investigation.
In the second example, various inhibitor-bound RT structures were superimposed onto a 
RT structure complexed with nevirapine, using a published ‘core’ subset (data tabulated 
in Appendix 7.5).138 The displacement of Ca atoms in the region of the non-nucleoside 
inhibitor binding site was measured and plotted (Figure 3.7). The average RMSD for 
the superimposition of four different inhibitor-bound crystal structures (lrth, lvru, lrti, 
and lrev) onto the nevirapine-bound structure (lvrt) was 0.60, using the DDM derived 
subset, as compared to the 0.48 for the ‘core’ subset. This was remarkably comparable 
considering the average ‘core’ subset was composed of 104 atoms, 6.8 % of the number 
used in the DDM based superimposition.
Comparison of Superimposition Techniques (Liganded Structures)
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Figure 3.7 Displacement of Ca  atoms of residues of the non-nucleoside inhibitor binding pocket 
upon superimposition of inhibitor-bound crystal structures onto lvrt using different techniques. 
Solid icons represent the data from the DDM derived superimposition; while outlined icons 
represent the superimposition data using the ‘core’ subset.
Once again the DDM based superimposition allowed conformational differences 
between the inhibitor bound structures to be clearly seen and more accurately presented. 
The use of the ‘core’ subset was rational and in accord with the philosophy of the DDM 
based method, but its derivation lacked impartiality and autonomy from bias. The 
results from the ‘core’ superimposition showed a similar averaging effect to that seen in 
the first comparison of superimposition techniques.
The DDM based superimposition did not purposely magnify conformational 
displacements induced by substrate or inhibitor binding. Rather it allowed those 
conformational changes to be seen in their full magnitude without being masked by 
averaging out effects or suppressed by being forced to superimpose. Consequently it 
became a valuable and objective method to study and quantify ligand and substrate 
induced conformational changes at active sites and structurally important motifs in the 
RT enzyme. The circumspect interpretation of these studies was conducted and led to a 
greater understanding of the mechanisms of enzyme function and inhibition.
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3.2.4 Superimposition for conformational studies
In the unliganded enzyme, the active sites and several structurally important motifs of 
the enzyme are found in a different conformation to that seen in substrate or inhibitor- 
bound structures. The structural changes required to adopt active or catalytic 
conformations, and those induced by the binding of non-nucleoside inhibitors, were 
studied in this work by the superimposition of all available unliganded, DNA-bound and 
inhibitor-bound crystal structures onto an unliganded structure (ldlo). The details of all 
crystal structures are given in Appendix 7.3. The displacement between the ldlo 
structure and all superimposed structures was measured for each atom of the residues of 
the active site or structural motif studied.
ldlo was used as the unliganded structure because of its higher resolution and data 
completeness compared to the lhmv structure, and because of irregularities in the 
crystal collection method of lrtj, as detailed in Section 3.2.2. The second unliganded 
structure used (lhmv) provided further verification of the conformation of the primary 
unliganded structure, and substantiated the comparative displacements between 
unliganded, substrate-bound and inhibitor-bound structures; this structure was referred 
to when incongruities were observed between the unliganded structures. The two DNA 
bound structures were differentiated as the RT-DNA-dNTP catalytic ternary complex 
(lrtd) and the RT-DNA binary complex (2hmi). In these structures, the primer and 
template strands of nucleic acid are jointly considered as one DNA entity. To simplify 
the explanation and help visualise the displacements of residues, the structural analogy 
of the clenched right hand in Figure 3.3 was used to illustrate the conformational 
changes.
The crystal structures used in the superimposition studies (Appendix 7.3), were derived 
predominantly from two different research groups, the CABM and the OCMS research 
groups. In addition, two significant structures (lhmv and lrtd) came from two separate 
groups at Harvard University, Cambridge. Most of the structures are in the C2 or 
P2\2\2\ space group, with 2hmi being the only exception in the F3212 space group. 
Comparisons between space groups were made based on previous findings that 
differences in the crystallographic space groups did not significantly affect the structure 
of the enzyme.147,151 Slight differential trends were noted between inhibitor-bound 
crystal structures that were obtained from one research group or the other, but these are 
small and in no way invalidate general inhibitor-induced structural changes noted in the
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enzyme. These differential trends could be extended to the corresponding space groups 
as nearly all the structures of the CABM group are in the C2 space group, and the 
OCMS structures are in the P2i2i2i space group. The differences between the 
structures are most likely due to the process of structure optimisation and model 
refinement within each research group, rather than solely due to the different 
crystallographic space groups.
Superimposition using the objective DDM based technique provided greater certainty 
and insight into the conformational changes in the unliganded structure induced by 
substrate and inhibitor binding. Two active sites, that of the polymerase and RNase H 
domains, and two structural motifs that make contact with the nucleic acid hybrid, the 
primer and template grips, were studied in the following work to quantitatively 
demonstrate the differences in the position and conformation between structures. These 
differences were interpreted to provide insight into the activation and inhibition of the 
PAS. Additionally, residues of the inhibitor binding pocket were compared between 
unliganded, and substrate or inhibitor-bound structures to gain a greater appreciation of 
flexibility of the pocket and the structural requirements necessary for inhibitor binding.
3.3 The polymerase active site
3.3.1 The polymerase active site and polymerisation
The polymerase active site (PAS) of HIV-1 RT is composed of the highly conserved 
YMDD motif (Tyrl83, Met 184, Aspl85, and Aspl86) and AspllO of the catalytically 
essential aspartic acid triad that includes Asp 185 and Asp 186. It lies on an antiparallel 
three-stranded (3-sheet ((36-(39-|310) in the palm subdomain of the p66 subunit, and forms 
the principal biological machinery for the reverse transcription of viral RNA into 
proviral DNA.
The faithful insertion of nucleotides in DNA synthesis is believed to involve dynamic 
interactions between the enzyme, the nucleic acid and dNTP substrates, during which 
RT is proposed to undergo at least three conformational changes.154 The first of these 
may occur when the nucleic acid primer-template binds to RT to form a tight E*DNA 
complex as shown in Figure 3.8.123,155
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Figure 3.8 Catalytic pathway for polymerisation.123 The abbreviations used: E, enzyme; DNA, 
deoxynucleic acid; n, nucleotide number; dNTP, deoxynucleotide triphosphate; E*, catalytically 
active enzyme, PPj, pyrophosphate.
The binding of a dNTP is postulated to result in the formation of a loose initial ternary 
E*DNA*dNTP catalytic complex, where the primer and template strand of the DNA are
considered as one entity. This complex is believed to undergo a rate-limiting
*
conformational change to form a tight, enzymatically competent E *DNA*dNTP 
complex, providing the dNTP has Watson-Crick complementarity to the appropriate 
nucleotide of the template. This putative conformational change is thought to facilitate 
the interaction of the incoming nucleotide with the 3’-OH of the primer, allowing a 
critical transition to be reached leading to the rapid chemistry of polymerisation forming 
the phosphodiester bond.123,156,157 After nucleotide incorporation, a final conformational 
change could allow the enzyme to return to the loose state in order to release the 
pyrophosphate (PPi), and translocate toward the new 3’-OH primer terminus to initiate 
the next round of reaction.123 Overall HIV-1 RT can complete this catalytic cycle 20 
times per second.156,158
The prevalent understanding that it is the rate-limiting conformational change that 
governs the maximum rate of incorporation of the correct nucleotide, and not the 
chemical step involving nucleoside phosphoryl transfer,123 accentuates the significance 
of the structural changes needed for a catalytic conformation. This can be further 
appreciated with an understanding of the intricate interplay of the residues of the PAS, 
template-primer, dNTP and divalent metal ions involved in polymerisation.
The recent crystallisation of a ‘catalytic’ complex of RT with a template-primer and 
dNTP poised for catalysis, has corroborated hypotheses concerning the chemistry of 
dNTP polymerisation via an SN2 displacement of pyrophosphate by the 3’-hydroxyl at 
the primer terminus.
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The most commonly accepted mechanism employs two Mg2+ ions, one catalytic (A) and 
one nucleotide binding (B), as depicted in Figure 3.9 from the catalytic lrtd structure. 
These cations are thought to facilitate an SN2 nucleophilic attack of the 3’-OH of the 
primer terminus on the a-phosphorus of the incoming dNTP and stabilise the negative 
charge of the transition state.123136160
Figure 3.9 Proposed coordination complex of polymerisation in the catalytic ternary crystal 
structure (lrtd), where the thin lines to the Mg ions represent postulated interactions. The 
phosphate backbone of the dNTP and the residues of the PAS are coloured by atom, phosphorus 
(magenta) oxygen (red), carbon (black), nitrogen (blue), sulfur (yellow); the base of the dNTP 
(orange); Mg ions (purple), primer strand (light green), and template strand at the bottom left hand 
corner (dark green). Residue Vail 11, which does not form part of the PAS but is believed to be 
coordinated to the nucleotide binding Mg ion, is shown as sticks.
The catalytic Mg2+ ion (A) is speculated to contact the 3’-OH of the primer terminus, 
and its coordination shell most likely includes the sidechains of all three aspartic acid 
residues, an oxygen of the a-phosphate of the dNTP and probably a water molecule. 
The 3’-OH is actually missing from the primer terminus, as seen in Figure 3.9, to help 
capture the catalytic crystal structure at the stage just prior to polymerisation, and 
prevent actual bond formation between the primer strand and the incoming dNTP. Thus 
the 3’OH position and possible contact with the Mg ion can only be postulated. The 
triphosphate moiety of the dNTP is wrapped around the second Mg2+ ion (B), with each 
of the phosphates contributing a non-bridging oxygen to the octahedral coordination of
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the Mg2+ ion. The contributions of the sidechains of AspllO and Aspl85 and the 
backbone carbonyl of residue 111 complete its coordination complex. This second 
Mg2+ ion likely contributes to the electropositive character of the a-phosphate 
facilitating a nucleophilic attack by the oxygen atom of the 3’-OH primer terminus. The 
elongated primer would be readied for the next polymerisation reaction and the by­
product, PPi, is thought to transiently bind to the aspartates via Mg2+ coordination prior 
to its release.154 This explanation illustrates the numerous structural elements that may 
be required to converge in a precise and discriminatory mechanism for the successful 
orchestration of the polymerisation reaction.
Virtually all literature on the crystallographic studies of RT has focussed on the 
conformational changes of residues in the non-nucleoside inhibitor binding pocket for 
drug design and optimisation purposes. The few that refer to changes in the active site 
have made vague qualitative observations of differences between only a few enzyme 
structures; the comparison techniques have not been objective, results not quantitative, 
and have been without detailed analysis of specific residues. One study had postulated 
a mechanism of inhibition after comparing three inhibitor-bound crystal structures 
against an unliganded structure (lrtj).29 Unfortunately, this unliganded structure was 
produced by soaking out a weak binding non-nucleoside inhibitor from pregrown 
crystals, making the observations from this structure dubious at best (see Section 3.2.2). 
Our studies have begun to rectify the lack of detail in this area of research by looking at 
the individual residues of the active site in all the crystal structures currently available.
3.3.2 Synopsis of the displacement of the PAS
The results of the superimposition showed clearly the differences in conformational 
change and displacement that are induced upon substrate or inhibitor binding, illustrated 
in Figure 3.10 and quantitatively summarised in Table 3.3 and Figure 3.11. The 
residues of the PAS are listed in Appendix 7.6, and displacement data is tabulated in 
Appendix 7.7. The data for Figure 3.11 was generated from superimpositions and 
distance measurements performed in the Insightll0 program,152 and graphed using 
Excel®153 (for further details see Chapter 6 Experimental).
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Figure 3.10 An illustration of the displacement of the PAS, in the palm subdomain, upon 
substrate and inhibitor binding relative to the fingers subdomain, on the left, and the thumb 
subdomain (in the ‘closed’ conformation), on the right. The backbone of ldlo is shown as a green 
line trace. Red and orange active sites represent inhibitor-bound structures, light and dark blue 
active sites represent DNA-bound structures. This view is the same used in the individual residue 
analysis, with details of the conformational changes in the text.
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Although the results in Figure 3.11 were only scalar, and did not express any direction 
of movement, they provided an initial snapshot description of overall conformational 
changes, showing the clustering of inhibitor-bound structures, and consistent changes of 
residues in a clear concise fashion. The breakdown of the average displacement into 
backbone and sidechain components (Table 3.3) indicated that the sidechains of all 
structures experienced additional conformational changes to those induced by the 
backbone. This additional conformational displacement of the sidechain was greater in 
the inhibitor-bound structures than the substrate-bound structures.
The comparison with the second unliganded structure (Ihmv), on the whole, 
substantiated the comparison in conformational changes between all the studied 
structures and the unliganded structure (ldlo). The average displacement of the 
backbone of lhmv was less than 1.0 A, and the backbone and sidechain elements also 
showed much smaller displacements than those seen in the inhibitor-bound structures; 
in Figure 3.12, only 2 atoms showed a displacement greater than 2 A. The binary RT- 
DNA (2hmi) structure showed similar conformational changes, in the backbone and 
sidechain, to the ternary (lrtd) structure, but these were all greater in magnitude. No 
explanation can be provided for the greater conformational similarity of lrtd and ldlo
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compared to 2hmi and ldlo. The 2hmi structure is better resolved than the lrtd 
structure, 2.8 A compared to 3.2 A, although it has been refined from an earlier 
structure. ’ The inhibitor-bound structures all showed considerable displacements 
of the PAS, ranging from an average of 2.1 -  3.4 A, with some individual atoms moving 
as much as 7.9 A (Figure 3.11). More significantly the consistency and prevalent trends 
of the line traces in Figure 3.11 provided evidence that there were patterns of 
conformational changes in the PAS among the structures, and differences in the residues 
were not merely random and attributable to entropy. The crystal structures of the 
CABM research group had greater average differences in the conformation of the PAS
o
(3.06 A), compared to the unliganded structure, than those from the OCMS research 
group (2.54 A).
average DNA-bound inhibitor-bound structures
displacement structures
....... (A)........... lhmv ternary binary total CABM OCMS
entire residue 1.24 1.69 2.36 2.70 3.06 2.54
backbone 0.92 1.31 1.85 2.15 2.59 1.95
sidechains 1.52 2.01 2.80 3.18 3.47 3.05
Table 3.3 Summary of the average displacement between the ld lo unliganded structure 
and the second unliganded (lhmv), substrate-bound (lrtd-ternary and 2hmi-binary), and 
inhibitor-bound structures for the entire PAS, and only the backbone or sidechain 
component. The three representative average displacements were calculated for all 19 
inhibitor bound structures (total), and based on the research groups that derived the 
crystal structures; six from the CABM research group, and 13 from OCMS research 
group.
3.3.2.1 Substrate induced conformational changes of the PAS
The PAS of the binary and ternary dsDNA crystal structures were remarkably similar in 
position and conformation to each other, as can be seen in Figure 3.11 and more clearly 
in Figure 3.12. The line-traces for 2hmi (grey diamond) and lrtd (black circle) followed 
similar trends and have comparable magnitudes of displacement. In Figure 3.13 (left), 
the thin stick structure of 2hmi is more similar to the pale structure of lrtd, than the 
thick stick structure of ldlo. DNA binding caused the PAS to be depressed into the 
palm comparative to the unliganded structure, illustrated in Figure 3.10 and more 
clearly seen in the later individual residue assessments (Section 3.3.3 -  3.3.7).
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Figure 3.11 Graphical representation of the displacement between the unliganded (ldlo) structure and all other RT structures for the PAS residues.
The YMDD m otif also showed a very small displacement forward away from the back 
of the hand, and very slight displacement left toward the fingers. The largest 
differences in displacement were seen in the sidechains of A spllO  (3.0 - 4.8 A), M etl84 
(3.8 - 7.4 A), and A spl85  and 186, with notably consistency. Figures 3.12 and 3.13 
(left) illustrate the relative similarity between the unliganded and DNA-bound 
structures, with differences being predominantly seen in the sidechains of the PAS.
In Figure 3.13, the changes in conformation are seen relative to the catalytic lrtd  
structure instead of the unliganded ldlo. It is uncertain if these different conformations 
of the unliganded (ld lo  and lhm v) and 2hmi structures could still suitably coordinate 
the PAS and the M g ions as in the lrtd  structure of Figure 3.9. These small differences 
may be sufficiently distinct from the catalytically active conformation such that these 
structures exist as different forms of the enzyme as postulated in Figure 3.8. These 
results provide evidence that the conformational changes required of the PAS to 
transform from an unliganded inactive form or a substrate-bound inactive form, as 
suggested by the 2hmi structure, to a catalytically active conformation such as that of 
E *DNA»dNTP from Figure 3.8, are subtle but distinct.
Figure 3.12 Graphical representation of the displacement between the unliganded (ldlo) structure, 
and the second unliganded (lhm v) and DNA-bound structures (lrtd  and 2hmi) for the PAS.
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3 3 .2 .2  Inhibitor induced conformational changes of the PAS
Inhibitor binding induced several concerted movements that displaced the PAS from its 
position and conformation in the unliganded state. The active sites of inhibitor-bound 
crystal structures showed consistent displacement left toward the fingers illustrated in 
Figure 3.10, as well as a small displacement toward the back of the hand. These 
displacements are quantitatively expressed in the multi-coloured line traces of the 
inhibitor-bound structures in Figure 3.11. Along with Figure 3.13, which illustrates the 
changes in conformation relative to lrtd instead of ldlo, this shows the basic and 
distinct differences in the magnitude of the conformational changes between inhibitor- 
bound structures and all other structures
Figure 3.13 (Left) The conformational differences between the unliganded structure ldlo (thick 
dark sticks) and the binary DNA structure 2hmi (thin dark sticks), seen relative to the proposed 
catalytic coordination complex of polymerisation in lrtd shown in pale ball-and-stick (see Figure 
3.9 for full legend details). (Right) Inhibitor-bound structures of lhni (thick dark sticks) from the 
CABM group and lvru (thin dark sticks) from the OCMS group, also seen relative to lrtd.
The disparity between crystal structures derived from the different research groups was 
seen in the average displacement of the PAS in Table 3.3, where the CABM group 
structures were displaced on average by 3.06 A, compared to 2.54 A for the OCMS 
structures. This was also observed in Figure 3.13 (right), where the thick stick structure 
of lhni (CABM) is displaced further to the left than the thin stick structure of lvru 
(OCMS). Those structures from the CABM group tended to display a slight additional
4
elevation from the palm relative to the unliganded structure, not seen in these 
illustrations.
The comparison of the inhibitor-bound structures of Figure 3.13 (right) to the catalytic 
lrtd shows clearly the active site residues being displaced to the left toward the fingers, 
intruding into the space occupied by the pale dNTP, primer strand and Mg ions in the 
catalytic structure. The coordination of the residues of the PAS, the Mg ions, as well as 
the incoming dNTP and the primer strand being would be difficult after such distinct 
conformational changes as observed in these studies.
3.3.3 Conformational changes for aspartic acid 110
The second unliganded structure (lhmv) showed a virtually identical conformation to 
that of the unliganded structure (ldlo). Only a negligible shifting toward the back of the 
hand accounted for the small displacement seen in the light grey square line trace of the 
backbone of this residue in Figure 3.12. The black line trace of the catalytic DNA 
complex (lrtd) also showed a similar orientation, but the residue was slightly forward of 
ldlo, in the direction of the RNase H subdomain, as illustrated by the dark blue residue 
on the left in Figure 3.14. The binary DNA complex (2hmi) overlaid that of ldlo, with
a small downward displacement 
into the palm. From Figures 3.11 
and 3.12 it can be seen that the 
grey diamond line trace for 2hmi 
is similar to the inhibitor-bound 
structures but, as seen in Figure 
3.14, the direction of the 
displacement is distinctly 
downward into the palm, for 
2hmi, rather than left toward the 
fingers subdomain. The Y- 
shaped carboxylate fork of this 
residue in the 2hmi structure was 
rotated to point toward the base 
of the thumb, in contrast to that 
of ldlo that pointed toward the
Figure 3.14 The displacement of AspllO (residues on the 
left) and Tyrl83 (residues on the right) upon substrate 
and inhibitor binding, ldlo ball-and-stick (green), lhmv 
(dark green), lrtd (dark blue), 2hmi (light blue), CABM 
structures (orange), and OCMS structures (red). The 
backbone of ldlo is shown as a green line trace, and the 
Mg ions in lrtd are shown as purple spheres. The fingers 
subdomain is to the left of Asp 110 and the thumb 
subdomain is to the right of Tyrl83, as can be more 
clearly seen in Figure 3.10, which is in the same 
orientation.
mi
fingers and thumb pinchpoint (Figure 3.10).
The inhibitor-bound structures show distinct and uniform displacements toward the 
fingers, and smaller displacements toward the back of the hand. The coloured line 
traces in Figure 3.11 follow all the same trends, with displacements greater in 
magnitude than those of the second unliganded (lhmv) and catalytic ternary (lrtd) 
structures. The CABM structures, seen as orange residues in Figure 3.14, were 
clustered together and showed a slightly greater displacement further left toward the 
fingers than those of the OCMS group. Although vertical displacements were not of a 
serious magnitude, the CABM structures as a whole showed a very slight elevation 
compared to the OCMS group structures which were more on level with the unliganded 
structure. The conformations of the carboxylate forks were generally unchanged, with 
slight deviations pointing more toward the fingers than the pinchpoint. The clustering 
of the inhibitor-bound structures as a whole, and their difference from ldlo and the 
DNA-bound structures, provided further support that small, inhibitor-induced 
conformation changes could be investigated in this manner, despite differences in 
crystal structure resolution and space groups.
AspllO forms part of the catalytic triad of aspartates crucial to the function of the PAS, 
with any amino acid substitution dramatically impairing the catalytic activity of the 
enzyme. The catalytic rate of the polymerase reaction of a D110A mutant enzyme is 
600 and 1000 fold lower than the wild type enzyme for RNA and DNA template- 
directed reactions respectively.161 Interestingly, a serine substitution at this position 
selectively inactivated the RNA directed DNA synthesis but significantly retained the 
DNA directed catalysis.161 Considering the contributions AspllO makes to the 
coordination of both Mg2+ ions (Figure 3.9) we postulate that even a minor 
conformational change could leave the aspartate unable to participate in the stabilisation 
and activation of the metal ions. Its displacement could also be propagated along the 
polypeptide to residue 111, whose carbonyl backbone in Figure 3.9 was also postulated 
to make a contribution to the nucleotide-binding Mg2+ ion.136 The positional differences 
seen between the two blue DNA-bound AspllO residues in Figure 3.14 may signal a 
vital conformational change necessary to transform between the inactive DNA-bound 
form of the enzyme, to a form that is poised for polymerisation. We hypothesise that 
the different conformational changes seen in the orange and red inhibitor-bound 
structures of Figure 3.14 and the dark residues of Figure 3.13 (right) undermine the
ability of AspllO to coordinate the nucleotide binding Mg ion necessary for catalysis. 
The binding of non-nucleoside inhibitors may ‘lock out’ the residue from more flexible 
conformations that could transform into passive and active or catalytic forms capable of 
coordinating the necessary cations and its surrounding residues.
3.3.4 Conformational changes for tyrosine 183
The tyrosine 183 of the lhmv unliganded structure was slightly different from that of 
ldlo, being positioned marginally more toward the back of the hand and slightly 
elevated from the palm. On the right hand side of Figure 3.14, the dark green residue of 
Tyrl83 of lhmv is almost hidden by the displacements of the inhibitor-bound 
structures, and the elevation is slightly exaggerated by the angle of the illustration. The 
phenyl sidechain in ldlo was in an upright diagonal position, with the phenol group 
directed to a point above the palm/base of palm, in the direction of the nucleic acid 
groove. The phenyl ring, which faced the connection subdomain in the unliganded 
structure, was rotated about 40-50° to face the thumb with a very slight displacement 
down into the palm in lhmv. The DNA-bound structures (lrtd and 2hmi), seen as dark 
and light blue sticks in Figure 3.14, were extremely similar to each other in position, as 
well as to ldlo; with a similar rotation to that of the phenyl ring in lhmv. The only 
displacement the DNA-bound structures showed was a slight displacement down into 
the palm; more noticeable in the 2hmi structure than lrtd. These displacements were all 
less than 2 A, and as such, could be considered as being conformationally invariable 
compared to the unliganded structure. The displacements followed a fairly consistent 
trend between the compared structures, as seen in the three line traces in Figure 3.12 for 
this residue.
Figure 3.14 illustrates how the inhibitor-bound crystal structures, as a group, showed a 
small displacement toward the back of the hand and a marginal elevation up from the 
palm compared to the unliganded ldlo. The magnitude of these displacements in Figure
3.11 for Tyrl83 was on average about 2.5 A, compared to about 1.3 A for the 
unliganded and DNA-bound structures seen separately in Figure 3.12. The CABM 
structures, seen as orange residues in Figure 3.14, showed a marginally greater upward 
displacement from the palm and a small displacement toward the fingers and less so 
toward the back of the hand than those structures from the OCMS group, which had 
negligible sideways displacement. The phenyl sidechains of the inhibitor-bound
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structures were similarly swivelled as in lrtd and 2hmi; in the OCMS group this was 
seen more consistently and clustered, but in the CABM structures this varied widely 
from 20-90° as illustrated in Figure 3.14.
Tyl83 plays no role in the coordination of the divalent Mg ions, nor does it interact with 
the incoming dNTP during polymerisation. Rather, it is one of the few amino acids of 
RT that is thought to interact with bases in the minor groove of the template-primer at 
the PAS, and its mutation can have varying effects on polymerase activity,
processivity, and fidelity. Its lack of participation in the coordination complexes 
involving the divalent Mg ions supports the observations that mutations of Tyrl83 show 
a reduction in polymerase activity, but never a total cessation of DNA incorporation.162 
Results of several other research groups have suggested that the hydroxy group and 
phenyl ring of the tyrosine appear to be crucial for the synthesis of the negative strand 
DNA while neither of these may have a significant role in the plus strand DNA 
synthesis.163
Tyrl83 is thought to also play a role in maintaining enzyme processivity, which is a 
measure of the number of nucleotides incorporated into a primer strand during a single 
binding event before the enzyme dissociates from the template-primer. Substitutions of 
Tyrl83 that increase the rigidity of an otherwise flexible dNTP-binding pocket are 
known to enhance the fidelity of polymerisation by accommodating only the correct 
nucleotide for catalysis. The mechanism for this occurs either during the initial binding 
step or by inhibition of the conformational change step after binding of the incorrect 
nucleotide.162,163 The ability of Tyrl83, unlike its mutants, to both incorporate incorrect 
nucleotides and extend mispairs on RNA templates,163 as well as its influence in enzyme 
processivity, alludes to a role in an evolutionary strategy that introduces variances in the 
genome which may be beneficial to the virus. This is significant mechanistically, and in 
the consideration of drug design since DNA synthesis on the RNA template is the more 
vital of the two rounds of synthesis; subsequently the RNase H digests the RNA 
template, and this primary copy of the viral genome is lost.
The sidechain of Tyrl83 can be seen, in Figure 3.9, to be quite close to the backbone of 
the penultimate nucleotide of the primer strand, possibly participating in its 
stabilisation. The DDM-based superimposition and comparison of unliganded and 
substrate-bound enzymes in Figure 3.13 (left), as well as the line traces of this residue in 
Figure 3.12, showed little differences in conformation. Any variance could be passed
off as natural flexibility in this residue of the dNTP-binding pocket, to accommodate a 
nucleotide, or different nucleotides. In contrast, the inhibitor-bound structures in Figure 
3.13 (right) showed more notable differences in conformation to the unliganded 
structure, with Tyrl83 displaced further toward the last nucleotide of the primer strand, 
that is poised to undergo polymerisation with the incoming nucleotide. We postulate 
that the displacement of Tyrl83 in the inhibitor-bound structures disrupts the 
positioning and ‘reading’ of the last nucleotide of the primer strand, leaving it in a 
position that is not optimal for the incoming nucleotide to interact with. Furthermore, 
the conformational changes to Tyrl83 may be disseminated to other neighbouring 
residues that in turn may play different and significant catalytic and structural roles in 
polymerisation.
3.3.5 Conformational changes for methionine 184
Figure 3.15 The displacement of Metl84 upon substrate 
and inhibitor binding, ldlo ball-and-stick (green), lhmv 
(dark green), lrtd (dark blue), 2hmi (light blue), CABM 
structures (orange), and OCMS structures (red). The 
backbone of ldlo is shown as a green line trace, and the 
Mg ions in lrtd are shown as purple spheres. The fingers 
subdomain is to the left of Asp 110 and the thumb 
subdomain is to the right of Tyrl83, as can be more 
clearly seen in Figure 3.10, which is in the same 
orientation.
The alkyl sidechain of this 
residue in the unliganded 
structure pointed upward toward 
the tip of the thumb, with the last 
atom of the sidechain pointing 
toward the base of the thumb, in 
a direction toward the back of 
the hand. The second 
unliganded structure lhmv, by 
comparison, showed a small 
displacement toward the back of 
the hand; retaining the same 
direction in the sidechain but 
with the last atom of the 
sidechain pointed toward the 
fingers, seen as the dark green 
residue in Figure 3.15. The 
DNA-bound structures both 
showed a downward 
displacement into the palm,
clearly illustrated by the light and dark blue residues in Figure 3.15, and a slight 
displacement forward, away from the back of the hand. Their sidechains angled 
diagonally upward across the palm toward the smallest finger, except for the last atoms 
of the sidechain which for the 2hmi structure pointed toward the RNase H and for lrtd 
pointed to the fingers/thumb pinchpoint. The last two atoms of Met 184 (S§ and Ce) 
caused the greatest displacement, seen in Figure 3.12, for the unliganded and substrate- 
bound structures. These displacements were of a similar magnitude to that seen in the 
multi-coloured line traces of the inhibitor-bound structures of Figure 3.11 but, as Figure 
3.15 illustrates, were in quite a different conformation and direction.
The inhibitor-bound structures seen in Figure 3.15 showed a displacement left toward 
the fingers subdomain and a marginal displacement toward the back of the palm. The 
orange CABM structures showed a very slight vertical elevation, and tended to be 
displaced furthest to the left of all the structures. This vertical displacement can be seen 
in the backbone of CABM structures, at the base of the residues in Figure 3.15. 
Practically all of the sidechains of the inhibitor-bound structures were similarly vertical 
as ldlo, with the last atom of the sidechain consistently pointing toward the fingers, 
accounting for the greatest displacements seen throughout the entire PAS.
Metl84 is the X-residue in the catalytically important YXDD motif, which is highly 
conserved in retroviral RTs.164 It lies in close proximity to the 3’-OH primer terminus 
and the bound dNTP, as seen in Figure 3.9, but plays no part in their coordination with 
either Mg2+ion. The methyl group of the sidechain, Ce in Figures 3.11 and 3.12, is 
believed to interact with the sugar moiety of the substrate dNTP, as do the Ca and Cp 
carbons with the ribose ring of the primer terminus.139,164 Figure 3.13 (left) shows small 
differences between the unliganded and the substrate-bound structures of Met 184 that 
may be due to the presence of the primer strand or the nature of the last nucleotide of 
the primer strand. The significantly greater inhibitor-induced conformational changes 
seen on the right of Figure 3.13 very likely disrupt the positioning of the 3’-terminus 
and interfere with the configuration it adopts with the incoming nucleotide to allow the 
chemical reaction of polymerisation to occur.
Metl84 plays similar roles to that of Tyrl83 in the dNTP-binding pocket, with effects 
on polymerase activity and fidelity. Changes in the size and bulk of the 184 sidechain 
appear to be factors in determining the catalytic activity of the enzyme; long and bulky 
sidechains seem to be detrimental to the polymerase activity, whereas the presence of
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smaller side chains exhibits no inhibitory effect on the activity.164 The specificity of 
methionine in this position is evident in the experimental data that shows that the 
difference between an alanine and valine can produce a highly error-prone enzyme or 
one exhibiting increased fidelity, without compromise to the efficiency of DNA 
synthesis.164,165 Similar to Tyrl83, the role Metl84 plays in the efficiency and fidelity 
of DNA synthesis is conditional on the nucleic acid template, suggesting that this 
sidechain may be dispensable in terms of enzymatic activity, but is essential for 
nucleotide selection during DNA-directed second strand (+ strand) DNA synthesis.165
The displacements of the methionine sidechain in inhibitor-bound structures seen by our 
DDM-based superimposition, and illustrated in Figure 3.13, could make it unable to 
correctly align the 3’-OH of the primer terminus with the a-phosphate moiety of the 
dNTP. This could only be postulated, as the 3’-OH of the primer terminus is not 
present in the catalytic lrtd structure.
PDB file ....<t>(°) ....¥ ( ° ) ...
ldlo 60.51 -160.58
lhmv 70.43 -147.55
lrtd 58.33 -106.33
2hmi 54.27 -106.86
lbqm 57.64 -83.76
lbqn 44.77 -94.53
lhni 14.66 -86.75
lhnv - -100.12
lklm 55.21 -130.89
lrev 54.50 -136.63
Irti 55.03 -122.74
lrt2 54.11 -108.50
lrt3 49.03 -138.82
lrt4 62.45 -120.72
lrt5 60.45 -118.01
lrt6 57.04 -131.99
lrt7 57.08 -131.56
lrth 68.18 -123.16
Irti 57.56 -117.00
ltvr 51.2 -116.51
luwb 56.92 -141.02
lvrt 53.80 -103.84
lvru 62.61 -116.35
It has been suggested that the conformational 
changes in its backbone may also affect the 
stabilisation of the dNTP-binding pocket by 
affecting the (39-(310 hairpin. This hairpin was 
observed to have an unusual (3-tum geometry, 
characterised by torsion angles of (j) ~ 60° and \|/ ~ 
-160° for Met 184 in the unliganded 
enzyme.29,135,139 Upon both substrate and inhibitor 
binding, Ding et al. observed that the (|) angle 
remained relatively unchanged while the \[/ angle 
increased to around -120°, which is the ideal value 
for a type IT P-tum. However, measuring the <|> 
and \\f angles for Met 184 in each of the structures 
used in our studies (Table 3.4) showed the \[/ 
angles for lrtd and 2hmi were virtually identical at 
-106°. They differed from the unliganded
structure by about 50° (40° in comparison to
Table 3.4 (J) and \j/ angles of M etl84. lhmv), supporting the notion of a substrate-
<|KN, C„, C, N+1) and v  (C.!, C, C„, C). r t ^  , r
induced conformational change. The \|/ angles ot
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the inhibitor-bound structures showed insufficient consistency, ranging from -83° to - 
141°, for any definitive correlation between the structure of the p-tum and inhibitor 
binding to be made. This reiterates the need for any study of RT to include as many 
different structures as possible, so that a more complete and comprehensive account can 
be made of the observations. Conformational changes in Met 184 were expected to 
propagate throughout the local region because of the stabilising hydrogen bonds 
methionine made with surrounding residues, effecting the stability of the dNTP binding 
pocket and thus dNTP substrate binding and polymerisation.
3.3.6 Conformational changes for aspartic acid 185
The orientation of the lhmv structure was similar to Idlo, as demonstrated by the light 
grey line trace in Figure 3.12, but showed a small displacement toward the back of the 
hand and a slight displacement toward the thumb (Figure 3.16). The carboxylate fork of 
Asp 185, which in ldlo pointed upward toward the fingers and thumb pinchpoint, 
instead was directed more toward the thumb. The light and dark blue residues of the 
DNA-bound structures were virtually identical to each other in position and orientation 
in Figure 3.16. In comparison to ldlo, they showed a definitive downward
displacement into the palm, and a 
very marginal displacement forward 
along the nucleic acid groove and left 
toward the fingers. Their carboxylate 
forks pointed upward similarly to 
ldlo, with differences in the torsion 
about the Cy atom.
A small displacement left toward the 
fingers and a slight displacement 
toward the back of the hand were the 
only discernible displacements seen 
in the inhibitor-bound structures. 
Most of the carboxylate forks of the 
inhibitor-bound structures pointed 
more horizontally toward the fingers, 
though a few maintained the same
Figure 3.16 The displacement of Aspl85 upon 
substrate and inhibitor binding, ldlo ball-and-stick 
(green), lhmv (dark green), lrtd (dark blue), 2hmi 
(light blue), CABM structures (orange), and OCMS 
structures (red). The backbone of ldlo is shown as a 
green line trace, and the Mg ions in lrtd are shown 
as purple spheres. The fingers subdomain is to the 
left of Asp 110 and the thumb subdomain is to the 
right of Tyrl83, as can be more clearly seen in 
Figure 3.10, which is in the same orientation.
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direction toward the fingers and thumb pinchpoint as ldlo. Aspl85 in Figure 3.16 did 
not show consistent clustering of inhibitor-bound structures, as other residues have 
(Figure 3.14 and Figure 3.15), but the displacement trends in the coloured line traces of 
Figure 3.11 affirm quantitatively consistent inhibitor-induced conformational changes in 
this residue.
Asp 185 is the second of the three essential aspartic acid residues of the PAS, its 
importance could be no more clearly illustrated than in Figure 3.9, where each of the 
oxygens of its carboxylate is involved in the coordination of the divalent metal ions. 
Experimental data from other research groups appears to indicate that this residue 
participates only in the forward reaction of polymerisation, by initially binding the 
incoming dNTP. 161>163’166 After the proposed conformational change to the 
enzymatically competent E*#DNA#dNTP complex, and the initiation of the bond 
formation and cleavage process, Aspl85 is believed to lose its coordination with the Mg 
ion and not participate in the reverse reaction of pyrophosphorolysis. Rather, the 
aspartate may interact directly with the 3’-OH of the primer, acting as a proton acceptor 
in a general base mechanism.161
The conformational changes of Asp 185 induced by substrate binding are clearly seen in 
Figure 3.16, and were hypothesised to be necessary to accommodate the coordination 
complex of both Mg ions and the incoming nucleotide. The changes induced by 
inhibitor binding were on average 0.7 A greater than substrate-induced changes. The 
average displacement of the multi-coloured line traces for the inhibitor-bound structures 
of Figure 3.11 was 2.6 A and, as seen Figure 3.13 (right), left no doubt that the correct 
complexation of both Mg2+ ions, the incoming nucleotide and the template and primer 
strands would be near impossible to coordinate. The entire residue occupied the space 
where the nucleotide binding Mg2+ ion was positioned in the catalytic lrtd structure, and 
began to encroach on the space occupied by the phosphates of the incoming nucleotide. 
It was also displaced too far toward the fingers domain to coordinate the catalytic Mg 
ion (Figure 3.16). It would be uncertain how much of an effect this would have on the 
ability of an incoming nucleotide to approach the 3’-terminus. Nevertheless we
hypothesise that the conformational changes seen in Figure 3.13 (right) and Figure 3.16 
would make it impossible to coordinate even the nucleotide, the Mg ions and the 
residues of the PAS, without considering the primer strand. Not only had Asp 185 been 
repositioned, but its conformational changes were also propagated to its equally
important neighbouring residues. The displacement of Aspl85 may not only interfere 
with its function in the polymerisation reaction, but may also affect other surrounding 
residues that may play roles in both forward and backward reactions that are equally 
important in the progressive DNA synthesis.
3.3.7 Conformational changes for aspartic acid 186
Only a small displacement toward the back of the hand and a slight displacement toward 
the fingers differentiated the second unliganded structure (lhmv) from ldlo. The two 
green unliganded structures in Figure 3.17 were very similar, just as the line trace in 
Figure 3.12 remains below 2 A. The DNA-bound structures show a small displacement 
downward into the palm, and a very slight displacement left toward the fingers and 
forward along the nucleic acid groove. The downward displacement is slightly greater 
in the case of the light blue structure of 2hmi (Figure 3.17), and the forward 
displacement is slightly more marginal in Irtd. The carboxylate forks of these 
structures point toward the middle inside edge of the thumb for lrtd and the base inside
edge of the thumb for 2hmi. This 
is compared to ldlo’s carboxylate 
fork that points directly upward 
toward the tip of the thumb, with 
the plane parallel to the face of the 
thumb.
The inhibitor-bound crystal 
structures showed a small uniform 
displacement left toward the 
fingers, and a slight displacement 
toward the back of the hand 
(Figure 3.17). Only a marginal 
elevation up from the palm was 
seen. The sidechains showed little 
conformational change or 
orientation, other than varying 
degrees of swivel about the Cy 
atom.
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Figure 3.17 The displacement of Aspl86 upon substrate 
and inhibitor binding, ldlo ball-and-stick (green), lhmv 
(dark green), lrtd (dark blue), 2hmi (light blue), CABM 
structures (orange), and OCMS structures (red). The 
backbone of ldlo is shown as a green line trace, and the 
Mg ions in lrtd are shown as purple spheres. The 
fingers subdomain is to the left of Asp 110 and the 
thumb subdomain is to the right of Tyrl83, as can be 
more clearly seen in Figure 3.10, which is in the same 
orientation.
The last of the crucial aspartic acid triad, the carboxylate of Asp 186 coordinates the
catalytic Mg2+ ion (A). Aspl86 is known to be involved in both the forward and the 
161
reverse reactions of DNA synthesis, most probably because of the significant position 
is takes in coordinating the catalytic Mg2+ ion. The changes in this residue from the 
unliganded position to the substrate-bound conformations, were postulated to be 
necessary to coordinate this cation in an optimal position for polymerisation. Aspl86’s 
precise coordination and geometry with this same ion is totally reordered by the 
inhibitor-induced conformational changes seen by the DDM-based superimposition, and 
illustrated in Figure 3.13 (right). These changes would most likely leave the 
carboxylate fork unable to coordinate to the Mg2+ ion, and also affect the positioning of 
the neighbouring Asp 185 as well as the architecture of the (39-P10 loop to some degree.
3.3.8 Activation and inhibition of the PAS
The dynamic nature and function of RT demands that it be more than just a static 
structural protein. Disregarding possible coupled functions and communications it may 
have with other active sites and structural motifs elsewhere in the enzyme, the PAS is 
responsible for the DNA synthesis on both RNA and DNA templates. In a series of 
processes that are measured in microseconds, the PAS must coordinate the direct 
positioning of no less than five catalytic residues with two Mg2+ ions, nucleotides from 
each of the primer and template strands, as well as the incoming nucleotide. It must 
recognise and differentiate between ribonucleic and deoxyribonucleic acids, and correct 
and incorrect nucleotides. Its residues must function to find a balance between the 
necessity of flexibility to function and allow viral diversity, the hallmark of retroviruses, 
and rigidity to maintain genomic integrity and ensure viable progeny. Once all of these 
components are in place, conformational changes ensue which lead to the chemistry of 
polymerisation, translocation and the repositioning of all those elements of DNA 
synthesis once again.
The results from our DDM-based superimpositions showed that the unliganded RT 
enzyme was indubitably unable to bind DNA without conformational rearrangement. 
On a gross scale, the thumb subdomain needed to extend away from the fingers to 
accommodate the nucleic acid in the active site region. On a much more fine scale, the 
residues of the PAS needed to settle down slightly deeper into the palm region to 
accommodate the separate primer and template strands. The conformation of the PAS
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in this E#DNA complex of the kinetic pathway (see Figure 3.8) was most likely 
represented by the 2hmi structure. We hypothesise that another conformational change 
of the PAS is required to incorporate the nucleotide into the E*DNA#dNTP complex 
before the rate limiting conformational change preceding nucleotide incorporation. 
That E*»DNA#dNTP complex in the kinetic pathway was most probably represented by 
the catalytic lrtd structure, and the conformational changes necessary to transform to 
this state were seen in the differences between the 2hmi and lrtd structures. The 
differences in the PAS conformations of these DNA-bound structures to those in the 
unliganded structure were clear and irrefutable. The differences between the two DNA- 
bound structures were less glaring, but still notable, especially in the displacements of 
the three aspartic acid residues. This was perhaps to be expected considering their 
dominant role in coordinating the Mg2+ ions and the triphosphate moiety. A recent 
qualitative graphical comparison of the binary and ternary DNA-bound structures had 
found that there were rearrangements of the carboxylate sidechains of the PAS.160 These 
rearrangements brought Asp 110 close enough to chelate with the nucleotide binding 
Mg2+ ion (B),160 but this published study did not provide further details or elaborate on 
the exact conformational changes of the remaining residues of the PAS.
Although a previous comparison of three different crystal forms of RT had proposed a 
rotation of the PAS relative to the rest of the enzyme,143 no other study has been able to 
quantify and so clearly illustrate the specific flexibility needed to allow nucleic acid 
binding and polymerisation. This molecular swiveling, around an axis that is nearly 
parallel to DNA when bound to the large active site cleft, is attributed to an allowance 
for the rotational and translational movements of the growing nucleic acid duplex 
needed while the asymmetric tRNALys3 acts as primer for first strand synthesis. This 
hypothesis can not be corroborated with our DDM-based conformational studies until 
RT crystal structures with RNA templates and primers become available.
Based on the premise that precise conformational changes are required at nearly every 
stage of the polymerisation process, it was anticipated that the failure of any one of 
these conformational changes to transpire, or the occurrence of an unforeseen 
conformational change, would disrupt the entire process. These DDM-based 
superimpositions have shown startling conformational changes that not only displace 
the PAS from its customary position, but may also immure it such that it cannot proceed 
to the next conformation necessary for polymerisation. Binding of non-nucleoside
inhibitors displaced the PAS 
predominantly toward the fingers 
subdomain, and slightly toward the 
back of the hand compared to both the 
unliganded and DNA-bound structures, 
as illustrated by the backbone of the 
PAS in Figure 3.18. Both DNA-bound 
structures, 2hmi and Irtd, showed a 
displacement down into the palm away 
from the template-primer, supporting 
previous observations made only with 
the 2hmi structure.139 A vertical 
displacement into the palm might have 
been expected in light of evidence that 
inhibitor-bound RT enzymes can bind 
various template/primers and 
nucleotides as well as, if not slightly 
better than, the unliganded enzyme.167 
However this may depend on how 
studies are conducted; with the inhibitor added to an E*DNA complex, as for the Spence 
et al. study, or with the primer-template added to an E#I complex, which would have 
been preferable for our studies. It is not presently known if a template-primer complex 
is able to bind to an inhibitor-bound enzyme with such conformational changes as 
identified by these superimpositions. The conformational changes we have studied in 
the available crystal structures of RT-inhibitor complexes were not affected by the 
presence of DNA, and may very well undergo an additional vertical displacement, 0 1  
completely different conformational displacements, were DNA to be also present. No 
E«I*DNA crystal structures are presently available to confirm this speculation.
The rate-limiting step in the synthesis of DNA is a conformational change that is 
induced by the binding and recognition of the correct dNTP. Kinetically, the NNRTIs 
work by slowing the rate of the chemical reaction such that the conformational change 
is no longer rate-limiting,1"3 but rather the chemical step is inhibited. Structuially, this 
may be explained by conformational rearrangements upon inhibitor binding that are less
Figure 3.18 The displacement of the backbone of 
the PAS upon substrate and inhibitor binding, 
ldlo (green ball-and-stick), lhmv (dark green), 
lrtd (dark blue), 2hmi (light blue), CABM 
structures (orange), and OCMS structures (red).
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than ideal for the polymerase machinery of the PAS, Mg2+ ions, template-primer and 
dNTP, which we have detailed in this study, slowing down the chemical reaction of 
polymerisation.
3.4 The primer grip
3.4.1 The primer grip and its role in reverse transcription
The ‘primer grip’ of HIV-1 RT consists of the (312-(313 hairpin (Phe227-His235) of the 
antiparallel three-stranded [3-sheet ((312-[313-(314) in the p66 palm subdomain, which 
contacts the primer strand near its 3’ terminus (Figure 3.19).132 168 Highly conserved 
among retroviral RTs, the primer grip plays a role in aligning the 3’-OH end of the 
primer strand in the optimal position for nucleophilic attack on an incoming dNTP. 
Alanine-scanning mutations of primer grip residues has previously shown disparate 
impairment of both DNA-dependent and RNA-dependent DNA polymerase activities, 
as well as RNase H activity.169,170172 None of the known mutations that confer 
resistance to NNRTIs are mediated by changes in the amino acids of the primer grip, 
suggesting that these residues also have a critical architectural role.
Figure 3.19 Conformation of the primer grip (lrtd) relative to the DNA primer strand (light 
green). The residues of the primer grip are coloured by atom, oxygen (red), carbon (black), 
nitrogen (blue), sulfur (yellow).
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Interestingly, amino acids Phe227, Trp229, and Leu234 of this region also line the 
hydrophobic pocket where non-nucleoside inhibitors are known to bind. Consequently 
it is not surprising that the binding of a NNRTI displaces the primer grip, probably 
affecting its conformation and/or mobility, and thus its ability to position the 3’ 
terminus of the primer strand at the dNTP-binding site. Alternatively, it may be the 
mobility of the primer strand itself that is affected by the shifting to the primer grip 
induced by inhibitor binding. These disturbances in the spatial relationship between the 
primer terminus, a bound dNTP, and associated divalent metal cation(s) means that an 
incoming dNTP could still bind without significant alteration of affinity, but the altered 
relative conformations would not favour the chemical reaction of polymerisation.139 
Furthermore, progressive DNA synthesis requires a translocation movement of about 4­
5 A of the nucleic acid relative to the protein following each nucleotide incorporation.139 
The structural elements of the protein and nucleic acid that participate in this movement 
are as yet not known, but are certain to include the primer grip. Repositioning of this 
structural motif would permit it to ‘reload’ for the conformational changes in the nucleic 
acid and enzyme that accommodate the next round in the catalytic cycle.139
Throughout the entire process of reverse transcription, the primer strand is required to 
deal with the unique structural demands of several different nucleic acid templates and 
primers. Almost all of the mutations in the primer grip have a drastic effect on RNA
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priming activity but not DNA priming activity. ’ These effects are not just localised 
to the polymerase active site, but are as far ranging as to effect the different activities 
and specificities of the RNase H active site.172 These observations led to the proposition 
that interactions of residues in the primer grip with RNA and DNA primers are 
qualitatively different and determined in part, by RT recognition of the helical structure 
of the hybrids formed with these primers. A DNA primer annealed to a DNA template, 
as in the case in (+) strand DNA elongation, will adopt a purely B-form helical 
structure, while an RNA primer annealed to an RNA template, as in the case in (-) 
strand initiation, will adopt a strictly A-form structure.171 RNA-DNA hybrids are 
neither strictly A- or B-form, having several unusual features, such as theirs helical 
structure, and a prominent bend in the double helix that distinguishes them from other 
nucleic acid hybrids. The tRNALys3 and PPT primers used solely by RT have additional 
idiosyncrasies which make their recognition and interaction with the enzyme an 
inordinately uncommon and complex event.174'176 Minor changes in the primer grip
could be sufficient to disrupt those interactions involved in RNA priming while leaving 
DNA priming activity relatively unaffected.171
3.4.2 Synopsis of the displacement of the primer grip
The primer grip is located at the base of the thumb, on the inner edge of the thumb that 
is closest to the fingers. It is not actually part of the loops of the protein that form the 
thumb, but rather lies against the thumb. It is composed of a U-shaped loop, with the 
arms of the loop beginning at the base of the thumb and extending roughly one-third up 
the thumb. Residues Met230 and Gly231 make the closest contacts with the sugar- 
phosphate backbone of the first couple of nucleotides of the primer strand (Figure 3.19), 
with separation distances of less than 4 A in the catalytic lrtd structure. The DDM 
based superimpositions showed a significant and consistent displacement of the entire 
primer grip, and not just conformational changes in the sidechains of these residues 
(Figure 3.20). The residues of the primer grip are listed in Appendix 7.6, and 
displacement data is tabulated in Appendix 7.8.
The comparison of the unliganded ldlo structure with the dark green lhmv unliganded 
structure, in Figure 3.20, proved to be quite similar, and provided support to compare all 
other studied structures against ldlo. The average displacement of the primer grip in 
lhmv was 1.13 A, slightly less than the average displacement of the PAS in lhmv
o
compared to ldlo, and on average 2.77 A less than the displacement seen by the
o
inhibitor-bound structures. The average sidechain displacement was only 1.16 A, 
predominantly caused by the gross backbone displacement. The binary RT-DNA 
structure of 2hmi showed a greater average displacement than the catalytic lrtd
o
structure, which actually displayed a smaller average backbone displacement of 1.08 A 
than the second unliganded lhmv enzyme. The average sidechain components in 2hmi 
and lrtd showed a slight increased difference in displacement from the backbone 
component, on average 0.31 A, than seen in lhmv indicating conformational changes in 
the primer grip sidechains in addition to the collective displacement of the backbone.
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Figure 3.20 An illustration of the displacement of the primer grip upon substrate and inhibitor 
binding relative to the fingers subdomain, on the left, shown in grey, and the thumb subdomain, on 
the right. The backbone of ldlo is shown as a green line trace. Red and orange primer grips 
represent inhibitor-bound structures, light and dark blue primer grips represent DNA-bound 
structures. Only the primer strand, in purple, is shown for clarity. This view is the same used in 
the individual residue analysis, with details of the conformational changes in the text.
The inhibitor-bound structures all showed considerable displacement of the primer grip 
from the ldlo structure, and compared to the DNA bound structures. This was most 
clearly seen in the difference between the multi-coloured, and the black and grey 
monotone line traces of Figure 3.21, which graphed the scalar displacements of the 
primer grip from the unliganded ldlo. The average displacement of the inhibitor-bound 
structures was 3.90 A, predominantly composed of the gross backbone displacement, 
although an average additional displacement of 0.29 A was seen solely by the sidechain 
component. Figure 3.21 shows clearly that in the inhibitor-bound structures, the 
polypeptide region of residues 227-231 was consistently displaced further than the 
region of residues 232-235. The average displacement for the region 227-231 was 4.82 A compared to 2.81 A for residues 232-235. The average displacement values for the 
inhibitor-bound structures in Table 3.5 also showed differences between the CABM and 
OCMS research groups, as already seen in the study of the PAS. In the primer grip, the 
CABM crystal structures were displaced an average 0.67 A further away from the 
unliganded ldlo structure than the crystal structures of the OCMS research group.
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average DNA-bound inhibitor-bound structures
displacement structures
..(A) lhm v ternary binary total CABM OCMS
entire residue 1.13 1.22 1.81 3.90 4.35 3.68
backbone 1.10 1.08 1.59 3.73 4.26 3.49
sidechain 1.16 1.31 1.98 4.02 4.43 3.83
Table 3.5 Summary of the average displacement between the ld lo  unliganded structure and the 
second unliganded (lhm v), substrate-bound (lrtd-ternary and 2hmi-binary), and inhibitor-bound 
structures for the entire primer grip, and only the backbone or sidechain component. The three 
representative average displacements were calculated for all 19 inhibitor bound structures (total), 
and based on the research groups that derived the crystal structures; six from the CABM research 
group, and 13 from OCMS research group.
3.4.2.1 Substrate induced conformational changes of the primer grip
The second unliganded structure (lhm v) was similar to ldlo, in both the backbone and 
sidechain configurations with no displacement forward toward the primer strand, and 
only a slight displacement left toward the fingers, most notably for the loop region and 
(313 strand (residues 230-235). The primer grip in the DNA-bound enzymes (lrtd  and 
2hmi) was similarly conformed and placed compared to the unliganded enzymes, ldlo 
and lhm v, but not so alike that differences could not be discerned, as seen in the 
different line traces of Figure 3.22.
M hmv
Figure 3.22 Graphical representation of the displacement between the unliganded (ldlo) structure, 
and the second unliganded (lhm v) and DNA-bound structures (lrtd  and 2hmi) for the primer grip.
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Figure 3.21 Graphical representation of the displacement between the unliganded (ldlo) structure and all RT structures for the primer grip.
DNA binding in the binary structure of 2hmi appeared to cause a small displacement of 
the primer grip backward away from the fingers or the bulk of the enzyme, as if from a 
backward retraction of the thumb to accommodate the primer and template strands (see 
also the extension of the thumb in Figure 3.3). This difference from the unliganded 
structures, and the catalytic lrtd structure, is seen in the grey diamond line trace of 
Figure 3.22, which shows higher than average displacements for Phe227, Gly231, and 
His235, and the sidechains of Leu228, Met230, Tyr231, and Glu233. It was also seen 
in the comparison of the dark thin and the dark thick stick structures of Figure 3.23 
(left). The catalytic lrtd structure did not appear to be as affected by DNA binding as 
the 2hmi structure. The black circular line trace of Figure 3.22 showed only small 
differences in displacement, not unlike those of the second lhmv structure. The pale 
ball-and-stick structure of Figure 3.23 (left) showed virtually no displacement away 
from the primer strand when comparing it to the dark thick sticks of the ldlo structure, 
and only a very small displacement toward the left of the figure, or the back of the hand. 
No significantly discernible vertical displacement in the plane of the thumb for the 
primer grip was seen.
3.4.2.2 Inhibitor induced conformational changes of the primer grip
Inhibitor binding induced several concerted displacements of the primer grip from its 
position in the unliganded state. The conformation of the primer grip loop was 
relatively unchanged, but the secondary structure of the motif was displaced forward 
toward the primer strand, even as the rest of the thumb was extended backward away 
from the primer strand (Figure 3.3 illustrates the movement of the thumb in RT). The 
two dark structures of Figure 3.23 (right) are distinctly forward of the pale ball-and- 
stick structure of lrtd, which closely approximates the structure of ldlo, seen in the 
same view and conformation in Figure 3.23 (left). The loop of the primer grip in both 
inhibitor-bound structures has intruded into the space occupied by the strand in the 
catalytic DNA-bound structure, most likely having some affect on the positioning of the 
last two nucleotides of the primer strand.
The primer grip also showed a vertical displacement upward from the palm in the same 
plane as the thumb, unlike the DNA-bound structures, which showed no significant 
vertical displacement. The (313 strand of the primer grip in the inhibitor-bound 
structures showed a slight displacement closer to the fingers subdomain, similar to the
displacement seen in Ihmv, even though the bulk of the primer grip was actually 
displaced away from the fingers. The p i2 strand of the primer grip did not seem to be 
displaced as such, and so the two strands of the loop appear to tighten. This was not 
directly manifested in the displacements measured for these residues (Figure 3.21), 
which appeared to show that residues 227-231 underwent the greatest displacement, 
though these are only scalar measurements and show no directionality. The direction of 
the primer grip loop (residues 229-231) also skewered slightly more toward the heel of 
the hand, or the RNase H subdomain, than the unliganded and DNA-bound structures. 
This is not so evident in Figure 3.23 (right), but can be seen in Figure 3.24 (right).
Figure 3.23 (Left) The conformational differences between the unliganded structure ldlo (thick 
dark sticks) and the binary DNA structure 2hmi (thin dark sticks), seen relative to the primer grip 
in lrtd shown in pale green ball-and-stick (see Figure 3.19 for full legend details). (Right) 
Inhibitor-bound structures of lhni (thick dark sticks) from the CABM group and lvru (thin dark 
sticks) from the OCMS group, also seen relative to lrtd
Once again, the differences in the inhibitor-bound crystal structures from each research 
group could be seen. Those from the CABM group (lbqm, lbqn, lhni, lhnv, Itvr and 
luwb), coloured in orange in Figure 3.24, showed an additional displacement of the 
backbone away from the fingers, which was more discernible than that already noted for
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the DNA-bound enzymes. The red-coloured inhibitor-bound crystal structures of the 
OCMS group also exhibited this displacement. Six of the thirteen from this group 
(lklm, lr tl , lrt4, lrt5, lrt6 and lrt7) had a more noticeable displacement away from the 
fingers. The direction of the primer grip loop also skewered toward the heel of the 
hand, or the RNase H domain, rather than the fingers region furthest from the thumb, as 
seen in Figure 3.24 (right). The remaining inhibitor-bound crystal structures of this 
group also showed a greater displacement away from the fingers than those of the 
CABM group, but not as extreme as those previously mentioned.
Figure 3.24 Two different conformational views of the displacement of the primer grip upon 
substrate and inhibitor binding. Both views are from the back of the hand rather than the normal 
view of Figure 3.1 or 3.3. ldlo (green), lhmv (dark green), lrtd (dark blue), 2hmi (light blue), 
CABM structures (orange), and OCMS structures (red).
Most of the sidechain displacements of the residues of the primer grip were primarily 
due to the additive effect of the displacement of the backbone. This was reflected in the 
similar average displacements of the backbone and sidechain (Table 3.5) and the 
uniformity and smoothness of the displacements seen in the line traces of Figure 3.21. 
However, some sidechain residues had interesting differences between the unliganded, 
DNA-bound and inhibitor-bound crystal structures that provided supporting evidence 
and insight into their function, and were individually investigated.
3.4.3 Conformational changes for phenylalanine 227
This residue’s position furthest away from the (312-(313 loop (see Figure 3.19) would 
have seemed to preclude it from any vital role or interaction with the primer strand. 
Additionally, mutation of this residue would appear not to have any direct effect on the
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positioning of the 3’ terminus end of the 
primer, yet Phe227 is known to play a role 
in the specific recognition of the RNA 
PPT primer, but not the RNA PBS
• 171primer.
Aside from the general forward 
displacement of the whole of the primer 
grip, no significantly different 
conformational displacements were seen 
in the sidechain of Phe227 in either the 
DNA-bound or inhibitor-bound structures. 
The grey diamond line trace of Figure 
3.22 shows more clearly than Figure 3.25 
the greater displacement of the light blue 
2hmi structure compared to the dark blue 
lrtd structure and the dark green second 
unliganded structure for Phe227. The 
catalytic lrtd structure was much more 
conformationally similar to Idlo, as 
illustrated in Figure 3.23 (left).
The inhibitor-bound structures had a wide 
spread of displacements in Figure 3.21, from a residue average of 2.82 A for lklm to 
6.50 À for lbqn. The inordinately high average of lbqn was primarily due to a very 
different sidechain conformation, seen in Figure 3.25 as the individuated orange phenyl 
ring, that produced displacements of up to 10.12 Â (Figure 3.21). The individual effect 
of the displacement of Phe227 in the inhibitor-bound structures was difficult to gauge. 
The slight differences between the unliganded and DNA-bound structures seen in the 
sidechain of this residue that pointed to the lower back of the hand, in the direction of 
the base of the first finger, also revealed little about what role it might play in the 
catalytically active enzyme. Its distance from actual contact with the primer strand, and 
its involvement in the structure of the non-nucleoside inhibitor binding pocket, would 
suggest a supportive role in the architecture of the primer grip, in particular the hairpin
Figure 3.25 The displacement of Phe227 upon 
substrate and inhibitor binding. Idlo ball- 
and-stick (green), lhmv (dark green), lrtd 
(dark blue), 2hmi (light blue), CABM 
structures (orange), and OCMS structures 
(red). The backbone of Idlo is shown as a 
green line trace, the primer strand is in 
purple. The fingers subdomain is to the left 
and the thumb subdomain is to the right, as 
can be more clearly seen in Figure 3.20, which 
is in the same orientation.
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loop that makes contact with the primer strand. Slight changes in its conformation may 
be sufficient to allow differential accommodation of one primer over another.
3.4.4 Conformational changes for tryptophan 229
A constituent of both the primer grip and the non-nucleoside inhibitor binding pocket, 
mutation of this residue results in defective DNA synthesis172 and reduced template­
primer affinity.169 It displayed the most consistent displacement seen of the entire 
motif, as evidenced by the multi-coloured line traces of Figure 3.21 for the residue. 
This was also apparent in both DNA-bound structures as well as the second Ihmv 
unliganded structure in Figure 3.22 where all three line traces stayed below 1.7 A, and 
were averaged at 1.1 A.
The average displacement of the inhibitor-bound structures was 5.0 A, notably greater 
than the unliganded and DNA-bound structures, and ranged between an average of 4.1 
A and 5.6 A. Figures 3.26 and 3.23 (right) illustrate how inhibitor binding induced 
Trp229 to approach the sugar-phosphate backbone between the third last and the 
penultimate nucleotide of the primer strand. While Trp229 in the inhibitor-bound
stmctures did not intrude into and occupy the space of the primer strand in the catalytic
Figure 3.26 The displacement of Trp229 upon 
substrate and inhibitor binding, ldlo ball-and-stick 
(green), lhmv (dark green), lrtd (dark blue), 2hmi 
(light blue), CABM structures (orange), and OCMS 
structures (red). The backbone of ldlo is shown as a 
green line trace, the primer strand is in purple. The 
fingers subdomain is to the left and the thumb 
subdomain is to the right, as can be more clearly seen 
in Figure 3.20, which is in the same orientation.
lrtd structure, we speculate that it 
must have some hydrophobic or 
electronic effect on the positioning 
of the primer terminus, 
notwithstanding effects propagated 
to neighbouring residues. The 
inhibitor-bound structures showed 
little difference in the 
conformation of the aromatic 
sidechain that pointed toward the 
middle of the palm. In a few of the 
structures (lbqm, lbqn, lrt4, lrt5, 
lrt6, and lrt7) the rings of the 
residue were flipped over by 
approximately 180° about the Cp- 
CT bond to occupy virtually the
m
same position 142 This conformational change would be unlikely to have a steric 
effect on Trp229 in its role in the non-nucleoside inhibitor binding pocket, but may be 
quite significant in the bonding interactions it would be capable of with a non­
nucleoside inhibitor.
The replacement of Trp229 with other aromatic residues, such as tyrosine or 
phenylalanine, has been speculated to have the effect of halting the enzyme within a 
hairpin loop of the PPT-DNA hybrid where the intramolecular base pairing needs to be 
disrupted in order to synthesise as far as the template 5’ terminus.173 This inhibition 
affected by only a very slight variation in the structure and nature of this sidechain 
speaks volumes of the exacting demands of the nature and role played by the primer 
grip. The Ti-electron-rich sidechain of Trp229 has been proposed to allow it to 
participate in stacking interactions with nucleic acid bases and thus interact with and 
position the primer stand.169 The greater distance between Trp229 and the sugar- 
phosphate backbone of the primer strand, compared to Met230 and Gly231, makes it 
likely that these interactions play only a small role, if any at all. It is more likely that its 
sidechain provides interactions to stabilise the (312-P13 connecting loop, which 
constitutes a tight P-tum, in the appropriate architecture of the primer grip.169 The 180° 
flipping about the Cp-Cy bond observed in our results and by other researchers142 may 
disrupt the interactions Trp229 is capable of, possibly weakening or totally abolishing 
its interactions necessary for the stabilisation of the P-tum of the primer grip.
Mutations of this residue and Phe227 have also been observed to have an effect on the 
fidelity of replication. Some amino acid substitutions reduce enzyme fidelity, while 
many increase it. The level of fidelity conferred by the natural amino acid sequence is 
advantageous for the survival of the vims, allowing the enzyme to introduce frequent 
changes into the genome177 The inherent flexibility and permissible conformations of 
these sidechains may directly affect the size and shape of the dNTP-binding pocket, or 
affect the orientation and/or accommodation of the 3’ terminus end in the active site to 
allow incorrect nucleotides to bind.
3.4.5 Conformational changes for methionine 230
Both the sidechain and backbone of Met230 make contact with the sugar phosphate 
backbone of the nucleic acid in lrtd, with distances of less than 4 A to the second 
nucleotide of the primer strand.136 The backbone of the unliganded ldlo was slightly
closer to the primer strand in lrtd, while lhmv and 2hmi are slightly further away. The 
last atoms of this residue in both DNA-bound structures point toward the primer strand 
(Figure 3.27) to make close contact with the C2 of the sugar of the second nucleotide. 
In ldlo and lhmv there is a swivelling about Cy which resulted in this sidechain 
pointing into the base of the thumb and the palm respectively, and increasing the 
separation to the primer strand. This swivelling caused the Q  atom to be displaced 
slightly further than the rest of the residue as seen by the increase in the line traces in 
Figure 3.22 for the last atom of this residue. The differences observed in Met230 
between the unliganded and DNA-bound structures were too slight to possibly correlate 
the conformation to the function or role served in polymerisation or positioning of the 
primer strand. These differences were also too small to postulate that the residue 
adopted certain conformations in response to the binding of substrates or to reach a 
catalytic state.
Inhibitor binding induced a 
drastic conformational
displacement of this residue 
forward toward the primer 
strand, such that Met230 and 
the neighbouring Gly231 now 
occupied the space the sugar- 
phosphate backbone of the 
second and third nucleotide 
occupied in lrtd. The residue 
was displaced an average of
5.5 A from ldlo, with the Ce 
atom of inhibitor-bound 
structures showing
displacements of up to 8.2 A. 
Figure 3.27 shows clearly the 
sidechain of Met230 in the inhibitor-bound structures tangling with and occupying the 
space where the penultimate nucleotide of the primer strand lies in the catalytic lrtd 
structure. This displacement indubitably would stall the polymerisation and 
translocation mechanism of any previously bound primer terminus and incoming dNTP,
Figure 3.27 The displacement of Met230 upon substrate 
and inhibitor binding, ldlo ball-and-stick (green), lhmv 
(dark green), lrtd (dark blue), 2hmi (light blue), CABM 
structures (orange), and OCMS structures (red). The 
backbone of ldlo is shown as a green line trace, the primer 
strand is in purple. The fingers subdomain is to the left 
and the thumb subdomain is to the right, as can be more 
clearly seen in Figure 3.20, which is in the same orientation.
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or make virtually infeasible the binding of a new primer-template complex for reverse 
transcription.
3.4.6 Activation and inhibition of the primer grip
The binding of NNRTIs undoubtedly repositioned the (312-pl3-pi4 sheet, including the 
primer grip, as several of these residues also comprised the binding pocket for these 
inhibitors. Despite the much noted hyperextension of the thumb139 upon inhibitor 
binding, the displacement of the primer grip revealed by the DDM-based 
superimposition actually decreased the width of the DNA binding cleft. The hairpin 
loop is displaced in a direction further down the length of the nucleic acid, away from 
the dNTP-binding site. Although a distinction can be seen between inhibitor-bound 
crystal structures from the different research groups (Figure 3.24), this does not lessen 
the unequivocal and complete displacement of the primer grip in these structures. The 
large differences seen between the multi-coloured, and the black and grey monotone 
line traces of Figure 3.21, especially for residues 227-231, illustrated clearly the 
magnitude of the displacement of the primer grip upon inhibitor-binding.
The gross displacement of the thumb (Figure 3.3) is speculated to be necessary for the 
accommodation of nucleic acid hybrids in the DNA-binding cleft. Curiously, despite its 
close proximity at the base of thumb, the primer grip in both DNA-bound structures 
showed virtually none of this extension to a more ‘open’ configuration. The slight 
differences in displacement of the primer grip between the unliganded and DNA-bound 
structures do little to shed light on structural changes that may be necessary to achieve a 
catalytic conformation. It may be that the minor shifting of the primer grip, in lrtd and 
2hmi compared to ldlo, was a case of local structural changes to conform to the 
structure of the bound DNA primer. The binding of different RNA primers necessary 
for the different initiation stages of reverse transcription would presumably require a 
greater flexibility of the primer grip, as these primers do not have the basically linear 
helical structure seen in dsDNA. This flexibility may be manifested as more significant 
structural and conformational changes of the primer, which may provide a rationale for 
experimental results showing differing polymerisation and dissociation rates between 
RNA and DNA primers. The slower extension rate of RNA primers may be due to the 
unique secondary and tertiary structure of the tRNALys3 and PPT primer complexes,178 
and the conformational changes in the primer grip necessary when accommodating and
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retaining these nucleic acids in the binding cleft. In the absence of different RNA- 
primer-bound crystal structures, the magnitude of this flexibility, and the 
conformational changes expected, can only be speculated at this time.
The DDM-based superimposition has demonstrated that inhibitor binding induces 
significant displacement of the primer grip, in the opposite direction to the 
hyperextension of the thumb. The primer grip intruded into the nucleic acid binding 
cleft, but this did not result in a decrease in its separation from the residues of the PAS. 
The distance between the Ca of Gly231, in the loop of the primer grip, and the Ca of the 
residues of the catalytic triad was measured and analysed in Figure 3.28 (data tabulated 
in Appendix 7.9).
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Figure 3.28 Graphical representation of the distance between Ca Gly231 of the primer grip and Ca 
of the residues of the catalytic triad in all of the crystal structures, ldlo (green), Ihmv (dark green), 
lrtd (dark blue), 2hmi (light blue), CABM structures (orange), and OCMS structures (red).
The smallest distances were measured in the unliganded structures, followed by the 
DNA-bound structures; the difference between the unliganded and substrate-bound 
structures was only an average 1.45 A. The inhibitor-bound crystal structures also 
displayed conformational changes in the primer grip, which was forced forward into the 
nucleic acid binding cleft, but in a direction which actually increased its distance from
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the active site residues. The orange coloured lines traces of the CABM research group 
crystal structures in Figure 3.28 averaged a 16.44 A separation between the primer grip 
and the PAS, while the red coloured OCMS structures had an average separation of 
18.68 A. This was a reversal of the average overall displacements of the primer grip in 
the inhibitor-bound structures seen in Table 3.5, where the crystal structures of the 
CABM research group displayed a greater average displacement from the unliganded 
ldlo structure.
The significance of the data in Figure 3.28 cannot be extrapolated beyond the 
observation that inhibitor binding changes the spatial relationship between the primer 
grip and the catalytic aspartates, increasing it by an average of 4.79 A from the 
substrate-bound structures. This is certain to effect the communication necessary 
between the primer grip and the aspartates, as it positions the 3’OH primer terminus in 
relation to the incoming nucleotide, the Mg2+ ions, and the catalytic residues of the 
PAS. While the horizontal displacement of the primer grip would seem to impede the 
binding of any nucleic acid, by occupying part of the binding cleft, the vertical 
displacement may compensate for this loss of space, and rationalise the observation that 
nucleic acids can still bind in the presence of NNRTIs. The conformation of the primer 
grip in an inhibitor-bound structure, or the ability of the template-primer complex to 
bind to the enzyme may depend on which event occurred first, inhibitor or template­
primer binding.
The binding of NNRTIs has been demonstrated to have a profound affect on both the 
primer grip motif and the thumb subdomain of RT (Figure 3.3 and 3.24). The binding 
of DNA substrates had a smaller effect on the primer grip, but an analogous effect on 
the thumb subdomain as inhibitor binding. These induced structural changes were in 
opposite directions, and those of the thumb subdomain warranted some further study by 
reason of its structural closeness to the previously studied primer grip. In the DNA- 
bound structures, the thumb subdomain underwent a hyper-extension to accommodate 
the binding of nucleic acids in the major cleft of the enzyme is seen in the blue Ca trace 
of lrtd in Figure 3.30 compared to the green trace of the unliganded ldlo. The 
extension from the ‘closed’ position in the unliganded structure was investigated by 
measuring the displacement from the ldlo unliganded structure to all other RT 
structures at three positions in the thumb subdomain (illustrated in Figures 3.29 and 
3.30, data tabulated in Appendix 7.10). DNA-bound structures showed an extension of
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residues 286, 296, and 306 in all structures 
represented by large, medium and small 
balls, respectively, representing various 
parts of the thumb, ldlo (green), lrtd 
(dark blue), lhni (orange), and lvru (red).
about 16.8 A in lrtd and 18.2 A in 2hmi. The 
inhibitor-bound structures demonstrated a 
greater extension of the thumb than 
previously seen in the DNA bound thumb 
subdomains, and was most notable in the red 
coloured structures from the OCMS research 
group (Figure 3.30).
In Figure 3.29 the differences in the Ca line 
traces are only slight, with the orange- 
coloured CABM structure (lhni) appearing 
almost the same as the dark blue DNA-bound 
structure (lrtd). However the consistent 
trends of Figure 3.30 show clearly the greater 
extension of the thumb in inhibitor-bound 
structures, on average 20.32 A.
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Figure 3.30 Graphical representation of the distance between the unliganded (ldlo) structure and 
all other RT structures for three residues representing various parts of the thumb (Figure 3.29). 
lhmv (dark green), lrtd (dark blue), 2hmi (light blue), CABM structures (orange), and OCMS 
structures (red).
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The OCMS structures averaged a thumb displacement of 21.51 A, while the CABM 
group displacement was only 17.75 A, just marginally greater than the average 
displacement of the DNA-bound thumb domains.
The greater extension of the thumb in inhibitor-bound structures as compared to 
substrate bound structures may affect inhibition of polymerisation. This may not only 
be in terms of affecting its mobility as suggested by the ‘molecular arthritis model’ of 
non-nucleoside inhibition (Section 3.13), but also possibly by influencing the stability 
of the primer grip which lies in close contact with the thumb. The movement of the 
primer grip forward into the DNA binding cleft is not followed by a forward movement 
of the thumb, but rather a backward hyperextension that may abolish or weaken 
stabilising interactions between the primer grip and the thumb subdomain. Further 
detailed analysis of the structural relationship between the primer grip and the thumb 
subdomain in future may provide further insight into this speculation.
Unlike the polymerase and RNase H active site, which catalyse chemical reactions, the 
primer grip serves more as a structural device to position and translocate the primer 
strand and incoming dNTP for each round of polymerisation. This is not to deprecate 
its function in reverse transcription, but rather clearly delineate the nature of its role. 
Subtle differences in the primer grip architecture, brought about by substitution of 
certain residues or induced by inhibitor binding, have profound detrimental effects on 
all aspects of all of the enzymatic activities of RT. The enzyme’s ability to discriminate 
between oligoribo- and oligodeoxyribonucleic acid primers in general, and tRNALys3 
and PPT primers in particular, is affected. This may stem from its altered position 
deeper in the nucleic acid binding cleft, or may be a result of reduced flexibility 
restricting its ability to perform dynamic movements such as translocation of the primer 
strand and adaptation to different primers and nucleotides.
The significance of the primer grip for enzyme activity and virus infectivity is reason 
enough for its intense study; the participation of several of its key residues in the 
formation of the non-nucleoside inhibitor binding pocket augments this need further. 
Residues such as Trp229, make ideal targets for drug design, as they form part of the 
binding pocket of non-nucleoside inhibitors, are vital for the integrity of the primer grip, 
and their mutation does not result in a high resistance profile to NNRTIs.
3.5 The template grip
3.5.1 The template grip and its role in reverse transcription
The ‘template grip’, consisting of the (34, aB, (35a, and the (38-aE connecting loop 
portions of the p66 palm and finger, is closely associated with the template strand as it 
is first reverse transcribed and then hydrolytically degraded by HIV-1 RT.168 Not as 
much data has been generated, collated or interpreted about the functions of the residues 
of the template grip, as for the PAS and primer grip. This may be due to an assumption 
that the template grip plays a less active role in reverse transcription by reason of its 
distance to the PAS and the 3’OH of the primer terminus where incoming nucleotides 
add to the growing DNA strand. Additionally its distance, and possible irrelevance to 
the non-nucleoside inhibitor binding pocket has meant that little effort has been exerted 
to understand the conformational changes that occur in the template grip upon inhibitor 
binding, and how these changes may promote inhibition of the enzyme.
What mutational data of the residues of the template grip is available is often 
fragmentary, with seemingly random residues investigated and their affect on 
polymerase or RNase H functions noted without any attempts at a complete or even 
general mechanism of action for the template grip. ' What is known is that many of 
the mutations that confer resistance to nucleoside inhibitors are clustered in the fingers 
and palm subdomains.180,181 Presumably, interactions between the (33-(34 region and the 
template affect the ability of the enzyme to discriminate nucleoside analogue drugs from 
natural dNTP substrates without compromising catalytic activities essential for viral 
replication.33
Regions of the fingers subdomain have been implicated in polymerisation 
processivity,160,180,181,183 which refers to the number of nucleotides added to a nascent 
DNA strand before the enzyme dissociates from the template primer complex. HIV-1 
RT is known to display a moderate-to-poor degree of polymerase processivity, which 
may have been evolutionarily conserved to facilitate the strand transfer reactions 
(Section 3.1.2). Several factors may contribute to low levels of processivity; weak 
template-enzyme interactions, secondary structure, and other sequence-specific 
structural variations along the nucleic template.183 A greater understanding of the 
structure of the template grip, and how substrate and inhibitor binding affect its
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constituent residues should provide more insight into its function and the exact role it 
plays in processivity.
The template grip is composed of three segments of polypeptide as seen in Figure 3.31. 
The first section runs horizontally across the middle of the fingers formed by the (34 and 
aB secondary elements. The second section composed of the (38-aE connecting loop 
lies across the middle of the palm, while the third section, formed by (35a, runs across 
the bottom of the fingers where the fingers meet the palm.
Figure 3.31 Conformation of the three segments of the template grip (lrtd) relative to the DNA 
template strand (yellow) and the incoming nucleotide (orange), viewed from above the hand, the 
primer strand has been removed for clarity. Two segments run across the middle and the bottom 
of the fingers, and third segment runs across the middle of the palm. The backbone of lrtd is in 
dark blue lines, the backbone of the template grip is in dark blue ball-and-stick, and the sidechains 
are in light blue ball-and-stick.
In the catalytic lrtd structure, several residues of the template grip were observed to 
make possible contact with the template strand of the DNA, as well as the incoming 
orange dNTP as seen in Figure 3.31. The sidechain of Glnl51 comes within 3.0 A of 
the incoming nucleotide that has been positioned to pair with the templating base. The
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base of the nucleotide awaiting based-pairing with the incoming dNTP, n, is 
approximately 3.5 Á away from the sidechain of Leu74. The sidechains of Asp76 and 
Asp78 lie 2.7 A and 3.8 A respectively away from the sugar phosphate backbone 
between n and n-1, the template nucleotide already base-paired to the last nucleotide of 
the primer strand. Lysl54 makes contacts with the sugar-phosphate backbone between 
n-1 and n-2, while Glu89 lies 3.7 Á from the sugar of the nucleotide n-2.
3.5.2 Synopsis of the displacement of the template grip
The template grip is composed of three segments of polypeptide. The first section runs 
across the middle of the fingers (residues 73-83), the second section lies across the 
middle of the palm (residues 86-93), and the third section runs across the bottom of the 
fingers (residues 148-154) where the fingers meet the palm. The residues of the 
template grip are listed in Appendix 7.6, and displacement data is tabulated in Appendix 
7.11.
The comparison of the lhmv unliganded structure revealed little difference with the 
ldlo structure in the backbone of the structures, with an average displacement of only 
0.68 A. The sidechain component showed more of a displacement than the backbone, 
shifting an average of 1.16 Á from the conformation of ldlo. The greatest differences 
in the sidechain conformations of the two unliganded structures were noted at residues 
Val90, Gln91, and Glnl51, as can be seen in the light grey square line trace of Figure
3.33 and detailed in Section 3.5.4 and 3.5.5. With the exception of these few residues, 
both the backbone and sidechains of the two unliganded structures were virtually 
indistinguishable, and served to verify and substantiate later comparisons with the ldlo 
unliganded structure.
The results of the DDM-based superimposition showed that there were several small 
differences in the conformations of the two DNA-bound structures compared to the 
unliganded structures, despite the almost identical average displacement values for lrtd 
and 2hmi, differing by an average of only 0.07 Á. The values in Table 3.6 for the 
ternary and binary structures were slightly misleading as they encompassed the 
conformational changes of the three separate segments of the template grip, which each 
behaved quite differently in terms of substrate-induced conformational changes. The 
average displacement of the lrtd catalytic ternary structure was observed to be 
marginally greater than that of the 2hmi structure in both the backbone and sidechain
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components. This was in contrast to the average displacements for these structures seen 
in the PAS and the primer grip, where the binary structure had displayed notably greater 
average displacements than lrtd.
The inhibitor-bound structures displayed an average displacement of the template grip
o
of 4.13 A, from the conformation in the ldlo unliganded structure. Figure 3.32 shows 
the difference of approximately 2.6 A between the multi-coloured, and the black and 
grey monotone line traces, representing the inhibitor-bound and substrate-bound or 
unliganded structures respectively. Consistent displacements of varying magnitudes 
were seen throughout most of the three segments of the template grip, separated by 
spaces in Figure 3.32, with larger displacements seen in the sidechains of the residues 
compared to the backbone. The least consistent residues of the template grip in the 
inhibitor-bound structures were residues 89-93 of the palm segment that showed 
displacements as great as 14.38 A in a leucine sidechain of lrt3 and as little as 2.24 A in 
lrt2. The continuing trend of greater average displacements in inhibitor-bound crystal 
structures of the CABM research group compared to the OCMS group was observed in 
Table 3.6, with CABM crystal structures being displaced 0.85 A further from the 
unliganded ldlo structure than those from the OCMS group.
average DNA-bound inhibitor-bound structures
displacement structures
(A) lhmv ternary binary total CABM OCMS
entire residue 0.94 1.83 1.76 4.13 4.71 3.86
backbone 0.68 1.69 1.61 3.83 4.33 3.60
sidechain 1.16 1.95 1.90 4.38 5.02 4.08
Table 3.6 Summary of the average displacement between the ldlo unliganded structure 
and the alternate unliganded (lhm v), substrate-bound (lrtd-ternary and 2hmi-binary), 
and inhibitor-bound structures for the entire template grip, and only the backbone or 
sidechain component. The three representative average displacements were calculated 
for all 19 inhibitor bound structures (total), and based on the research groups that 
derived the crystal structures; six from the CABM research group, and 13 from OCMS 
research group.
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Figure 3.32 Graphical representation of the displacement between the unliganded (ldlo) structure and all RT structures for the template grip.
3.5.2.1 Substrate induced conformational changes of the template grip
In Figure 3.33, the DNA-bound structures of lrtd and 2hmi did not appear to show great 
similarity to the unliganded structures in the template grip, but closer observation of 
Figure 3.34 (left, top and bottom) revealed some residues that were quite comparable in 
conformation and positioning. Specifically, in the segment of the template grip running 
across the bottom of the fingers (residues 148-154) there was virtually no difference in 
the template grip between the DNA-bound enzymes and the unliganded enzyme (Figure
3.34 left, bottom). The black circle and grey diamond line traces of Figure 3.33 in this 
region showed fairly consistent average displacements of 1.1 Á, with only a few 
deviations in the occasional sidechain, such as Glnl51 in 2hmi, displaced 4.85 Á.
Most of the segment of the polypeptide across the middle of the fingers, furthest from 
the thumb, showed uniformity between lrtd, 2hmi and ldlo. This portion of the 
segment was composed of residues 76-83. The remainder of this segment, 73-75, 
closest to the thumb, had the DNA-bound structures displaced slightly lower in the 
plane of the fingers, with average displacements of about 2.8 A seen in Figure 3.33 for 
these residues in the black circle and grey diamond line traces. The thin dark stick 
structure of 2hmi in Figure 3.34 (left, top) was, overall, slightly displaced back into the 
fingers, as if from an opening or extension of the hand, while pale ball-and-stick 
structure of lrtd was slightly displaced forward of the thick dark stick structure of the 
unliganded enzyme. This was also seen in the dark and light blue backbone traces of 
Figure 3.35 (left). In lrtd this could be speculated to be a movement associated with 
clamping of the template-primer grip to interact with the nucleic acid as it is reverse 
transcribed.
Along the palm of the hand, the DNA-bound structures were very similar to ldlo, as 
illustrated by the almost overlapping structures for these residues in Figure 3.34 (left, 
top), and the smaller valued black and grey line traces of Figure 3.33. The exceptions to 
this were the residues Val90 and Gln91, where the polypeptide curved slightly toward 
the PAS, before the last few residues curved back to a similar position as the unliganded 
enzyme (Figure 3.35). This deviation in conformation, was not totally evident in Figure
3.34 (left, top), but was manifested in the greatest displacement of about 7.5 Á from the 
unliganded structure in the entire template grip in Figure 3.34. No discernible vertical 
displacement in the plane of the palm was noted for either DNA-bound structure.
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Figure 3.33 Graphical representation of the displacement between the unliganded (ldlo) structure, 
and the second unliganded (lhm v) and DNA-bound structures (lrtd  and 2hmi) for the template 
grip.
3.5.2.2 Inhibitor induced conformational changes of the template grip
The binding of non-nucleoside inhibitors induced unambiguous conformational changes 
in the three separate segments of the template grip. The clustering of multi-coloured 
line traces for the inhibitor-bound structures was distinct from the lower placed black 
and grey line traces of the unliganded and DNA-bound structures in Figure 3.33. 
Consistent displacements were seen across the sequences of the template grip, with the 
exception of residue 78 and residues 89-93, which showed much greater displacement 
and lacked the clustering effect seen in residue regions such as 80-82 and 86-88.
Varying displacements back into the fingers were seen for the section of the primer grip 
that runs across the middle of the fingers (Figure 3.34, right, top, Figure 3.35). This 
displacement varied, with a number of crystal structures (lrtl, lrt2, lrt6, lrt7, lrth and 
lrti) clustering close to the light blue 2hmi DNA-bound structure in Figure 3.35 (left), 
and the remainder being displaced further back into the fingers. A smaller displacement 
downward, in the plane of the fingers was also seen in this segment of the template grip.
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In the segment of the template grip that runs across the palm, residues Asp86 to Trp88, 
near the fingers, displayed a slight displacement down into the plane of the palm (Figure 
3.35, above). The residues Val90 and Gln91 of all the inhibitor-bound enzymes, with 
the exception of lrt2 and lrt3, showed a greater curvature toward the polymerase active 
site than the slight curving displacement already previously noted in the DNA-bound 
enzymes. The dark black and grey structures of Figure 3.34 (top, right) and the orange 
and red structures of Figure 3.35 (left) show clearly how the last couple of residues, 
Leu92 and Gly93, of this segment of the template grip curve back to a similar position 
to the unliganded and DNA-bound structures. This segment of the template grip was 
also displaced vertically upward from the plane of the hand; on average 2-3 A, possibly 
affecting the template strand that runs through the nucleic acid binding cleft.
The final segment along the bottom of the fingers in the inhibitor-bound structures 
behaved similarly to the section of the template grip along the middle of the fingers. 
There was a general displacement back into the fingers, away from where the template 
strand of DNA would contact the fingers subdomain (Figure 3.34, left), and a small 
downward displacement in the plane of the fingers (Figure 3.34, right, bottom). An 
additional slight displacement was noted where the polypeptide of the inhibitor-bound 
structures was displaced toward the thumb, in the plane of the fingers, that is, toward the 
first finger and away from the smallest finger. This can be seen in Figure 3.34 (right, 
bottom) where the thick and thin dark structures are shifted upward in the illustration.
The larger number of residues of the template grip and the smaller body of literature on 
this motif make it difficult to confidently correlate the conformational changes observed 
by the DDM-based superimposition to functional roles of the residues, or how these 
roles may be stalled by inhibitor binding. Several residues of particular interest were 
analysed in more detail to provide some basis for speculation to the roles as residues of 
the template grip.
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Figure 3.34 (Left, top and bottom) The conformational differences between the unliganded 
structure ldlo (thick dark sticks) and the binary DNA structure 2hmi (thin dark sticks), seen 
relative to the template grip in lrtd shown in pale ball-and-stick. (Right, top and bottom) 
Inhibitor-bound structures of lhni (thick dark sticks) from the CABM group and lvru (thin dark 
sticks) from the OCMS group, also seen relative to lrtd. (Top) The middle of the fingers and palm 
segments of the template grip. (Bottom) The bottom of the fingers segment of the template grip. 
The conformation of all figures is the same as in Figure 3.31; the incoming nucleotide is in orange, 
the backbone of lrtd is in pale dark blue ball-and-stick, and the sidechains are in pale light blue 
ball-and-stick; the backbone of ldlo, 2hmi, lhni, and lvru are in dark black, and the sidechains are 
in dark grey. This view is the same used Figure 3.31
Figure 3.35 (Left, above) Two different views 
of the displacement of the backbone of the 
template grip upon substrate and inhibitor 
binding, ldlo (green), lhmv (dark green), lrtd 
(dark blue), 2hmi (fight blue), CABM (orange), 
and OCMS structures (red).
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3.5.3.Conformational changes for Leu74-Asp76-Arg78
Of the substrate-bound and unliganded structures, only ldlo and lrtd had resolved 
sidechains for Leu74, and these were notably different from each other. In lrtd the 
sidechain of Leu74 was able to make contact with the template nucleotide that is base 
paired with the incoming dNTP. In ldlo, this residue, while not displaced back into the 
fingers, showed a very small movement upward in the plane of the fingers subdomain 
and further away from the template. The backbone of 2hmi, seen as a light blue 
structure in Figure 3.36, showed that it was much further displaced back into the fingers 
away from the nucleic acid binding cleft. Residues Asp76 and Asp78 are much more 
similar between the four DNA-bound and unliganded structures, as seen in Figure 3.33.
The red and orange inhibitor-bound 
structures for these residues in 
Figure 3.36 all showed essentially 
the same displacement of this 
segment of the template grip deeper 
into the fingers, as if the fingers of 
the hand were opening up, or 
unclenching. Varying sidechain 
conformations were seen for the 
inhibitor-bound structures of these 
three residues, but the only 
significantly notable deviation is in 
the sidechain of Arg78. In most 
structures, including the unliganded 
and DNA-bound structures, the 
sidechain points directly upward to 
the top of the fingers following the 
plane of the subdomain. The 
exceptions were lhni, lhnv, ltvr, and luwb which pointed in the opposite direction, 
down the plane of the fingers, toward the palm. This difference in conformation 
explained the suddenly high line traces of some of the inhibitor-bound structures for this 
residue in Figure 3.32. Leu74 in all the inhibitor-bound structures showed an additional
Figure 3.36 (Left) The displacement of Leu74, 
Asp76, and Arg78 upon substrate and inhibitor 
binding. The view is from above the fingers and 
hand. ldlo ball-and-stick (green), lhmv (dark 
green), lrtd (dark blue), 2hmi (light blue), CABM 
structures (orange), and OCMS structures (red). 
The template strand in lrtd is shown in yellow ball- 
and-stick, the incoming nucleotide is in orange.
shifting upward in the plane of the fingers subdomain to a vertical position similar to the 
unliganded ldlo structure.
Mutations of Leu74 have been shown to affect the fidelity of DNA synthesis,162 with 
speculation that the residue is involved in template repositioning. An amino acid 
change at this position could lock the templating base tightly in place, possibly also 
influencing dNTP binding through interactions with the sidechains of Arg72 and 
Glnl51. There was insufficient evidence in the small changes seen between the lrtd 
and ldlo structures of Leu74 to theorise that the conformational changes were substrate 
induced. It may be possible that Leu74 undergoes a conformational change to bring it 
close enough to the n nucleotide about to be base-paired, to stabilise it so that it is 
correctly identified for base pairing. Alterations in the structure of the residue may 
perturb the correct stabilisation and identification of the template base, thus affecting 
the fidelity of replication. The inhibitor-induced conformational changes seen in Figure 
3.36 would surely reposition Leu74 too far away from the n base of the template strand 
to allow it to function as speculated in its normal role.
Residue Asp76 has been postulated to interact with the template nucleotide that base 
pairs with the incoming dNTP, promoting mispairing by occasionally interfering with 
base pairing of the template nucleotide to the incoming nucleotide. Mutations of 
Asp76 have the effect of increasing replicational accuracy, and may not have been seen 
in clinical isolates because increased fidelity may be detrimental to viral fitness. 
Only small differences were seen in the line traces of Figure 3.33 between the 
unliganded and the DNA-bound structures for Asp76; the blue and green structures of 
Figure 3.36 were also quite similar. As literature appears to indicate that the role played 
by Asp76 in DNA replication is not vital, it is likely that the conformational 
displacements induced by inhibitor binding (Figure 3.36) did not have a direct affect in 
the inhibition of the enzyme, but were rather due to the shifts observed for other 
residues of the template grip, and possibly other structural motifs.
Arg78 is believed to interact directly with the phosphate backbone between n, the 
template nucleotide about to be base paired to the incoming dNTP, and n-1, the template 
nucleotide already base-paired to the last nucleotide of the primer strand, as well as 
Asp76. Literature revealed little about possible roles it might play in template 
positioning and ultimately DNA replication, but they are likely to include a structural 
supportive role as evidenced by its likely interaction with Asp76. The results of the
DDM-based superimposition definitively showed that the binding of non-nucleoside 
inhibitors induced a displacement of Asp78 deeper into the fingers, and away from the 
nucleic acid binding cleft, as well as altering its structural relationship with Asp76. The 
interpretation of these results requires further experimental and mutational evidence of 
the role played by both Asp78 and Asp76 in the function of the template grip.
3.5.4 Conformational changes for Glu89-Val90-Glu91-Leu92
This short section of residues along the palm of the hand showed several notable 
differences between the unliganded and the DNA-bound structures, most especially for 
residues Glu91 and Leu92. Only small differences were seen between both DNA- 
bound structures and the two unliganded structures for Glu89 and Val90, as indicated by 
the black and grey line traces of Figure 3.33. Generally the DNA-bound structures were 
placed slightly more toward the fingers domain than the unliganded structures, as 
illustrated clearly by the blue structures shifted left compared to the green structures of 
Figure 3.37.
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Figure 3.37 (Left) The displacement of Glu89 and Gln91 upon substrate and inhibitor binding. 
(Right) The displacement of Val90 and Leu92 upon substrate and inhibitor binding, ldlo ball-and- 
stick (green), lhmv (dark green), lrtd (dark blue), 2hmi (light blue), CABM structures (orange), 
and OCMS structures (red). The template strand in lrtd is shown in yellow ball-and-stick.
The sidechain of Glu89 in the unliganded and DNA-bound structures pointed in the 
general direction of the first finger, or toward the back of the hand, with the clustering 
of the blue and green structures of Figure 3.37 (left) giving an indication of how 
conformationally similar they were. The sidechain of Val90 in these four structures was 
oriented to point downward into the palm, though the substrate-bound structures
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showed a displacement toward the fingers and the back of the hand. In none of the 
structures was Val90 within contact distance of the template strand. Both DNA-bound 
structures displaced Glu91 higher in the plane of the palm than the green ldlo 
unliganded structure of Figure 3.37 (left) and the residue pointed toward the back of the 
hand and the thumb, in a downward direction. The backbone of this residue in the 
unliganded structure was lower in the plane of the palm, and the sidechain curved to 
point down into the palm, away from the template. Residue Leu92 was quite similar in 
the 2hmi substrate-bound structure to both unliganded structures, with the sidechains 
directed toward the wrist and RNase H subdomain, while in the lrtd structure this 
residue was displaced notably toward the fingers subdomain (Figure 3.37, right).
In the inhibitor-bound structures, Glu89 did not show significant displacement in the 
backbone, but the sidechains were different to the unliganded and DNA-bound 
structures, all pointing toward the RNase H subdomain along the plane of the palm. 
The exceptions to this were the lrt2, lrt3, and lrev structures which pointed upward 
toward the middle of the fingers (Figure 3.37, left). The sidechains in lbqm, lbqn, 
lhni, lhnv, and luwb also differed as they pointed upward toward where the template 
strand would lie, close enough to make contact with where its sugar-phosphate 
backbone would lie in the lrtd structure. In the inhibitor-bound structures, Val90, with 
the exception of lrt2 and lrt3, always showed a displacement away from the unliganded 
position toward the back of the hand, or toward the PAS. This was illustrated as an 
upward shift in Figure 3.37 (right), as well as a vertical displacement upward from the 
plane of the palm. The structures of lrt2 and lrt3 were instead similarly placed to the 
unliganded and DNA-bound structures, but still showed the vertical displacement of the 
other inhibitor-bound structures. In Val90 this upward displacement did not extend 
sufficiently to force the residue into the space where the nucleic acid would lie. The 
sidechains of Glu91 were varied and inconsistent in their displacements in the inhibitor- 
bound structures, but most were displaced backward, closer toward the back of the hand 
and the PAS, and slightly higher in the plane of the palm. However, these displacement 
generally did not force Glu91 to contact the template strand, as it would lie in the 
catalytic lrtd structure, because of the backward displacement toward the PAS 
previously mentioned. A higher displacement in the palm and a shifting left toward the 
fingers subdomain did cause Leu92, in most of the inhibitor-bound structures, to intrude
m
into DNA-binding cleft sufficiently to occupy the space where the template strand lies 
in the lrtd structure.
3.5.5 Conformational changes for Glnl51
This residue in ldlo and lrtd was similarly positioned, with the sidechain pointing 
toward the back of the hand in the direction of the thumb, or toward the incoming dNTP 
in the lrtd structure. The only difference in conformation of the sidechain was a 
swivelling about the CY atom of about 90° (Figure 3.38). In the light blue 2hmi and dark 
green lhmv structures, Glnl51 was displaced slightly deeper into the fingers, toward the 
left of Figure 3.38, and its sidechain pointed into the fingers subdomain in the direction 
of the first finger. The slight differences in the conformations of the two DNA-bound 
structures may be due to the presence of the incoming dNTP in lrtd, that is lacking in 
2hmi, as well as the different conformations of the template strands resolved by 
different techniques for each structure. Whether these differences compared to the ldlo 
unliganded structure were substrate induced could not be reasonably hypothesised as the 
structure of the dark green alternate unliganded lhmv was so different from ldlo.
The inhibitor-bound structures 
displayed an inconsistent variety of 
conformational changes. Those from 
the CABM research group were 
displaced in the plane of the fingers 
more toward the first finger or toward 
the back of the hand, and had the 
Glnl51 sidechain pointing upward to 
the top of the fingers, and unable to 
make contact with the incoming dNTP. 
A very slight displacement deeper into 
the fingers was also seen. Structures 
from the OCMS research group 
displayed a similar backbone 
displacement, but their sidechains 
generally were still directed toward the 
incoming dNTP, such that those
Figure 3.38 The displacement of Glnl51 upon 
substrate and inhibitor binding. The view is 
from above the hand, ldlo ball-and-stick (green), 
lhmv (dark green), lrtd (dark blue), 2hmi (light 
blue), CABM structures (orange), and OCMS 
structures (red). The template strand in lrtd is 
shown in yellow ball-and-stick, the incoming 
nucleotide is in orange.
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sidechains in lklm, lr tl, lrt2, lrt4, lrt6, lrt7, and lrth were still within interacting 
distance with the dNTP.
Glnl51 is a constituent of the highly conserved LPQG motif present in all reverse 
transcriptases, and is thought to interact directly with the 3’-OH and the (3-phosphate of 
the dNTP. It also forms a part of the flexible binding pocket for the incoming dNTP 
and exerts both direct and indirect influences on other residues of the dNTP-binding 
pocket. It interacts directly with the sidechain of Arg72, that is implicated in stabilising 
the transition state ternary complex before and after the phosphodiester bond 
formation.161,186,187 Mutations of Glnl51, thought to be unable to stabilise this 
sidechain, have been found to be devoid of pyrophosphorolytic activity on RNA-PBS 
template-primers, necessary as the release of pyrophosphate (PR) to complete 
polymerisation. Glnl51 also indirectly affects the mainchain carbonyl oxygen of
residue 73 that hydrogen bonds with Glnl51, bridging the palm and fingers subdomain.
188 Glnl51 is also hypothesised to influence the ability of the enzyme to recognise and 
discriminate against the sugar moieties of nucleotide substrates, due to its influence on 
the flexibility of the dNTP binding pocket. Researchers believe Glnl51 may have 
different and independent roles to play in reverse transcription depending on whether 
the template is DNA or RNA.187,189
The multiple and exacting roles that Glnl51 is believed to play in both the formation of 
the phosphodiester bond and the release of pyrophosphate, the recognition of different 
nucleic acid templates, as well as in the stabilisation of other significant residues, would 
likely mean that even a slight change in the conformation and position of the residue 
could affect the performance of its function. While slight changes may be necessary for 
the dynamic and varied functions Glnl51 serves, changes too great or in the wrong 
direction, or changes affecting flexibility may restrain the residue from all its functions. 
The conformational changes induced by inhibitor binding, seen in Figure 3.38, could be 
sufficient to exact such change on Glnl51 and restrict its full functioning, and extend to 
influencing other residues that are indirectly dependent on the correct positioning and 
conformation of Glnl51.
3.5.6 Activation and inhibition of the template grip
This DDM-based superimposition study has allowed quantification of the displacement 
of the residues of the template grip upon substrate and inhibitor binding, but in the
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absence of more supporting evidence, such as thorough mutational and activity data, 
limited conclusions could be made about substrate or inhibitor-induced conformational 
changes. The comparisons between the unliganded ldo structure and the two DNA- 
bound structures have revealed two short sections of residues that might tentatively be 
considered to display substrate-induced conformational changes. Residues 73-75, of the 
segment of the template grip running across the middle of the fingers, in the catalytic 
lrtd structure were displaced downward in the plane of the fingers subdomain, and 
forward toward the template strand, compared to the unliganded structure (Figure 3.34, 
left, top). The same residues in the binary DNA-bound structure of 2hmi showed the 
same displacement down the plane of the fingers, but were displaced deeper into the 
fingers rather than forward toward the template strand. This difference between the two 
DNA-bound conformations may be induced by the incoming dNTP.136 Residues 73-75 
may be part of a large closing down of the fingertips to momentarily trap the template 
strand and the dNTP, that is possibly held in place by its contact with Leu74136,160. 
Accordingly, lrtd represents the ‘closed’ fingers state where the template strand and 
dNTP are positioned for optimal base-pairing and imminent polymerisation with the 
3’OH of the primer terminus. Following phosphodiester bond formation the fingertips 
are postulated to bend back to an ‘open’ position to release pyrophosphate, allow 
template translocation and the binding of the next dNTP.136 The 2hmi structure is most 
likely to be a snapshot of this ‘open’ fingers conformation.
Along the palm segment of the template grip residues Val90 and Glu91 showed 
differences between the two DNA-bound structures that were in contrast to the relative 
conformity seen in the neighboring residues 86-89. Both lrtd and 2hmi were differently 
conformed to the unliganded ldlo structure, but these differences did not appear 
sufficient to bring them within contact distance of the phosphate backbone to affect any 
influence on the positioning or support of the template strand (Figure 3.37). The 
differences between lrtd and 2hmi were also difficult to rationalise, as no one structure 
appeared to have a significantly greater association with the template strand than the 
other. It could be speculated that the conformations of the structures play varying 
supportive roles to surrounding residues or secondary structures, and slight differences 
may be sufficient to alter the local architecture to distinguish between the two 
conformational states these structures are believed to represent.
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The binding of non-nucleoside inhibitors induced conformational changes of the 
template grip that were much more distinct than those seen in substrate-bound 
structures. Both segments of the template grip composed of elements from the fingers 
subdomain showed displacements deeper into the fingers, or toward a more ‘open’ form 
using the analogy of the hand. These conformations forced the residues further away 
from the template strand, ending any stabilising contacts they would have had with the 
bases of the nucleic acid. This would most likely have an effect upon the processivity 
of polymerisation, but this could not be verified, as no data on how non-nucleoside 
inhibitors affect enzyme processivity was available. The permanence of these 
conformational changes can also only be speculated at, as the fingers subdomain have 
been noted to be flexible in their motions, and on substrate binding could move to 
compensate the changes seen in these DDM-based superimpositions.
Part of the segment of the template grip that lies across the palm subdomain saw 
emphatic conformational changes in the inhibitor-bound structures that were most likely 
to affect the binding of the template strand in the nucleic acid binding cleft. Like the 
residues of the PAS on the palm, but further toward the back of the hand, this segment 
of the template grip showed a vertical displacement up from the plane of the palm, and 
back toward the back of the hand. Leu92 in most of the inhibitor-bound structures was 
displaced sufficiently to occupy the space of the template strand in lrtd. Neighboring 
residues were also vertically displaced, and while these displacements did not have the 
same impression upon the template strand as did Leu92 in Figure 3.37 (right), it would 
be reasonable to expect that they may also have been propagated to surrounding regions 
of the protein. This may possibly influence other contacts the template strand could 
have with the palm subdomain.
The seemingly passive and supportive role that the template grip plays in the complete 
process of reverse transcription has meant that less progression has been made toward 
understanding its exact functions as a whole and the functions of its individual residues. 
The significance of the influence the displacements of the template grip induced by non­
nucleoside inhibitor binding, seen in these DDM-based superimpositions, have on the 
inhibition of the enzyme can only be guessed. But it is likely to be notable, as the exact 
and complete process of reverse transcription requires the synchronous performance of 
all the components of the replication machinery, and no one component, such as the 
template grip can be deprecated. Further concerted and focussed research on the
biological functions of the residues of the template grip will be needed to support or 
challenge the results from these superimposition studies.
3.6 The RNase H active site
3.6.1 The RNase H active site and hydrolysis of RNA
The ribonucléase hybrid (RNase H) activity is the least understood and studied of all the 
functions of HIV-1 RT even though its role in reverse transcription is equally as 
important as polymerisation. The RNase H subdomain of HIV-1 RT has been 
crystallised in free form,190 however this isolated form is not active. Embedded in the 
structure of the p66/p51 heterodimer, the RNase H subdomain is a carboxy-terminal 
extension of the p66 connection subdomain, and interacts predominantly with the p66 
connection and the p51 thumb subdomains191 (for the structure of the heterodimer, refer 
back to Figure 3.1). The RNA hydrolytic activity of this internal enzyme selectively 
degrades the RNA template strand when it is part of an RNA-DNA hybrid; when
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hydrolysis occurs on an RNA homopolymer this activity is designated RNase H*. 
RNase H cleavage can occur if the rate of DNA polymerisation is lower than the rate of 
RNA hydrolysis.192
The HIV-1 RT RNase H domain is folded into a five-stranded p-sheet flanked by four 
asymmetrically arranged a-helices. The RNase H active site is located in a shallow 
cavity containing four acidic amino acid residues Asp443, Glu478, Asp498, and 
Asp549, as well as His539 (Figure 3.39). All five residues are highly conserved in 
retroviral and bacterial RNase H; the mutation of a single residue from this group 
renders the RNase H subdomain inactive.193195
. • • 191 196RNase H has at least three specific functions in the reverse transcription process ’ 
(see Section 3.1.2). First, the enzyme partially degrades the 5’end of the viral RNA 
template during or after (-)ssDNA synthesis, leaving intact a specific polypurine tract 
(PPT) to serve as an RNA primer, and facilitating the first strand transfer. Second, it 
excises the PPT primer from the (+) strand DNA, by hydrolysis of the phosphodiester 
bond at the RNA-DNA junction, for the initiation of second-strand (+) DNA synthesis. 
Finally, the RNase H removes the (-) strand tRNA and the (+) strand primer, enabling 
synthesis of full-length dsDNA to be completed.
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Figure 3.39 Proposed coordination complex of the RNase H active site of the catalytic Irtd 
structure with possible interactions with the Mg2+ ion; Mg2+ ion (purple), template strand (dark 
green). The residues of the active site are coloured by atom, oxygen (red), carbon (black), and 
nitrogen (blue).
Two distinct modes of RNase H activity have been identified, a polymerase-dependent 
and a polymerase-independent mode.128'197"199 In the polymerase-dependent mode, 
RNase H degrades the RNA template upon elongation of the DNA strand, and its 
specificity is defined, in part, by binding of the PAS to the 3’terminus of the primer 
strand.200 The RNase H active site is believed to need only be positioned at a site 
transiently during reverse transcription to enhance the hydrolysis at the site, resulting in 
products of 18-20 bases in length.196 The polymerase-independent activity of RNase H 
is not coupled to polymerase catalysis, and may possibly be sequence dependent. It 
results in degradation products of down to seven bases, as it can catalyse RNA 
hydrolysis at many sites in the RNA up to six nucleotides from the ribonucleotide 
complementary to the 3’terminal deoxynucleotide of the primer. Both modes of RNase 
H activity are required for the completion of the enzyme’s role in reverse transcription. 
Removal of the tRNA primer by RNase H, one nucleotide removed from the DNA-
m
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RNA junction, leaving a single ribonucleotide 5-phosphate at the 5’terminus of the 
DNA genome, can be polymerase dependent196 or independent.201
RNase H exhibits 3’-5’ exonuclease activity in addition to endonuclease activity.198,202 
The exonuclease activity removes nucleotides one at a time from the end of the template 
strand, while the endonuclease activity cleave the phosphodiester bond from within the 
RNA strand. Studies have suggested that the RNase H domain and active site may 
function in two conformations; one in which both the endonuclease and exonuclease 
activities occur, and another in which only the endonuclease is active.203 The 
conformational state of the enzyme may depend on the nature and structure of the 
nucleic acid substrate, and the divalent cation activator at the active site.
The contention with regard to the divalent metal ion(s) involved in the RNase H activity 
of HIV-1 RT has been wide-ranging and ongoing. Although, most studies appear to 
agree that Mg2+ is the preferred ion of choice, other ions have been shown to be almost 
as effective. The replacement of Mg2+ by Fe2+ in the RNase H active site confers the 
ability to cleave dsDNA. The cleavage mechanism, oxidative or enzymatic, as well as 
the positions of the cut can vary depending on whether DNA or RNA, respectively, is 
the template.192 In some mutated enzymes that have lost natural RNase H activity, the 
addition of Mn2+ has restored activity, suggesting that the Mg2+and Mn2+ occupy 
different active sites within the mutant enzyme. The alternative coordination and 
stabilisation of specific conformations of the active site that Mn2+ may allow, could 
possibly compensate for the mutation.195 The question of which divalent ion is naturally 
used by RNase H is still not clarified with the available crystal structures. The ternary 
catalytic structure bound with dsDNA (lrtd), and an inhibitor-bound structure (lrev), 
showed only one Mg2+ ion,136’138 although the ion in the latter structure was not fully 
identified, and only modelled on the assumption that it was a magnesium ion. In Figure 
3.39 the structure of the RNase H active site in lrtd is shown with respect to the 
magnesium ion and the template strand, which were separated by only 3.72 A. The 
contact between Asp443 and the Mg2+ ion was verified in the crystal structure,136 while 
the contacts to Asp498 and Asp549, at 3.16 A and 2.53 A, respectively, are only 
postulated. Glu478 was mutated to a glutamine residue to inactivate the RNase H 
activity in crystallising the lrtd structure. Mn2+-doping studies, as well as a crystal 
structure of the free RNase H subdomain, have revealed two bound Mn2+ ions, 
separated by approximately 4 A.190,204 This alludes to a hypothesis that there may exist
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two distinct and mutually exclusive Mg2+ binding sites; depending on the reaction that 
is catalysed, with only one metal ion site populated for any specific reaction.204
The catalytic mechanism of RNase H hydrolysis of the phosphodiester bond has not yet 
been elucidated. The metal ions have been speculated to play a role in the stabilisation 
of the negatively charged nucleophile (OH") and the transfer of the negative charge from 
the nucleophile to the phosphate.191 Two alternative catalytic mechanisms have been 
proposed to satisfy the contentious issue of how many ions are involved.205 One is a 
two-metal ion mechanism, in which the hydrolysis of the P -03’ bond is promoted by 
two metal ions, such that the first metal ion activates an attacking water molecule, and 
the second metal ion stabilises the transient pentavalent phosphorus intermediate and 
facilitates the release of the 3’oxyanion. The other is a general acid-base mechanism, in 
which His539 activates an attacking water molecule as a general base and a single metal 
ion stabilises a transient intermediate by forming an outer sphere complex.
The PAS and the RNase H active sites can contact an RNA-DNA duplex 
simultaneously; the contact points lie approximately 18 base pairs apart on the double­
stranded nucleic acid, though this number has been the source of much 
debate.132,136’196’197,199,202’206 In the catalytic lrtd structure there are 17 base pairs 
between the two active sites, and 17-18 base pairs for the binary 2hmi structure. The 
number of base pairs between the catalytic sites is dependent on the state of the enzyme 
as the protein, the nucleic acid, or both, are expected to undergo conformational changes 
as part of the polymerase and RNase H reactions.
The RNase H subdomain and its activity are not autonomous; mutations in the primer 
grip,171,172,207 finger, and thumb208 subdomains can alter the positioning of the nucleic 
acid substrates and decrease RNase H activity. The binding of the NNRTI nevirapine 
has been shown to cause sufficient distortion of the enzyme to affect the specificity of 
RNase H cleavage.209 The lack of RNase H activity data for NNRTIs has hampered 
efforts to further correlate and corroborate the hydrolytic inhibition effects of 
nevirapine, and this deficiency needs to be addressed for further study. Investigation of 
the substrate and inhibitor-induced conformational displacement of the active site 
RNase H residues can form a basis of quantitative evidence of long range 
conformational changes affecting all of RT’s enzymatic activities. Along with further 
experimental evidence, this data may be able to fully assess and assign the functions of
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the residues and explain how substrate and inhibitor binding affect their roles in 
polymerisation and hydrolysis.
3.6.2 Synopsis of the displacement of the RNase H active site
The results of the superimposition showed clearly the small differences in positioning 
and conformation induced by substrate binding, and the larger displacements that were 
induced by inhibitor binding (Figures 3.40 and 3.41). The residues of the RNase H 
active site are listed in Appendix 7.6, and displacement data is tabulated in Appendix 
7.12.
The comparison of Idlo with the second unliganded structure lhmv, on the whole, was 
favourable with low RMSD values for the superimposition. The only deviation seen 
between the unliganded structures was in residue His539, where the light grey square 
line trace of Figure 3.41 and 3.42 showed an average displacement of 1.98 A, compared 
to 0.76 A for the remaining four residues.
Figure 3.40 The residues of the RNase H active site, upon substrate and inhibitor binding. The 
connection and thumb subdomains are to the left of the illustration. The backbone of Idlo is shown 
as a green line trace, and the template strand and Mg ion in lrtd is shown as a purple stick 
structure and purple sphere respectively. Red and orange active sites represent inhibitor-bound 
structures, light and dark blue active sites represent DNA-bound structures. This view is the same 
used in the individual residue analysis, with details of the conformational changes in the text.
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The binary and ternary RT-DNA structures showed similar conformational changes, 
with the differences being predominantly in the sidechain displacements which showed 
greater variation. The conformation and placement of His539 in both DNA-bound 
structures was also quite different from ldlo, resulting in high black and grey line traces 
for this residue in Figures 3.41 and 3.42, that were not easily discernible from the multi­
coloured line traces of the inhibitor-bound structures. Like the residues of the PAS, the 
RNase H residues of the catalytic lrtd structure showed a greater similarity to the 
unliganded ldlo structure, than the binary 2hmi structure, particularly in terms of the 
average backbone displacement. The inhibitor-bound structures all showed 
considerable shifting of the RNase H active site residues, with displacements consistent 
in magnitude and direction, as well as conformation. Clustering effects due to the 
origins of group crystal structures were most notably seen in Asp498 in Figure 3.41, 
where the two groups of multi-coloured line traces were separated by an average 
difference of about 1.66 A. The average displacement values of Table 3.7 for the two 
groups of crystal structures, in all separate components, consistently varied by 
approximately 1.0 A. A clear delineation of the different conformational displacements 
could be seen between unliganded or DNA-bound structures and inhibitor-bound 
structures for all residues save His539, and the sidechain of Glu478 (Figure 3.41).
average DNA-bound inhibitor-bound structures
displacement structures
o
........ (A ).._ ..... lhmv ternary binary total CABM OCMS
entire residue 1.07 1.21 1.36 3.02 3.72 2.69
backbone 0.91 0.85 1.03 2.90 3.60 2.57
sidechain 1.22 1.60 1.69 3.12 3.83 2.80
Table 3.7 Summary of the average displacement between the ld lo unliganded structure 
and the second unliganded (lhm v), substrate-bound (lrtd-ternary and 2hmi-binary), and 
inhibitor-bound structures for the entire RNase H active site, and only the backbone or 
sidechain component. The three representative average displacements were calculated 
for all 19 inhibitor bound structures (total), and based on the research groups that 
derived the crystal structures; six from the CABM research group, and 13 from OCMS 
research group.
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Figure 3.41 Graphical representation of the displacement between the unliganded (ldlo) structure and all liganded RT structures for the RNase H.
3.6.2.1 Substrate induced conformational changes of the RNase H active site
The RNase H active site was situated in a shallow groove, at the mouth of which the 
template strand runs (Figure 3.40). The roof of this groove was formed by a (3-strand 
flanked by two a-helices; Glu478, Asp443 and Asp549 lie side-by-side across the roof 
of the groove. A P-strand and a connecting loop containing Asp498 and His539 
respectively form the floor of the groove. In the lrtd structure a Mg ion was 
coordinated to the O52 of Asp443, and was approximately situated in the middle 
between Asp443, Asp549, Asp498, and His539, at the centre of the groove.
Residues Glu478 and Asp443, at the top of the groove, in both DNA-bound crystal 
structures did not show any significant displacement relative to the ldlo unliganded or 
lhmv structure. This is clearly demonstrated by the overlapping blue and green 
structures in Figure 3.40, and the thin dark sticks and pale ball-and-stick structure of 
Figure 3.43 (left) compared to the thick sticks of ldlo. The slight exceptions seen in the 
black and dark grey line traces of Figure 3.42 were in the sidechain of 2hmi’s Asp443, 
due to a torsion about the Cp atom changing the conformation of the aspartate fork, and
o
the sidechain of Glu478Gln in lrtd. The displacement in this sidechain of 3.87 A may 
be due to the deliberate mutation to inactivate the RNase H activity. Relative to the 
uniformity of Glu478 and Asp443, the small average displacements of Asp549 in 2hmi 
and lrtd, of 2.71 A and 2.18 A respectively, attracted some slight attention for their 
disparity. In 2hmi, the displacement was represented by the dark thin stick structure at 
the bottom of Figure 3.43 (left), shifted relative to the dark thick structure.
Asp498 at the bottom of the groove in the DNA-bound structures was identically 
orientated and positioned to the unliganded structure, as evidenced by the line traces of 
Figure 3.42, showing an average displacement of 0.55 A and 0.27 A for 2hmi and lrtd 
respectively. His539 conversely showed a tangle of line traces for this residue, that 
actually only appeared notable because of the small scale of displacements seen in the 
other residues of the RNase FI active site (Figure 3.42). The sidechains of this structure 
at the bottom of Figure 3.43 (left) show the disparity in conformation between the 
unliganded and DNA-bound structures. This has been proposed to be a catalytic 
residue, so the changes observed upon substrate binding could be significant.
Figure 3.42 Graphical representation of the displacement between the unliganded (ldlo) structure, 
and the second unliganded (lhm v) and DNA-bound structures (lrtd  and 2hmi) for the RNase H 
active site.
3.6.2.2 Inhibitor induced conformational changes of the RNase H active site
All of the residues of the roof of the groove in the inhibitor-bound structures showed a 
small common displacement toward the thumb, and a much more significant 
displacement inward into the groove and away from where the template strand would lie 
at the mouth of the groove. This is seen as shifts toward the top of Figure 3.43 (right) 
and shifts toward the right side of the illustration. As such, the groove containing the 
active site appeared to be displaced out, away from the nucleic acid binding cleft. This 
could be better described as an elaboration of the opening of the hand-like structure of 
the enzyme seen in the fingers and thumb domains in the studies of the primer and 
template grips. The crystal structures of the CABM group generally showed greater 
displacements than those of the OCMS group, as seen in the clustering and 
displacement of the orange coloured structures of Figure 3.40 toward the top of the 
illustration, compared to the red coloured structures.
Asp498 and His539, at the bottom of the groove, in the inhibitor-bound structures 
showed a similar consistent displacement deeper into the groove, and a small 
displacement toward the thumb (Figure 3.43, right). A small elevation was seen in the 
inhibitor-bound structures for these residues, as if the groove had been slightly 
compressed with the floor of the groove elevating toward the roof. Residue His539, on
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the floor of the groove, did not appear to be moved as consistently as those at the roof of 
the groove or Asp498, as clearly seen in the erratic-like displacements measured for 
His539 in Figure 3.41. The inhibitor-bound structures represented by lhni and lvru in 
Figure 3.43 (right) show clearly the increased distance between the RNase H active site 
upon inhibitor-binding and the template strand that must be degraded for the successful 
completion of reverse transcription. The altered relationship between the active site 
residues could make it impossible to correctly coordinate the Mg2+ ion for hydrolysis, 
even if other motifs in the enzyme were able to compensate for inhibitor binding and 
adapt or readjust the positioning of the template strand closer to the active site residues.
Figure 3.43 (Left) The conformational differences between the unliganded structure ldlo (thick 
dark sticks) and the binary DNA structure 2hmi (thin dark sticks), seen relative to the proposed 
catalytic coordination complex of RNase H hydrolysis in lrtd shown in pale ball-and-stick (see 
Figure 3.39 for full legend details). (Right) Inhibitor-bound structures of lhni (thick dark sticks) 
from the CABM group and lvru (thin dark sticks) from the OCMS group, also seen relative to 
lrtd.
3.6.3 Displacement of aspartic acid 443
Asp443 is situated in the middle of the roof of the RNase H groove, and showed 
virtually identical conformations and negligible displacements between all four 
unliganded and DNA-bound structures. The Y-shaped carboxylate fork of the Asp443 
structures in both unliganded structures and the ternary DNA-bound structures pointed 
toward the Mg"+ ion at the centre of the groove, to which it is coordinated in the 1 rtd 
structure. The carboxylate fork of the binary DNA structure (2hmi) showed a swivel of
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approximately 90° at the CY atom, which would be unlikely to affect its coordination to 
the Mg2+ ion.
The similarity of conformation and position in Asp443 between the unliganded and 
substrate-bound structures lend support to the supposition that this residue is not 
affected by the binding of the nucleic substrate, and may not require conformational 
changes to become catalytically active. This superposition, for Asp443 and other 
residues of the RNase H active site, can only be tentative at the moment, as the nucleic 
substrate in the 2hmi and lrtd structures was dsDNA, which is not the natural substrate
The inhibitor-bound structures showed a distinct 
and uniform displacement deeper into the groove, 
in addition to a smaller displacement out, away 
from the thumb, as depicted by shiftings of the 
orange and red coloured structures of Figure 3.44 
to the top of the illustration, and toward the right 
hand side, respectively. The average 
displacement of this residue in the inhibitor-bound 
structures was 3.15 A compared to 0.66 A for the 
unliganded and DNA-bound structures. The 
conformation of the carboxylate forks were 
generally unchanged, with the exception of lrev, 
lrt3, lvrt, and lvru from the OCMS group which 
swivelled at the Cp atom to point down to the 
floor of the groove. Swivelling about this atom, 
unlike that seen in the CY atom of 2hmi, further 
increased the displacement away from the Mg2+ 
ion, and it would be unlikely that the carboxylate 
fork of any of the inhibitor-bound structures could coordinate to the Mg ion if it was 
similarly placed as seen in the lrtd structure. The structures of the OCMS research 
group tended to be more modest in their displacements than those of the CABM group, 
with an average difference of 1.08 A.
of the RNase H active site.
Figure 3.44 The displacement of 
Asp443 upon substrate and inhibitor 
binding, ldlo ball-and-stick (green), 
lhmv (dark green), lrtd (dark blue), 
2hmi (light blue), CABM structures 
(orange), and OCMS structures (red). 
The backbone of ldlo is shown as a 
green line trace, and the Mg2+ ion in 
lrtd is shown as a purple sphere. The 
thumb subdomain is to the left, as can 
be more clearly seen in Figure 3.40, 
which is in the same orientation.
3.6.4 Displacement of glutamic acid 478
This residue is situated at the roof of the groove closest to the thumb subdomain, and is 
composed of a glutamic acid residue in all of the structures except for the Irtd ternary 
DNA-bound structure in which a glutamine was substituted instead to inactivate the 
enzyme for crystallisation purposes. The dark green lhmv and light blue 2hmi 
structures of Figure 3.45 were extremely similar in orientation and position; their 
carboxylate forks pointing toward Asp443 and the Mg2+ ion in lrtd, just as in the green 
ball-and-stick ldlo unliganded structure. The only small difference in the DNA-bound 
structures appeared in the sidechain of lrtd that pointed out into the groove toward the 
template strand due to a swivel at the CY atom. This displacement in lrtd, seen clearly in 
the black circle line trace of Figure 3.42, could be explained by the mutation to 
glutamine in the lrtd structure. With this small exception, the DNA-bound stmctures 
appeared not to display any substrate induced changes from the unliganded state that 
could be postulated to be catalytically active conformations.
Figure 3.45 The displacement of Glu478 upon substrate and 
inhibitor binding, ldlo ball-and-stick (green), lhmv (dark 
green), lrtd (dark blue), 2hmi (light blue), CABM structures 
(orange), and OCMS structures (red). The backbone of ldlo 
is shown as a green line trace, and the Mg2+ ion in lrtd is 
shown as a purple sphere. The thumb subdomain is to the 
left, as can be more clearly seen in Figure 3.40, which is in 
the same orientation.
The conformational
displacements of Glu478 in 
the inhibitor-bound
structures showed distinct 
and uniform movement 
deeper into the groove, with 
smaller displacements out, 
away from the thumb, 
similarly to Asp443. With 
the exception of lbqn 
(orange Y-shaped structure 
in the middle of Figure 3.45) 
whose side chain is pointed 
toward Asp443, all the
liganded structures pointed out into the groove like lrtd. The sidechains of the red 
coloured OCMS structures of Figure 3.45 appear not to be as far displaced backward 
into the groove compared to the orange coloured structures in the top left hand comer of 
the illustration. However, they still had a noteworthy average displacement of 2.42 A
from the green ball-and-stick unliganded structure.
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3.6.5 Displacement of aspartic acid 498
Asp498 is situated on the floor of the groove, closest toward the thumb. As for Asp443, 
negligible differences could be found in the orientations and positions of the four 
unliganded and DNA-bound structures. The blue and green structures of Figure 3.46 
show Asp498 in these structures almost as one structure. All of their carboxylate forks 
pointed upward into the groove toward the Mg2+ ion without even notable swivelling 
about the Cp atom. Once more, the DDM-based superimposition revealed little 
evidence that the binding of the DNA substrates in lrtd and 2hmi had any affect on the 
conformation of Asp498, and no postulations could made concerning catalytically 
active conformations that the residue might adopt.
Following in the same trend previously 
seen, the inhibitor-bound structures in 
Figure 3.46 showed distinct and 
singularly consistent displacements 
deeper into the groove, with smaller 
displacements out, away from the 
thumb. The conformation and 
orientation of this residue in the 
inhibitor-bound structures was 
comparable with the unliganded and 
DNA-bound structures, pointing toward 
the roof of the groove. Asp498 
provided the most manifest example of 
the clustering of the residues in crystal 
structures from the two different 
research groups. Those orange 
coloured structures from the CABM 
group showed the greatest displacement deeper into the groove, as well as a small 
elevation upward from the floor of the groove, depicted as shifts toward the top and the 
left hand side of Figure 3.46. The red coloured OCMS structures were displaced, on 
average, 1.66 Á less than the CABM structures, but still displayed a notable 
displacement of 2.02 Á from the ldlo unliganded structure.
Figure 3.46 The displacement of Asp493 upon 
substrate and inhibitor binding, ldlo ball-and-stick 
(green), lhmv (dark green), lrtd (dark blue), 2hmi 
(light blue), CABM structures (orange), and OCMS 
structures (red). The backbone of ldlo is shown as a 
green line trace, and the Mg2+ ion in lrtd is shown as 
a purple sphere. The thumb subdomain is to the left, 
as can be more clearly seen in Figure 3.40, which is in 
the same orientation.
3.6.6 Displacement of histidine 539
This residue situated on the floor of the groove furthest away from the thumb, appeared 
to be the most inconsistent amongst all the crystal structures, and this was reflected in 
the displacements measured and the erratic line traces of Figures 3.41 and 3.42.
His539 in the dark green lhmv 
structure of Figure 3.47 was similarly 
orientated to that in ldlo, except for a 
small downward depression into the 
floor of the groove and a displacement 
away from the thumb, or toward the 
right hand side of the illustration. The 
sidechain, that in ldlo is orientated to 
point toward the fingers with the 
plane of the histidine ring 
approximately facing the palm 
subdomain, instead has its plane 
facing the connection subdomain. In 
the dark blue lrtd, His539 showed a 
small displacement deeper into the 
groove than ldlo. The backbone of 
this residue was slightly depressed 
down, but a change in the dihedral 
angle (O, C, Ca, Cp), from -  35 ° in 
ldlo to -  4 ° in lrtd, resulted in little change to the relative sidechain elevation 
compared to ldlo. The sidechain in lrtd was orientated to point more toward the 
thumb, while actually displaced slightly further away from the thumb, with the plane of 
the ring in a similar orientation to ldlo. This all resulted in the residue in lrtd being 
approximately 4.0 A from the Mg"+ ion, closer than ldlo, but not quite within contact 
distance. Both ldlo and lrtd were 2.77 A and 3.64 A respectively from the sugar 
phosphate backbone of the template strand in lrtd. In the binary DNA-bound structure, 
His539 showed a small displacement out of the groove and further from the thumb, and 
had a slight depression downward into the floor of the groove. The sidechain was quite 
different from the other structures, pointing to some point over the wrist, with the plane
Figure 3.47 The displacement of His539 upon 
substrate and inhibitor binding, ldlo ball-and- 
stick (green), lhmv (dark green), lrtd (dark blue), 
2hmi (light blue), CABM structures (orange), and 
OCMS structures (red). The backbone of ldlo is 
shown as a green line trace, and the Mg2+ ion in 
lrtd is shown as a purple sphere. The thumb 
subdomain is to the left, as can be more clearly 
seen in Figure 3.40, which is in the same 
orientation.
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of the ring facing the connection subdomain, and distinctly out of contact range with 
both the Mg2+ ion and the template strand in lrtd.
The differences between the two DNA-bound structures, and also compared to the two 
unliganded structures could be conformationally induced by the binding of the DNA 
substrate. The differences between the light and dark blue structures could be 
postulated to be a conformational change of the residue from a substrate-bound inactive 
form, to one poised to interact with the magnesium ion and the template strand for 
hydrolysis, though no further evidence was available to support such a postulation. The 
lack of greater similarity between lhmv and ldlo did not provide strong support for any 
comparisons of the DNA-bound structures with an unliganded structure.
Although the inhibitor-bound crystal structures of this residue did not show the tight 
clustering and uniformity typically seen in other residues, a general displacement deeper 
into the groove, or toward the top of Figure 3.47, was observed. With the exception of 
lbqm and lbqn, the residues also showed a displacement out, away from the thumb. 
The sidechains of lbqm and lbqn, unaffected by the gross residue displacements seen in 
the other inhibitor-bound structures, pointed toward the template strand in lrtd, with a 
difference in distance to the sugar-phosphate backbone of less than 1.0 A. His539 in the 
inhibitor-bound structures was slightly elevated from the floor of the groove, such that 
the sidechains of this residue in the orange coloured lhni and lhnv structures virtually 
displaced the site occupied by the Mg ion in the catalytic lrtd structure. The greatest 
variation between the crystal structures was seen in the sidechains of this residue. 
Generally the sidechains were directed toward the fingers and thumb subdomains, with 
a variety of different swivelling motions of the plane of the ring, though most of them 
were still within contact distances of less than 4.0 A from the sugar phosphate 
backbone. It is unknown what possible role His539 may play in coordinating the 
backbone of the template strand for hydrolysis. These DDM-based superimposition 
results indicate that it may be not as greatly affected by inhibitor-binding as other roles 
this residue may have in synchronization with the other residues of the RNase H active
site.
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3.6.7 Displacement of aspartic acid 549
Figure 3.48 The displacement of Asp443 
upon substrate and inhibitor binding, ldlo 
ball-and-stick (green), lhmv (dark green), 
lrtd (dark blue), 2hmi (light blue), CABM 
structures (orange). The backbone of ldlo is 
shown as a green line trace, and the Mg"+ 
ion in lrtd is shown as a purple sphere. The 
thumb subdomain is to the left, as can be 
more clearly seen in Figure 3.40, which is in 
the same orientation.
Asp549 is situated at the roof of the 
groove, furthest from the thumb, and the 
absence of the carboxylate sidechain in the 
ldlo unliganded structure limited the 
comparisons that could be made with this 
residue. Despite this, the backbones of 
lrtd and lhmv were similar in orientation, 
though they were both displaced slightly 
deeper into the groove compared to ldlo, 
seen as a slight shifting toward the top of 
Figure 3.48. The carboxylate forks of lrtd 
and lhmv were directed downward into 
the groove toward His539, with the their 
sidechains 2.53 À and 3.95 Â respectively 
from the purple Mg2+ ion in lrtd. The 
binary Ihmi structure was similarly 
conformed to the unliganded and DNA-
bound structures, but show a very small 
displacement out, further away from the 
thumb, and the other residues on the roof of the groove, and 4.30 À away from the Mg^+ 
ion. This difference between the lrtd and 2hmi structures may be a conformation 
change from a DNA-bound inactive form to a catalytically-poised form able to 
coordinate to the necessary Mg2+ ion.
The number of inhibitor-bound structures with which to compare this residue was less 
than previously used, as all crystal structures from the OCMS group did not have this 
residue resolved. Those inhibitor-bound structures available showed the distinct and 
uniform displacements deeper into the groove seen by all the residues of the RNase H 
active site, as well as a very small elevation deeper into the roof of the groove. The 
sidechains of lhnv, Itvr and luwb pointed downward into the groove, or toward the 
bottom of Figure 3.48, and angled slightly more toward the back of the groove than 
toward His539. The lhni sidechain pointed downward into the groove, but in the
opposite direction to the connection subdomain; the sidechain of lbqm pointed toward 
the fingers subdomain due to a torsion of the angle about Cp.
Although the lack of data for Asp549 made speculation tentative, the consistent 
displacements seen of the structures available, and their difference from the black and 
grey line traces of Figure 3.41 could cautiously provide a basis to postulate that Asp549 
was subject to inhibitor-induced changes. These induced changes, horizontally and 
vertically deeper into the groove, had the effect of increasing the distance of the residue 
to the Mg ion out of coordination range, and possibly conforming Asp549 into an 
inactive conformation.
3.6.8 Activation and inhibition of the RNase H active site
Despite the significant role it plays in the complete reverse transcription of viral RNA, 
no published study has been made of the conformational changes of the RNase H active 
site upon the binding of nucleic acid substrates or inhibitors in the NNIBP. The results 
of this DDM-based superimposition study have shown that the binding of NNRTIs 
caused singularly consistent and significant displacement of the residues of the RNase H 
active site. In the absence of any hydrolysis activity data, for the inhibitors in the 
inhibitor-bound crystal structures, and more detailed postulations of mechanism of 
RNase H activity, only conjectural observations could be made of these results. Based 
on these initial and promising findings there needs to be serious consideration to include 
RNase activity data when testing and studying NNRTI inhibition.
Unlike the previously studied PAS, and primer and template grips, the substrate induced 
conformational changes of the RNase H were difficult to interpret, and scarcely any 
rationalisations could be made for certain displacements. The unliganded and DNA- 
bound structures were all remarkably similar in conformation and placement, with the 
exceptions of His539 and Asp549. His539 has been suggested to interact with the 
sugar-phosphate backbone of the template strand in the duplex region of the template- 
primer.206 The sidechain of Asp549 is postulated to be essential for coordinating the 
second Mn2+ ion in the two-metal ion mechanism,191 as well as possibly coordinating 
the Mg2+ ion as seen in the lrtd structure. The difference between the structures in the 
binary and ternary DNA-bound structures may be due to the differing lengths of the 
dsDNA used in each structure, and/or the presence of a Mg2+ ion in the ternary 
structure. While the template strand in 2hmi lay approximately 8 A away from the
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RNase H active site, and was not in a proper position for cleavage, the lrtd structure had 
the template strand in a much more favourable orientation. It is possible that this 
template in lrtd could be cleaved, if not for the glutamine mutation at Glu478. 
However, one needs to remember that dsDNA is not the natural substrate for RNase H, 
and that the conformations observed in these studies might be different for other nucleic 
acids.
The inhibitor-bound structures showed clearly that NNRTI binding caused a slight 
compression and withdrawal away from the template strand of the shallow groove 
containing the residues of the RNase H active site. This conformational change further 
reiterated the analogy of the opening of the hand. Even though the RNase H groove 
underwent a slight compression, as if this local motif was closing, the RNase H active 
site as a whole showed a displacement extending it out away from the template strand. 
Individual residues were displaced at a greater distance from each other, the template 
strand, and the Mg2+ ion, making catalytic hydrolysis seem unlikely. Much of the focus 
of the efficiency and specificity of RNase H activity has been on the appropriate 
positioning of the nucleic acid by the PAS,172 and the various pitches, tilts, groove 
widths, and forms adopted by nucleic acid hybrids. ’ These factors are thought to 
induce the RNase H into the appropriate conformations for activity. The results from 
these DDM-based studies indicated that in the absence of nucleic acids, long range 
conformational changes of the RNase H active site could be induced by NNRTI 
binding. This provided preliminary evidence that structural motifs in the enzyme 
remote from the RNase H subdomain could play dominant roles in the conformational 
changes of RNase H, and possibly the nucleic acid as well. These conformational 
changes could be required for the recognition of correct substrates and complete 
hydrolysis of the phosphodiester bond, roles that may not be limited to the structure of 
the nucleic acid and its interactions with active site residues. This is not to say that 
distinctions in different nucleic acid structure could not be communicated to the enzyme 
to exert conformational changes. An even more confounding possibility exists that the 
nucleic acid structure influences such motifs as the PAS, primer, and template grips, 
which in turn induce conformational changes of the RNase H, and perhaps the nucleic 
acid itself; a vicious circle of dependency.
Two of the proposed functions of the RNase H involved interaction with the tRNA y 
primer; the initial cleavage at the 5’end of the viral RNA template to facilitate the first
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strand transfer, and final removal of the tRNALys3 primer from the synthesised (+) 
strand DNA. This demands that the RNase H active site be able to differentiate between 
the viral RNA-tRNALys3 initiation complex and the later DNA-tRNALys3 hybrid. This 
differentiation has been seen in the PAS, where studies into the three-dimensional 
structure and interactions of the viral RNA-tRNALys3 complex and r t 176,210-212 have 
suggested that conformational changes in both are required to prevent steric clashes, and 
provide a perfect fit of primer-template and enzyme for reverse transcription. In 
addition, it has been observed that RT is able to recognise the difference between RNA- 
tRNALys3 and DNA-tRNALys3 212,213 when extending the primer, possibly adopting 
different orientations of binding to allow extension. Could this ability be extrapolated 
to the RNase H? Both are active sites involved in enzymatic catalysis with similar 
divalent ions and acidic residues, both involve precise and intimate interactions with 
both RNA and DNA, both work in tandem and independently to reverse transcribe viral 
RNA. Although this question could not be answered with the present data available, it 
poses an intriguing and possibly fortuitous site for potential rational drug design.
3.7 The non-nucleoside inhibitor binding pocket
3.7.1 Inhibitor binding
The binding of inhibitors at the non-nucleoside inhibitor binding pocket (NNEBP) has 
been at the heart of the DDM-based superimposition studies. Conformational changes 
induced at the local level in this allosteric pocket were seen to influence the neighboring 
PAS and primer grip, as well as remote structural motifs such as the template grip and 
the RNase H active site (Sections 3.3 - 3.6). The logical conclusion to these studies was 
the analysis of the pocket itself, which, in the absence of an inhibitor, exists as a mere 
surface depression surrounded by residues Leu 100, LyslOl, Lysl03, Val 179, Tyrl81 
and Tyrl88 of p66, and Glul38 of p51.30
The NNIBP is composed primarily of amino acid residues from the P5b-P6 loop 
(LeulOO, LyslOl, Lysl03), P6 (Vall06), the P9-P10 hairpin (Vall79, Tyrl81, Tyrl88, 
Glyl90), the P12-P13 hairpin (Phe227, Trp229, Leu234, His235, Pro236), pi5 (Tyr318) 
and the P7-P8 loop of p51 (Glul38). The structural definition of the pocket can vary 
amongst the literature. Most of the amino acid residues that form the binding pocket are 
hydrophobic and five of them have aromatic side chains. The only hydrophilic residues
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around the pocket (LyslOl and Lysl03 of p66 and Glul38 of p51) are located at the 
putative entrance.134
Non-nucleoside inhibitors are thought to insert between two hydrophobic surfaces of the 
pocket which have complementary shapes, with electrostatic interactions (charge and 
hydrogen bond) contributing to the final strength of binding and assisting in the 
orientation of the compound.133 Specificity of binding is believed to come from the 
interactions with bulky hydrophobic residues, in particular from a number of ring­
stacking interactions.31'214 The intrinsic flexibility of RT, expressed here as a plasticity 
in the structure of the protein surrounding the bound inhibitors, allows unfavorable 
contacts to be relieved without changing the overall binding.133 The inhibitors 
crystallised in the stmctures of RT presently available (see Figure 3.4 for the chemical 
structures of the inhibitors) are structurally diverse, and each has its own particular 
structural characteristics. However, a common binding mode suggestive of the shape of 
a butterfly has been proposed for the inhibitors of this pocket.30 215 The DDM-based 
superimpositions provided an objective method to compare the binding modes of the 
inhibitors, illustrating the V-shape of the butterfly wings in Figure 3.49 (left), which are 
believed to play an integral role in 7i-stacking interactions with the hydrophobic 
residues of the pocket.30“ 1
Figure 3.49 The crystallised non-nucleoside inhibitors of RT in the NNIBP by DDM-based 
superimpositions. (Left) Inhibitors coloured by the research groups that resolved the structures, 
CABM structures (orange), and OCMS structures (red). (Right) Inhibitors coloured by atom, 
oxygen (red), carbon (green), nitrogen (blue), sulfur (yellow), chlorine (pale green) bromine 
(brown).
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A large proportion of the literature pertaining to RT has been based on intense studies of 
the nature and structural movements of the residues of the NNIBP, analysing how these 
could be better understood to refine and optimise current inhibitors,138,216 and rationalise 
mutational resistance.136,215,217 Our DDM-based studies were proposed not to follow in 
this same path, but rather to individually analyse a few residues with significant 
displacements from the conformation of the ldlo structure, and to begin to examine the 
movements and extent of the pocket. This investigation would provide the basis for 
optimisation and de novo inhibitor design that could fully exploit all the potential 
protein interactions available and not be limited to those bonding interactions currently 
realised by known inhibitors within the NNIBP (Chapter 4).
3.7.2 Synopsis of the displacement of the NNIBP
The NNIBP lies seemingly between the palm and thumb subdomain, composed of 
residues from both enzyme subunits, and inclusive of several residues of the primer 
grip. Its position at the base of the thumb has been the basis for some speculation that it 
may function as a hinge between the palm and the thumb subdomains.134 The binding 
of an NNRTI could distort the conformation of the primer grip and restrict the mobility 
of the thumb subdomain, believed to be necessary for interaction with the nucleic acid 
during recognition of the template-primer. In Figure 3.50, the location of the residues 
of the NNIBP is illustrated relative to the subdomains of RT and the PAS upon which it 
has such a profound effect. The residues of the NNIBP are listed in Appendix 7.6, and 
displacement data is tabulated in Appendix 7.13.
The binding of nucleic acid substrates appeared to do little in changing the 
conformation of the NNIBP as evidenced by the average displacements of lrtd and 
2hmi in Table 3.8. The average displacement of the catalytic lrtd structure was actually 
less than that of the alternate lhmv unliganded structure in both backbone and sidechain 
components by 0.14 A and 0.25 A respectively. The difference was even greater with 
the binary 2hmi structure, which showed the greatest displacement from the unliganded
o
and substrate-bound structures with an average difference in distance to ldlo of 1.48 A. 
The black circle and dark grey diamond line traces of Figures 3.51 and 3.52 showed no 
remarkable differences from the unliganded structure, with occasional increases in 
displacement attributed to slight conformational changes in sidechains.
m
Figure 3.50 The displacement of the NNIBP, in the palm subdomain, upon substrate and 
inhibitor binding relative to the fingers subdomain, on the left, and the thumb subdomain (in the 
‘closed’ conformation), on the right. The backbone of ldlo is shown as a green line trace, the 
residues of the NNIBP is shown as green ball-and-stick, and the PAS is shown as the yellow ball- 
and-stick structure. Red and orange residues represent inhibitor-bound structures, light and 
dark blue structures represent DNA-bound structures. The inhibitors of inhibitor-bound crystal 
structures shown as grey lines.
average DNA-bound inhibitor-bound structures
displacement
(A) lhmv
structures 
ternary binary total CABM OCMS
entire residue 1.17 0.92 1.48 3.01 3.51 2.77
backbone 0.89 0.75 1.27 2.17 2.81 1.88
sidechain 1.39 1.04 1.64 3.65 4.06 3.45
Table 3.8 Summary of the average displacement between the ldlo unliganded structure and the 
alternate unliganded (lhmv), substrate-bound (lrtd-temary and 2hmi-binary), and inhibitor- 
bound structures for the entire NNIBP, and only the backbone or sidechain component. The three 
representative average displacements were calculated for all 19 inhibitor bound structures (total), 
and based on the research groups that derived the crystal structures; six from the CABM research 
group, and 13 from OCMS research group.
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Figure 3.51 Graphical representation of the displacement between the unliganded (ldlo) structure, 
and the second unliganded (lhm v) and DNA-bound structures (lrtd  and 2hmi) for the NNIBP.
Fundamentally, the binding of NNRTIs caused an approximate 30 ° differential twisting 
of the pl2-(313-pl4 sheet that resulted in the formation and expansion of the pocket.30 
However the NNEBP is composed of more residues than solely those of the P12-P13- 
P14 sheet, and their displacements from the conformation in the unliganded structure 
are most succinctly summarised in Figure 3.52. As the multi-coloured line traces 
clearly showed, the values of displacement in Table 3.8 consisted predominantly of the 
displacements of the sidechains of Tyrl81 and 188, residues Phe227 and Trp229 of the 
primer grip, and to a smaller extent, Pro236 and Glul38. Removing the dominating 
aromatic residues from consideration brought the average displacement of the NNIBP in 
the inhibitor-bound structures to 2.20 A, a much more modest displacement, but still 
distinct from the unliganded and DNA-bound structures. The four residues of 181, 188, 
227, and 229 as a collective had an average displacement of 4.51 A in the inhibitor- 
bound structures.
The NNIBP of the crystal structures of the CABM research group showed a greater 
displacement than that seen by the OCMS group by an average of 0.74 A. Interestingly, 
the larger part of this difference in displacement was in the backbone component, 0.93 A, rather than the sidechain component, 0.61 A. The difference between the binding 
pockets of the two research groups was most likely to be a continuance of the greater 
displacements seen in the previous studied motifs, rather than due to the larger 
collective volume occupied by the red-coloured inhibitors of Figure 3.49 (left).
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Figure 3.52 Graphical representation of the displacement between the unliganded (ldlo) structure and all liganded RT structures for the NNIBP.
3.7.3 Conformational changes for tyrosine 181 and 188
In the unliganded and DNA-bound structures, the sidechains of Tyrl81 and Tyrl88 of 
p66 pointed into the hydrophobic core and, as a consequence, the NNIBP did not exist. 
The binding of non-nucleoside inhibitors caused a rotation in the sidechains of both 
residues away from their positions in the hydrophobic core in the unliganded structure,
At the bottom of 
Figure 3.53 the blue 
and green structures 
of the unliganded 
and DNA-bound 
structures can be 
seen to slightly 
occupy some of the 
space where a few of 
the NNRTIs bind in 
the NNIBP. A 
swivelling about the 
Cp angle in all the 
inhibitor bound 
structures, excluding 
lrti and lrt3, brought
the sidechain of Tyrl81 within approximately 1.5 A of Tyrl83 of the PAS. The lack of 
this swivel by the Tyrl81 sidechain in lrti and lrt3 resulted in small displacements from 
the unliganded ldlo structures as evidenced by the dark orange and pale green circle 
line traces of Figure 3.52 that lie close to the black and grey line traces. The sidechain 
torsion angle, of Tyrl81 in all the crystal structures was determined in Table 3.9. 
The average %\ of the unliganded and DNA-bound structures was —87.9 , compared to
169.6 ° for all inhibitor-bound structures, excluding lrt3 and lrti, a difference of 
approximately 102.5 °. The average value for lrti and lrt3 was —80.3 , practically 
the same as the unliganded and DNA-bound structures.
to point upward toward the surface of the palm, and the PAS.
Figure 3.53 The displacement of Tyrl81 and Tyrl88 upon substrate 
and inhibitor binding seen relative to the PAS of ldlo in yellow ball- 
and stick, ldlo ball-and-stick (green), lhmv (dark green), lrtd (dark 
blue), 2hmi (light blue), CABM structures (orange), and OCMS 
structures (red). The inhibitors of inhibitor-bound crystal structures 
shown as grey lines. The fingers subdomain is to the left of the PAS 
and the thumb subdomain is to the right of the inhibitors.
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PDB file
ldlo
lhmv
lrtd
2hmi
lbqm
lbqn
lhni
lhnv
lklm
lrev
Irti
lrt2
lrt3
lrt4
lrt5
lrt6
lrt7
lrth
Irti
ltvr
luwb
lvrt
lvru
Tyrl81
-98.20
-68.63
-98.98
-85.94
169.14
159.95
172.25
-176.96
169.68
170.68 
173.44 
171.97 
-80.28 
166.64 
167.28 
167.53 
175.86 
158.94 
-80.09 
168.39
173.79
171.22
Tyrl88
169.03
165.09
161.08
154.54
-74.27
-69.20
-77.10
-65.27
-72.63
-59.66
-63.53
-53.03
-61.72
-62.93
-66.23
-63.46
-69.49
-65.07
-65.09
-81.63
-69.11
-62.07
No reasonable thorough explanation can be 
proposed for why the Tyrl81 sidechain in these two 
crystal structures do not swivel. The structure of 
HEPT in lrti was analogous to those of MKC-442 
and TNK-651, but the angles of lrti and lrt2, the 
respective crystals structures with these inhibitors 
bound, were on average 172.7 °, approximately
107.2 ° greater than in lrti. The average difference 
between the %\ angles of the unliganded and DNA- 
bounds structures compared to most of the inhibitor- 
bound structures was 102.5 °. In Figure 3.55 (left), 
the comparison of the dark HEPT and the pale 
MKC-442 and TNK-651 inhibitors showed no 
altered binding modes or steric features of the 
inhibitors that could explain the difference in the 
sidechain conformation. The inhibitor of the lrt3 
structure was the nevirapine analogue, 1051U91.
Table 3.9 Sidechain torsion angles 
of Tyrl81 and T yl88 (N, Ca, Cp,
Gp).
While the lrth and lvrt structures, that have 
1051U91 and nevirapine bound respectively, had 
values generally comparable with most of the
inhibitor-bound structures, these were native enzymes, unlike lrt3 which was an AZT- 
resistant RTMC mutant.218 The mutations, two of which included Thr215 and Lys219,
were known to give rise to conformational changes that propagate to the active site 
aspartates, as well as the NNIBP.218 In Figure 3.55 (right), the 1051U91 and nevirapine 
structures all overlaid in a fairly common binding mode that provided little explanation 
for the position of Tyrl81 in lrt3. The phenyl ring in the lrth and lvrt structures was 
close enough to the left-hand aromatic ring of the NNRTIs in Figure 3.55 (right) to have 
staggered planar 7r-bonding interactions. The tyrosine sidechain in lrti was an equal 
distance away from the same ring system of the 1051U91 inhibitor, but not orientated in 
a manner to allow any hydrophobic ring stacking interactions. This difference in the 
sidechain of Tyrl81, among others observed in lrt3, has been implicated in the
discrimination between the inhibitor, AZT-triphosphate, and the natural dTTP substrate
218by the mutant enzyme.
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Figure 3.54 Structures of HEPT, MKC-442, TNK-651,1051U91, nevirapine and BHAP U90152.
Figure 3.55 (Left) The conformational differences in the Tyrl81 residue between the unliganded 
structure ldlo (green ball-and-stick), lrti (dark sticks), and lr tl and lrt2 (pale sticks) seen relative 
to the PAS in ldlo (yellow ball-and- stick). (Right) The conformational differences in the Tyrl81 
residue between the unliganded structure ldlo (green ball-and-stick), lrt3 (dark sticks), and lrth 
and lvrt (pale sticks) seen relative to the PAS in ldlo (yellow ball-and-stick). Inhibitor-bound 
structures coloured by atom; oxygen (red), carbon (black), nitrogen (blue), sulfur (yellow).
Unlike Tyrl81, all the inhibitor-bound structures of Tyrl88 showed a change in the X\ 
angle to swivel away from the hydrophobic core of the pocket and upward toward the 
surface of the palm. The sidechains in the green and blue unliganded and DNA-bound 
structures also occupied some of the volume of the inhibitors in the pocket. The 
average change in X\ from the unliganded and DNA-bound structures to the inhibitor-
181
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bound structures was 130.8 °, and allowed the aromatic sidechain to be positioned for 
possible similar staggered planar 71-bonding interactions as in Tyrl81, as well as bring 
the residue within approximately 1.5 A of Aspl86 of the PAS. These changes in the Xi 
of Tyrl81 and 188 verified the previous observation that the sidechain torsion angles 
differed by about 120° in the structures derived in the presence and absence of 
inhibitors.30
3.7.4 Conformational changes for phenylalanine 227 and tryptophan 229
Phe227 and Trp229 form part of the primer grip and their distinct conformational 
changes have already been analysed to establish the changes induced by substrate and 
inhibitor binding (Sections 3.4.3 and 3.4.4). With respect to how they form the NNIBP, 
Figure 3.56 illustrates the shifting of the red and orange-coloured structures outward 
from the grey clustered inhibitors.
The green and blue 
unliganded and 
substrate bound 
structures of Trp229 
occupied a
significant volume of 
the pocket where the 
grey line inhibitors 
were bound in the 
NNIBP of inhibitor- 
bound structures. 
Phe227 in the 
unliganded and
DNA-bound 
structures did not
superimpose over any of the volume occupied by the grey NNRTIs. The shifting of the 
red and orange-coloured inhibitor-bound structures, in this residue, served primarily to 
increase the size of the NNIBP, possible for entry into the pocket, rather than solely to 
accommodate the bulk of the inhibitor. Phe227 and Trp229, are conserved residues of
Figure 3.56 The displacement of Phe227 and Trp229 upon substrate 
and inhibitor binding seen relative to the PAS of ldlo in yellow ball- 
and stick, ldlo ball-and-stick (green), lhmv (dark green), lrtd (dark 
blue), 2hmi (light blue), CABM structures (orange), and OCMS 
structures (red). The inhibitors of inhibitor-bound crystal structures 
shown as grey lines. The fingers subdomain is to the left of the PAS 
and the thumb subdomain is to the rieht of the inhibitors.
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the pocke and are believed to participate in significant 7t-bonding interactions with 
the NNRTI to help determine the specificity of binding.
3.7.5 Conformational changes for proline236 and glutamine 138
The conformational displacements of the Pro236 and Glul38 seen in the multi-coloured 
line traces of Figure 3.52 showed that, although they were not of the same consistency 
and magnitude as Tyrl81, Tyrl88, Phe227, and Trp229, they were markedly different 
from most of the remaining residues of the NNEBP. Pro236 was of particular interest as 
it is positioned at the mouth of the pocket and is next to His235 of the primer grip. This 
residue in the Irtl, lrt2, lrti structures and most particularly in the lklm structure 
showed little displacement from the conformation and position in the unliganded and 
DNA-bound structures. The grey inhibitor seen toward the top of Figure 3.57 was that 
of the BHAP U90152 (113, Figure 3.54) inhibitor of the lklm stmcture. The similar
conformation of Pro236 in lklm
Figure 3.57 The displacement of Pro236 and Glut 38 
(p51) upon substrate and inhibitor binding seen relative 
to the PAS of ldlo in yellow ball-and stick, ldlo ball-and- 
stick (green), lhmv (dark green), lrtd (dark blue), 2hmi 
(light blue), CABM structures (orange), and OCMS 
structures (red). The inhibitors of inhibitor-bound crystal 
structures shown as grey lines. The fingers subdomain is 
to the left of the PAS and the thumb subdomain is to the 
right of the inhibitors.
to that in ldlo was necessary to 
accommodate the methyl 
sulfonamide sidechain, as well 
as providing hydrophobic 
interactions to the inhibitor 
indole ring.217 The proline 
sidechains of most of the 
inhibitor-bound structures were 
actually displaced forward at 
the mouth of the pocket from 
the unliganded stmcture, and 
occupied the volume of the 
indole ring of BHAP U90152 in 
the crystallised lklm structure. 
This movement may constitute 
a narrowing of the mouth of the 
pocket and could affect how the 
association and disassociation 
kinetic rates of the inhibitor by
m
restricting its exit from the pocket. A comparison of the kinetic rates of the inhibitors to 
the space or volume of the mouth of the pocket would be worthy of note, but may be 
quite difficult as many more variables such as the bonding interactions within the 
pocket and the total energy of the inhibitor and the protein need to be considered. More 
detailed study of this residue could provide further understanding of the process of 
inhibitor entry into the pocket, and provide another bonding interaction for inhibitor 
optimisation that may not have been fully exploited thus far.
Glul38 is only residue of the p51 subunit to form part of the NNIBP. It does not lie 
near the collective volume occupied by the grey inhibitors of Figure 3.57, but its 
position and conformation could influence such residues as Tyrl81 that can impact 
directly on the binding of the inhibitors. The dark green structure of lhmv in Figure 
3.57 and the light grey square line trace in Figure 3.52 revealed that the alternate 
unliganded structure had a much more similar conformation and position to the 
inhibitor-bound structures than to ldlo and the DNA-bound structures.
3.7.6 The binding of non-nucleoside inhibitors
The stimulus for the DDM-based superimposition study of the NNIBP was 
predominantly as a basis for structure-based drug design studies, and the observations 
presented in this section of research represent only the initial stages of the research 
potential of this significant structural motif of RT. However, the results provide an 
exciting glimpse at the latent wealth of information for optimisation and de novo drug 
design, as well as understanding the mechanisms of resistance within the NNIBP.
Resistance mutations are thought to function primarily by altering the binding of 
NNRTIs to RT; that is, by the loss of favorable contacts between enzyme and inhibitor, 
and slower inhibitor binding due to changes at the entrance of the NNIBP. NNRTI 
resistance is believed to arise from a combination of loss of stabilising interaction, and 
the emergence of steric and thermodynamic barriers for drug binding, depending on the 
particular amino acid substitution involved.220,221 The objective and rational approach 
of the DDM-based superimpositions provides an ideal method to study the possible 
conformations of the residues of the NNIBP, and so indirectly evaluate the flexibility of 
the pocket. Residues furthest away from the central volume occupied by the inhibitors 
could provide a measure of how far the pocket is able to expand to accommodate 
NNRTIs, and help in designing drugs that fit better and bind optimally to the enzyme.
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3.8 Overall displacement trends and activity correlation
The DDM-based superimposition studies of the structural motifs of RT implicated in 
the inhibition of polymerisation, or RNase H hydrolysis, have detailed considerable and 
consistent displacement trends in both substrate and inhibitor-bound structures. Also 
revealed has been an insight into the complexity of the mechanism of activation and, in 
particular, inhibition of the enzyme. The multiple functions necessary for successful 
reverse transcription and the dynamic nature of these functions was likely to require the 
synchronous convergence of numerous structural elements of the enzyme, metal cations, 
template-primers and dNTPs. No single motif could be responsible for the entire 
function of the enzyme, nor for its inhibition by NNRTIs. The exact relationships 
between the active sites and the nucleic acid grips was likely to be important for 
communication throughout the enzyme as it reverse transcribes an RNA strand into 
DNA, before hydrolysing the copied template. Consequently, the binding of NNRTIs 
that induced the conformational changes detailed in this research was anticipated to alter 
these vital relationships.
The analogy of the opening of the hand has been previously used in literature to 
describe the structural changes of the primer and template grips upon inhibitor 
binding.79,160,222'224 The results of the DDM-based superimpositions have supplemented 
this hypothesis to include the polymerase and RNase H active sites. The binding of 
NNRTIs caused the four structural motifs studied in Sections 3.3 - 3.6 to be displaced 
further away from the nucleic acid template-primer, essentially an opening or 
unclenching of the hand. The PAS was elevated up from the palm, away from the 
expansion of the elements of the NNIBP, to accommodate the non-nucleoside inhibitor. 
The primer grip was elevated up the plane of the thumb and, and even though it was 
displaced forward into the primer strand, the end result was a distancing away from its 
positioning in the unliganded and DNA-bound structures. The thumb subdomain was 
hyper-extended beyond the ‘open’ conformation of the DNA-bound structures, as were 
the fingers segments of the template grip, that were displaced deeper into the fingers 
domain and further out away from the nucleic acid. The RNase H active site also 
showed a gross displacement further away from both the primer-template complex, and 
the bulk of the p66 subunit.
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3.8.1 Spatial relationships between structural motifs
The distance between the Gly231 Ca atom of the primer grip loop to the aspartates of 
the PAS in all the available crystal structures has already been measured and analysed 
(Section 3.4.6, Figure 3.28). A clear increase in this distance was seen in the inhibitor- 
bound structures as compared to the unliganded and DNA-bound enzymes, and this 
difference in distance must be noted as a possible factor in the consideration of the 
changes between motifs that may cause inhibition. The spatial relationship between the 
template grip motif, and primer grip and PAS were also considered in the inhibition of 
the polymerase activity. The segment of the template grip running across the fingers 
was analysed by measuring the distance between Lys73 Ca at the end of this segment, 
closest to the first finger, and Gly231 Ca of the primer grip loop (data tabulated in 
Appendix 7.13). The results were graphed in Figure 3.58 as a blue line diamond trace, 
with the different crystal structures coloured.
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Figure 3.58 Graphical representation of the distance between fingers segment of the template grip 
to the primer grip (Ca Lys73 to Ca Gly231 — blue line diamond trace), and between the palm 
segment of the template grip to the PAS (Ca Gln91 to Ca Aspl85 -  green line triangle trace) in all of 
the crystal structures, ldlo (green), lhmv (dark green), lrtd (dark blue), 2hmi (light blue), CABM 
structures (orange), and OCMS structures (red).
The diamond line trace showed an increase in this distance in the red and orange 
coloured inhibitor-bound structures compared to the unliganded ldlo (5.10 A) and the 
catalytic lrtd (7.11 A). The relative similarity in the distance in the 2hmi structure was
due to a displacement of this segment of the template grip deeper into the fingers 
domain, and a downward displacement in the plane of the fingers.
The increase in the distance between these two motifs is likely to affect the 
communication necessary to correctly and efficiently base pair incoming nucleotides at 
the 3 OH terminus of the primer strand to the n nucleotide of the template strand that is 
presently being reverse transcribed. The greater distance between the two motifs 
primarily responsible for this positioning could mean that bonding interactions 
necessary for base recognition, if possible at all, would be extremely weak. Processivity 
as well as fidelity of replication are likely to be affected, as would the rate of chemical 
polymerisation and DNA replication
The function of the segment of template grip that runs across the palm subdomain has 
not been clearly determined, and as such, the significance of changes in spatial 
relationships between this motif and others of the enzyme can only be speculated at. 
The spatial relationship between Gln91 Ca of this segment of the template grip and Asp 
185 Ca of the PAS was determined, and presented in the green line triangle trace of 
Figure 3.58 (data tabulated in Appendix 7.13). With the exception of the lrev and lrt3 
structures, the inhibitor bound structures showed a decrease in the distance between this 
palm motif and the catalytic aspartate residue by an average of 3.30 A compared to the 
two green unliganded structures. The two blue DNA-bound structures also showed an 
average decrease in this distance of 2.93 A when compared to the unliganded structures, 
but were approximately equivalent to the distances observed for the inhibitor-bound 
structures, 13.37 A compared to 13.00 A respectively.
o
The similarity between the distances measured in the unliganded structures (16.32 A 
and 16.27 A) provided a strong basis with which to compare against the average 
distance in the inhibitor-bound structures, excluding lrev and lrt3, of 13.00 A. The 
distances between the template grip palm motif and the PAS in the lrtd and 2hmi 
structures, while reasonable similar, differed by 1.59 A, providing a weaker point from 
which to compare the spatial relationships. This segment of the template grip is known 
to affect the activity of the PAS,181 with long-range interactions that may require 
exacting specificity for proper communication. The decreases in distances seen in the 
DNA-bound structures may be necessary for conformational changes to a catalytically 
competent and active form. The similar decrease seen in the inhibitor-bound structures 
may appear to bring the enzyme closer to an active form, but there is also the
consideration that the spatial relationship may not solely be a matter of distance, but 
also direction. These rudimentary relationships studied provide little insight into the 
palm segment’s role in polymerisation, other than noteworthy observations such as 
those of Figure 3.58. This palm motif could possibly provide a structural 
communication relay point between the PAS and the RNase H active sites, that can 
function in a concerted manner.197 More studies into these spatial relationships may 
provide greater insight and yet may also further increase the complexity of the spatial 
equations necessary for enzyme activation and inhibition.
The relationships the RNase H active site has with the other motifs of RT are often 
neglected, with so much focus centred on the polymerisation reaction, with little regard 
to the complete function of the enzyme. The connection to the palm motif of the 
template grip has not been studied here, but both small and large relationships have 
been observed to the PAS and the primer grips. In the blue line circle trace of Figure 
3.59, a small difference was noted between the inhibitor-bound structures and the 
unliganded and DNA bound structures (data tabulated in Appendix 7.13).
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Figure 3.59 Graphical representation of the distance between RNase H active site to the PAS (Ca 
Asp498 to Ca Metl84 -  blue line circle trace), and between the RNase H active site to the primer 
grip (Ca Asp498 to Ca Gly231 -  green line square trace) in all of the crystal structures, ldlo 
(green), lhmv (dark green), lrtd (dark blue), 2him (light blue), CABM structures (orange), and 
OCMS structures (red).
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The average distance between Asp498 Ca of the RNase H active site to Metl84 Ca of 
the PAS in the inhibitor-bound structures was 62.74 A compared to 60.93 A in the ldlo 
unliganded structure, and 62.12 A in the alternate lhmv structure. The mean distance in 
the substrate-bound structures was 61.06 A. The average differences in the distances 
between the inhibitor-bound, unliganded and DNA-bound structures were all less than
o
2.0 A, seemingly insignificant compared to some previously studied differences, and 
less than 4% of the distance measured between the two Ca atoms. However, the blue 
circle line trace of Figure 3.59 does appear to show an increased trend, supporting 
speculation that communication between the active sites could be in terms of precise 
spatial distances, with changes to those exacting distances affecting what could be 
communicated between the two sites. While the evidence presented, in reality, does 
little to corroborate this speculation, the challenge remains for further research to verify 
or refute these hypotheses.
The relationship of the RNase H to the primer grip motif was fortunately not as 
ambiguous, as seen in the green square line trace of Figure 3.59 (data tabulated in 
Appendix 7.13). The distance between Asp498 Ca and Gly231 Ca of the primer grip 
loop showed an average of 59.42 A for the unliganded structures, and 58.75 A for the 
DNA-bound structures. Interestingly, the unliganded structure of ldlo showed greater
o
similarity to the catalytic lrtd structure (0.37 A difference) than to the alternate 
unliganded lhmv structure (2.10 A difference), and greater similarity than between the 
two substrate-bound structures (1.48 A). The average decrease in the distance between 
the RNase H and the primer grip in the inhibitor-bound structures compared to the 
unliganded structure was 2.83 A, but quite definite as seen in Figure 3.59. The lack of 
equivalence between the unliganded structures made it difficult to more definitively 
establish this change in the spatial relationship, and correlate it to a mechanism of 
inhibition. Likewise, the difference between the DNA-bound structures made 
comparisons difficult, but this difference may be significant in another light, as a change 
in the spatial relationship to signify a conformational change from a nucleic acid bound 
inactive form to a catalytically active form.
An infinite series of measurements could be made to establish an infinite number of 
spatial relationships within the dynamic and multifunctional reverse transcriptase 
enzyme. The scope of such a project was beyond the field of this research, but there is 
no denying that such relationships do exist, and may very likely be the key to a
complete mechanism of activation or inhibition. This research has shown rudimentary 
evidence of associations and connections from the PAS to both nucleic acid grips, 
between the two active sites, the two nucleic acid grips, and between the RNase H and 
the primer grip. Further study will only serve to develop and augment these observed 
results.
3.8.2 Activity correlation to structural and conformational changes
One of the foremost hopes of this research was to find a correlation or mathematical 
relationship between the structural and conformational changes of RT, observed and 
quantified by the rational and objective DDM-based superimposition technique, and the 
inhibitory data of enzymes bound with NNRTIs. Previous attempts have been made to 
relate levels of polymerase activity to the measured distance between the primer grip 
and dNTP binding regions in modelled solvated wild-type and mutated RT enzymes, 
with and without a NNRTI complexed.225 However, no other published study has 
included 19 inhibitor-bound crystal structures or correlated activity to inhibitor-induced 
conformational changes within and between structural motifs. The sometimes small 
changes within a structural motif, or between motifs, required that inhibitory data be 
precise so that variations in inhibitor structure could be differentiated. Unfortunately 
this endeavor was, with the presently available data and means, wishful thinking.
Several stumbling blocks make this objective presently infeasible. The multiple 
functions of the enzyme would require separate activity data for each of the functions 
studied, in particular RNA- dependent and DNA-dependent DNA polymerase activities, 
as well RNase H activities, in both native and inhibitor-bound enzymes. Other aspects 
of function need also be considered; processivity, fidelity, and phosphorolytic activity. 
Screens and assays would need to be consistent, with the same cell lines and 
experimental conditions used for all inhibitor testing. The impossibility of obtaining 
this data has already been previously observed, ’ ’ and so such studies were not 
investigated beyond preliminary consideration with the crude activity data (Appendix
7.3 X-ray crystallographic structures of reverse transcriptase) acquired for the ligand 
and structure-based drug design studies of Chapter 4.
3.9 Integrated mechanism of activation and inhibition
No one study can hope to definitively and exhaustively analyse all the interactions of an 
enzyme to determine its mechanisms of activation and inhibition. There are numerous 
additional motifs and single amino acid residues of significance in RT that have yet to 
be studied, and may play consequential and critical roles in the enzyme function and 
dysfunction. This research has established the methodology by which any other 
structural motif can be objectively examined and its conformational displacement, upon 
substrate or inhibitor binding, quantitatively analysed. The active sites and motifs 
studied in this research have given an insight into the complexity of the reverse 
transcriptase enzyme, its multiple and dynamic functions, and the subtle conformational 
changes with which it carries out it biological functions and is inhibited by the binding 
of non-nucleoside inhibitors.
3.9.1 DNA vs RNA
The primary function of RT is to reverse transcribe double stranded proviral DNA from 
a single strand of viral RNA to ensure the genetic survival of the virus. This seemingly 
simple function requires an elaborate process of primer and template bindings, 
polymerisation, strand transfers, and RNase H hydrolysis (Section 3.1.2). However at 
each stage of the reverse transcription process, one basic yet crucial prerequisite is 
needed, the differential recognition of ribonucleic and deoxyribonucleic acids. A study 
of the differences between the structural features and forms of single and double strand 
RNA and DNA, RNA-DNA hybrids, and the primers of HIV-1, tRNALys3 and the PPT, 
was beyond the scope and intent of this research, as was an analysis of the differences in 
nucleic acid conformation in RT (For reviews 162’163’168’174’175’211’226'229). However, 
evidence that some functions of RT are sensitive and respond to the differences in RNA 
and DNA, provides a basis for the postulation that structural elements of RT are 
responsible for nucleic acid recognition, changing conformation to accommodate the 
correct form and function appropriately to that form.
Although reverse transcriptase uses both DNA and RNA templates in its natural 
replicative reaction, the enzyme has been shown to exhibit a marked preference for the 
correct RNA template.5 RT preferentially binds to tRNALys3 even in the presence of a 
100-fold excess of other tRNAs,230 and unerringly selects the PPT amongst all other
Theshort RNA segments for synthesis of (+)-strand strong-stop DNA. 171>173’231 
nucleotide incorporation rate during DNA synthesis was found to be significantly 
greater on RNA than DNA templates, 10 to 15 nucleotides per second in contrast with
0.6 to 0.7.178,232'235 Furthermore, the fidelity, or rate of faithful replication, during 
polymerisation was greater with RNA templates.236,237 The rate of dissociation, as a 
counter measure of processivity, has been observed to be greater for duplex DNA than 
for RNA/DNA heteroduplexes.156 The rate and specificity of RNase H cleavage has 
also been observed to differ depending on which substrate, DNA/RNA or RNA/RNA, 
was used.127,195,203,238'240
This wealth of evidence alludes to fine and subtle variances between the interactions of 
the enzyme with RNA and DNA that are augmented to produce distinctively different 
effects. Whether it is the structure of the nucleic acid itself that determines and induces 
the conformational changes of RT, or the structure of RT which identifies the nucleic 
acid and conformationally rearranges in response to govern the recognition process, or 
even a synergy of the two, can only be postulated. However, this discrimination and its 
suspected accompanying conformational changes are believed to be detrimentally and 
differentially affected by the binding of NNRTIs, influencing all the aspects of RT 
function. Consequently the answer to the question of how RT is activated and 
functions, as well as how it is inhibited, takes on an incalculable sum of variables and 
dimensions. When one considers that the RT enzyme, in vivo, is not believed to
127
function in isolation, but rather aided by the viral nucleocapsid protein, even more 
variables need to be considered in a mechanism of activation or inhibition. The 
nucleocapsid protein (NC) is believed to promote annealing between the tRNALys3 
primer and RNA template, stimulate the initiation of (-) strand DNA synthesis and 
strand transfer, and increase the efficiency of polymerase-independent RNase H
3 127 195activity, as well as the processivity of DNA synthesis. ’ ’
3.9.2 Snapshots and conformations
The results of the DDM-based superimposition have also helped form the tentative 
hypothesis that at the most simplistic level, RT and its elemental motifs exist in at least 
six basic global conformations.
■  imxme tmmwtfpitme
1. E
2. E»RNA(template)*RNA(primer)
3. E •RNA(template)*RNA(primer)
4. E»DNA(template)»RNA(primer)
5. E •DNA(template)#RNA(primer)
6. E-I
(E -  enzyme, E* - catalytically active enzyme, I -  NNRTI)
Another four possible conformations may exist for the nucleic acid template-primers 
bound to enzyme-inhibitor complexes. The ldlo and lhmv structures are obviously 
representative of the unliganded E conformation. The 2hmi structure may be a close 
approximation of the E»DNA(template)*RNA(primer), with a homoduplex DNA in 
place of the DNA-RNA hybrid. It is likely to represent the enzyme bound to the nucleic 
acid before RT is activated and begins polymerisation, or the conformation of the 
enzyme between successive additions of dNTPs.136,160 The lrtd structure is believed to 
be a comparable snapshot of the E*#DNA(template)#RNA(primer) conformation, once 
more with a homoduplex DNA in place of the DNA-RNA hybrid.136,160 All the 
inhibitor-bound crystal structures are believed to be representative of a diversity of E#I 
conformations. Naturally, there are expected to be differences due to the variations in 
the structures of nucleic acids (Section 3.9.1), but the basic hypothesis remains as such. 
The differences between the dsDNA in lrtd and 2hmi, illustrated in Figure 3.60 (left), 
and the previously studied active sites of the two structures (Sections 3.3 and 3.6) 
support the postulation of differences between active and inactive conformations of RT. 
Most especially near the two active sites, the structure of the nucleic acids are seen to 
differ notably, and by association, it could presumed that the conformations of the 
motifs of the protein would also differ. They may adapt to each other, reciprocally 
making conformational changes to accommodate the other, for the mutual benefit of the 
virus.
With regard to the active site and nucleic acid grips studied in this research, this 
hypothesis of basic conformations of RT postulates that each motif has its own distinct 
and unique conformational features that distinguishes it from other conformations. 
Collectively, their individual ‘snapshots’, and the three-dimensional spatial relationships 
connecting them into one dynamic protein, form one of the six postulated global 
conformations.
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Figure 3.60 (Left) The structural differences between the dsDNA in Irtd (blue ball-and-stick) and 
in 2hmi (green sticks), seen relative to the incoming nucleotide (orange) and the polymerase and 
RNase H active sites in lrtd. Active site residues are coloured by atom, oxygen (red), carbon 
(black), nitrogen (blue), sulfur (yellow). (Right, top and bottom) Magnified views of the two active 
sites.
For ongoing studies into the mechanisms of activation and inhibition of RT, there is a 
need for more crystal structures or computer-generated models, in particular those with 
the natural RNA primers and templates bound, and structures with both nucleic acids 
and inhibitors concurrently bound. These structures will assuredly provide further 
insights into possible enzyme conformations and the ramifications of such structures. 
Such an inundating wealth of information may also provide enough information for 
distinct trends and patterns in conformational changes within motifs, and between 
motifs, to emerge. Despite the postulated complexity of the enzyme and its 
mechanisms, some simple structural and conformational relationships could be 
revealed, hopefully validating these present results and proposed conclusions.
Further study of the NNIBP using the DDM-based superimposition techniques should 
provide a means of characterising, and possibly quantifying, the conformational 
flexibility of the pocket, with the objective of using this information to predict inhibitor 
binding. The advantage to current drug optimisation and de novo inhibitor design 
would be an understanding of the mechanics of the pocket, possible movements and 
expansion that could allow the targeting of new binding interactions with conserved or 
newly realised residues of the pocket.
The information from the NNIBP could help in docking studies to predict drug binding 
modes and affinities. Current docking studies allow some flexibility in the binding site 
during minimisations, following initial docking, by allowing the sidechains to move and 
adopt new conformations around the inhibitor. However, the fundamental backbone of 
the binding site is restrained, producing a flawed simulation. The understanding and 
characterisation of the flexibility of the NNIBP will assist in the design of a more 
effective and efficient pseudo-pocket, representing the flexibility of entire individual 
residues. These residues could be allowed freedom of conformational change during 
docking minimisations, only limited by a spatial parameter defined by the least and 
most distant position the residues are found in recrystallised structures from a central 
inhibitor-binding position. Consequently, the potential of the pocket to bind inhibitors 
is more thoroughly and faithfully expressed.
♦ Chapter 4 ♦
Integrated Drug Design
♦
4.1 Computer aided ligand design
Computer aided ligand design (CALD) is a more accurate term for what is commonly 
known as computer aided drug design (CADD), and has two primary focuses; ligand- 
based and structure-based ligand design. The greater accuracy of the CALD term lies in 
the consideration that the research tools of the computational chemist are only able to 
stimulate and test ideas and concepts for the design of small molecules to bind 
specifically to biomolecules to induce a biological response. Whether these small 
molecules or ligands progress through to be synthesised and undergo rigorous iterative 
optimisation cycles to pass tests for biological activity, specificity, bioavailability, lack 
of toxicity, medical need, manufacturing requirements and market potential to become a 
drug is another matter altogether. The objective of CALD is to use the diverse 
methodologies of computational chemistry to help discover novel or optimised chemical 
structures with properties that might qualify them to enter the drug discovery pipeline.
CALD secured its place in the drug discovery process predominantly by virtue of the 
economics of bringing a new chemical entity, or drug, from the laboratory bench to the 
patient, estimated to be anywhere from $200-$500 million dollars.241 This cost includes 
not only the cost of the new drug, but also the cost of research on the multitude of failed 
lead compounds.78 The tools of CALD are designed not only to conceive novel 
medicinal agents, but also to analyse their potential as drugs and determine problems 
with such issues as biological activity, specificity, bioavailability, and lack of toxicity as 
early in the drug discovery process as possible. Examples of the use of CALD are too 
numerous to detail in this short review, but include the design of inhibitors of HIV-1
protease242 and reverse transcriptase,243 beta-lactamase,244 influenza virus sialidase,245 
and angiotensin converting enzyme246 and have been well reviewed.243,247'250
CALX) computational tools can be divided into two classifications; ligand-based and 
structure-based design tools. The terms receptor, binding site, active site, protein and 
enzyme are used interchangeably in this study, as are the terms ligand, and inhibitor, 
and molecule.
4.1.1 Ligand-based drug design
Traditionally ligand-based drug design, also known as analog-based drug design, has 
been used in the absence of three-dimensional structural information about the protein 
or receptor. It relies predominately on information about a series of compounds or 
inhibitors and their biological interaction with the protein. The value of the data 
depends on the specificity of the biological target. A series of compounds with a range 
of activities from an enzyme assay is much more valuable than compounds tested on 
whole cell assays. Ligand-based drug design utilises such computational tools as 
QSAR, CoMFA and pharmacophores to improve the biological activity of current 
drugs, and conceive new medicinal agents.
4.1.1.1 Quantitative structure activity relationships
Classical QSAR correlates the biological activities of drugs with their physicochemical 
properties or indicator variables that encode certain structural features such as 
lipophilicity, polarisability, electronic properties, steric properties.251 QSAR can be 
used to gain a deeper understanding of the influence of lipophilicity, and ionisation and 
dissociation on the transport and distribution of drugs in biological systems.252 The 
methods have been used to describe the affinity of ligands to their receptor in terms of 
different interaction forces between non-bonding molecules.252 QSAR also allows the 
rational derivation and refinement of working hypotheses to aid drug design and lead 
optimisation.
The underlying assumption of all QSAR models is that the biological activity of 
different analogs is the sum of the contributions from individual substituents or groups 
of the parent compound.252 Biological activities are defined as molar properties, on a 
logarithmic scale. All QSAR techniques assume that all the compounds being studied 
bind noncovalently to the same biological target; that structurally similar compounds
are similarly orientated at that common receptor or binding site; and that the dynamics 
of the system can be ignored.253 QSAR methods differ in the way they describe the 
compounds, and in how they detect the relationships between the three-dimensional 
properties and biological activities of the compounds. However, all QSAR 
methodologies consist of three fundamental steps; molecular alignment, calculation of 
the molecular properties, and computational analyses of the relationships. An 
examination of the variations and technical details of these steps of QSAR has been 
reviewed by Oprea and Waller, and Greco et a/.253,254
The term QSAR describes numerous different computational techniques, though the two 
most recognised are Hansch and Free-Wilson analyses. Hansch analysis, or the 
extrathermodynamic approach, of QSAR correlates the dependence of various 
biological activities on different physicochemical properties, while the Free-Wilson 
analysis of QSAR correlates it on the presence and absence of certain structural 
features. In Hansch analysis, global properties such as partition coefficients, molar 
refractivity, lipophilicity, electronic, polar, and steric properties of substituents are 
correlated with biological activities.252 In Free-Wilson analysis, values of 0 or 1 are 
assigned to indicator variables to code the presence or absence of certain structural 
features. The potential and applicability of both methods can be augmented by 
QSAR models derived from a mixed approach of both Hansch and Free-Wilson
252parameters.
The physicochemical properties used in QSAR are only limited by what can be 
described mathematically. Hydrophobic properties can include partition coefficients, 
solubility parameters, distribution coefficients, substituent constants, and hydrophobic
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fragmental constants. Electronic descriptors can include Hammett constants, 
ionisation constants, 13C and !H NMR shifts, electrostatic potentials, energies of highest 
occupied and lowest unoccupied molecular orbitals, and atomic net charges. Steric 
descriptors can include molar volume, molecular weight, van der Waals radii and 
volumes, and molar refractivity.
Quantitative models or regression equations can be derived, and the significance of the 
complete or individual terms of the model can be tested by linear or nonlinear multiple 
regression analysis, discriminant analysis, principal component analysis (PCA), or 
partial least squares analysis (PLS).252 The relevance and legitimacy of the QSAR
model can be tested by cross-validation, or lateral validation.252 In the validation 
process the QSAR model is compared with closely related biological systems.
A classical QSAR regression equation is described in Scheme 4.1, where -log [Cone] is 
the negative logarithm of the concentration needed to evoke a biological activity. The 
coefficients, a, b, c, and so forth, are determined by regression analysis.254
Scheme 4.1
-log [Cone] a stericdescriptor + b
electronic
descriptor + c
hydrophobic
descriptor +
Three-dimensional QSAR methods are those that locate structural properties based on 
the three-dimensional structure of the modelled compounds.254 These methods attempt 
to identify spatial regions for complementary molecular properties that match the 
binding site.
The quality of a QSAR analysis, its ability to predict values, such as the biological 
activity or toxicity, of compounds it has not seen, its capacity to explain the mechanism 
of action of individual ligands at the binding site, and its pharmacological relevance, 
define its value as a drug design tool.254 The fulfillment of these criteria is as much 
dependent on the quality of the data or training set, as the QSAR method used, and this 
prerequisite is recurrent in all other drug design techniques.
4.1.1.2 Comparative molecular field analysis (CoMFA)
Comparative molecular field analysis (CoMFA) is a widely used tool for the study of 
three-dimensional quantitative structure-activity relationships, predominantly used in 
the field of ligand-protein interactions, to describe affinity and inhibition constants. 
Originally developed by Cramer et al.,256 CoMFA relates the biological activity of a 
series of molecules with their steric and electrostatic fields sampled at grid points 
defined by a three-dimensional box around the molecule. It is an important 
precondition of these molecules that they all interact with the same receptor, enzyme, 
ion channel, or transporter in the same manner, with identical binding sites and in the
251same relative geometry.
The descriptors, or field values, for CoMFA are usually calculated by means of different 
atomic probes such as a carbon atom, a positively or negatively charged atom, a
hydrogen bond donor or acceptor, or a lipophilic probe.251 Classical CoMFA steric 
fields are calculated as Lennard-Jones potentials and the electrostatic fields are 
calculated as coulombic potentials.257,258 Other CoMFA fields can include 
hydropathicity, hydrogen bonding, molecular orbitals, similarity indexes, and 
desolvation energy fields.254 These field values are calculated at each grid point, and 
present the energy values that the particular probe would experience in the 
corresponding position of the three-dimensional lattice.
A relationship is developed between the independent variables, such as the steric and 
electrostatic potentials, and the dependent variable, such as biological activity or 
binding affinity, using a partial least squares regression method, that produces a 
regression equation with possibly thousands of coefficients.251,257 This model equation, 
or equations, is most often graphically presented as a set of isocontour maps. These 
maps indicate the regions where the variation in steric and electrostatic properties of 
different molecules in a data set correlate with the variation in biological activity, or 
binding affinity.251,257
One of the biggest challenges in CoMFA studies is alignment, or superimposition, of 
the molecules of the test set, that is, the specification of which part of one molecule 
relates to a particular part of another molecule.258 This can be complicated in cases of 
seemingly closely related analogs having different binding modes.251 Alignment rules 
need not directly reflect the relative molecular orientations in the binding site of the 
receptor or enzyme. X-ray crystallographic, multidimensional NMR, and docking 
alignments of the ligand in ligand-protein complexes have been used for CoMFA.259'261 
However, they often fail to produce models that are as predictive as alignments based 
on shared substructure elements. Superimposing common substructures tends to 
wash out field variations at the corresponding coordinates and focuses the analysis on 
those positions where structural variation is most relevant. ’ Thus CoMFA 
alignment can be evaluated by either a pharmacophore hypothesis of common 
substructures, a receptor site model from crystallographic, spectroscopy or docking 
data, or by a hybrid approach.254
Related techniques include comparative molecular similarity indices analysis 
(CoMSIA), and comparative molecular moment analysis (CoMMA). CoMSIA was 
devised to overcome rapidly changing steric fields near the van der Waals radius of an
t • 254atom that result in ambiguities and fragmentation of the contours at these points.
Contour maps from CoMSIA are smoother, and more coherent, and thus are easier to 
interpret.251,262 CoMMA has the advantage that molecules do not need to be 
superimposed.263
4.1.1.3 Pharmacophores
A pharmacophore can be defined as the critical three-dimensional arrangement of points 
in space, each having some specific property such as charge, hydrophobicity, or 
hydrogen bonding capability, that is responsible for creating patterns of atoms and 
charge distributions that allow recognition by, and binding to, the target receptor 
site(s).254,264 The most traditional method of pharmacophore characterisation begins 
with the identification of crucial functional groups in a ligand which have been 
observed to bind to a receptor or enzyme binding site.264 Numerous conformations of 
the ligand may exist, and those in which the balance between the deformation energy to 
fit into the receptor and binding energy to the receptor is such that binding is 
thermodynamically permitted are examined in the pharmacophore analysis.264
A second approach to the generation of a pharmacophore involves the analysis of the 
receptor or active site. Information about the active site can be in the form of mutation 
data of single amino acid residues of the site that reveal their significance to receptor or 
enzymatic activity.264 Increasingly, receptor site information comes in the form of x-ray 
crystallographic and NMR spectroscopic data of the protein structure.264
One of the most powerful applications of pharmacophores is in the mining or searching 
of electronic databases of three-dimensional structures to determine structures that 
contain the features of the pharmacophore that can elicit the desired biological 
response.246 During such searches, the spatial dimensions of the pharmacophore are 
used to identify compounds in the database that contain the pharmacophoric features.264 
Multiple conformations of these compounds are generated and examined to determine if 
they fit the pharmacophore within reasonable energy terms. Pharmacophores can also 
be used for de novo generation of structures (Section 4.1.2.2).
Pharmacophores are invaluable tools for the identification of lead structures that can be 
examined for the appropriate biological activity, then chemically modified so as to 
improve the geometry, incorporate new binding interactions, or optimise their transport 
properties. Iterative modifications of this lead compound, guided by refined 
pharmacophores and molecular modelling, produce potential drug candidates with
optimal biological activity and minimal negative properties faster and more efficiently 
than traditional medicinal chemistry approaches to drug design.264 However, despite the 
power of pharmacophores in rational drug design, their potential is often curbed by the 
structural diversity of the drugs that have spawned them. Any new drugs to emerge 
from these design principles can only make use of the same ligand-protein interactions 
as the parent drugs may have had.
4.1.2 Structure-based drug design
Advances in structure determination methods over the last couple of decades have 
supplied an increasing abundance of information on the three dimensional structures of 
proteins.249 As of November 2000, the Research Collaboratory for Structural 
Bioinformatics (RCSB) Protein Data Bank contained 13 672 structures; 11 232 derived 
from x-ray crystallographic techniques, 2138 from nuclear magnetic resonance studies, 
and 302 theoretical models.265 Parallel with this growth was the development and 
application of new computational approaches to exploit this structural information in the 
drug discovery process.
Structure-based drug design is essentially the design of chemical structures to fit a 
macromolecular target of known architecture.266 Knowledge of the three-dimensional 
steric and electrostatic environment of the active site of a receptor, and possibly the 
interactions between the residues of the active site and a bound ligand, can enable lead 
compounds to be modified while preserving the intermolecular interactions that confer 
binding affinity and specificity.77 This also allows the design of totally novel ligands 
based upon shape and function complementarity with the known receptor structure. The 
two principal tools of structure-based drug design are molecular docking and de novo 
design; both are based on the analysis of protein structure, and ligand-receptor 
interactions.
4.1.2.1 Ligand docking
Molecular docking studies attempt to find the binding mode of a ligand in a ligand- 
receptor complex by searching the conformations and relative orientations of the ligand 
and receptor for a geometry with a favorable binding energy.267 Knowledge of the 
bioactive conformation and binding mode of a ligand aids in the rational explanation of 
some of the features of structure-activity relationships for the ligand. Docking
programs can also screen databases of small molecules to identify ligands that will fit 
the target receptor site, to be used as leads for further drug development.268
Accurately modelling ligand-receptor interactions is difficult because of the large 
number of intermolecular interactions and degrees of freedom available to the ligand­
protein complex. Three rotational and three torsional degrees of freedom are available 
between the ligand and the protein, as well as internal torsional degrees of freedom 
within the ligand and the protein. 69 Consequently, docking algorithms can be divided 
into four classes depending on the degree to which they consider molecular flexibility. 
Algorithms can regard both the ligand and protein as rigid molecules, the ligand as a 
flexible molecule while keeping the protein rigid, the ligand as a rigid molecule with the 
protein flexible, or with both ligand and protein as flexible molecules.270 273 
Conformational flexibility of the ligand is often incorporated into docking by 
calculating multiple conformations of the ligand, and then docking each individual 
conformer as a rigid ligand.268,274 Conformational flexibility in the protein is often 
considered by holding the protein backbone rigid while allowing systematic variation of 
the amino acid side chains amongst a predetermined set of conformations determined 
from analysis of high resolution protein structures.275 Ideally, the consideration of 
molecular flexibility should involve molecular mechanics, or molecular dynamics, 
however this is computationally infeasible for practically all ligand-receptor systems.273
Continuing developments in molecular docking will improve how the flexibility of the 
ligand and the protein are considered, as well as improving the methods for scoring the 
receptor binding affinity of each ligand relative to the others.267 Molecular docking can 
be an effective tool for assessing the prospect of a ligand binding to a receptor, as well 
as for screening electronic databases for potential new ligands. However, this is 
provided that the intensive theoretical calculations estimating the binding affinity, and 
scoring functions are fast enough to be practically useful.
4.1.2.2 De novo ligand design
While de novo ligand design can also be used with ligand-based pharmacophores, its 
prevailing use has been in structure-based studies.247 De novo ligand design includes 
three basic computational methods, fragment positioning, molecular growth, and 
database search methods.268 The fragment positioning method determines the 
energetically favorable binding site positions for various functional groups or chemical
fragments, and includes such programs as GRID®,276 and LUDI®.277,278 The optimal 
molecular fragments are then clustered and connected to form chemically conceivably 
and synthesisable candidate ligands.268 The diversity of the resultant ligands is only 
limited by the variety of chemical moieties or fragments available.279 Another 
advantage of this method is that the synthetic accessibility of the ligands can be 
controlled at the fragment connection stage.
In molecular growth methods, a seed atom or fragment is placed in the binding site and 
a ligand is successively formed by bonding another atom or fragment to it.268 The 
ligand is scored as it is built, based on its chemical complementarity with nearby atoms 
in the binding site of the receptor active site. The disadvantage of this method is that 
the results are often very much dependent on the initial positioning of the seed atom in 
the binding site, and many of the resulting ligands may be too difficult to synthesise.268
The final computational method incorporates the use of database searching techniques 
to extract existing molecules, from an electronic database, that can be docked into the 
binding site with the desired fragments or functional groups in their optimal position. 
Programs such as Unity 3D®,280 and the recent Structure-Based Focusing module of
?(r) 9R1 9R9Cerius , ’ can be used to determine or combinatorially generate possible structure-
based pharmacophores or queries. These are a collection of pharmacophoric features 
placed at optimal positions to the residues of the three-dimensional active site, where a 
functional group from a ligand could be placed to form an intermolecular interaction 
with the residue of the active site. They can then be used to search databases in the 
same fashion as ligand-based pharmacophores.
Another important aspect of de novo design is the scoring function that allows some 
judgement to be made on the quality of the ligands proposed.247 It is used to screen 
large numbers of structures or fragments to determine their fit in the receptor, and also 
used to rank the binding affinities of a few selected putative ligands before the 
determination is made on which is the best to synthesise and use as a lead compound. 
Developments in de novo ligand design include the optimisation of these scoring 
methods to better assess the binding affinity of ligands.249,279 Further advancements 
include the consideration of protein flexibility in ligand design, and the structural
- • 249 279changes induced by the ligand onto the protein, and vice versa. '
Structure-based design strategies have the superior advantage that they are not limited 
or overly influenced by the structure of current drugs and inhibitors. All of the possible
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ligand-protein interactions in a receptor site may be studied and utilised in the drug 
design process of novel medicinal agents, including new interactions that may avoid 
resistance mutations of the active site.33 The potential of these structure-based design 
tools is limited by the need for nuclear magnetic resonance, x-ray crystallographic, or 
homology model data of the protein. However, the increasing challenge to understand 
and model the nature of protein-ligand interactions, and the need to accelerate the drug 
discovery process, is providing a driving force for the development of advanced 
methods for structure-based design able to consider these difficulties current being 
faced in drug design.
4.1.3 Integration of ligand- and structure-based drug design techniques
The complexity of any natural system is such that only one or a few facets of its 
complexity can ever be modelled at any one time. For too long, the understanding of 
protein ligand interactions, and consequently the drug design process, has been a case of 
two different facets of a natural system being modelled and studied separately; ligand- 
based and structure-based. This was because the entire puzzle has been too immense to 
study as a whole, and because parts of the puzzle have been missing. Although the 
immensity of the puzzle has not changed, more pieces of the puzzle have been revealed, 
as have more computational drug design techniques. This research was embarked upon 
to endeavour to bring together ligand and structure-based design techniques, to exploit 
the strengths from these two design methodologies; and compensate for their 
shortcomings and limitations.
Other combinations of computational tools have been utilised to augment their 
individual capabilities; 3D QSAR and receptor modelling, pharmacophores and 
molecular docking, ' pharmacophores and pseudoreceptor modelling, ’ and 
pharmacophores and 3D QSAR with excluded volumes from x-ray crystallographic 
structures.289,290 In this undertaking, the central foundation is based on the concept of 
pharmacophores; classical ligand-based and emerging structure-based pharmacophores, 
and their fusion into one all-encompassing pharmacophore.
4.1.3.1 Strategy for the integration of ligand- and structure-based pharmacophores
Our proposed integration of ligand and structure-based drug design is illustrated in 
Figure 4.1. It is based on the fundamental concept of pharmacophores (see Section
4.1.1.3 Pharmacophores).
Ligand Structures/Activities 
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1
Ligand-Based Drug Design Integrated Drug Design
Protein Structure/Homology Model 
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Figure 4.1 The integration of ligand-based and structure-based drug design strategies.
The strategy proposes to develop a traditional ligand-based pharmacophore with a 
standard tool of the ligand-based design, such as Catalyst®.291 From structure-based 
design techniques, the receptor active site will be characterised by such programs as 
Unity 3D®,280 Leapfrog®,292 LUDI®,293 or GRID276. These programs determine the 
spatial coordinates of ‘site points’, or points in space that describe the potential location 
and type of atoms or chemical moieties of a ligand, which would make favorable 
interactions with one or more of the protein atoms, as illustrated in Figure 4.2. Site 
points provide a measure of all of the potential ligand-protein interactions in a receptor; 
not just those previously identified by known ligands. As there can be hundreds of
sitepoints produced for a typical receptor site, they need to be clustered or averaged to 
locate the optimal position for a feature on a putative ligand molecule.
Figure 4.2 The generation of site points. Green dots represent where a hydrophobic aromatic 
chemical function may lie on a ligand, the red lines represent a hydrogen bond acceptor 
functionality, orange dots present hydrophobic aliphatic functionality, and the blue lines represent 
a hydrogen bond donor moiety. Typically, the hydrophobic aromatic and aliphatic site points are 
designated with one type of site point encompassing the two different interactions. Site points 
presenting positive charges, not shown, can also be generated.
Site point features will then be assimilated to form the superligand. Our proposed 
superligand is a structure-based pharmacophore that represents the largest and most 
optimal ligand that could possibly fit into the receptor or binding site. It will utilise all 
favourable and conceivable binding interactions with the protein, and will also include 
accurate excluded-volume information from the receptor structure. It does not take into 
account possible obstacles such as entry into a binding pocket. The structure of the 
receptor active site can be derived from x-ray crystallographic and NMR data, as well as 
from homology models.
The proposed combiphore will then be created by a merging of the classical 
pharmacophore derived from ligand-based design, with the superligand derived from 
structure-based methods. It would represent the most comprehensive synergy of ligand 
and structural information to date. The combiphore will, hopefully, employ all the 
strengths from these two design methodologies; and try to compensate for shortcomings 
and limitations in present design techniques.
In a supplementary attempt to try and compare the contrasting ligand- and structure- 
based techniques, only the ligands from x-ray crystallographic enzyme-inhibitor 
complexes will be used for the ligand-based pharmacophore, while the corresponding 
crystal structures will be used in the generation of the structure-based superligand. This 
will ensure that neither technique has a biasing effect on the final combiphore. And
although this may mean the number of the ligands in the ligand-based pharmacophore 
would be extremely small, the usual uncertainty of whether all the ligands bound at the 
receptor site or not would be removed.
Reverse transcriptase is an attractive drug target as it is an essential and unique enzyme 
in the replicative of HIV-1 (see Chapter 1). It is an excellent example to evaluate the 
potential power of our combined ligand- and structure-based pharmacophores for drug 
design as it is a well-documented protein. There are available numerous high-resolution 
crystal structures of RT with a variety of inhibitors bound in the non-nucleoside 
inhibitor binding pocket (NNIBP). These inhibitors, along with a multitudinous series 
of analogues, also provide biological activity data that has already been used 
extensively in ligand-based drug design as recently reviewed by Garg et a l294 The 
availability of both ligand- and structure-based data will also allow for the comparison 
between the established pharmacophore methodology and the developing superligand 
concept, and hence validation of the superligand as a drug design tool. The inherent 
flexibility of RT and its propensity for mutation to evade inhibiting drugs also poses a 
challenge to rational drug design, which may be tackled by this new design approach.
4.2 Ligand-based pharmacophore generation with Catalyst
The first stage of the integrated drug design process involves the generation of a typical 
ligand-based pharmacophore, using the Catalyst® software program (Molecular 
Simulations Inc.).291 Catalyst consists of three modules.250 The first of these is the 
catConf module that computes an electronic representation of the structure of the 
ligands that emphasises coverage of conformational space. The second catHypo 
HypoGen module calculates chemical feature-based pharmacophore models from a 
training set of compounds with biological activity data, usually IC50 or Kj values. A 
related module called HipHop can, calculate pharmacophore models with common 
features in a training set without activity data. The third module is catDB, a compound 
database building program that can be searched with several kinds of queries, such as 
pharmacophore and compound shape models derived from catHypo and HipHop.
Catalyst pharmacophore models are called hypotheses, and the terms ‘pharmacophore’, 
and ‘hypothesis’ are used interchangeably in this study. Hypotheses are constructed 
from five types of ligand-receptor binding interactions; hydrophobic, hydrogen bond 
donating (HBD) and accepting (HBA), salt bridges, and aromatic ring n stacking
interactions. These interactions are termed the features of a hypothesis, and are 
represented as points in space surrounded by a tolerance sphere. A hypothesis is a 
collection of these spheres that models the three-dimensional attributes of a molecule 
that are most important for binding of a ligand to its receptor. Each sphere represents 
the region in space that should be occupied by a chemical functionality capable of the 
kind of interaction specified by the feature type, for optimal drug-receptor interaction.250 
Each chemical functionality is assigned a weight, which specifies its relative importance 
in the hypothesis; a large weight indicates that the feature is more important, or plays a 
greater role in exerting biological activity, than the other features of the hypothesis.295 
The version of the Catalyst program used in this research291 assigned the same weight to 
each feature during the automated hypothesis generation.
A Catalyst hypothesis can be constructed by using positioning data from x-ray 
crystallographic, NMR experiments or modelled receptors, or from structure activity 
data. Chemical feature-based pharmacophores derived from structure activity data can 
be a successful drug design tool provided two assumptions about the data can be made. 
The first of these is that all of the active compounds in the set bind to the same receptor, 
and in roughly the same fashion.250 The second assumption is that compounds that have 
more binding interactions with the receptor or binding site are more active than those 
compounds that have fewer interactions. The corollary to this second assumption is that 
less active compounds tend to be smaller and possess fewer chemical features than more 
active compounds. However, in any data set there may be some large and feature- 
rich molecules that are not very active, possibly due to a conflicting steric interaction 
between the receptor and a portion of the molecule that may not be actually mapped to 
the pharmacophore. These can be identified by the use of exclusion spheres that 
describe receptor constraints, added manually to the hypothesis. In the event that no 
information about the receptor structure is available, such compounds are better left out
250of the analysis as Catalyst overestimates their activities.
4.2.1 Training set selection
The selection of compounds in the training set is essential to a successful application of 
the pharmacophore analysis, as the hypotheses are derived entirely from the information 
in the training set.296 Structurally diverse compounds, containing clear and concise 
information, are required; each compound should be selected to provide as much unique
information in terms of structure or activity as is possible.250 Structural redundancy 
needs to be avoided as this biases the statistical calculations used to correlate predicted 
and measured activities during the analysis.
The training set ideally needs to contain at least sixteen compounds to be statistically 
significant. Activity values should span four orders of magnitude, and each order of 
magnitude should be represented by at least three compounds. If there are two 
structurally similar compounds, they are both retained only if their activities differ by 
one order of magnitude, otherwise only the most active of the two compounds should be 
selected. If two compounds have similar activities, within one order of magnitude, they 
must be structurally distinct for both to be included in the analysis, or else only the most 
active of the two should be selected. Compounds known to be inactive due to steric 
obstruction of the receptor should be excluded, though this is not a consideration in this 
particular study.
The training set for these studies was derived from the structures of inhibitors 
previously crystallised in RT-inhibitor complexes (Appendix 7.3 X-ray crystallographic 
structures of reverse transcriptase). Not all inhibitor structures were used in the training 
set, as activity data could not be obtained for all of the inhibitors. It was impossible to 
obtain reliable and consistent activity data for all of the structures, as screens, assays, 
cell lines and experimental conditions used for inhibitor testing varied between research 
groups, as discussed in Section 3.8.2. However, for these preliminary studies of 
integrated drug design techniques, the judicious use of consistent and comparable 
activity data was deemed satisfactory. IC50 values used were obtained preferably from 
the same publication that reported the crystallographic data. In cases where this was not 
possible, IC50 values were obtained from publications reporting the synthesis of the 
inhibitors.
Inhibitors were identified by the corresponding PDB file code of the RT-inhibitor 
complex, and those used in the training set are illustrated in Figure 4.3.
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Figure 4.3 Structures of the HIV-1 RT pharmacophore training set.
Six of the inhibitor structures were excluded from the pharmacophore analysis for 
several different reasons. The lbqn inhibitor, HBY097 (111), was excluded as it was 
crystallised in a mutant enzyme, and the same inhibitor was available in the lbqm RT- 
inhibitor complex, lhni and lrt4 were excluded, as no activity data could be determined 
for the inhibitors Br-a-APA R 95845 (112) and UC781 (117), respectively. Irt3 and 
luwb were excluded as they had the same inhibitor as lrth, 1051U91 (116), and lhnv, 
8-C1 TIBO (11) respectively, and both were crystallised in a mutant RT enzymes, ltvr 
was not included in the training set as the same inhibitor was available in the lrev
o o
complex that had a higher resolution, 2.6 Á compared to the 3.0 A of ltvr. The 
rationale of excluding structures crystallised in mutant enzymes from the selection of
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compounds for the training set was in consideration of the subsequent structure-based 
drug design methodology. The training set of thirteen compounds (Figure 4.3) fulfilled 
none of the fundamental requirements for a pharmacophore training set, and as such the 
results could only be used in a qualitative manner, and as a model for the proposed 
method of integrated drug design.
4.2.2 Conformational analysis
In Catalyst, the flexibility of a molecule, and thus its ability to conform to a receptor or 
active site, is modelled by considering each compound as a collection of conformers.246 
The conformers represent a broad coverage of conformational space available within a 
reasonable and specified energy range, and are selected so that differences in 
interfunction distances are maximised. A maximum of 256 conformations can be 
generated for each ligand.297 The Best-quality conformation generation method is 
recommended for hypothesis generation as it provides the most comprehensive 
treatment of flexible ring systems, as well as the greatest conformational coverage 
within Catalyst.298 The fundamental goal of this approach is to find, from the test set 
compounds, the simplest set of chemical functions that correlate best with the observed 
activity.246
The inhibitor crystal conformations were imported into Catalyst and categorised as 
Single RT ligands, and no conformations were generated for this training set. A second 
set of these thirteen inhibitors was created, and from this set, conformational models 
were generated; the original crystal conformation was included with these models. This 
second set of inhibitors was categorised as Multiple RT ligands. Table 4.1 details the 
number of conformers generated for each ligand in the Multiple RT series. This gives a 
qualitative measure of the flexibility of a molecule.
inhibitor no. conformations activity (nM)
bqm 37 80
hnv 39 4.3
klm 82 1100
rev 44 1.5
rtl 21 12
rt2 28 6
rt5 68 200
rt6 51 150
rt7 40 280
rth 10 400
rti 58 66000
vrt 5 84
vru 142 5
Table 4.1 Inhibitor crystal structures and the number of 
conformations generated using the Best-quality method. The 
IC 50 inhibition data to be utilised for the pharmacophore 
development is also shown.
4.2.3 Hypothesis generation
Catalyst hypotheses are generated based on the assumption of Occam’s razor, a 
principle which proposes that a theory that provides a unified, common treatment of 
different phenomena is preferable to a theory that treats each phenomenon as a separate 
and independent problem.299 In terms of pharmacophore generation, Occam’s razor 
signifies that between otherwise equivalent alternatives, the simplest model is best.297
Catalyst generates its pharmacophores in three basic phases. In the initial constructive 
phase, Catalyst identifies hypotheses that are common among the active compounds in 
the training set, before removing hypotheses that are common among the inactive 
compounds in the subtractive phase. In the final optimisation stage, modifications are 
made to the hypotheses to improve their score, which provides a measure of the quality 
of the hypothesis.
A maximum number of five different types of descriptors or features are allowed for 
consideration in the hypothesis generation,297 and can be chosen from hydrogen bond 
donors and acceptors, aliphatic and aromatic hydrophobes, and positive and negative 
ionisable groups.300 Hydrogen bond donors and acceptors are composed of a heavy 
atom on the ligand and a vector projecting to the point of a complementary receptor 
atom. This provides directionality and further discrimination in the search query. 
Aromatic hydrophobes are also specified as ring aromatics, which more specifically
describes the n-n interaction between aromatic features, by restricting the plane of the 
aromatic system instead of just defining the centre point of the aromatic ring system. A 
vector is also projected to the centre point of the interacting aromatic system of the 
receptor in this feature. Function mapping of the inhibitors can identify features that are 
sterically accessible to the receptor for intermolecular interactions; the mapping of some 
features may depend on the conformation of the ligand. Five features were identified 
from the test set ligands; hydrogen bond acceptor, hydrogen bond donor, hydrophobic 
aliphatic, positive ionisable, and ring aromatic groups, and these were selected, 
unmodified, for use in the pharmacophore generation. A positive ionisable feature 
represents a functional group, such as a tertiary amine, that can be protonated under 
physiological pH. The ring aromatic function was utilised instead of the hydrophobic 
aromatic, as it was a more specifically defined functionality, containing more 
information about the location of the interacting n system on the protein.
Catalyst pharmacophores for the Single RT and Multiple RT training sets were 
generated in HypoGen using standard parameters,297,298 with two exceptions. The 
Minimum Total Features parameter was increased from the standard value of 1 to 3 for 
the Single RT, and to 3 and 4 for the Multiple RT training sets. A Minimum Total 
Features value of 4 and 5 for the Single RT and Multiple RT training sets, respectively, 
failed due to unfavorable cost values. Increasing this parameter changes the hypothesis 
space created in the constructive and subtractive phase of the pharmacophore generation 
and forces Catalyst to search for hypotheses with more features.301 Hypotheses with 
more features are more likely to be further discriminating and specific for that particular 
receptor or biological target.
The second parameter that was modified was the forceAbsoluteSterochemistry option 
that is generally set to 0, indicating that the Mirror Image function is on. This function 
considers the mirror image of the ligands during the hypothesis analyses to obtain 
greater conformational coverage at less computational expense.301 However, the mirror 
image of ligands in which an absolute chiral center is assigned are not utilised in the 
hypothesis analysis. As the structures of the ligands in the training sets had been 
obtained from crystallographic structures, and the conformations of those in the Single 
RT set are actually those observed in the binding pocket, it was determined that the 
Mirror Image function was unnecessary, and might dilute the specificity of the resulting 
hypothesis. Pharmacophores of the Single RT and Multiple RT training sets were
therefore generated with the Mirror Image function on and off and were designated 
Singlepharm and Multipharm, and Chiralsinglepharm and Chiralmultipharm, 
respectively.
4.2.4 Hypothesis analysis and selection
To design a pharmacophore, Catalyst generates up to ten unique hypotheses according 
to how well the training set fits the descriptors used. Cost analyses of the hypotheses 
are calculated to determine the ranking of the pharmacophores, and mapping patterns of 
the compounds help to decide which hypothesis best correlates the data. The cost 
analyses of all the hypotheses generated are presented in Table 4.2.
At the start of an automated hypothesis generation HypoGen calculates the cost of two 
theoretical hypotheses representing the upper and lower bounds of the training set.296’297 
A fixed hypothesis represents the ideal hypothesis cost, a value assigned to the simplest 
possible hypothesis that fits the data precisely. The null hypothesis assumes that there 
is no statistically significant structure within the data, and that the experimental 
activities are randomly distributed about their mean. A fixed cost and a null hypothesis 
cost are generated to give an initial indication of the probability of finding useful 
pharmacophores. They are expressed in bits, and the difference between the two is a 
measure of the probability of finding statistically valid and useful pharmacophore
297models; the greater the difference, the higher the probability.
The null cost of the pharmacophore runs of Table 4.2 were all the same, while the fixed 
cost varied slightly with changes in the Minimum Total Features parameter and the use 
of the multiple conformations of the inhibitor crystal structures in the Multiple RT 
training sets. The Mirror Image parameter had no affect on the fixed and null 
hypotheses, and only influenced the ten individual hypotheses generated in each 
pharmacophore run. The average difference between the fixed and null hypotheses in 
the pharmacophores generated from the Single RT training set, where only the 
conformations from the crystal structures were used, was 35.1. This average difference 
in the pharmacophores of the Multiple RT training set, where conformational analyses 
of the ligands were performed, was 30.0. This appeared to indicate that the hypotheses 
generated from the Single RT training set were more likely to be statistically valid and a 
more faithful correlation of the training set ligand structures and inhibition data than for 
those pharmacophores generated from the Multiple RT training set.
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Table 4.2 Summary of the cost analyses of Single RT and Multiple RT pharmacophores.
Hypothesis features summarises the number and type of features in the ten returned pharmacophores. The first set was the most common. 
A -  hydrogen bond acceptor, P - positive ionisable, H - hydrophobic aliphatic, R -  hydrophobic ring aromatic 
Relative cost is the difference between the cost of the null hypothesis and the cost of the individual hypothesis.
* - one or both of the 2 most active compounds did not map well onto the hypothesis.
§ - the three top active compounds mapped well onto the hypothesis.
# - hypothesis has a hydrophobic aliphatic feature missing from the first described set of features.
A - hypothesis corresponds to the second set of features.
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Initially this observation appeared erroneous when one considered that the Single RT 
training set contained only 13 conformations of ligands compared to the 625 ligand 
conformations of the Multiple RT training set. However, the fact that the 13 singular 
conformations of the ligands of the Single RT training set were derived from 
crystallographic structures, and were most likely to be, or very closely approximate, the 
active conformation of the inhibitor, meant that more accurate information was used to 
calculate those hypotheses. The use of the multiple conformations in the Multiple RT 
training set thus appeared to dilute the pharmacophoric analysis, returning less 
statistically robust hypotheses.
Each of ten hypotheses generated is also accorded a cost value in HypoGen. The 
relative cost is the difference between the cost of each of these hypotheses and the cost
of the null hypothesis, and relates to its probability of representing a true correlation of
297 . ,
the data. A difference of more than 60 bits means that there is a greater than 90 % 
chance that the hypothesis is a true correlation, a difference of 40-60 bits equates to a 
probability of 75-90 %, and for any value below 40 the percentage drops to below 50 %. 
Under these last conditions it is unlikely that the models will be predictive, or represent 
a statistically valid correlation of the training set data.
The relative costs of the hypotheses of Table 4.2 revealed that all cost analyses fell well 
outside of the range considered functional for pharmacophore analysis. Furthermore, 
nearly all of the returned hypotheses had relative costs less than 20, a situation in which 
the model, as a rule, has little chance of succeeding, and it is generally advised to 
reconsider the training set. However, this was not considered overly significant in 
this study where the primary objective was to assess the integration of ligand- and 
structure-based drug design tools. Moreover, unlike most pharmacophore studies, all of 
these ligands were definitively known to bind at this one biological target, and in the 
case of the Single RT training set, the actual binding mode of the ligands was available 
for the pharmacophore analysis.
There was surprisingly little difference between highest ranking hypotheses of the 
Single RT and Multiple RT training sets, with average relative costs of 21.0 and 20.2 
respectively. However, it was noted that the hypotheses generated from the Single RT 
training set displayed a gradual decrease in the relative cost from the first hypothesis to 
the last hypothesis, whereas the hypotheses of the Multiple RT training set often
displayed a large difference between the first and second hypotheses. This was most 
notable in the multipharm pharmacophore where the Minimum Total Features 
parameter was set to 4; the difference between the first and second hypotheses was 10.1 
bits.
Very little difference was also seen between hypotheses generated with and without the 
Mirror Image function. In the Single RT training set, for the highest ranking 
pharmacophore, the average relative cost was 20.8 with the Mirror Image function on 
compared to 21.3 without the same function, and similarly the average of all ten 
hypotheses was 15.3 and 15.9 with the function on and off respectively. In the Multiple 
RT training set, the reverse effect was observed with the average relative cost slightly 
higher with the Mirror Image function on rather than off, 20.3 compared to 20.1 
respectively for the highest ranking hypothesis, and 11.8 compared to 10.3 for all ten 
generated hypotheses.
Modification of the Minimum Total Features parameter appeared not to have a 
significant or compelling influence on the relative costs of the returned hypotheses, 
despite the observation that the highest ranked hypothesis of 22.5 was generated in the 
multipharm pharmacophore where the Minimum Total Features was set at 4. In the 
case of the chiralsinglepharm pharmacophore, increasing this parameter from 1 to 3 
improved the costing of the hypotheses, while in the case of the singlepharm 
pharmacophore, it decreased the costs of the highest ranking hypotheses. In the 
multipharm and chiralmultipharm pharmacophores the modification of the Minimum 
Total Features parameter from 1 to 3 to 4, first decreased and then increased the cost of 
the highest ranking hypothesis. The pattern observed for the overall average of the ten 
returned hypotheses in each of the pharmacophore runs, for both the multipharm and 
chiralmultipharm pharmacophores, was first an increase and then a decrease in the 
average hypotheses cost.
Another gauge of the validity of the hypotheses is the entropy, or configuration cost, a 
parameter describing the complexity of the hypothesis space HypoGen must analyse, 
equal to the exponent to the base 2 of the number of models Catalyst will attempt to 
optimise during the hypothesis run.296,297 Entropy values up to 17 are reasonable for the 
optimisation of initial hypotheses. Values greater than 17 generally indicate that the 
training set ligands may be too flexible to allow a correct space coverage during 
conformational analysis, and not all pharmacophore models may be considered.296 The
entropy in the Single and Multiple RT training sets were not affected by the Mirror 
Image function, but were affected by the Minimum Total Features parameter, generally 
decreasing as this parameter was increased. The average entropy, or configuration cost, 
for pharmacophores derived from the Single RT training set was 5.042, and twice as 
much for pharmacophores derived from the Multiple RT training set, which had average 
entropy values of 10.2.
Although the cost elements are a significant consideration in the selection of a final 
hypothesis from the ten returned hypotheses of a pharmacophore run, other factors need 
to be taken into account to fully exploit the Catalyst generation process.296 The main 
assumption made by HypoGen is that an active ligand should map more features than an 
inactive ligand. Consequently the mapping information of the ligands, should be used 
to assess the quality of the hypotheses.296 In particular, the two most active ligands 
should map all features of a pharmacophore, as the initial hypotheses are derived from 
the top two ligands of the training set.
The pharmacophores derived from the Multiple RT training set were generally four- 
feature hypotheses, compared to the Single RT training sets that generated only three- 
feature hypotheses. The Multiple RT pharmacophores usually consisted of a hydrogen 
bond acceptor, two hydrophobic aliphatic functionalities, and one ring aromatic system. 
Most of the returned hypotheses were fairly similar on a gross level, with small 
differences predominately seen in the spatial positioning of features, the angle of the 
plane of the aromatic ring system, the direction of the vector describing the location of 
the interacting n system on the protein, and the positioning and directionality of the 
heavy atom and vector of the hydrogen bond acceptor. In the multipharm 
pharmacophore where the Minimum Total Features parameter was set at 3, and the 
chiralmultipharm pharmacophores where this parameter was set at 3 or 4, hypotheses 
were generated that included a positive ionisable group instead of the second 
hydrophobic aliphatic group. These hypotheses had fairly poor relative costs, the 
highest being only 14.676, and most probably were only generated because the two 
most active ligands, rev and hnv, each included a positive ionisable function, which was 
absent from all other ligands. The similarity in the structures and biological activities of 
rev and hnv would customarily have meant that hnv, with the lower IC50 value of 4.3 
nM, would have been excluded from the training set as redundant data. However, given 
that the size of the training set was only thirteen ligands, the evaluation was made that
€Hw%mr4
its inclusion was necessary and an allowance could be made for the bias that its 
contribution to the pharmacophore generation would engender. This compromise was 
reached by examining hypotheses in which the top three compounds mapped, and not 
just considering hypotheses in which the top two ligands mapped. These hypotheses are 
marked by § in Table 4.2, and take into account the structure and activity of vru. They 
occur notably more often in the pharmacophores generated from the Multiple RT 
training set, in particular when the Mirror Image function is off.
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Figure 4.4 Overlay of a typical three-feature 
hypothesis generated from the Single RT training set 
and a four-feature hypothesis generated from the 
Multiple RT training set. The wire-cage spheres 
represent the pharmacophore features, the small blue 
dot within the blue hydrophobic feature signifies the 
centre of the sphere, or the point that the ligand 
functionality maps in the feature. The blue square grid 
and blue arrow of the beige ring aromatic feature 
represents the mapped plane of the aromatic ring and 
the projected interaction with the corresponding 
aromatic amino acid of the receptor. The blue arrow 
within the green hydrogen bond acceptor feature, 
sometimes seen as a green cone) represents the 
projected hydrogen bond donor of the receptor at the 
blue dot.
The returned hypotheses from the 
Single RT training set all 
contained only three-feature 
pharmacophores, most of which 
were composed of a hydrogen 
bond acceptor, a hydrophobic 
aliphatic functionality, and a ring 
aromatic system. Figure 4.4 
illustrates the difference between 
the highest ranking multipharm 
pharmacophore (.Minimum Total 
Features parameter set at 4), a 
four-feature pharmacophore, and 
the highest ranking hypothesis 
from the singlepharm
pharmacophore (Minimum Total 
Features parameter set at 1). The 
last one or two hypotheses 
generated in each of the Single RT 
training set pharmacophore runs 
were hypotheses in which the 
hydrophobic aliphatic group was 
replaced by a positive ionisable
group. This occurrence was 
likewise explained by the biasing of the pharmacophore by the inclusion of rev and hnv, 
two similarly structured and active ligands with inherent positive ionisable
functionalities. Only two of the returned hypotheses from the Single RT training set 
fulfilled the requirements of the compromised examination of hypotheses to consider 
the top three most active compounds; the highest ranking hypothesis from the 
chiralsinglepharm pharmacophore run with 1 set in Minimum, Total Features parameter, 
and the eighth highest ranking hypothesis from the singlepharm pharmacophore run 
with the Minimum Total Features parameter set also at 1.
One point of interest noted in the examination of the returned hypotheses of Table 4.2 
was the lack of an expected second aromatic ring system. Literature describing the non­
nucleoside inhibitor binding pocket (NNIBP), and the ‘butterfly’ conformation adopted 
by many inhibitors bound in this pocket, refers often to ring aromatic 7i-stacking 
interactions between the hydrophobic ‘wings’ of the butterfly and aromatic residues of 
the pocket, in particular Tyrl81, Tyrl88, Phe227, and Trp22930’215 (see Section 3.7.1 
Inhibitor binding in the NNIBP and Figure 3.49). These pharmacophores indicate that 
the hydrophobic ‘wings’ of the butterfly are composed of one hydrophobic aromatic 
ring system, and one hydrophobic aliphatic functionality. In Figure 4.4 the hydrophobic 
aliphatic and aromatic ring system common to the two overlaid pharmacophores are 
opposite each other, as if to represent the wings of the butterfly conformation, with the 
hydrogen bond acceptor serving as the body of the butterfly.30
With the relative costs and mapping information of the returned pharmacophores 
considered, several hypotheses were selected for further analysis and validation, and for 
incorporation into a more comprehensively descriptive pharmacophore. From those 
pharmacophores generated with the Single RT training set, the highest ranking 
hypothesis from the singlepharm (Minimum Total Features set at 1) and 
chiralsinglepharm (Minimum Total Features set at 3) pharmacophores were selected. 
Also selected was the ninth ranking hypothesis from the singlepharm (Minimum Total 
Features set at 3) pharmacophore, that had a relative cost of 10.967; the highest ranking 
hypothesis that also contained the positive ionisable functionality. From the Multiple 
RT training set, the highest ranking hypothesis of the multipharm (Minimum Total 
Features set at 4) pharmacophore, and the fourth highest cost hypothesis from the 
multipharm (Minimum Total Features set at 3) pharmacophore, containing a positive 
ionisable group, were selected. These choices were subjective, based loosely on the 
relative costs and mapping information available, and may not be ideal, but rather they
provide an example of the techniques and validation processes that one might choose to 
explore for greater application of pharmacophoric ligand-based drug design strategies.
4.2.4.1 Merged hypotheses
Depending on the ligands of the training set submitted to HypoGen, the generation of 
Catalyst pharmacophores can produce varying results in which a particular functionality 
may only appear in some hypotheses. The incorporation of a particular feature into 
another hypothesis either without that feature, or lacking that feature in a specific 
position relative to other common features, can be accomplished by manually adding 
and positioning the feature, or by merging hypotheses.201,208 The amalgamation of two 
hypotheses has the advantage of allowing the construction of more comprehensively 
descriptive and specific pharmacophores. However, this can also exclude compounds, 
during a database search, that may bind just as well in the receptor site, but may not 
have all of the features of the pharmacophore, and are consequently not considered at 
the outset of the search. This depends on the particular search algorithm used, and if 
partial-match queries, in which not all the features need to be mapped by a ligand in 
order for it to be a ‘hit’, are available for database mining.280,302 Notwithstanding this 
particular obstacle, four hypotheses were selected to be merged, and while they may be 
unsuitable and ineffective for database mining, they are likely to be valuable in de novo 
ligand design, where no penalties are made for more complicated or feature-rich 
pharmacophores.
The highest ranking hypothesis from the singlepharm (Minimum Total Features set at 1) 
pharmacophore and the ninth ranking hypothesis from the singlepharm (Minimum Total 
Features set at 3) pharmacophore were chosen to be merged (Figure 4.5). The 
expectation of this choice was to construct a pharmacophore that incorporated the high 
ranking spatial placement of the hydrogen bond acceptor, hydrophobic aliphatic and 
aromatic ring system of the higher ranked hypothesis with the positive ionisable 
functionality of the other hypothesis. This was achieved using the Merge 
Hypothesis/Features tool in Catalyst. In this tool, a Distance Tolerance parameter 
specifies the maximum separation between a pair of common features from two 
hypotheses for them to be merged into one feature which can be considered the average
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of the pair of common features. This parameter was increased from the standard 0.1
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A to 0.5 A, to allow complete merging of the two singlepharm pharmacophores, into a
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four feature pharmacophore with hydrogen bond acceptor, hydrophobic aliphatic, ring
This Distance Tolerance parameter 
had to be increased further to 0.8 A 
in the merging of the highest ranking 
hypothesis of the multipharm 
(.Minimum Total Features set at 4) 
pharmacophore and the fourth 
hypothesis from the multipharm 
0Minimum Total Features set at 3) 
pharmacophore, containing a positive 
ionisable group. In Catalyst 4.0, the 
version in which the greater part of 
the research was realised, the two 
hydrophobic aliphatic features 
needed to be renamed. This was 
because the merging process first 
overlaid the A hydrophobic aliphatic 
of the lower ranking hypothesis 
(Figure 4.5) to the A’ hydrophobic aliphatic of the higher ranking hypothesis, rather 
than the B’ function as preferred. A Distance Tolerance value of 0.8 A was just 
sufficient to ensure that the hydrogen bond acceptor and ring aromatic functions were 
merged properly, however it was insufficient to merge the two common hydrophobic 
aliphatic functions, A and B \ The A hydrophobic aliphatic function was ultimately 
chosen for the merged hypothesis as it was placed further away from the other 
functionalities, and would hopefully ‘open up’ the pharmacophore rather than 
constructing it so densely packed with features in the middle, and the B’ hydrophobic 
aliphatic was removed. In retrospect, it may have been better to use the B hydrophobic 
aliphatic function, as this came from the higher ranking hypothesis, or merge the two 
common aliphatic features within the pharmacophore to achieve an average 
representation. The final pharmacophore contained a hydrogen bond acceptor, two 
hydrophobic aliphatic functionalities, an aromatic ring and a positive ionisable function 
that lay in contact with one of the hydrophobic aliphatic spheres. The two resulting
aromatic and positive ionisable functions.
Figure 4.5 Merged multipharm pharmacophores. 
The A hydrophobic aliphatic function was from the 
hypothesis including the positive ionisable group. 
The A’ and B’ aliphatic functions were from the 
higher ranking hypothesis.
* - 223
merged hypotheses were referred to as the merged singlepharm and merged multipharm 
hypotheses
4.2.5 Hypothesis validation
Validation of a hypothesis is achieved be determining how well activities of non­
training set compounds are estimated, visually and mathematically.250 The best 
hypotheses will estimate the activities of the training set compounds correctly to within 
one order of magnitude, as well as passing standard statistical tests for non­
randomness. Although numerous analogues of the ligands used in the 
pharmacophore generation and illustrated in Figure 4.2 could have been used for this 
validation process, the premise of using inhibitors from crystallised RT-inhibitor 
complexes was continued in the selection of ligands for the test set. The ligands from 
two recent RT crystallographic references,303’304 not used in the training set, were 
obtained and processed in the same fashion as those used in the pharmacophore 
generation (Section 4.2.2 Conformational analysis). These crystallographic structures 
were tabulated in Appendix 7.3.1. The three ligand structures, illustrated in Figure 4.6, 
were identified by their PDB file code, and categorised as Single or Multiple test sets, 
dependent on whether they contained the ligands in their original crystal conformations 
or multiple conformations generated in the Best-quality mode of the catConf module.
ep4 - S-1153 (123) cOt - BM +21.1326 (124) cOu - BM +50.0934 (125)
IC50 = 450 nM IC50 = 4100 nM IC50 = 220 nM
Figure 4.6 Structures and names of inhibitors from recent x-ray crystallographic RT-inhibitor 
complexes to be used as ligands in the test or validation set.
Once more, the difficulty in obtaining reliable and consistent activity data among these 
ligands, and among those used in the pharmacophore generation, caused the validation 
process to be rather problematic, with results having only qualitative value. The IC 50 
values for the ligands ep4,305 cOt306 and cOu were 450, 4100 and 220 nM respectively, 
and were obtained from different sources. Realistically, comparisons could only be
made between cOt and cOu, as they had the same testing procedures, and even then they 
could only be qualitatively assessed as the pharmacophores to which they were mapped 
were generated with uncertain inhibition data from varying testing protocols.
The test sets were mapped or overlaid onto the selected pharmacophores of Table 4.3 
with the Compare/Fit tool to calculate how well they correlated geometrically and/or 
functionally to the hypothesis.297
singlepharm chiral singlepharm multipharm multipharm
min. feature - 1 min. feature - 3 min. feature - 4 min. feature - 3
hypothesis - 1 hypothesis - 1 hypothesis - 1 hypothesis - 4 
21.0 21.3 22.5 14.7
rms 1.416 1.427 0.867 1.448
correl. 0.833 0.827 0.954 0.828
fit estimate fit estimate fit estimate fit estimate
-3>eP4 4.7 89 4.6 90 5.6 5100 4.7 460
Si
n
o 
o 
O
 O 2.8 6200 3.9 470 5.4 8300 4.5 760
4.8 68 3.8 570 5.4 9600 4.6 510
<D
£? ep4 6.8 1 6.7 1 7.8 39 6.9 3
3  cOt 4.7 82 5.3 20 6.9 300 4.7 400
§  cOu 4.8 57 4.3 200 6.0 2400 4.9 260
Table 4.3 Summary of the fit and estimate values for the test set ligands, in the conformation found 
in the RT-inhibitor crystal complex (Single) and in the multiple conformations derived from 
conformational analysis (Multiple), overlaid on four selected Catalyst hypotheses. Each 
pharmacophore is identified by the name, number used in the Minimum Total Features parameter, 
ranking of the hypothesis, and its relative cost (Refer to Table 4.2). The IC50 values of ep4, cOt and 
cOu were 450, 4100 and 220 nM, respectively.
This was done by geometrically aligning the features of the ligand to corresponding 
features in a hypothesis to meet specified topology, angle, torsion and chemical- 
function constraints. The Fast Fit option was used preferentially as it searches each 
conformation for the optimum fit; in the case of the Single ligand training set, only the 
one crystal conformation is used. The alternative Best Fit option manipulates all 
conformers within a specified energy threshold to minimise the distances between
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hypothesis features and mapped functionalities of the ligand. It was not used because 
a Fast Fit method is used to fit ligands onto the pharmacophores during hypothesis 
generation for their evaluation, and no ‘tweaking’ or optimising is done. We have 
observed in the past that Best Fit can lead to overestimation of the activities 
(unpublished data). Both options return an optimum set of mappings representing
different alignments of ligand features to pharmacophore features. The fit value 
indicates the quality of the mapping and is dependent on how close the features of the 
ligand are to the centres of the corresponding location constraints; the higher the fit 
value, the better the mapping of features.297
The root-mean-square (rms) and correlation (correl.) values for each of the hypotheses 
of Table 4.3 represent the deviation of the logarithmic of the estimated activities from 
the logarithmic of the measured activities normalised by the log of the uncertainty, and 
the linear regression derived from the geometric fit index, respectively.298 The rms 
indicates the quality of the prediction for the training set, and the correlation gives an 
assessment of the relationship between the actual and the predicted activities.
From the values of Table 4.3 it appeared that the first multipharm pharmacophore was 
the most successful hypothesis as it had the highest correlation between the actual and 
predicted, and the lowest deviation, for the training set compounds used to generate the 
hypothesis. However, the estimates of activity for the ligands of the Single and 
Multiple test sets showed that the pharmacophore erroneously calculated the cOu ligand 
to be less active than the cOt ligand, 9600 compared to 8300 and 2400 compared to 300 
for the crystal and multiple conformations test sets, respectively. The chiralsinglepharm 
pharmacophore also returned the same result. Only the second multipharm 
pharmacophore and the singlepharm pharmacophore predicted the cOu ligand to be 
more active than the cOt ligand; in both cases this proved true for the ligands in the 
Single and Multiple test sets. However, neither of these hypotheses, for the Single or 
Multiple test sets, were able to closely approximate the relative ratio of activities of cOt 
and cOu.
As expected, the ligands of Multiple test set had lower estimated IC50 values than the 
restrictive Single test set. While some of the hypotheses were able to estimate the 
activity of the test set ligands within one order of magnitude, no one hypothesis was 
able to predict the activities of all three ligands within that same range, not even just cOt 
and cOu which can be more confidently compared. The closest approximation of this 
was the singlepharm pharmacophore that estimated cOt at 6200, compared to the actual 
4100, and cOu at 68 compared to 220.
4.2.5.1 Merged hypotheses
The validity and predictive power of the merged singlepharm and merged multipharm 
hypotheses were analysed by seeing how well they correlated the activity of the test set 
ligands. The Regression Hypothesis tool in Catalyst allows a merged or manually 
constructed hypothesis to be used to estimate the activities of a training set by 
computing a linear structure-activity regression equation between the training set 
ligands and the hypothesis, and using this regression information to score a newly 
produced hypothesis.297 The resulting hypothesis is used to estimate the activities of the 
ligands of training set, and these can be graphed against the true activities.
In Figure 4.7, the red Single RT training set ligands showed good correlation against the 
merged singlepharm pharmacophore, with an RMS in the regression hypothesis of 
0.783. The same training set ligands on the merged multipharm pharmacophore of 
Figure 4.8 (red data series) had a slightly lower RMS regression value of 0.773. Figure
4.9 shows the overlay of the crystallographic conformation of rev, the most active 
ligand in the Single RT training set, on the merged singlepharm pharmacophore. All of 
the four features of the hypothesis were mapped and returned a Fit value of 5.700 out of 
a perfect fit of 8.792. The perfect fit was calculated by the sum of the average weights 
for the hydrogen bond donor and ring aromatic functions from the individual 
hypotheses, and the weight of the hydrophobic aliphatic function from one hypothesis 
and the positive ionisable function from the other hypothesis. This was calculated 
manually, and was not a value returned by Catalyst. The same crystallographic 
conformation of rev on the merged multipharm pharmacophore returned a Fit value of 
7.668 out of 13.250, but only mapped the positive ionisable, and both hydrophobic 
aliphatic features; the ring aromatic feature failed to map. The perfect fit for the merged 
multipharm pharmacophore was calculated in a similar fashion as the merged 
singlepharm pharmacophore.
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Figure 4.7 Graphed correlation of the true and estimated activities for the Single RT (red circle) 
and Multiple RT (blue square) training sets on the merged singlepharm pharmacophore. The line 
of best fit is drawn in the corresponding colour.
Single RT and Multiple RT ligands on the merged multipharm
Estimated activity
+ -
Figure 4.8 Graphed correlation of the true and estimated activities for the Single RT (red circle) 
and Multiple RT (blue square) training sets on the merged multipharm pharmacophore. The line 
of best fit is drawn in the corresponding colour
Figure 4.9 The crystallographic conformation (Single RT) of the most active ligand (rev) overlaid 
onto the merged singlepharm pharmacophore. (Left) The wire-cage spheres represent the 
pharmacophore features (see Figure 4.3 caption for full details). (Right) The coloured spheres 
represent the hypothesis features that have mapped to the corresponding features of the ligand.
The blue Multiple training set ligands of Figures 4.7 and 4.8 showed both the worst and 
best correlation values for the merged regression hypotheses, of all the training sets. In 
Figure 4.7 the blue data series displayed a RMS regression value of 0.357, denoting no 
correlation to the merged singlepharm pharmacophore. The correlation of the Multiple 
RT ligands on the merged multipharm pharmacophore of Figure 4.8 was much higher, 
at 0.836. These results showed, as may be anticipated, that the set of ligands used to 
generate the hypotheses of the merged pharmacophore correlated better with the merged 
pharmacophore compared to another set of ligands. This was even when the difference 
between the sets was a case of single versus multiple conformations of the same ligands. 
This can also be seen in the mapping of the optimum conformer of rev ligand from the 
Multiple RT training set, onto the merged singlepharm pharmacophore (Figure 4.10) 
and onto the merged singlepharm pharmacophore (Figure 4.11). The overlay of the 
optimum conformation of rev, the most active ligand in the Multiple RT training set, on 
the merged singlepharm pharmacophore in Figure 4.10, shows the same mapping as 
seen in Figure 4.9. All of the four features of the hypothesis were mapped and returned 
a Fit value of 7.058 out of likely perfect fit of 8.792. This particular conformation 
overlaid more optimally onto the merged singlepharm pharmacophore than the 
conformation actually found in the RT-inhibitor crystal complex of rev, which had a fit 
of 5.700 on this merged pharmacophore. The overlay of an optimum conformation of 
rev on the five-feature merged multipharm pharmacophore in Figure 4.11 shows the
♦ -
same mapping of all features excluding the second hydrophobic aliphatic function. This 
appeared to coming close to mapping the methyl substituent, which was actually within 
the blue wire-cage sphere, but the absence of the small blue dot signified that this 
feature was not mapped.
hydrophobic 
aliphatic
positive 
ioni sable
ring aromatic
Figure 4.10 The optimum conformation (Multiple RT) of the most active ligand (rev) overlaid onto 
the merged singlepharm pharmacophore.
ring
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Figure 4.11 The optimum conformation (Multiple RT) of the most active ligand (rev) overlaid onto 
the merged multipharm pharmacophore. (Right) The blue circle outline represents the second 
hydrophobic function that comes close to the methyl substituent, but does not actually map to the 
ligand.
hydrogen bond 
acceptor
The overlay and Fit values of the test set ligands on the merged pharmacophores 
presented in Table 4.4 shed no further light on their validity or predictive power. Only 
the merged singlepharm pharmacophore showed a better Fit value for the cOu ligand 
than the cOt ligand, which had IC50 values of 220 nM and 4100 nM respectively. The 
Fit value is qualitatively inversely proportional to the IC50 value. This was definitively 
seen in ligands in the Single test set, with the conformation found in the RT-inhibitor 
crystal complex, but not as certainly seen in the Multiple test set where the Fit values 
where almost identical at 4.389 and 4.293. If one could assume the relative order of 
activity increased from the cOt to ep4 to cOu ligand as suggested by the experimental 
activities in Figure 4.6, the merged singlepharm pharmacophore was the only 
pharmacophore to successfully predict this order of activity among the ligands. 
However, these tentative findings can only be considered interesting coincidences with 
test sets of this size. Further validation with more ligands would be required to more 
thoroughly test the robustness of the merged pharmacophores.
jl)
Tl)
cn
Fit values
merged singlepharm merged multipharm
Perfect fit 8.792 13.250
ep4 4.198 6.544
cOt 2.430 5.428
cOu 4.323 5.369
ep4 5.876 8.593
cOt 4.293 6.681
cOu 4.389 5.452
Table 4.4 Summary of the fit values for the test set ligands, in the conformation 
found in the RT-inhibitor crystal complex (Single) and in the multiple 
conformations derived from conformational analysis (Multiple), overlaid on the 
merged singlepharm and merged multipharm pharmacophores.
These results are not a comprehensive or complete examination of the validity of the 
hypotheses. Rather they establish an approach to the design of new pharmacophores
4.2.6 Database searching
Searching of the NCI database was performed with the two merged pharmacophores 
using Catalyst’s Best Flexible Searching Tool, in Catalyst version 4.5.307 There is no 
option for partial match searches, in which a search can be conducted where a match
From an NCI database of 123 219 compounds, the merged multipharm pharmacophore 
identified 1162 suitable compounds. A search of these 1 162 compounds with the 
merged singlepharm pharmacophore revealed 984 compounds that mapped the four- 
feature hypothesis. Conversely, screening the 123 219 compounds of the full NCI 
database with the merged singlepharm pharmacophore resulted in 3490 compounds, 
compared with 1162 when the merged multipharm pharmacophore was first used. 
When the 3490 compounds from this search were screened with the merged multipharm 
pharmacophore the resulting hitlist totalled 984 compounds, most likely the same 
compounds derived from using the reverse order of merged pharmacophores to screen 
the original database. However, this does not necessarily signify that the merged 
singlepharm pharmacophore is a less specific hypothesis than the merged multipharm 
pharmacophore. Rather it means that for this particular search algorithm, hypotheses 
containing more features are considered to be more specific. Searching the full database 
with each of the original hypotheses that formed the merged pharmacophores resulted in 
hitlists in excess of a predetermined maximum of 10 000 compounds. These 984 
compounds can now be further investigated by screening with the novel 
pharmacophores to be developed in this study (see Sections 4.3 and 4.4).
4.3 Structure-based superligand
The superligand was generated using structure-based queries with the Unity 3D®280 
program from Tripos Inc. SitelD®308 and Unity 3D®280 software from Tripos Inc. was 
used for a one month trial period to explore some of its capabilities and their potential 
use in the proposed integrated drug design strategy of this research. What is presented 
here is the preliminary methodology for the generation of the superligand component of 
the integrated drug design strategy of Figure 4.1. Considerable further refinement, 
validation and supporting literature will be required to fully develop this computational 
tool.
4.3.1 Binding pocket definition
To rationally and impartially define the residues of the binding pocket to be used for the 
superligand generation, the SitelD module of Sybyl309 was used to identify the residues
will contain only some of the features of the pharmacophore. Returned hits must
contain at least all of the features of the pharmacophore used in the search.
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that form the pocket. To do this, the protein is solvated with a single layer of water 
molecules, as illustrated in Figure 4.12.310
Figure 4.12 Solvation of the protein (outlined in red and represented in red spheres) with a single 
layer of water (blue spheres) in SitelD to determine the binding pockets, and to identify the 
residues of the pocket the water spheres come into contact with. The default for the radius of the 
black circle is 8.0 A. Site A is identified as a pocket, and potential binding site, while Site B is only a 
depression and not classified as a pocket
The number of non-hydrogen atoms lying within a user-specified radius of each solvent 
molecule is counted. If this number exceeds a user-specified limit, the solvent atom is 
retained, or else it is removed. The solvent molecules that remain are those that are 
typically found in pockets. As seen in Figure 4.12, the first water molecule marked with 
a star, on the outer surface of the protein, has only three depicted red protein heavy 
atoms within a radius circumscribed by the black circle. The second water molecule, 
within an actual pocket, has six protein atoms within its radius, and will be retained. 
The default settings are 8.0 A and 75 heavy atoms for ¿he radius and atom count, 
respectively.
Two other significant variables in the determination of potential pockets are the 
Minimum Pocket Concavity and the van der Waals bump scaling factor for solvent 
atoms. The Minimum Pocket Concavity, with a default value of 2 from a range of 0 
(flat) to 10 (very narrow well), determines the type of surface depressions to be 
considered as pockets.310 A low value will consider nearly all surface depressions such 
as Site B in Figure 4.12, while a higher value will selective identify only Site A. The 
van der Waals bump scaling factor specifies the sum of scaled van der Waals radii 
around the solvent atom in which any atom lying within this distance will cause the
solvent atom to be excluded.310 The default value is 0.8 A; a higher value will mean 
more solvent atoms are excluded, and not considered in the calculation to identify 
potential pockets. Finally, all protein atoms lying within a 3.0 A radius of each solvent 
atom in the identified pocket are identified as solvent accessible protein atoms of that 
pocket, and are considered as belonging to the active site.310 These can be listed to 
define the pocket.
By virtue of the size of reverse transcriptase-inhibitor crystal complexes, it would be 
unreasonable and unnecessary to solvate the entire enzyme, especially considering that 
the purpose of this study is not to find the pocket, but rather just to characterise it. The 
protein was initially truncated using only residues within a 25 A radius of the inhibitors. 
In the SitelD module, the truncated protein was solvated and the solvent molecules in 
any pockets in the enzyme were located. Two series of parameters were used to try to 
fully characterise the pocket. The first series of parameters used was the default, where 
the Minimum Pocket Concavity was set at 2 and the van der Waals bump scaling factor 
for solvent atoms was set at 0.80 A, and could be considered the more strict set of 
parameters. In several instances the pocket was identified as being composed of two 
smaller pockets; the volume between them not identified as a solvent volume with the 
standard parameters, and these two smaller pockets were combined. In the second 
series of parameters the concavity was adjusted to 10 and the bump scaling factor to
o
0.70 A, to try and reveal all the small recesses of the pocket not identified by the 
standard parameters. The second series of parameters, considered the more lenient set 
of parameters, may be seen as identifying and defining a larger pocket.
The residues that came into contact with the solvent spheres identified by the two series 
of parameters, for each crystal structure, were listed and tallied individually in Table 
4.5. Each residue, for each parameter set, had a possible maximum tally of nineteen, in 
which case that residue came into contact with a solvent sphere in all 19 crystal 
structures. In the second, more lenient, series of parameters, a residue was identified as 
defining the pocket if its tally was greater than or equal to seven. Residues with a tally 
of less than seven were included if their tally in the first series was greater than seven; 
this occurred only with Ilel42 in p51. All other residues were removed in a second 
truncation step to leave the sixty three residues forming the final binding pocket. This 
methodology ensured that a complete identification of the residues of the pocket could 
be made without either missing any that might be considered potentially important, or
including too many to handle easily. Six additional residues cited in literature as having 
contact with inhibitors, but not identified by SitelD, were included in the pocket 
definition. Thirty of the sixty-three residues had tallies of greater than or equal to seven 
in both series of parameters.
The residues of the newly defined pocket in Table 4.5 were divided into two sets, 
Primary Features and Secondary Features. Residues that had a tally of greater than ten 
as identified by the first series of standard parameters, and residues cited in the literature 
as having H-bonding interactions with inhibitors, were named as Primary Feature 
residues and the remaining residues of the pocket were designated Secondary Feature 
residues.
Residue details Parameters Lit. cited Features
Series 1 Series 2 Primary Secondary
Trp 88 A 4 11 X
Glu 89 A 8 9 X
Val 90 A 7 12 X
Gin 91 A 13 17 X
Leu 92 A 9 13 X
Gly 93 A 12 18 X
He 94 A 9 18 X
Pro 95 A 12 19 X
His 96 A 4 17 X
Pro 97 A 1 13 X
Gly 99 A 5 15 X
Leu 100 A 13 19 X
Lys 101 A 14 18 X
Lys 102 A 1 1 literature X
Lys 103 A 9 18 X
Val 106 A 8 18 X
Gin 161 A 14 19 X
Ser 162 A 5 8 X
Met 164 A 1 8 X
Thr 165 A 9 17 X
Leu 168 A 1 7 X
Arg 172 A 8 12 X
Val 179 A 17 19 X
Ile 180 A 14 19 X
Tyr 181 A 16 18 X
Gin 182 A 13 19 X
Tyr 183 A 7 19 X
Met 184 A 6 16 X
Asp 186 A 1 10 X
Leu 187 A 0 8 X
Tyr 188 A 13 18 X
Val 189 A 1 6 literature X
Gly 190 A 3 9 X
Glu 224 A - - literature X
Pro 225 A - 2 literature X
Pro 226 A - - literature X
Phe 227 A 7 19 X
Trp 229 A 13 19 X
Met 230 A 6 13 X
Tyr 232 A 2 9 X
Leu 234 A 1 18 X
His 235 A 2 9 X
Pro 236 A 1 6 literature X
Tyr 318 A 7 14 X
lie 380 A 3 7 X
Val 381 A 6 16 X
lie 382 A 2 16 X
Pro 25 B 1 9 X
Leu 26 B 2 10 X
He 31 B 5 10 X
Thr 131 B 1 8 X
He 132 B 3 7 X
Pro 133 B 6 15 X
Ser 134 B 13 18
He 135 B 9 17 X
Asn 136 B 4 17 X
Asn 137 B 16 19 X
Glu 138 B 19 19 X
Thr 139 B 19 18 X
Pro 140 B 15 19 X
Gly 141 B 13 16 X
He 142 B 8 3 X
Arg 143 B 5 8 X
T a b l e  4 .5  L i s t  o f  a l l  t h e  r e s i d u e s  d e f i n e d  a s  f o r m i n g  t h e  b i n d i n g  p o c k e t  in  o n e  o r  m o r e  o f  t h e  
n i n e t e e n  R T - i n h i b i t o r  c r y s t a l  s t r u c t u r e s ,  b y  b e i n g  in  c o n t a c t  d i s t a n c e  (3  A) o f  a  s o l v e n t  s p h e r e ;  A  
r e f e r s  t o  t h e  p 6 6  s u b u n i t  a n d  B  r e f e r s  t o  t h e  p 5 1  s u b u n i t  o f  R T .  T h e  n u m b e r  o f  t i m e s  t h a t  r e s id u e  
i s  l i s t e d  a s  p a r t  o f  t h e  b i n d i n g  p o c k e t  f o r  t h e  f i r s t  o r  s e c o n d  s e r i e s  o f  p a r a m e t e r s  ( s e e  t e x t )  i s  t a l l i e d  
o u t  o f  n i n e t e e n .  T h e  r e s i d u e s  i n c l u d e d  in  t h e  p o c k e t  d e f i n i t i o n  d u e  t o  r e f e r e n c e s  in  t h e  l i t e r a t u r e  
a r e  n o t e d .  A l l  o f  t h e  r e s i d u e s  o f  t h e  p o c k e t  a r e  s e g r e g a t e d  in t o  a  p r i m a r y  o r  s e c o n d a r y  f e a t u r e s  s e t  
( s e e  t e x t ) .
4.3.2 Consideration of protein flexibility
The need to account for the dynamic nature of a drug receptor has long been recognised 
as a complicating factor in computational drug design, and improvements in 
methodology to simulate and manipulate protein flexibility and its influence on ligand 
recognition have been recently reviewed.311 A protein exists in multiple conformations, 
and as such a ligand may bind preferentially to any available conformation. The use of
a single protein structure can only identify ligands for that particular protein 
conformation.311
Two noteworthy methods for the consideration of flexibility were those of Sudbeck et 
al.312 and Carlson et ¿z/.311,313,314 Sudbeck et al. overlaid the structures of nine crystal 
inhibitor complexes of fflV-1 RT using the Ca of residues 97-213, and used the 
positions of the nine inhibitors in the overlay to create a composite binding site; a 
representation of the surface area encompassed by those nine inhibitors in the 
NNIBP. This was qualitatively compared to small molecules docked and minimised 
in a single structure of RT. Carlson et al. used molecular dynamic simulations to 
generate a subensemble of 11 conformations, or snapshots, of uncomplexed HIV-1 
integrase. ’ The multi-unit search for interacting conformers method (MUSIC) is a 
Monte Carlo simulation that was used to simultaneously calculate multiple gas-phase 
minimisations for hundreds of probe molecules within the active site of the 11 
conformations. The binding sites for functional groups were identified by different 
molecular probes; methanol molecules identified hydrogen bond donor sites, and 
acetone probes identified hydrogen bond acceptor groups.313 An overlay of those 
conformations of the active site of the protein revealed complementary binding regions 
that were conserved over many protein structures despite the inherent flexibility of the 
active site. These conserved complementary regions represent a ‘dynamic’ 
pharmacophore model that allows a measure of the flexibility of the protein to be 
incorporated into the drug design process.311
In this research, protein flexibility was considered by using modified structures of the 
binding pocket defined previously from 19 different enzyme-inhibitor complexes. 
Taking the average coordinate of each atom of each residue created a modified structure 
for the nineteen structures, used to form an ‘average’ pocket structure. ‘Largest’ and 
‘smallest’ pocket structures were created by using the coordinates of residues most 
distant from, or closest to, the center of the bound inhibitors. These pockets were not 
meant to represent actual conformations that the pocket might adopt, but rather were for 
the study of how the protein was induced to change at different locations by different 
known inhibitors previously crystallised. This would not only be a characterisation of 
the pocket flexibility, but could also be used to design new ligands that could induce 
multiple changes in the pocket and bind more tightly by forming more intermolecular 
interactions with protein residues. A ‘weighted’ pocket structure was also created by
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taking into consideration the activity of the inhibitor that had been bound in that RT- 
inhibitor crystal structure. This structure would allow an indirect comparison with the 
techniques and results from the ligand-based pharmacophore derived from ligand 
structure-activity data.
To generate the coordinates for the modified pockets, the original crystal coordinates 
were superimposed upon the unliganded crystal structure (ldlo) in the same fashion as 
for the study of the conformational studies of reverse transcriptase (Chapter 3). The 
coordinates of all residues not included in the definition of the pocket (Section 4.31) 
were deleted. Taking the average value for the corresponding x, y, and z coordinates, 
and the temperature factor for each atom from the nineteen crystal structures generated 
the ‘average’ pocket.
In order to take into consideration the flexibility of reverse transcriptase without 
resorting to expensive dynamics calculations, the ‘largest’ and ‘smallest’ pockets were 
generated by considering each individual residue defining the pocket, and how far it 
‘expanded’ to create the pocket. The x, y and z coordinates of each atom of all the 
inhibitors of the crystal structures were averaged to generate a central reference point 
(■KiOhjZi). This method is reasonable if one bears in mind that these inhibitors were also 
overlaid by the initial superimposition of all the original crystal coordinates; this overlay 
can be seen in Section 3.7.1 Inhibitor binding, Figure 3.49.
The atoms of the residues defining the pocket were segregated into two groups, 
backbone and sidechain atoms, for each residue. These were averaged f e  y2, Z2) so that 
each residue had one point which represented its backbone and one which represented 
its sidechain. The distance between the central inhibitor reference point, and the 
backbone and sidechain point was calculated.
d = y/(x 1 ~ x 2)2 +{yx - y 2)2 +(Zj -  z2)2
The crystal structure with the minimum and maximum distance values for the backbone 
and sidechain of each residue was noted, and the complete coordinates for this residue 
from this crystal structure were then used for the modified pockets (for further details 
see Chapter 6 Experimental). Thus four new pockets were generated; the smallest and 
largest pockets based on how far the backbone was away from the central inhibitor
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reference point, and the smallest and largest pocket based on the sidechain displacement 
from the reference point.
The activity ‘weighted’ pocket was generated to directly parallel the ligand-based 
pharmacophore generated in Catalyst (Section 4.2). The inverse logarithm of the 
activities of the crystal structures used in the generation of the ligand-based 
pharmacophores was normalised by giving lrti, the least active inhibitor, a weight of 
1.00 as in Table 4.6. The *, y, z coordinates of each atom of each crystal structure was 
multiplied by that crystal structure’s weighting. The sum of these coordinates was 
calculated and then divided by the sum of the weightings used in that calculation, 
generally 68.2851. If the sidechain of a residue was missing from one particular crystal 
structure, then it was not included in the calculations, and the sum of the coordinates 
was divided by a reduced total weighting.
It had been noted in the conformational study of the binding pocket (Section 3.7) that 
the sidechain of Tyrl81 for all the crystal structures, excluding rti and rt3, were 
clustered together. In rti and rt3, the tyrosine had a 90-100° swivel about the Cp atom. 
The ‘average’ pocket of all the crystal structures excluding lrti and lrt3 was generated, 
as well as the ‘average’ pocket of just rti and rt3. It was noted, retrospectively, that 
although rti was included in the generation of the ‘weighted’ pocket, it was not expected 
to play a dominant role in the weighting process, having the lowest activity and a 
weighting of 1.00. The ligand rt3 was not included in the ‘weighted’ pocket as it had 
previously not been used for the ligand-based drug design (see Section 4.2.1 Training 
set selection).
The results of these binding pocket modifications resulted in several interesting ‘binding 
sites’ for further study. In particular, the comparison of the superligands derived from 
the four ‘flexible’ pockets; the smallest and largest backbone-based pockets and the 
smallest and largest sidechain-based pockets, were certain to reveal more information 
about how different modelled conformations of the pocket can affect the binding of 
ligands. However, the brevity of the trial period for the Tripos software curbed 
extensive study of all the proposed modified pockets, and further research towards the 
generation of the superligand was undertaken only with the ‘weighted’ modified pocket.
IC50 (nM) log (IC50) 1 /  log (IC50) Weighting
bqm 80 1.90 0.53 2.5325
hnv 4.3 0.63 1.58 7.6082
klm 1100 3.04 0.33 1.5847
rev 1.5 0.18 5.68 27.3696
rtl 12 1.08 0.93 4.4659
rt2 6 0.78 1.29 6.1936
rt5 200 2.30 0.43 2.0945
rt6 150 2.18 0.46 2.2148
rt7 280 2.45 0.41 1.9694
rth 400 2.60 0.38 1.8522
rti 66000 4.82 0.21 1.0000
vit 84 1.92 0.52 2.5046
vru 5 0.70 1.43 6.8952
_________________________  Total 68.2851
T a b l e  4 .6  C a l c u l a t i o n  o f  t h e  c r y s t a l  s t r u c t u r e  w e i g h t i n g s .
4.3.3 Superligand generation with Unity queries
Unity 3D®280 is a rapid database searching program for the identification of structures 
matching ligand-based pharmacophores and receptor-site constraints. Its recent 
emergence as a computational tool has meant that published literature of the use of the 
program has been exceedingly sparse. Only one reference has been published with its 
ligand-based pharmacophore use,316 and one recent reference to its use with receptor- 
site constraints. The basic premise of its structure-based functions is illustrated in 
Figure 4.13, where the inverse pharmacophoric feature of a chemical function of a 
particular residue of the receptor or binding pocket is placed at an optimal position for a 
ligand functional group to interact with that residue. Thus the carbonyl of a residue in 
the receptor site, which may possibly function as a hydrogen bond acceptor, has a 
hydrogen bond donor pharmacophoric feature (purple sphere) matched to it within the 
binding pocket. The collection of pharmacophoric spheres is referred to as a structural 
query.
Figure 4.13 (Left) Coloured spheres represent the pharmacophoric features of a chemical 
structure. (Right) Coloured spheres represent the inverse pharmacophoric features of a protein 
structure. Beige spheres are ring aromatic features, green spheres represent hydrogen bond 
acceptor features, purple spheres represent hydrogen bond donor features, red spheres represent 
positive ionisable functions, and blue spheres represent hydrophobic aliphatic functions.
Additionally Unity 3D allows the user to build structural queries from molecules, 
molecular fragments, and pharmacophore models. Multiple excluded volumes 
representing the binding site can be used to exclude structures that may have steric 
problems binding within the receptor, or help define the containing volume of the 
receptor cavity.318 The flexible three-dimensional database searching function of Unity 
3D allows these structural queries to be used to search databases to find molecules that 
can achieve a matching conformation to the query, regardless of the stored 
conformation in the database.318 Significantly, Unity 3D also allows partial match 
directives, which tolerate searches for ligands containing only some of the features 
specified in the query. The generation of the structural query may be best summarised 
in Figure 4.14, actually derived from a description of the Structure-Based Focusing 
module of Cerius2®281,282 The three-dimensional database in which the query searches 
may be user-created, public (National Cancer Institute), or commercially available 
(Maybridge, Derwent’s World Drug Index, MDL Dmg Data Report, and 
Comprehensive Medicinal Chemistry databases). Thus these latest additions to the 
range of computational tools available are ideal substitutes for the method of 
superligand generation previously proposed by the integrated drug design scheme of 
Figure 4.1. In our case, the generation of the Ludi interaction map and clustering of the 
interaction site vectors are exactly the same steps proposed to generate the superligand 
in Figure 4.1.
F ig u r e  4 .1 4  B a s i c  s c h e m a t i c  o f  t h e  p r o c e s s  t o  g e n e r a t e  a n d  u s e  s t r u c t u r a l  q u e r i e s .282
Unity can create numerous different types of features to generate a structural query. 
These can include atoms, bonds, lines, planes, centroids, extension points, hydrogen 
bond sites, hydrophobic sites, and spatial features which define spheres, lines, planes, 
caps and toruses in which a feature must lie for it to be considered a ‘hit’.318 However, 
the most common features used in automated feature searching of receptors and active 
sites are the hydrogen bond donating and accepting, and hydrophobic features, which 
are illustrated in Figure 4.15. The residues of the ‘weighted’ binding pocket were 
searched for all possible hydrogen bond donor and acceptor features, and these were 
displayed graphically as extensions from the protein residue. A manual selection 
process was then required to choose those features suitable for inclusion in the structural 
query. Donor and acceptor features projecting into the binding pocket were selected, 
while those that projected out of the pocket, and most likely into a space of the protein 
that had been cut away during the initial preparation and definition of the pocket 
(Section 4.3.1), were deleted. Hydrophobic residues could not be selected 
automatically, and so all of the aromatic residues listed in the pocket definition (Table 
4.5) were selected to generate the corresponding hydrophobic feature of the ligand in 
the binding pocket. Aliphatic amino acid residues were not selected, as this would have 
increased the already extremely large number of features to an ungainly size, and 
hydrophobic aromatic features in the binding pocket had already been noted as being of 
particular importance.30,215
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Figure 4.15 (Left, top) Hydrophobic features for Tyrl81 and Tyrl88; the residues of the protein 
are shown in blue and the features of the query are shown in grey. (Left, bottom) Hydrogen bond 
acceptor functions on the residues of the protein project the possible spatial volume (bifurcated cap 
for Glul38 and cap for Tyrl88) in which a hydrogen bond donor function on the ligand could lie to 
make an intermolecular contact with the protein. (Right) Hydrogen bond donor functions on the 
residues of the protein project the possible spatial volume (torus for Serl34 and Tyrl81, and small 
spheres for LyslOl and Glnl82) in which a hydrogen bond acceptor function on the ligand could lie 
to make an intermolecular contact with the protein.
Another significant element of a structural query is the inclusion of excluded volumes. 
These are generally placed to represent residues of the binding pocket to ensure that, 
during database searching, ligands are not chosen that will fit all features but intrude 
into a space occupied by the receptor, and thus be unlikely to bind due to steric 
problems. A well defined excluded volume for a receptor will also function well as an 
inclusive volume, which forces a ligand to be within that volume to register as a hit, 
without being as restrictive. A useful parameter of the excluded volumes feature is that 
of the van der Waals radius that allows a user to specify the radius of the excluded 
volume sphere around each atom. By reducing this value, one in fact allows for protein 
flexibility to some degree.
Three queries were created from the ‘weighted’ pocket to use to sequentially screen the 
NCI database as implemented in Unity 3D®, version 4.1.280 Ideally, one would generate
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a single, all-encompassing, structural query, equivalent to the superligand concept, with 
all the pharmacophoric features of the primary and secondary features sets of Table 4.5 
to be used for database searching. However, this becomes computationally infeasible, 
as there are too many conformational and binding possibilities to explore for all save 
very small databases. This is especially the case when one considers the best and 
preferable form of searching also considers the flexibility of the ligand, searching for an 
appropriate conformation to fit the pharmacophoric query. In addition, one of the 
emerging and promising functions of database search algorithms is the capacity for 
partial-match searches, where a minimum and maximum number of features that are 
required to map to the pharmacophore, can be set.280,302.
The first query generated from the ‘weighted’ binding pocket used the spatial 
hydrophobic features of Tyrl81 and Tyrl88, and the excluded volumes of all residues in 
the secondary features set with the default van der Waals scaling factor of 1.0. The two 
tyrosines act as anchor or reference points for the database ligand searching to narrow 
the possibilities, while the excluded volumes limit the number of very large 
hydrophobic-feature containing ligands that would otherwise be considered as hits. 
Residues 181 and 188 were used as anchor points, as the literature has shown that these 
two residues provide the most significant intermolecular binding interaction with the 
ligand in the pocket.30,215 This boxing-in effect of the excluded volumes is illustrated in 
Figure 4.16 (left). This is not an ideal search method as the residues of the secondary 
features set have been identified in some RT-inhibitor complexes as being solvent 
accessible, and hence having possible interactions with the ligand, or potential ligands, 
in the binding pocket (see Section 4.3.1 and Table 4.5). However, this compromise was 
necessary in consideration of computational time and power.
The second query was the same as the initial query with the addition of all residues of 
the primary features set, excluding Tyrl81 and Tyrl88, defined as excluded volumes 
with a van der Waals scaling factor of 0.5. This query further increased the stringent 
criteria required of ligands if they were to be considered as potentially capable of 
binding into the pocket, and is illustrated in Figure 4.16 (right). The concession of 
using a van der Waals scaling factor of 0.5 allows potential ligands to approach closer to 
residues of the primary features set. These were residues that were identified as being 
in contact with a solvent sphere in at least ten of the RT-inhibitor-complexes, or noted
in the literature as being significant, and are more likely to be involved in 
intermolecular interactions with the ligand.
Figure 4.16 (Left) Structural query 1 with the residues of the secondary features set shown as 
purple excluded volume spheres, van der Waals radius 1.0 A. The two hydrophobic features of 
Tyrl81 and Tyrl88 have been annotated as red spheres. (Right) Structural query 2 with the 
residues of the secondary features set shown as purple excluded volume spheres, van der Waals 
radius 1.0 A, and the residues of the primary features set also shown as purple excluded volume 
spheres, van der Waals radius 0.5 A.
Figure 4.17 Structural query 3, the superligand of the ‘weighted’ 
binding pocket. The residues of the defined binding pocket are 
seen in blue, while the features of the structural query are seen as 
grey volumes.
The third query, 
illustrated in Figure 
4.17, was composed of 
all features generated, 
including 52 donor, 46 
acceptor and 10
hydrophobic features
from the appropriate 
residues from both the 
primary and secondary 
features sets. In fact, 
this third query is the 
superligand initially
proposed as the
structure-based
pharmacophore, as it describes with pharmacophoric features, all of the potential 
binding interactions the residues of the pocket are capable of.
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4.3.4 Database searching with Unity queries
All three queries were used to search an NCI database using Unity’s Flex Query option, 
which allows database ligands to be considered flexible while searching for matches to 
the query. The results from the first query were saved as a separate database, and the 
second query was then used to search this subset database. The results from the second 
query search were also saved as a subset database for the third query to search. The 
third query was performed using Unity’s Partial Match Constraint Dialog, which allows 
a search to be conducted where a match will contain only some of the features specified 
in the query. The results of the database searching are presented in Table 4.8.
The first structural query was performed on an NCI database of 117 649 compounds. 
The requirement of the minimum number of features of two ensured that all ligands had 
two hydrophobic features spaced apart approximately the same distance as the two 
tyrosines of the ‘weighted’ pocket. The macro screen removes from consideration any 
compounds in the database that did not meet this first criterion of having two 
hydrophobic functionalities. Of the remaining 71 951 compounds, 27 329 were 
considered as hits; mapping both hydrophobic features and being within the binding 
pocket circumscribed by the excluded volumes of the secondary features set. A number 
of the searched compounds (682) were noted as timed out; these compounds were likely 
to have contained numerous flexible bonds that needed extensive conformational 
searching to find a fit to the structural query. A fit was not found for these compounds 
after a preset time of 90 seconds, and the search algorithm moved on to the next 
structure. As these compounds were likely to contain too many rotatable bonds to be of 
interest, they were discarded and not added to the subsequent search volume.
The second structural query further increased the strictness of the criterion for ligand 
binding in the pocket, and reduced the number of potential compounds to 11 110. The 
number of compounds that timed out as the search algorithm investigated conformations 
so the compound that could fit into the reduced binding pocket was 701. Once again 
these were excluded from the next collection of compounds to be screened. At this 
point, one could say with some degree of confidence that all 11 110 resulting 
compounds could potentially bind in the pocket as they all had two hydrophobic 
features capable of possibly interaction with Tyrl81 and Tyrl88, and were all of 
approximately suitable size.
Query 1 Query 2 Query 3
Features Tyrl81 and Tyrl88 Tyrl81 and Tyrl88 Primary Features 
Secondary Features
Excluded Volumes Secondary Features 
(vdW 1.0)
Primary Features 
(vdW 0.5) 
Secondary Features 
(vdW 1.0)
not used
min. features 2 2 8
max. features 15 15 16
database size 117 649 27 329 11 110
macro screen 71 951 27 325 11 110
hits 27 329 11 110 172
timed out 682 701 7537
T a b l e  4 .8  R e s u l t s  o f  c o n s e c u t i v e  s e a r c h e s  w i t h  d i f f e r e n t  s t r u c t u r a l  q u e r i e s  t o  s c r e e n  t h e  N C I  
d a t a b a s e .  T h e  F e a t u r e s  r o w  d e n o t e s  f e a t u r e s  in  t h e  q u e r y  t h a t  w e r e  a v a i l a b l e  f o r  a  l i g a n d  t o  f i t  o r  
m a p  t o .  T h e  E x c l u d e d  V o l u m e s  d e s c r i b e s  t h e  r e s i d u e s  t h a t  w e r e  s e t  a s  e x c l u d e d  v o lu m e s ,  a n d  t h e  
v a n  d e r  W a a l s  s c a l i n g  f a c t o r  o f  t h o s e  r e s i d u e s .  T h e  m in .  a n d  m a x .  f e a t u r e s  a r e  t h e  v a lu e s  u s e d  in  
t h e  p a r t i a l  m a t c h  s e a r c h  a l g o r i t h m  t o  s p e c i f y  t h e  m i n i m u m  a n d  m a x i m u m  f e a t u r e s ,  r e s p e c t iv e ly ,  
t h a t  a  l i g a n d  n e e d s  t o  f i t  t o  b e  c o n s i d e r e d  a  h i t .  T h e  r e m a i n i n g  n u m b e r s  a r e  t h e  r e s u l t s  o f  t h e  
d a t a b a s e  s e a r c h i n g .
The final structural query endeavored to reduce this hit list down to a reasonable size of 
less than two hundred, for further manual selection and consideration. In this search, all 
of the features identified as having possible binding interactions with the residues of the 
primary and secondary features sets were considered to form part of the structural 
query. The extremely high number of compounds that timed out, 7 537 compounds, 
was due to the large number of features in the query. Imposing a minimum of eight 
features that needed to be mapped onto the structural query meant that the search 
algorithm needed to search multiple conformations of the compound to see if they could 
fit onto multiple possible combinations of eight features. This was a considerable 
computational undertaking, and explained the high number of compounds that were not 
able to find a fit in the allocated time span of 90 seconds. Ideally, these timed-out 
compounds should be searched with longer allocation times per structure. Conversely, 
the same previous argument could be made that these timed-out compounds were likely 
to be too flexible for consideration. Regardless, the number of returned hits was now at 
a reasonable size and no further database searching was conducted.
The activities of the 172 compounds, that were identified as potential ligands for the 
‘weighted’ pocket, were estimated by importing them into a spreadsheet in Catalyst, and 
using the Score Hypothesis tool. Two ligand-based pharmacophores generated in 
Catalyst were selected to estimate the activities of the compounds of the hitlist with the 
Score Hypothesis tool. The highest ranking hypotheses from the singlepharm 
pharmacophore, where the Minimum Total Features parameter was set at 1, and the 
multipharm pharmacophore, where that parameter was set at 4 (see Section 4.2.4 
Hypothesis analysis and selection), were selected. These estimated values were only 
one small point of consideration in the selection of compounds to be requested from the 
NCI for antiviral and anti-malarial testing. Additional criteria included the structural 
diversity of ligands, both rigidity and flexibility in the ligand, size and molecular 
weight. The inclusion of familiar structural motifs encountered in antiviral natural 
products and current anti-HIV drugs, such as multiple aromatic features, a possible 
‘butterfly’ conformation of the compound, and dimeric structures were also taken into 
account. With these considerations in mind, ten compounds were requested from the 
NCI, of which seven were donated. These seven compounds, shown in Figure 4.18, 
were sent for both anti-HIV and antimalarial testing (see Section 2.9).
As the database searched was that of the NCI, its Development Therapeutics Program 
(DTP) had available the anticancer and antiviral screen results of some of the 
compounds of that database. A search of the structures of Figure 4.18 showed that 
compounds 7231 and 55233 had IC50 values of > 1.00 x 10'4 and 3.17 x 10'4, 
respectively. The activity of 7231 was noted as active, while that of 55233 was 
inactive. No data was available for the remaining compounds. Notably, NCI anti-HIV 
screens use whole cell assays. These results provide a preliminary and tentative 
validation of the structure-based query.
The DTP searchable database319 was only used after the selection of the compounds for 
biological testing, however, it remains a useful tool in the assessment of larger hitlists 
obtained from database searching. Compound selection should still be based on some 
of the criteria previously noted, and on fitting to select pharmacophores.
4.3.5 Compound selection for biological testing
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Figure 4.18 Structures of NCI donated compounds selected from database search with NSC code 
number and CAS registration number.
4.3.6 Structural queries in Catalyst
In addition to the CatHypo tool for automatic hypothesis generation, Catalyst® also has 
a utility for the generation of ‘manually’ constructed hypotheses, called Hypoedit. The 
Cartesian coordinates and constraints of all typical pharmacophore features can be 
described, as can excluded volumes. Constraints describe the volume and locations of 
the spheres typically seen with the Catalyst pharmacophores. This utility has been 
previously used to incorporate structural x-ray crystallographic data in the form of 
excluded volumes to ligand, or docking-derived pharmacophores. ’ ’ The default
settings specify that features have a constraint tolerance of 150 picometres (pm) on the 
ligand, 200 pm for the corresponding interacting feature of the receptor, and 250 pm for 
excluded volumes.
Using this utility, one could reconstruct the structural queries from Unity 3D in Catalyst 
and not only compare this structure-based pharmacophore to the ligand-based 
pharmacophores previously generated in Catalyst (Section 4.2), but also fit ligands to 
the structural query. Given that the structural queries from Unity only included
hydrogen bond donor, acceptor, and hydrophobic functions and excluded volumes, 
these were the only types of features used.
The first step in the process of translating the structural query to a Catalyst hypothesis 
involved retrieving the structural query from Unity 3D. The third query used in the 
database search was used to test the feasibility of this translation. Structural queries can 
be saved as text files, and provide the coordinates for each feature of the query. A 
donor atom on the receptor is designated RD and the corresponding location of the 
acceptor atom on the ligand is designated LA, coordinates are provided for both RD and 
LD and together they describe a hydrogen bond acceptor function for a ligand-based 
pharmacophore. The same is true of the hydrogen bond donor function that is described 
by an acceptor atom on the receptor, RA, and a corresponding donor atom on the ligand, 
designated LD. Hydrophobic features and excluded volumes only have one set of 
coordinates rather than two.
Two additional considerations had to be made in the selection of features to be 
‘translated’ with the Hypoedit utility. One concerned the use of bifurcated features in 
Unity, that is, features where an acceptor or donor site on the receptor projects two 
separate donor or acceptor sites, respectively, to possible corresponding features on the 
ligand. A bifurcated feature is illustrated in Figure 4.15 (left, bottom). Catalyst was 
unable to deal with these bifurcated features, believing that there were too many 
constraints to the one feature. With these bifurcated features from Unity, only the 
coordinates from the first feature of the bifurcation were used. The second 
consideration was related to the first, and involved receptor features that could act as 
both hydrogen bond donors and acceptors. This occurred twice, and in each case the 
feature where the ligand contained the acceptor features was used preferentially to the 
feature where the ligand contained the donor atom. This was due to the greater number 
of donor features (52) compared to acceptor features (46) in the structural query in 
Unity, including bifurcated features.
A Hypoedit script file is provided with the utility (Appendix 7.14), and this is copied 
and edited with the coordinate data of the features extracted from the Unity structural 
query. Two reconstructions of the Unity structural query were made with the Catalyst 
Hypoedit utility, one with features, seen in Figure 4.19 (top) (Appendix 7.14.1), and one 
with both features and exclusion volumes, seen in Figure 4.19 (bottom). This latter 
pharmacophore has 87 excluded volumes from the excluded volumes defined by the
residues of the secondary features set (Table 4.5). A maximum limit of 1000 excluded 
volumes and 100 features has been noted for the Hypoedit utility.301
Figure 4.19 (Top) Structural query from Unity seen as a Catalyst hypothesis. Green wire-cages 
represent hydrogen bond acceptor features, purple represents hydrogen bond donor features and 
aqua represents hydrophobic features. (Bottom) The same structural query with excluded 
volumes. Black wire-cages represent excluded volumes.
Unfortunately, attempts to use the structural query pharmacophore generated with 
Hypoedit and compare the merged singlepharm and merged multipharm 
pharmacophores were unsuccessful as the only common feature between the structural 
query pharmacophore and the merged pharmacophores was the green hydrogen bond
acceptor feature. Furthermore, database searching with the structural query 
pharmacophore was not possible with the particular version of the software used,307 as it 
did not allow the necessary partial match searching. The search algorithm of Catalyst
4.5 requires that a ligand at least have the same number and type of features as the 
searching pharmacophore to even be considered
4.4 Future directions for integrated drug design
This research, endeavoring to realise the optimal synergism of ligand and structure 
based design principles, has only taking the first step towards fully utilising all the 
available information for drug design. No studies towards the actual integration of the 
ligand and structure based pharmacophores have been attempted, and admittedly no 
tangible or prospective strategies to integrate the ligand and structure-based 
pharmacophores to create the proposed combiphore have been formulated. This 
remains a significant and worthy challenge for future research efforts.
Medicinal agents designed from the combiphore are proposed to be able to consider 
both present data about inhibitors known to be active at a binding site, as well as all 
potential interactions the binding site may be capable of. The complete exploration of 
the binding interactions of a pocket provides the combiphore drug strategy the ability to 
target the residues of a protein that may not previously have been utilised, and aid in the 
design of novel agents effective against mutant strains of proteins resistant to present 
drugs. Potentially, the mode in which mutations of residues in the binding site diminish 
or eliminate inhibitor activity may also be easily studied and quantified using the 
combiphore. Each feature of the combiphore can be weighted; these weightings can be 
increased, reduced or abolished as mutations in the pocket differentially affect binding 
interactions. Combiphores may be an effective tool in studying how different ligands 
acting at one binding site can exert both agonistic and antagonistic effects, as they can 
include agonistic and antagonistic pharmacophores from ligand-based design.
Naturally, these potential utilisations can only be possible after much more thorough 
study and research with the two foundations of the combiphore, the ligand-based 
pharmacophores and the structure-based queries. In the ligand-based studies, further 
refinement of the individual pharmacophores and database searching strategies are 
required to improve the quality of the hits from a database search. The inclusion of 
excluded volumes may be possible by docking an individual hypothesis, or a merged
hypothesis, into an actual x-ray crystal structure of the pocket. Docking using the 
‘weighted’ pocket created for the structure-based studies would provide an interesting 
study. The coordinates of the residues of the pocket could be transformed relative to the 
pharmacophore, and added to the pharmacophore in Catalyst with the Hypoedit utility. 
The docking of pharmacophores into individual x-ray crystal structures may also be 
interesting to see how the crystallised ligand of the RT-inhibitor complex overlays with 
the pharmacophoric features.
In the structure-based studies, potentially valuable and interesting research should be 
conducted into docking studies of the ligands from the Unity database searches in the 
newly created and modified binding pockets. These would help in the identification of 
the most likely lead compounds to consider for synthesis and biological testing. 
Conversely, compounds identified from the ligand-based pharmacophore searches 
should be either docked into these structure-derived queries with various docking 
algorithms, or fitted with pharmacophoric search algorithms.
Pharmacophore, or structural query cross searching should also be explored further than 
the preliminary attempts in the selection of compounds for biological testing from the 
Unity 3D database searching (Section 4.3.4). That is, searching a selection of 
compounds considered hits on the ligand-derived pharmacophore with the structural 
query pharmacophore, and vice versa. Partial match querying is absolutely required for 
this process, as the structural query pharmacophore would be expected to have too many 
features.
It would not be an exaggeration to state that the inventory of research that could 
potentially arise from the basic concepts of the superligand and combiphore presented in 
Figure 4.1 is significant. In reality such ambitions have already produced such 
computational tools as Unity 3D®,280 and the Structure-Based Focusing module of 
Cerius The future for this research therefore remains as vast and open as its 
potential was seen several decades ago with the advent of computer aided ligand design.
♦ Chapter 5 • f
Conclusions and Future Directions
♦ ♦
5.1 Synthetic studies
The research undertaken to synthesise analogues of the antiviral michellamine alkaloids 
(Figure 5.1) established synthetic methodologies for biaryl cross-coupling and homo­
coupling reactions. The Suzuki reaction was used successfully to form the biaryl bond 
to replace the tetrahydroisoquinoline moiety of the michellamines, and to construct the 
central biaryl axis to yield the dimer analogues. Coupling reactions using the Stille 
methodology, also yielded cross-coupled and homo-coupled products, however the poor 
yields made this an unattractive synthesis.
Cross-coupled products in the Suzuki reaction were synthesised with the boronic acid or 
ester moiety on either the naphthyl ring system that would form the michellamine 
skeleton, or on the moiety replacing the tetrahydroisoquinoline. The most common 
catalyst used was dichloro[l,T-bis(diphenylphosphino)ferrocene]palladium, 
PdCl2(dppf), as this accelerated the coupling, and ensured reaction times were of the 
order of 24 hours, compared to tetrakis(triphenylphosphine) palladium(O), Pd(PPh3)4, 
with which most reactions required at least 36 hours to complete. Another catalyst used 
was palladium acetate, for the synthesis of the pyridine-substituted analogue. The most 
common solvent for the coupling reactions was THF, and only the synthesis of the 
pyridine-substituted analogue specifically required the use of DME. The choice of base 
was dependent on the reaction; weaker bases were generally used in the cross-coupling 
reactions to minimise homo-coupled by-products, and stronger bases were used in the 
homo-coupling reactions to accelerate the formation of the product and minimise 
deboronation. Deprotection of the synthesised monomeric and dimeric analogues was
performed to yield the desired potential inhibitors. However, future synthetic studies 
should consider optimisation as the current conditions produced unsatisfactory yields 
for the last reaction in a multi-step synthesis.
The synthetic studies established and, in some measure, optimised a methodology for 
the cross-coupling of aryl and alkyl substituents to a brominated naphthyl moiety, and 
the homo-coupling of that ortho-brominated cross-coupled product to form binaphthyl 
analogues of the michellamines. One of the initial aims of this research, to determine if 
these monomeric and dimeric analogues were active against HIV-1 reverse transcriptase 
or showed activity in antimalarial screens, was not wholly achieved at this time, 
however, biological testing results will be available soon.
The most immediate next step of this research is the completion of the synthesis of the 
dimeric and monomeric series of designed inhibitors; in particular the pyridine 
substituted compounds. The monomeric and dimeric phenyl, naphthyl, methyl, 
pyrimidyl and pyridyl X-substituted inhibitors of Figure 5.1 also require transformation 
of their Y-substituents; ethyl ester to carboxylic acid, methyl alcohol, and methyl 
groups. Hydroxy substitutions in this position should also be considered to introduce 
significant and necessary structure-activity relationship (SAR) data to add to those 
inhibitors currently being tested, as should varying the methoxy group to Z-substituents. 
The synthesis and design of further michellamine analogues and antiviral inhibitors will 
require the contributions from SAR data, and ligand- and structure-based drug design.
Michellamine (26)
Figure 5.1 The michellamine alkaloid and proposed substituent points for analogue synthesis.
5.2 Conformational changes of the reverse transcriptase enzyme
The studies of the conformational changes of the reverse transcriptase enzyme induced 
by substrate and inhibitor binding established an objective, and quantitative method to 
analyse a large number of x-ray crystallographic structures. In this research, crystal 
structures with and without DNA, and non-nucleoside inhibitors bound were used. In 
the substrate-bound crystal structures, the polymerase active site showed displacements 
from the position adopted in the unliganded structure that are most likely explained as 
movements to accommodate the double stranded nucleic acid and the incoming 
nucleotide, to prime the enzyme for catalysis of the chemical reaction. Similar small, 
but notable, conformational changes were observed in the RNase H active site and the 
primer and template grips.
The inhibitor-bound crystal structures displayed quite large displacements in the studied 
active sites and structural motifs. In the polymerase and RNase H active sites, the 
conformational changes relative to other structural features and motifs, as well as 
between the residues of the active sites, saw a change in the coordination complexes 
that the catalytic residues may be able to adopt. These coordination complexes are quite 
involved, requiring the exact positioning of the residues of the active site, nucleic acid 
template and primer strands, incoming nucleotides and Mg2+ ions for the successful 
chemical steps of polymerisation and hydrolysis. The primer and template grip motifs 
demonstrated distinct displacements from the positions adopted in the unliganded and 
DNA-bound structures, occupying some of the space of the double-stranded DNA in the 
substrate-bound structures. The most direct inference from these results was that non-
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nucleoside inhibitor binding affected the intermolecular interactions between the 
magnesium ion(s), the incoming nucleotide, the template and primer strands of nucleic 
acid, and the corresponding enzyme grips. This may either make it impossible for the 
nucleic acid to bind and/or hinder its mechanism of translocation during the synthesis of 
the DNA chain.
The non-nucleoside inhibitor binding pocket was also analysed in substrate- and 
inhibitor-bound crystal structures and changes were found to be predominantly caused 
by the displacement of Tyrl81 and Tyrl88, and residues that the binding pocket has in 
common with the primer grip. The supposition from these observations is that the 
displacement of the residues of the pocket, in particular the swivelling of the two 
tyrosines, creates the space that becomes occupied by the non-nucleoside inhibitor, and 
in doing so shifts the position and conformation of neighbouring residues. These 
structural disturbances have both short- and long-range consequences, as observed in 
the two active sites and nucleic acid grips studied.
Consideration of the conformational changes in the substrate and inhibitor-bound 
structures resulted in the postulation that the mechanism of non-nucleoside inhibition 
involved not just one structural motif, such as the PAS, as has been suggested in the 
literature. More likely, the inhibition and activation of RT is achieved by integrated and 
synchronous conformational changes of all significant structural motifs of the enzyme. 
However, the results of this study did support some literature speculation that the 
mechanism of inhibition involved an opening of the hand-shaped structure of the 
enzyme. Structural changes in the enzyme were also hypothesised to be involved in the 
enzyme’s recognition and response to different nucleic acid substrates. The enzyme 
was proposed to exist in six basic global conformations, depending on the activation 
state of the enzyme, the nature of the nucleic acid template and primer bound, and the 
presence or absence of non-nucleoside inhibitors. Further research in this field will 
require more crystal structures or computer-generated models, in particular those with 
the natural RNA primers and templates bound, and structures with both nucleic acids 
and inhibitors concurrently bound. More detailed study of the non-nucleoside inhibitor 
binding pocket should advance the characterisation of its flexibility and aid in rational 
drug design by understanding the intermolecular interactions the pocket is capable of 
forming to a bound ligand.
m
5.3 Drug design studies
Investigations into the optimal use of ligand and protein derived structural information 
for rational computer aided ligand design established the preliminary methodology for 
the integration of ligand- and structure-based methodologies. Traditional ligand-based 
pharmacophores were generated using inhibitors that had previously been crystallised 
with RT, so that their bioactive conformation and unambiguous binding to the active 
site were known. These pharmacophores were composed of different combinations of a 
hydrogen bond acceptor, a ring aromatic, a hydrophobic aliphatic and a positive 
ionisable feature. Selected hypotheses were also merged to form more specific 
pharmacophores. Individual and merged hypotheses were tested and validated with the 
inhibitors from crystal structures not used in the pharmacophore generation, however, 
the results were ambiguous, and this was primarily attributed to the statistical invalidity 
of the training set used to generate the hypotheses. Database searching with these 
pharmacophores demonstrated that the merged hypotheses with more features were 
more effective in returning more manageable hitlists of compounds to be further 
considered as potential leads. These large hitlists of compounds can now easily be 
screened with more specific pharmacophores, such as those generated by structure- 
based design methods, to reduce the current hitlists of several thousand compounds to 
approximately a couple of hundred. These can then be manually sorted and analysed 
with the screening data provided by the National Cancer Institute.
A structure-based query/pharmacophore was developed from an activity ‘weighted’ 
model of the three-dimensional x-ray structures whose inhibitors were used in the 
ligand-based pharmacophore. This was used to search the NCI database to identify 
compounds that fit the structural and conformational requirements of the structure-based 
pharmacophore. Of the compounds returned from database searching and identified as 
possible lead compounds to investigate, two had been previously tested by the NCI, and 
one had been noted as showing anti-viral activity. This served as preliminary validation 
of the structure-based methodology. The ‘superligand’ query/phramacophore described 
all potential binding interactions of residues of the active site to a potential ligand in the 
pocket. It was converted to a traditional pharmacophore form with the Hypoedit utility 
in Catalyst, and represented the first step toward the generation of the ‘combiphore’, an 
integration of ligand- and structure-based pharmacophores.
The last objective of this research, to fully integrate these pharmacophores and fully 
exploit the twofold sources of information in one methodology, was not realised at this 
time, however, this can be achieved readily with only small additional refinement of the 
individual ligand- and structure-derived pharmacophores necessary. Comparisons of 
the pharmacophore and the superligand with superimposition and docking studies, as 
well as databases searching, will be stimulating and potentially rewarding areas of 
research to investigate. The combiphore, and its constituent pharmacophore and 
superligand, represent exciting emergent computational tools for the optimal 
exploitation of ligand and receptor structure information for rational drug design. They 
will potentially be able to study and consider both existing data about inhibitors known 
to be active at a binding site, as well as all potential interactions the binding site may be 
capable of.
Chapter 6 ♦
Experimental
6.1 Synthesis
Reagents and solvents were purchased reagent grade and used without further 
purification, unless otherwise stated. THF, ether and dioxane were dried over KOH and 
distilled from sodium. DCM was distilled from phosphorus pentoxide. DMF was 
distilled from C aS04 under reduced pressure, and glacial acetic acid was distilled from 
C uS04. All reactions were performed in standard glassware under an inert atmosphere 
of nitrogen. Organic solvent extracts were dried with anhydrous M gS04 and the solvent 
removed under reduced pressure in a rotary evaporator. Compounds were dried at 10'2 
Torr. Analytical thin layer chromatography (TLC) was performed on Merck Kieselgel 
60 F254 silica on aluminium sheets. Column chromatography was performed using 
Merck Kieselgel 60 (0.040-0.063 mm, 230-400 mesh, or 0.063-0.200 mm, 70-230 
mesh). All chromatographic solvent proportions were volume for volume.
Melting points (mp) were determined on a Reichert hot-stage melting point apparatus. 
Temperatures were expressed in degrees Celsius (°C) and were uncorrected.
Proton nuclear magnetic resonance (!H NMR) spectra were acquired with Varian Unity- 
300 or -400 spectrometers at 300.1 and 399.9 MHz respectively. All spectra were 
recorded using solutions in deuterochloroform, obtained commercially from Aldrich 
Chemical Company, Inc. or Cambridge Isotope Laboratories, Inc., with chloroform as 
the internal standard (5 7.26 ppm). Carbon nuclear magnetic resonance ( C NMR) 
spectra were acquired with Varian Unity-300 or -400 spectrometers at 75.4 and 100.0 
MHz respectively and using deuterochloroform solutions with chloroform as the
internal standard (5 77.00 ppm). Chemical shifts (5) and coupling constants (7 ) were 
expressed in ppm relative to the internal standard, and cycles per second (Hz) 
respectively. Multiplicities are denoted as s (singlet), d (doublet), bd (broad doublet), 
dd (doublet of doublets), q (quartet), p (quintet), and m (multiplet). Each resonance was 
listed according to the following convention: chemical shift, multiplicity, coupling 
constant, integration, and assignment.
Mass spectra were obtained on a Shimadzu QP-5000 (chemical ionisation, Cl), or on a 
VG Quattro-triple quadropole or MAT-44 quadropole (electrospray, ES) 
spectrophotometer via a direct insertion technique, with an electron beam energy of 70 
eV and a source temperature of 200 °C. High resolution mass spectra (HRMS) (Cl or 
ES) were obtained using a Fison/VG Autospec-TOF mass spectrometer.
M icroanalyses (elemental analyses) were performed by the Microanalytical Service, 
Department of Chemistry, The University of Queensland, Brisbane.
Ethyl 8-bromo-5-isopropoxy-4-methoxy-2-naphthalenecarboxylate (65)
(65)
Compound (65) was synthesised in 7 steps according to literature
53,62 xhe overall yield for 7 steps of the synthesis to (65) was 
12.7%. The only modification to the literature was the 
methylation reaction as detailed following. A mixture of (64)
(1.00 g, 2.83 mmol), potassium carbonate (1.17 g, 8.47 mmol) 
and iodomethane (1.76 mL, 28.27 mmol) in dry distilled acetone (200 mL) was heated 
at reflux under N 2  for 24 hours. The solvent was removed under reduced pressure, and 
the residue was extracted with chloroform (4 x 50 mL) and water. The organic phase 
was dried (MgSOzO, and concentrated in vacuo , before being subjected to flash column 
chromatography (10% ethyl acetate:hexane). Recrystallisation from isopropanol 
yielded (65) (945 mg, 91%) as an orange solid: mp 66.6-67.4 °C; !H NMR (CDCI3, 400 
MHz) 5 1.40 (d, 7 = 6.0 Hz, 6 H, CH (CH3)2), 1.45 (t, 7 = 7.0 Hz, 3H, CH 2 CH3), 4.00 (s,
3H, OCH3), 4.45 (q, 7 = 7.2 Hz, 2H, C772 CH3), 4.53 (p, 7 = 6.0 Hz, 1H, C77(CH3)2), 6.87 
(d, 7 = 8.4 Hz, 1H, H-6), 7.46 (d, 7 - 1 . 2  Hz, 1H, 77-3), 7.70 (d, 7 -  8.4 Hz, 1H, 77-7), 
8.56 (d, 7 -  1.2 Hz, 1H, 77-1); 13C NMR (CDC13, 75 MHz) 5 14.36 (CH 2 CH3), 21.93 
(CH(CH3)2), 56.42 (OCH3), 61.33 (CH 2 CH3), 73.34 (CH(CH3)2), 105.84 (C-3), 114.82 
(C-6 ), 115.52 (C-8 a), 122.62 (C-4a), 122.73 (C -l), 129.19 (C-2), 131.08 (C-7), 134.40 
(C-8 ), 154.98 (C-5), 157.65 (C-4), 166.47 (COO); (CC) 369 (M +l, Br81, 93), 367
(M +l, Br79, 100), 327 (Br81, 12), 325 (Br79, 1 1 ), 289 (25), 247 (6 ); HRMS (CI+) calcd 
for C 1 7 H 2 oBr04: 367.0545 found 367.0541.
Ethyl 5-isopropoxy-4-methoxy-8-phenyl-2-naphthaIenecarboxyIate (68)
A mixture of (65) (500 mg, 1.36 mmol), phenylboronic acid (350
mg, 2.87 mmol), barium hydroxide (700 mg, 4.08 mmol) and
PdCl2 (dppf) (115 mg, 141 pmol) in dry distilled THF (30 mL)
was heated at reflux under N 2  for 48 hours. The solvent was
removed under reduced pressure, and the residue was partitioned
between chloroform and 2M NaOH. The aqueous layer was
. (68)
extracted with chloroform (4 x 50 mL), and the combined
organic layers washed with water. The organic phase was dried (M gS04), and
concentrated in vacuo , before being subjected to flash column chromatography ( 1 0 %
ethyl acetate:hexane). Recrystallisation from isopropanol yielded (6 8 ) (480 mg, 9 7 %)
as a yellow solid: mp 104.7-106.9 °C; lU  NMR (CDC13, 400 MHz) 5 1.34 (t, 7 -  7.0 Hz,
3H, C R 2CH3), 1.45 (d, 7 -  6.4 Hz, 6 H, C H (C //3)2), 4.03 (s, 3H, OCH3), 4.34 (q, 7 = 1 2
Hz, 2H, CH 2 CH3), 4.59 (p, 7 - 6 . 1  Hz, 1H, CH(CH3)2), 7.09 (d, J  -  8.0 Hz, 1H, H-6),
7.36 (d, 7 -  8.0 Hz, 1H, H -l), 7.44 (m, 5H, aryl), 7.48 (d, 7 - 1 . 6  Hz, 1H, H-3), 8.22 (d, 
7 -  1.6 Hz, 1H, H -l); 13C NMR (CDC13, 75 MHz) 5 14.27 (CH 2 CH3), 22.14 
(CH(CH3)2), 56.46 (OCH3), 61.00 (CH 2 CH3), 73.33 (CH(CH3)2), 105.19 (C-3), 114.64 
(C-6 ), 121.69 (C-4a), 122.13 (C -l), 127.15 (C-7), 127.88 (C-2), 128.27 (C-2 ’, 6 ’),
128.36 (C-4’), 130.26 (C-3’, 5 ’), 134.66 (C-l*), 135.17 (C-8 ), 140.81 (C-8 a), 154.50 
(C-5), 157.55 (C-4), 166.83 (COO); m/z (CI+) 365 (M +l, 100), 323 (16), 263 (16); 
HRMS (CI+) calcd for C 2 3 H 2 5 0 4: 365.1753, found 365.1749.
Ethyl 5-isopropoxy-4-methoxy-8-naphthyl-2-naphthalenecarboxylate (72)
A mixture of (65) (500 mg, 1.36 mmol), naphthylboronic acid 
(350 mg, 2.73 mmol), potassium acetate (535 mg, 5.45 mmol) 
and PdCl2 (dppf) (110 mg, 135 pmol) in dry distilled THF (20 
mL) was heated at reflux in a sealed tube under N 2  for 48 hours. 
The solvent was removed under reduced pressure, and the 
residue was partitioned between chloroform and 2M NaOH. The 
aqueous layer was extracted with chloroform (4 x 50 mL), and
the combined organic layers washed with water. The organic phase was dried (M gS04), 
and concentrated in vacuo, before being subjected to flash column chromatography 
( 1 0 % ethyl acetate:hexane). Recrystallisation from isopropanol yielded (72) (510 mg, 
91%) as a yellow solid: mp 166.6-167.3 °C; !H NMR (CDC13, 400 MHz) 6  1.20 (t, J  =
7.2 Hz, 3H, CH 2 CH3), 1.49 (d, J  = 6.4 Hz, 6 H, C H (C //3 )2 ), 1.50 (d, J  = 6.0 Hz, 6 H, 
CH(CH3)2), 4.05 (s, 3H, OCH3), 4.21 (q, J  = 6 . 8  Hz, 2H, C tf 2 CH3), 4.66 (p, J  = 6 . 1  Hz, 
1H, CH(CH3)2), 7.14 (d, J  = 8.0 Hz, 1H, H-6), 7.29 (ddd, J  = 1.3, 7.0, 8.4 Hz, 1H, 
naphthyl), 7.37 (s, 1H, naphthyl), 7.39 (d, J =  1.6 Hz, 1H, H-3), 7.41 (d, J  = 8.0 Hz, 1H, 
H -l), 7.46 (ddd, J  -  1.2, 4.0, 4.0 Hz, 1H, naphthyl), 7.47 (ddd, J  -  1.3, 4.1, 4.1 Hz, 1H, 
naphthyl), 7.58 (dd, J  = 0.8, 7.2 Hz, 1H, naphthyl), 7.74 (d, J  = 1.2 Hz, 1H, H -l), 7.94 
(dd, J  = 1.4, 8.2 Hz, 2H, naphthyl)-, 13C NMR (CDC13, 75 MHz) 5 14.11 (CH2 CH3), 
22.16 (CH(CH3)2), 22.22 (CH(CH3)2), 56.46 (OCH3), 60.86 (CH 2 CH3), 73.23 
(CH(CH3)2), 105.12 (C-3), 114.17 (C-6 ), 121.45, 122.43 (C -l), 125.31 (naphthyl), 
125.71, 125.94, 126.37, 127.93, 128.16, 128.24, 128.57, 129.33, 132.92, 133.14, 
133.70, 135.89, 138.27, 154.78 (C-5), 157.54 (C-4), 166.66 (COO); m/z (C f)  415 (M+, 
56), 401 (12), 338 (25), 263 (44); HRMS (CI+) calcd for C 2 7 H 2 7 O4 : 415.1909, found 
415.1887.
Ethyl 5-isopropoxy-4-methoxy-8-(4',4',5',5'-tetramethyl-[l,3,2]dioxaborolan-2-yl)- 
2-naphthalenecarboxylate (73)
) OCH3
C 02Et
(73)
A mixture of (65) (200 mg, 5.45 mmol), bis(pinacolato)diboron 
(280 mg, 1.10 mmol), potassium acetate (220 mg, 2.24 mmol) 
and PdCl2 (dppf) (45 mg, 55.10 pmol) in dry distilled THF (25 
mL) was heated at reflux under N 2  for 24 hours. The solvent was 
removed under reduced pressure, and the residue was extracted 
with chloroform (4 x 50 mL) and water. The organic phase was 
dried (M gS 04), and concentrated in vacuo, before being 
subjected to flash column chromatography ( 1 0 % ethyl acetate:hexane). 
Recrystallisation from isopropanol yielded (73) (215 mg, 95%) as a pale yellow solid: 
mp 98.7-101.3 °C; *H NMR (CDC13, 400 MHz) 5 1.25 (s, 3H, C(CH3)2), 1.26 (s, 3H, 
C(CH3)2), 1.41 (d, J  = 6.0 Hz, 6 H, C H (C H j )2), 1.42 (s, 3H, C(CH3)2), 1.42 (s, 3H, 
C(CH 3)2), 1.45 (t, J  = 7.2 Hz, 3H, C H 2C / / j ), 3.97 (s, 3H, OCH3), 4.41 (q, J  = 7.1 Hz, 
2H, C // 2 CH3), 4.64 (p, J =  6 .1 Hz, 1H, C7/(CH3)2), 6.97 (d, J  = 8.0 Hz, 1H, H-6), 7.39 
(s, 1H, H -3), 7.99 (d, J  = 8.0 Hz, 1H, H -l), 9.19 (d, J  = 1.2 Hz, 1H, H -l); I3C NMR
(CDC13, 100 MHz) 5 14.26 (CH 2 CH3), 21.96 (CH(CH3)2), 24.92 (C(CH3)2), 24.99 
(C(CH3)2), 56.34 (OCH3), 60.88 (CH 2 CH3), 72.27 (CH(CH3)2), 83.47 (C(CH3)2), 83.65 
(C(CH3)2), 104.97 (C-3), 112.36 (C-6 ), 121.07 (C-2, 4a), 124.40 (C -l), 128.10 (C-8 a),
137.17 (C-7), 140.47 (C-8 ), 157.58 (C-4), 157.93 (C-5), 167.21 (COO); m/z (CL) 415
(M +l, 100), 373 (13), 289 (5); HRMS (CI+) calcd for C 2 3 H 3 2 B 0 6: 415.2292, found 
415.2290.
Ethyl 5-isopropoxy-4-methoxy-8-methyl-2-naphthaIenecarboxylate (79)
A mixture of (65) (400 mg, 1.09 mmol), methylboronic acid (130 
mg, 2.17 mmol), potassium carbonate (600 mg, 4.34 mmol) and 
PdCl2 (dppf) (90 mg, 110 jamol) in dry distilled THF (30 mL) was 
heated at reflux under N 2  for 48 hours. The solvent was removed
CH3
under reduced pressure, and the residue was partitioned between
(79)
chloroform and 2M NaOH. The aqueous layer was extracted 
with chloroform (4 x 50 mL), and the combined organic layers washed with water. The 
organic phase was dried (M gS04), and concentrated in vacuo , before being subjected to 
flash column chromatography (10% ethyl acetate:hexane). Recrystallisation from 
isopropanol yielded (79) (311 mg, 94%) as a pale orange solid: mp 207.8-209.1 °C; *H 
NMR (CDC13, 400 MHz) 5 1.38 (d, J  = 6.0 Hz, 6 H, CH(CH3)2), 1.44 (t, / =  7.2 Hz, 3H, 
CH2CH3), 2.65 (s, 3H, Ar-CH3), 4.01 (s, 3H, OCH3), 4.44 (q, J=  7.2 Hz, 2H, CH2 CH3),
4.46 (p, J  = 6.0 Hz, 1H, CH(CH3)2), 6.09 (d, J  = 7.6 Hz, 1H, H-6), 7.24 (d, J  = 8.0 Hz, 
1H, H -l), 7.43 (d, J  = 0.8 Hz, 1H, H -3), 7.31 (d, J  = 0.8 Hz, 1H, H -1); 13C NMR 
(CDC13, 100 MHz) 6  14.32 (CH 2 CH3), 19.75 (Ar-CH3), 21.94 (CH(CH3)2), 56.14 
(OCH3), 61.00 (CH 2 CH3), 73.47 (CH(CH3)2), 104.82 (C-3), 115.88 (C-6 ), 119.97 (C-l), 
121.71 (C-4a), 127.45 (C-8 a), 127.74 (C-7), 128.94 (C-2), 135.19 (C-8 ), 153.20 (C-5),
157.46 (C-4), 166.83 (COO); m/z (CI+) 303 (M +l, 100), 261 (13); HRMS (CI+) calcd 
for C 1 8 H 2 3 0 4: 303.1596, found 303.1518.
A mixture of (65) (200 mg, 545 nmol),
bis(pinacolato)diboron (280 mg, 1 . 1 0  mmol), potassium 
carbonate (300 mg, 2.17 mmol) and PdCl2 (dppf) (50 
mg, 61 pmol) in dry distilled THF (30 mL) was heated 
at reflux in a sealed tube, under N2. After 24 hours a 
mixture of methyl iodide (110 pL, 1.77 mmol), barium 
hydroxide (380 mg, 2.22 mmol), and a second 
equivalent of PdCl2 (dppf) (50 mg, 61 pmol) was added 
and heated at reflux under N 2  for a further 24 hours. The solvent was removed under 
reduced pressure, and the residue was partitioned between chloroform and 2M NaOH. 
The aqueous layer was extracted with chloroform (4 x 50 mL), and the combined 
organic layers washed with water. The organic phase was dried (M gS04), and 
concentrated in vacuo , before being subjected to flash column chromatography (2 0 % 
ethyl acetate:hexane). Recrystallisation from isopropanol yielded (80) (144 mg, 92%) 
as an orange solid: mp 173.1-174.6 °C; *H NMR (CDC13, 400 MHz) 5 1.21 (t, J  = 7.2 
Hz, 6 H, CH 2 CH3, CH ’2 CH ’3% 1.47 (d, J=  6.0 Hz, 6 H, CH(CH3)2, CH \C H ’3)2), 1.49 (d, 
J  = 6.4 Hz, 6 H, CH (CH3)2, C H ’(CTT5)2), 4.04 (s, 6 H, OCH3, OCHb), 4.21 (q, J  = 7.2 
Hz, 2H, CH2CH 3, C H \C H ’3), 4.22 (q, J  = 7.2 Hz, 2H, CH 2 CH3, C tf '2 CH ’3), 4.65 (p, J  
= 6.0 Hz, 2H, C tf(CH 3)2, C7T(CH’3)2), 7.13 (d, J =  8.0 Hz, 2H, H-6 , H-6 ’), 7.37 (d, J  =
7.6 Hz, 2H, H - l , H -7’), 7.38 (d, J =  1.6 Hz, 2H, H -3, H -3’), 7.68 (d, / =  1.6 Hz, 2H, H- 
1, H -1’); 13C NMR (CDC13, 75 MHz) 5 14.12 (CH 2 CH3, C ’H 2 C ’H3), 22.09 (CH(CH3)2, 
C ’H i C ^ ) ^ ,  22.17 (CH(CH3)2, C ’H fC 'H s^), 56.38 (OCH3, O C ’H3), 60.85 (CH 2 CH3, 
C ’H ^ ’H ^ , 73.27 (CH(CH3)2, CT1(C’H 3)2), 105.01 (C-3, C-3’), 114.43 (C-6 , C-6 ’),
121.62 (C-4a, C-4a’), 122.23 (C -l, C - l’), 127.85 (C-2, C-2’), 129.68 (C-7, C-7’), 
132.80 (C-8 , C-8 ’), 136.15 (C-8 a, C-8 a’), 154.68 (C-5, C-5’), 157.46 (C-4, C-4’), 
166.66 (COO, C ’OO); m/z (ES+) 575 (M+1, 38), 529 (43), 487 (8 ); HRMS (ES+) calcd 
for C 3 4 H 3 9 0 8: 575.2645, found 575.2647.
Diethyl S^'-diisopropoxy^^’-dimethoxy-S^'-diphenyl-lS^'-binaphthyl)-!,!'-
dicarboxylate (80)
(80)
A mixture of (65) (200 mg, 0.54 mmol), bis(pinacolato)diboron 
(280 mg, 1 . 1 0  mmol), potassium acetate ( 2 2 0  mg, 2.24 mmol) 
and PdCl2 (dppf) (45 mg, 0.06 mmol) in dry distilled THF (30 
mL) was heated at reflux in a sealed tube, under N2. After 24 
hours a mixture of 5-bromopyrimidine (260 mg, 1.64 mmol), 
barium hydroxide (375 mg, 2.19 mmol), and a second equivalent 
of PdCl2 (dppf) (45 mg, 0.06 mmol) was added and heated at 
reflux under N 2  for a further 24 hours. The solvent was removed under reduced 
pressure, and the residue was partitioned between chloroform and 2M NaOH. The 
aqueous layer was extracted with chloroform (4 x 50 mL), and the combined organic 
layers washed with water. The organic phase was dried (M gS04), and concentrated in 
vacuo, before being subjected to flash column chromatography (40% ethyl 
acetate:hexane). Recrystallisation from isopropanol yielded (83) (154 mg, 7 7 %) as a 
yellow solid: mp 175.7-177.9 °C; ' H N M R  (CDC13, 400 MHz) 8  1.34 ( t , / =  7.2 Hz, 3H, 
CH2C //j), 1.45 (d, J  = 6.0 Hz, 6 H, C H iC ftb ) , 4.02 (s, 3H, OCH3), 4.35 (q, J  = 7.2 Hz, 
2H, C tf 2 CH3), 4.64 (p, J = 6.0 Hz, 1H, C tf(CH 3)2), 7.07 (d, J = 8.4 Hz, 1H, 6 ), 7.32
(d, J  = 8.0 Hz, 1H, H -l), 7.44 (d, J  = 0.8 Hz, 1H, 3), 7.96 (d, = 1.2 Hz, 1H, 1),
8.83 (s, 2H, H-4’, 6 ’), 9.27 (s, 1H, H-2’); 13C NMR (CDC13, 100 MHz) 8  14.24 
(CH 2 CH3), 21.98 (CH(CH3)2), 56.37 (OCH3), 61.25 (CH 2 CH3), 72.89 (CH(CH3)2),
105.62 (C-3), 112.98 (C-6 ), 119.88 (C -l), 121.38 (C-8 a), 126.43 (C-4a), 128.99 (C-2), 
129.32 (C -l), 134.34 (C - l’), 134.56 (C-8 ), 156.13 (C-5), 157.41 (C-2’, C-4’), 157.98 
(C-4), 166.28 (COO); m/z (C f )  367 (M +l, 100), 338 (4), 325 (6 ); HRMS (C f)  calcd 
for C 2 1 H 2 3 N 2 0 4: 367.1658, found 367.1648. (MA found: C, 69.06; H, 6.00; N, 7.72; O, 
17.22; C 2 1 H 2 2 N 2 0 4  requires C, 68.84; H, 6.05; N, 7.65; O, 17.47).
Ethyl 5-isopropoxy-4-m ethoxy-8-(5’-pyrimidyl)-2-naphthalenecarboxyIate (83)
A mixture of (73) (225 mg, 543 pmol), 2-bromopyrimidine (105 
(iL, 1.10 mmol), potassium carbonate (225 mg, 1.63 mmol), 
triphenylphosphine (145 mg, 553 mmol) and palladium acetate 
(15 mg, 67 pmol) in DM E (15 mL) was heated at reflux in a 
sealed tube, under N 2, for 24 hours. The solvent was removed 
under reduced pressure, and the residue was partitioned between 
chloroform and 2M NaOH. The aqueous layer was extracted 
with chloroform (4 x 25 mL), and the combined organic layers washed with water. The 
organic phase was dried (M gS04), and concentrated in vacuo, before being subjected to 
flash column chromatography (35% ethyl acetate:hexane). Recrystallisation from
isopropanol yielded (84) (90 mg, 45%) as a pale yellow solid: mp 71.4-72.7 °C; *H 
NMR (CDC13, 400 MHz) 5 1.36 (t, J  = 7.2 Hz, 3H, CH 2 C773), 1.44 (d, 7 = 6.0 Hz, 6 H, 
CH(C775)2), 4.02 (s, 3H, OCH3), 4.36 (q, 7 = 7.1 Hz, 2H, C772 CH3), 4.62 (p, 7 = 6 . 1  Hz, 
1H, C77(CH3)2), 7.11 (d, 7 = 8.0 Hz, 1H, 77-6 ), 7.31 (ddd, 7 = 0.8, 7.4, 7.4 Hz, 1H, ¿7­
5 ’), 7.42 (d, 7 = 1.2 Hz, 1H, 77-3), 7.54 (d, 7 = 7.6 Hz, 1H, 77-3’), 7.54 (d, 7 = 8.4 Hz, 
1H, ¿7-7), 7.81 (ddd, 7 = 1.6, 7.6, 7.6 Hz, 1H, ¿7-4’), 8.39 (d, 7 = 1.2 Hz, 1H, 77-1), 8.78 
(bd, 7 = 4.0 Hz, 1H, 77-6’); 13C NMR (CDC13, 100 MHz) 5 14.24 (CH 2 CH3), 21.99 
(CH(CH3)2), 56.34 (OCH3), 60.99 (CH 2 CH3), 73.13 (CH(CH3)2), 105.17 (C-3), 114.13 
(C-6 ), 121.53 (C -l), 121.61 (C-4a), 121.86 (C-55), 125.17 (C-7), 128.24 (C-2), 129.06 
(C-3’), 133.25 (C-8 ), 134.23 (C-8 a), 136.35 (C-4’), 149.50 (C-6 ’), 155.43 (C-5), 157.54 
(C-4), 159.11 (C-2’), 166.76 (COO); m/z (C l4") 366 (M +l, 100), 324 (10); HRMS (C f)  
calcd for C 2 2 H 2 4 N 0 4: 366.1705, found 366.1697.
Ethyl 6-bromo-5-isopropoxy-4-methoxy-8-phenyl-2-naphthalenecarboxylate (85)
To a solution of (68) (365 mg, 1.00 mmol) in dry chloroform 
(60 mL) was added dropwise pyridinium tribromide (355 mg,
1.11 mmol) in distilled glacial acetic acid (15 mL) under N2, at 
0 °C. The resulting solution was allowed to stir at room 
temperature for 3 hours followed by the addition of saturated 
N aH C 0 3 (250 mL). The aqueous layer was extracted with 
chloroform (3 x 50 mL), and the combined organic layers were
Ethyl 5-isopropoxy-4-m ethoxy-8-(2’-pyridyI)-2-naphthalenecarboxylate (84)
washed with water. The organic phase was dried (M gS04), and concentrated in vacuo, 
before chromatography with a short silica plug ( 1 0 % ethyl acetate:hexane). 
Recrystallisation from isopropanol afforded (85) (340 mg, 76%) as an orange solid: mp 
132.4-133.5 °C; 'H  NMR (CDC13, 400 MHz) 8  1.34 (t, J  = 7.0 Hz, 3H, CH2CH3), 1.38 
(d, J = 6.0 Hz, 6 H, C H (C iR )2), 4.06 (s, 3H, OCH3), 4.35 (q, = 7.0 Hz, 2H, C //2 CH3),
4.56 (p, J  = 6.2 Hz, 1H, CH(CH3)2), 7.43 (d, 1.6 Hz, 1H, 3), 7.47 (m, 5H, aryl),
7.65 (s, 1H, I  1-1), 8.17 (d, J  = 1.2 Hz, 1H, 1); 13C NMR (CDC13, 75 MHz) 8  14.23
(CH 2 CH3), 22.04 (CH(CH3)2), 56.04 (OCH3), 61.13 (CH 2 CH3), 78.12 (CH(CH3)2), 
105.48 (C-3), 118.19 (C-6 ), 122.26 (C -l), 124.08 (C-4a), 127.75 (C-4 ’), 128.09 (C-2), 
128.38 (C-3’), 130.05 (C-2’), 132.51 (C -l), 138.82 (C-8 a), 138.22 (C - l’), 139.15 (C-8 ),
150.17 (C-5), 155.98 (C-4), 166.43 (COO); (CR) 445 (M +l, Br81, 67), 443 (M+ 1, 
Br79, 70), 429 (74), 401 (43) 387 (47); HRMS (CR) calcd for C 2 3 H 2 4 Br0 4: 443.0858, 
found 443.0856.
Ethyl 6-bromo-5-isopropoxy-4-methoxy-8-naphthyl-2-naphthalenecarboxylate (86)
To a solution of (72) (230 mg, 555 pmol) in dry chloroform (60 
mL) was added dropwise pyridinium tribromide (195 mg, 610 
pmol) in distilled glacial acetic acid (15 mL) under N 2 , at 0 °C.
The resulting solution was allowed to stir at room temperature 
for 3 hours followed by the addition of saturated NaHCC>3 (250 
mL). The aqueous layer was extracted with chloroform (3 x 50 
mL), and the combined organic layers were washed with water.
The organic phase was dried (MgSCL), and concentrated in vacuo, before 
chromatography with a short silica plug (10% ethyl acetate:hexane). Recrystallisation 
from isopropanol afforded (8 6 ) (266 mg, 97%) as an orange solid: mp 142.8-145.0 °C; 
'H  NMR (CDCI3 , 400 MHz) 8  1.20 (t, J  = 7.2 Hz, 3H, CH2CH3), 1.43 (d, J  = 6.0 Hz,
6 H, CH(Ctfs)2), 4.08 (s, 3H, OC H 3),4.22 (q, J  = 7.2 Hz, 2H, CH 2 CH3), 4.64 (p, = 6.1 
Hz, 1H, CH(CH3)2), 7.33 (m, 2H, naphthyl), 7.43 (d, J  = 1.6 Hz, 1H, H-3), 7.47 (s, 1H, 
H -l), 7.48 (m, 3H, naphthyl), 7.70 (d, J  = 1.2 Hz, 1H, 1), 7.95 (m, J  = 8.4 Hz, 2H,
naphthyl)-, 13C NMR (CDC13, 100 MHz) 8  14.11 (CH 2 CH3), 22.10 (CH(CH3)2), 22.13 
(CH(CH3)2), 56.06 (OCH3), 61.03 (CH 2 CH3), 78.21 (CH(CH3)2), 105.40 (C-3), 118.13 
(C-6 ), 122.53 (C -l), 123.91 (naphthyl), 125.24, 125.92, 126.00, 126.27, 128.16, 128.26, 
128.49, 132.69, 133.44, 133.62, 135.05, 136.33, 136.53 (C-8 ), 150.46 (naphthyl), 
154.33 (C-5), 155.93 (C-4), 166.28 (COO); m/z (CR) 495 (M +l, Br81, 95), 493 (M +l,
Br79, 100), 453 (Br81, 64), 451 (Br79, 62); HRMS (Cl*) caled for C 2 7 H 2 6 B r0 4: 493.1014, 
found 493.1020.
Ethyl 6-bromo-5-isopropoxy-4-methoxy-8-methyl-2-naphthalenecarboxylate (87)
A o c h 3
BiyV
c h 3
^  CO
(87)
To a solution of (79) (150 mg, 0.50 mmol) in dry chloroform 
(60 mL) was added drop wise pyridinium tribromide ((175 mg,
0.55 mmol) in distilled glacial acetic acid (15 mL) under N 2, at 
0 °C. The resulting solution was allowed to stir at room 
temperature for 3 hours followed by the addition of saturated 
NaHCOs (250 mL). The aqueous layer was extracted with 
chloroform (3 x 50 mL), and the combined organic layers were washed with water. The 
organic phase was dried (M gS04), and concentrated in vacuo, before chromatography 
with a short silica plug (20% ethyl acetate:hexane). Recrystallisation from isopropanol 
afforded (87) (172 mg, 91%) as a white solid: mp 88.1-89.2 °C; ‘H NMR (CDC13, 400 
MHz) 5 1.32 (d, J  = 6.0 Hz, 6 H, CH (C ff,)2), 1.44 (t, = 7.2 Hz, 3H, CH 2 CHj ), 2.64 (s,
3H, Ar-C H3\4.03 (s, 3H, OC H3),4.45 (q, J  = 7.2 Hz, 2H, G tf2 CH3), 4.47 (p, J  = 6.0
Hz, 1H, CH(CH3)2), 7.46 (d, J  = 1.6 Hz, 1H, 3), 7.54 (s, 1H, 7), 8.26 (d, J = 1.6
Hz, 1H, H -1); 13C NMR (CDC13, 100 MHz) 6  14.39 (CH 2 CH3), 19.59 (Ar-CH3), 21.92 
(CH(CH3)2), 55.93 (OCH3), 61.25 (CH 2 CH3), 77.78 (CH(CH3)2), 105.39 (C-3), 118.19 
(C-6 ), 120.07 (C -l), 123.85 (C-4a), 127.83 (C-8 a), 132.16 (C-7), 132.27 (C-2), 134.46 
(C-8 ), 149.07 (C-5), 156.12 (C-4), 166.58 (COO); m/z (C f )  383 (M +l, Br81, 91), 381 
(M+1, Br79, 96), 339 (Br81, 100), 341 (M +l, Br79, 92), 302 (61), 261 (56); HRMS (C f)
caled for C18H22B r04: 381.0701, found 381.0693.
Ethyl 6-bromo-5-hydroxy-4-methoxy-8-(5’-pyrimidyI)-2-naphthalenecarboxyIate
(88)
To a solution of (83) (130 mg, 355 pmol) in dry chloroform (40 
mL) and distilled glacial acetic acid (10 mL), was added 
dropwise pyridinium tribromide (125 mg, 391 pmol) in distilled 
glacial acetic acid (15 mL) under N2, at 0 °C. The resulting 
solution was allowed to stir at room temperature for 3 hours 
followed by the addition of saturated NaHCOs (250 mL). The 
aqueous layer was extracted with chloroform (3 x 50 mL), and
(88)
the combined organic layers were washed with water. The organic phase was dried 
(M gS 04), and concentrated in v a c u o ,before chromatography with a short silica plug 
(40% ethyl acetateihexane). Recrystallisation from isopropanol afforded (88) (155 mg, 
98%) as a light orange solid: mp 201.8-203.4 °C; 'H  NMR (CDC13, 300 MHz) S 1 . 3 5  (t, 
J = 7.2 Hz, 3H, CH 2 CH3), 1.39 (d, J = 6.0 Hz, 6 H, C H IC //,),), 4.08 (s, 3H, OCH3), 4.37 
(q, J  = 7.1 Hz, 2H, CH 2 CH3), 4.58 (p, J  = 6.1 Hz, 1H, CH(CH3)2), 7.52 (d, = 1.2 Hz, 
1H, H -3), 7.64 (s, 1H, H -l) , 7.93 (d, J  = 1.5 Hz, 1H, H -1), 8.85 (s, 2H, H-4 ’, 6 ’), 9.33 
(s, 1H, H-2’); 13C NMR (CDC13, 75 MHz) S 14.29 (CH 2 CH3), 22.08 (CH(CH3)2), 56.14 
(OCH3), 61.50 (CH 2 CH3), 78.69 (CH(CH3)2), 106.11 (C-3), 118.07 (C-6 ), 120.31 (C-l),
124.18 (C-4a), 129.27 (C-2), 130.23 (C-8 a), 133.16 (C - l’), 133.32 (C-7), 133.57 (C-8 ), 
151.91 (C-5), 156.30 (C-4), 157.32 (C-2’, 4 ’), 158.05 (C-2’), 165.99 (COO); m/z (CR) 
447 (M +l, Br81, 59), 445 (M +l, Br79, 54), 405 (Br81, 24), 403 (Br79, 25), 365 (33); 
HRMS (CI+) calcd for C 2 lH 2 2 BrN 2 0 4: 445.0727, found 445.0749.
Ethyl 6-bronio-5-hydroxy-4-methoxy-8-(5’-pyridyI)-2-naphthalenecarboxylate (89)
o  o c h 3
C 02Et
To a solution of (84) (85 mg, 233 pmol) in dry chloroform (30 
mL) and distilled glacial acetic acid (5 mL), was added 
dropwise pyridinium tribromide (82 mg, 256 umol) in distilled 
glacial acetic acid (10 mL) under N2, at 0 °C. The resulting 
solution was allowed to stir at room temperature for 3  hours 
followed by the addition of saturated N aH C 0 3 (100 mL). The 
aqueous layer was extracted with chloroform (3 x 50 mL), and 
the combined organic layers were washed with water. The organic phase was dried 
(M gS04), and concentrated in vacuo, before chromatography with a short silica plug 
(35% ethyl acetate:hexane). Recrystallisation from isopropanol afforded (89) (83 mg, 
81%) as an orange solid: mp 94.2-97.8 °C; ‘H NMR (CDC13, 400 MHz) 8  1.35 (t, J =
7.2 Hz, 3H, CH 2 C H j), 1.37 (d, J =  6.0 Hz, 6 H, CH(CH3)2), 4.05 (s, 3H, OCH3), 4.35 (q,
(89)
J  = 7.1 Hz, 2H, CH 2 CH3), 4.55 (p, /  = 6.1 Hz, 1H, CH(CH3)2), 7.37 (ddd, J  = 0.8, 5.0,
7.4 Hz, 1H, H - 5 ’), 7.46 (d, J  = 1.2 Hz, 1H, H-2), 7.55 (d, J  = 8.0 Hz, 1H, H-2’), 7.80 (s, 
1H, H -l), 7.84 (ddd, J  = 1.6, 7.6, 8.4 Hz, 1H, H-4 ’), 8.31 (d, J  = 1.2 Hz, 1H, H -l), 8.80 
(d, J  = 4.4 Hz, 1H, H-6’); I3C NMR (CDC13, 100 MHz) 8  14.26 (CH 2 CH3), 22.00 
(CH(CH3)2), 56.01 (OCH3), 61.18 (CH 2 CH3), 78.39 (CH(CH3)2), 105.49 (C-3), 118.17 
(C-6 ), 121.79 (C -l), 122.52 (C-5’), 124.15 (C-4a), 125.18 (C-7), 128.48 (C-2), 133.12 
(C-3’), 133.40 (C-8 ), 134.36 (C-8 a), 136.66 (C-4’), 149.65 (C-6 ’), 151.21 (C-5), 155.94
(C-4), 157.57 (C-2’), 166.42 (COO); m/z (CI+) 446 (M+l, Br81, 100), 444 (M+l, Br79, 
84), 404 (Br81, 13), 402 (M+l, Br79, 15), 366 (Br81, 21), 364 (Br79, 27), 324 (33); HRMS 
(CI+) calcd for C22H23BrN0 4: 444.0810, found 444.0805.
Diethyl ^^'-diisopropoxy^^'-dimethoxy-S^'-diphenyl^h^'-binaphthyl)-^'-
dicarboxylate (91)
A mixture of (85) (100 mg, 226 jumol), 
bis(pinacolato)diboron (115 mg, 453 pmol), 
potassium carbonate (125 mg, 904 pmol) and Et02c  
PdCl2(dppf) (20 mg, 25 jumol) in dry distilled 
THF (25 mL) was heated at reflux in a sealed 
tube under N2. After 24 hours a second 
equivalent of (85) (100 mg, 226 pmol), 
potassium carbonate (125 mg, 904 pmol) and 
PdCWdppf) (20 mg, 25 pmol) was added and heated at reflux under N2 for a further 24 
hours. The solvent was removed under reduced pressure, and the residue extracted with 
chloroform (4 x 30 mL) and water. The organic phase was dried (MgSCL) and 
concentrated in vacuo, before being subjected to flash column chromatography (20% 
ethyl acetate:hexane). Recrystallisation from isopropanol yielded (91) (82 mg, 50%) as 
a yellow solid: mp 204.8-206.7 °C; 'H NMR (CDC13, 400 MHz) 5 1.11 (d, = 5.2 Hz,
12H, CH(CH3)2, CH’(CH ’3)2), 1.35 (t, J  = 7.0 Hz, 6H, CH2CH3, CH’2CH’3), 4.06 (s, 
6H, OCH3, OCH’s), 4.11 (p, J  = 6.1 Hz, 2H, CH(CH3)2, H ’3)2), 4.36 (q, J = 7.0
Hz, 4H, CH2CH3, C tf’2CH’3), 7.45 (s, 10H, aryl”, aryl” '), 7.47 (s, 2H, 3, 3’), 7.96
(s, 2H, H-l, H-T), 8.22 (d, J = 1.6 Hz, 2H, HA, H A ’); 13C NMR (CDC13, 75 MHz) 6 
14.29 (CH2CH3, C’H2C’H3), 21.88 (CH(CH3)2, C’H(C’H3)2), 55.71 (OCH3, OC’H3),
61.05 (CH2CH3, C ’H2C’H3), 74.80 (CH(CH3)2, C’H(C’H3)2), 104.82 (C-3, C-3’),
122.02 {CA, C A ’),124.58 (C-4a, C-4a’), 127.29 (C-4” , C-4’” ), 127.87 (C-2, C-2’), 
128.21 (C-2” , C-6” , C-2’” , C-6’” ), 130.18 (C-3” , C-5” , C-3’” , C-5’” ), 130.83 (C-6, 
C-6’), 131.96 (C-7, C-7’), 134.06 (C -l” , C -l’” ), 137.08 (C-8, C-8’), 140.28 (C-8a, C- 
8a’), 150.66 (C-5, C-5’), 157.42 (C-4, C-4’), 166.76 (COO, C’OO); m/z (ES+) 727 
(M+l, 100), 685 (26), 643 (32); HRMS (ES+) calcd for CisEbOg: 727.3271, found 
727.3296.
Diethyl 5,5'-diisopropoxy-4,4'-dimethoxy-8,8'-(l,,, l ’"-dinaphthyl)-(6,6'-
binaphthyl)-2,2'-dicarboxylate (96)
A mixture of (86) (100 mg, 203 pmol), 
bis(pinacolato)diboron (105 mg, 413 pmol), 
potassium carbonate (115 mg, 832 pmol) and 
PdCl2(dppf) (18 mg, 22 jumol) in dry distilled 
TI IF (25 mL) was heated at reflux in a sealed 
tube under N2. After 24 hours a second 
equivalent of (86) (100 mg, 203 pmol), 
potassium carbonate (115 mg, 832 pmol) and 
PdCl2(dppf) (18 mg, 22 pmol) was added and heated at reflux under N2 for a further 24 
hours. The solvent was removed under reduced pressure, and the residue extracted with 
chloroform (4 x 30 mL) and water. The organic phase was dried (MgSCL) and 
concentrated in vacuo, before being subjected to flash column chromatography (20% 
ethyl acetateihexane). Recrystallisation from isopropanol yielded (96) (85 mg, 51%) as 
a yellow solid: mp 286.7-289.3 °C; lH NMR (CDC13, 400 MHz) 5 1.13 (d, J = 6.4 Hz, 
12H, CH(C//5)2, CH’(CH ’3)2), 1.20 (t, J = 7.2 Hz, 6H, CR2CH3, CW 2CH’3), 4.03 (s, 
6H, OCH3, OCH’s), 4.21 (q, J  = 7.2 Hz, 4H, C//2CH3, CH’2C¥L’3), 4.24 (p, J = 6.8 Hz, 
2H, G£/(CH3)2, C i/’(CH’3)2), 7 30 (t, J = 7.4 Hz, 2H, naphthyl”, naphthyl’”), 7.40 (d, J 
= 1.2 Hz, 2H, H-3, H-3’), 7.46 (m, 6H, naphthyl”, naphthyl’”), 1.57 (t, J = 7.6 Hz, 2H, 
naphthyl”, naphthyl’”), 7.74 (s, 2H, H-1, H-V), 7.93 (dd, J = 2.0, 8.0 Hz, 4H, 
naphthyl”, naphthyl’”), 8.04 (s, 2H, H -l, H-T)\ 13C NMR (CDC13, 75 MHz) 5 14.14 
(CH2CH3, C’H2C’H3), 22.11 (CH(CH3)2, C’H(C’H3)2), 55.73 (OCH3, OC’H3), 60.91 
(CH2CH3, C*H2C’H3), 75.09 (CH(CH3)2, C ’H(C’H3)2), 104.83 (C-3, C-3’), 122.30 (C-l, 
C -l’), 124.40 (naphthyl”, naphthyl’”), 125.27, 125.69, 125.95, 126.41, 127.99, 128.03, 
128.09, 128.15, 130.90, 132.85 {C-l, C -l’), 132.99 {naphthyl”, naphthyl’”), 133.59, 
135.13, 135.24, 137.84, 151.00 (C-5, C-5’), 157.36 (C-4, C-4’), 166.58 (COO, C’OO); 
m/z (ES+) 827 (Af+1, 37), 391 (100); HRMS (ES+) calcd for C54H51O8: 827.3583, found 
827.3953.
A mixture of (88) (20 mg, 45 pmol), 
bis(pinacolato)diboron (25 mg, 98 pmol), 
potassium carbonate (25 mg, 181 pmol) and 
PdCl2(dppf) (4 mg, 5 pmol) in dry distilled THF 
(25 mL) was heated at reflux in a sealed tube 
under N2. After 24 hours a second equivalent of 
(88) (20 mg, 45 pmol), potassium carbonate (25 
mg, 181 pmol) and PdCl2(dppf) (4 mg, 5 pmol) 
were added and heated at reflux under N2 for a further 24 hours. The solvent was 
removed under reduced pressure, and the residue extracted with chloroform (4 x 20 mL) 
and water. The organic phase was dried (MgS04) and concentrated in vacuo, before 
being subjected to flash column chromatography (30% ethyl acetate:hexane to remove 
trace starting material; 80% ethyl acetate:hexane to elute product). Recrystallisation 
from isopropanol yielded (97) (23 mg, 71%) as a yellow solid: mp 227.5-229.8 °C; 
NMR (CDC13, 400 MHz) 5 1.12 (d, J  = 6.0 Hz, 12H, CH(C773)2, CH’(C77’3)2), 1-36 (t, J 
= 7.2 Hz, 6H, CH2C773, CH’2C77’5), 1.36 (t, J = 7.2 Hz, 6H, CH2C773, CH'2CH’3), 4.08 
(s, 6H, OCH3, OCH’3), 4.15 (p, J = 6.0 Hz, 2H, C77(CH3)2, C77’(CH’3)2), 4.380 (q, J =
7.1 Hz, 4H, C772CH3, CH’2CH’3), 4.382 (q, J  = 7.2 Hz, 4H, CH2CH3, CH^CH^), 7.53 
(s, 2H, H-3, H - y \ 7.97 (s, 4H, H-1, H-1’, H-l, 77-7’), 8.88 (s, 4H, 77-4” , 77-4” ’, 77-5” , 
77-5” ’), 9.31 (s, 2H, 77-2” , 77-2’” ); 13C NMR (CDC13, 75 MHz) 5 14.31 (CH2CH3, 
C’H2C ’H3), 21.95 (CH(CH3)2, C’H(C’H3)2), 55.84 (OCH3, OC’H3), 61.42 (CH2CH3, 
C ’H2C’H3), 75.43 (CH(CH3)2, C ’H(C’H3)2), 105.72 (C-3, C-3’), 120.03 (C-l, C -l’), 
124.72 (C-8a, C-8a’), 129.17 (C-8, C-8’), 129.31 (C-4a, C-4a’), 130.18 (C-6, C-6’), 
132.65 (C-7, C-l'), 133.88 (C-2, C-2’), 134.11 (C-5” , C-5’” ), 152.26 (C-5, C-5’),
157.36 (C-4” , C-4’” , C-6” , C-6’” ), 157.71 (C-4, C-4’), 157.76 (C-2” , C-2’” ), 166.16 
(COO, C ’OO); m/z (ES+) 731 (M+l, 92), 387 (100); HRMS (ES+) calcd for 
C42H43N40 8: 731.3081, found 731.3078.
Diethyl 5,5'-diisopropoxy-4,4'-dimethoxy-8,8'-(5",5",-dipyrimidyl)-(6,6’-
binaphthyl)-2,2'-dicarboxylate (97)
N x N
(97)
Diethyl 5,5'-diisopropoxy-4,4’-dimethoxy-8,8'-dimethyl-(6,6'-binaphthyl)-2,2'-
dicarboxylate (98)
ITC
H3CO
C 02Et
(98)
A mixture of (87) (160 mg, 420 jumol), 
bis(pinacolato)diboron (215 mg, 850 jamol), Et° 2C 
potassium carbonate (235 mg, 1.70 mmol) and 
PdCl2(dppf) (35 mg, 43 pmol) in dry distilled 
THF (25 mL) was heated at reflux in a sealed 
tube under N2. After 24 hours, a second 
equivalent of (87) (160 mg, 420 pmol), potassium carbonate (235 mg, 1.70 mmol) and 
PdCl2(dppf) (35 mg, 43 pmol) was added and heated at reflux under N2 for a further 24 
hours. The solvent was removed under reduced pressure, and the residue extracted with 
chloroform (4 x 30 mL) and water. The organic phase was dried (MgS04) and 
concentrated in vacuo, before being subjected to flash column chromatography (10% 
ethyl acetate:hexane). Recrystallisation from isopropanol yielded (98) (128 mg, 51%) 
as a yellow solid: mp 164.8-166.9 °C; !H NMR (CDC13, 400 MHz) 5 1.03 (d, J  = 5.2 
Hz, 12H, CH(CH3)2, CH\C H ’3)2), 1.46 (t, J = 7.2 Hz, 6H, CH2CH3> CH’2C77’5), 2.70
(s, 6H, Ar-C775, Ar’-CH ’3\  3.93 (p, J = 6.0 Hz, 2H, C77(CH3)2, C H \CH’3)2), 4.06 (s, 
6H, OCH3, OCH ’j), 4.47 (q, J =1.1 Hz, 4H, C772CH3, CH’2CH’3), 7.48 (s, 2H, 77-3, 77­
3’), 7.84 (s, 2H, 77-7, 77-7’), 8.34 (d, J=  1.2 Hz, 2H, 77-1, 77-1’); 13C NMR (CDC13, 100 
MHz) 5 14.47 (CH2CH3, C’H2C ’H3), 19.65 (Ar-CH3, Ar’-CTf3), 29.69 (CH(CH3)2, 
C’H(C’H3)2), 55.62 (OCH3, OC’H3), 61.18 (CH2CH3, C H2C’H3), 74.41 (CH(CH3)2, 
C’H(C’H3)2), 104.76 (C-3, C-3’), 119.89 (C-l, C -l’), 124.53 (C-6, C-6’), 127.59 (C-4a, 
C-4a’), 130.55 (C-8a, C-8a’), 131.00 (C-2, C-2’), 131.50 (C-7, C-7’), 134.67 (C-8, C- 
8’), 149.51 (C-5, C-5’), 156.65 (C-4, C-4’), 166.95 (COO, C’OO); m/z (CI+) 603 (M+1, 
42), 589 (16) 561 (21), 519 (30); HRMS (CI+) calcd for C36H430 8: 603.2958, found 
603.2953.
Ethyl 5-hydroxy-4-methoxy-8-phenyl-2-naphthalenecarboxyIate (99)
To a solution of (68) (95 mg, 261 pmol) in DCM (20 mL) was 
added dropwise boron trifluoride diethyl etherate (125pL, 1.06 
mmol) under N2, at 0°C. The resulting solution was allowed to stir 
at room temperature for 24 hours, followed by the addition of 
methanol (5 mL). The solvent was removed under reduced 
pressure, and the residue extracted with chloroform (4 x 20 mL) 
and water. The organic phase was dried (MgS04), and concentrated in vacuo, before 
being subjected to flash column chromatography (20% ethyl acetate:hexane). 
Recrystallisation from isopropanol yielded (99) (54 mg, 64%) as a yellow solid: mp 
104.1-105.2 °C; !H NMR (CDC13, 400 MHz) 5 1.35 (t, J  = 7.2 Hz, 3H, CH2CH5), 4.15 
(s, 3H, OCH3), 4.36 (q, / =  7.1 Hz, 2H, CH2CH3), 7.05 (d, J=  8.0 Hz, 1H, H-6), 7.39 (d, 
J = 8.0 Hz, 1H, H-l), 7.43 (m, 5H, aryl), 7.48 (d, /  = 1.2 Hz, 1H, H-3), 8.22 (d, J = 1.2 
Hz, 1H, H-l), 9.49 (s, 1H, OH); 13C NMR (CDC13, 100 MHz) 5 14.24 (CH2CH3), 56.42 
(OCH3), 61.16 (CH2CH3), 102.94 (C-3), 112.65 (C-6), 116.81 (C-4a), 123.30 (C-l),
127.09 (C-l), 127.57 (C-2), 128.29 (C-2’), 129.80 (C-4’), 130.20 (C-3’), 132.98 (C -l’), 
133.52 (C-8), 140.43 (C-8a), 153.98 (C-5), 156.41 (C-4), 166.43 (COO); m/z (CI+) 323 
(M+, 100), 309 (6); HRMS (CI+) calcd for C20H19O4: 323.1283, found 323.1277.
Ethyl 5-hydroxy-4-methoxy-8-naphthyl-2-naphthalenecarboxyIate (100)
To a solution of (72) (45 mg, 109 pmol) in DCM (20 mL) was 
added dropwise boron trifluoride diethyl etherate (125pL, 1.06 
mmol) under N2, at 0°C. The resulting solution was allowed to stir 
at room temperature for 24 hours, followed by the addition of 
methanol (5 mL). The solvent was removed under reduced 
pressure, and the residue extracted with chloroform (4 x 20 mL) 
and water. The organic phase was dried (MgS04), and concentrated in vacuo, before 
being subjected to flash column chromatography (20% ethyl acetate:hexane). 
Recrystallisation from isopropanol yielded (100) (36 mg, 89%) as a yellow solid: mp 
174.0-176.8 °C; ‘H NMR (CDC13, 400 MHz) 8 1.21 (t, / =  7.2 Hz, 3H, CH2CH3), 4.17 
(s, 3H, OCH3\  4.23 (q, J = 7.1 Hz, 2H, C//2CH3), 7.12 (d, 8.0 Hz, 1H, H-6), 7.31 (d,
J = 6.8 Hz, 1H, naphthyl), 7.39 (d, J = 8.0 Hz, 1H, H-l), 7.45 (d, 1.6 Hz, 1H, 3),
7.45 (m, 1H, naphthyl), 7.59 (t, J  = 6.8 Hz, 1H, naphthyl), 7.73 (q, J = 6.4 Hz, 2H, 
naphthyl), 7.81 (s, 1H, H-l), 7.95 (d, J = 8.4 Hz, 2H, naphthyl), 9.55 (s, 1H, OH); 13C 
NMR (CDC13, 75 MHz) 6 14.09 (CH2CH3), 56.47 (OCH3), 61.03 (CH2CH3), 102.95 (C- 
3), 112.53 (C-6), 123.64 (Cl), 125.30 {naphthyl), 125.72, 125.95, 126.25, 127.65, 
127.95, 128.17, 128.34, 130.77, 130.82, 133.12, 133.69, 134.82, 135.11, 137.87, 154.22 
(C-5), 156.43 (C-4), 166.29 (COO); m/z (CR) 373 (Af+1, 26), 263 (100); HRMS (CI+) 
calcd for C24H2i0 4: 373.1440, found 373.1441.
Ethyl 5-hydroxy-4-methoxy-8-(5’-pyrimidyl)-2-naphthaIenecarboxylate (101)
To a solution of (83) (50 mg, 136 pmol) in DCM (10 mL) was 
added dropwise boron trifluoride diethyl etherate (35 pL, 276 
pmol) under N2, at 0°C. The resulting solution was allowed to stir 
at room temperature for 24 hours, followed by the addition of 
methanol (5 mL). The solvent was removed under reduced 
pressure, and the residue extracted with chloroform (4 x 20 mL) 1̂01^
and water. The organic phase was dried (MgS04), and concentrated in vacuo, before 
being subjected to flash column chromatography (20% ethyl acetate:hexane). 
Recrystallisation from isopropanol yielded (101) (25 mg, 56%) as a pale yellow solid: 
decomposes 219 °C; *H NMR (CDC13, 400 MHz) 5 1.36 (t, J = 7.0 Hz, 3H, CH2CH5), 
4.17 (s, 3H, OCH3), 4.37 (q, J = 1.1 Hz, 2H, CH2CH3), 7.08 (d, J = 8.4 Hz, 1H, H-6), 
7.37 (d, J = 8.0 Hz, 1H, H-l), 7.45 (d, J=  0.8 Hz, 1H, HA), 8.05 (d,J =  1.6 Hz, 1H, H- 
1), 8.83 (s, 2H, H -4\ H-6’), 9.28 (s, 1H, H-T), 9.61 (s, 1H, OH); 13C NMR (CDC13, 100 
MHz) 6 14.27 (CH2CH3), 56.66 (OCH3), 61.51 (CH2CH3), 103.75 (C-3), 112.81 (C-6),
117.06 (C-8a), 121.33 (C-l), 124.78 (C-4a), 128.85 (C-2), 130.74 (C-7, C -l’), 133.42 
(C-8), 155.61 (C-5), 156.72 (C-4), 157.42 (C-25, C-4’), 165.97 (COO); m/z (CR) 325 
(M+, 100), 311 (5); HRMS (CR) calcd for Ci8H17N20 4: 325.1188, found 325.1184.
Ethyl 5-hydroxy-4-methoxy-8-methyl-2-naphthalenecarboxylate (102)
To a solution of (79) (190 mg, 628 pmol) in DCM (30 mL) was 
added dropwise boron trifluoride diethyl etherate (300 pL, 2.54 
mmol) under N2, at 0°C. The resulting solution was allowed to stir 
at room temperature for 24 hours, followed by the addition of 
methanol (10 mL). The solvent was removed under reduced
(102)
pressure, and the residue extracted with chloroform (4 x 30 mL) and water. The organic 
phase was dried (MgS04), and concentrated vacuo, before being subjected to flash 
column chromatography (10% ethyl acetate:hexane). Recrystallisation from 
isopropanol yielded (102) (89 mg, 55%) as a pale green solid: mp 71.6-73.8 °C; ‘H 
NMR (CDC13, 400 MHz) 6 1.45 (t, J  = 7.0 Hz, 3H, CH2C 2.62 (s, 3H, Ar -CH3),
4.12 (s, 3H, O CH3),4.45 (q, J = 7.2 Hz, 2H, CH2CH3), 7.90 (d, J  = 7.6 Hz, 1H,
7.26 (d, J  = 8.0 Hz, 1H, H-l), 7.38 (d, 7 =  1.2 Hz, 1H, 3), 8.33 (d, / =  1.6 Hz, 1H,
1), 9.25 (s, 1H, OH); l3C NMR (CDC13, 100 MHz) 8 14.40 (CH2CH3), 19.38 (Ar-CH3),
56.35 (OCH3), 61.29 (CH2CH3), 102.92 (C-3), 112.51 (C-6), 116.97 (C-4a), 121.47 (C- 
1), 126.39 (C-2), 127.27 (C-8a), 129.20 (C-7), 134.28 (C-8), 152.85 (C-5), 156.63 (C- 
4), 166.63 (COO); m/z (CI+) 261 (M+l, 100), 247 (33); HRMS (CI+) calcd for 
C15H17O4: 261.1127, found 261.1122. (MA found: C, 69.42; H, 6.47; O, 24.41; 
C,5H i60 4 requires C, 69.22; H, 6.20; O, 24.59).
Diethyl 5,5'-dihydroxy-4,4'-dimethoxy-8,8'-diphenyl-(6,6'-binaphthyl)-2,2'-
dicarboxylate (103)
OH 9 CH3 
H3CO OH ^
C 02Et
(103)
To a solution of (91) (40 mg, 55 pmol) in DCM 
(15 mL) was added drop wise boron trifluoride 
diethyl etherate (60 pL, 507 mmol) under N2, at Et02C'
0°C. The resulting solution was allowed to stir at 
room temperature for 24 hours, followed by the 
addition of methanol (5 mL). The solvent was 
removed under reduced pressure, and the residue 
extracted with chloroform (4 x 20 mL) and water.
The organic phase was dried (MgS04), and concentrated in vacuo, before being 
subjected to flash column chromatography (20% ethyl acetate:hexane). 
Recrystallisation from isopropanol yielded (103) (24 mg, 68%) as a green solid: mp 
249.8-252.2 °C; *H NMR (CDC13, 400 MHz) 8 1.37 (t, J = 7.2 Hz, 6H, CH2CH3, 
CH’2CH’3), 4.14 (s, 6H, OCH3, OCH’3), 4.37 (q, J=  7.2 Hz, 4H, CH2CH3, CH’2CH’3), 
7.43 (d, / =  1.2 Hz, 2H, H-3, H-3’), 7.46 (m, 10H, aryl”, aryl'”), 7.59 (s, 2H, H-l, II- 
T), 8.35 (d, J  = 1.6 Hz, 2H, H-l, H -l’), 9.99 (s, 2H, OH’); 13C NMR (CDC13, 100
MHz) 8 14.27 (CH2CH3, C’H2C’H3), 56.54 (OCH3, OC’H3), 61.20 (CH2CH3, 
C ’H2C’H3), 103.38 (C-3, C-3’), 117.12 (C-6, C-6’), 122.11 (C-4a, C-4a’), 123.37 (C-l, 
C -l’), 127.11 (C-4” , C-4’” ), 127.58 (C-2, C-2’), 128.29 (C-2” , C-6” , C-2’” , C-6’” ),
m
130.35 (C-3” , C-5” , C- 3 C - 5 ’” ), 132.61 (C - l” , C -l’” ) , 132.66 (C-7, 133.29
(C-8, C-8’), 140.31 (C-8a, 8a’), 150.92 (C-5, C-5’), 156.71 (C-4, C-4’), 166.52 (COO, 
C 0 0 ); m/z (ES+) 643 (M+l, 8), 338 (89), 225 (23); HRMS (ES+) calcd for C40H35O8: 
643.2332, found 643.2323. (MA found: C, 74.72; H, 5.52; O, 19.76; C4oH340 8 requires 
C, 74.75; H, 5.33; O, 19.92).
Diethyl 5,5,-dihydroxy-4,4'-dimethoxy-8,8'-(l",l"’-dinaphthyl)-(6,6’-binaphthyl)- 
2,2'-dicarboxylate (104)
To a solution of (96) (180 mg, 218 pmol) in 
DCM (30 mL) was added dropwise boron 
trifluoride diethyl etherate (205pL, 1.73mmol) 
under N2, at 0°C. The resulting solution was 
allowed to stir at room temperature for 24 hours, 
followed by the addition of methanol (10 mL).
The solvent was removed under reduced 
pressure, and the residue extracted with 
chloroform (4 x 20 mL) and water. The organic phase was dried (MgSCL), and 
concentrated in vacuo , before being subjected to flash column chromatography (25% 
ethyl acetate:hexane). Recrystallisation from isopropanol yielded (104) (110 mg, 68%) 
as a yellow solid; ‘H NMR (CDC13, 400 MHz) 5 1.22 (t, 7.1 Hz, 6H, CH2Cffj,
CH’2C H ’3),4.15 (s, 6H, OCH3, O C H ’3), 4.23 (q, / =  7.1 Hz, 4H, CH2CH3, CH’2CH’3), 
7.31 (m, 2H, n a p h t h y l ”, naphthyl’”), 7.39 (d, / =  1.2 Hz, 2H, 3, 3’), 7.54 (m, 8H,
naphthyl”, naphthyl'”), 7.66 (s, 2H, H - l , H7.82 (d, = 1.5 Hz, 2H, 1, 
7.91 (d, J  = 7.8 Hz, 4H, naphthyl”, naphthyl” ’), 10.05 (s, 2H, OH, OH’); l3C NMR 
(CDC13, 75 MHz) 8 14.12 (CH2CH3, C’H2C’H3), 56.52 (OCH3, OC’H3), 61.05 
(CH2CH3, C ’H2C’H3), 103.25 (C-3, C-3’), 117.00 (C-6, C-6’), 121.94, 123.65 (C-l, C- 
1’), 125.31 0 naphthyl”, naphthyl’”), 125.67, 126.00, 126.43, 127.54, 127.93, 128.12,
128.50, 130.34, 133.13, 133.60, 133.67, 134.50 (C-7, C-7’), 137.73, 151.16 (C-5, C-5’), 
156.64 (C-4, C-4’), 166.36 (COO, C ’OO); m/z (ES+) 743 (M+l, 100), 675 (63); HRMS 
(ES+) calcd for C48H390 8: 743.2645, found 743.2654. (MA found: C, 77.68; H, 5.43; O, 
16.89; C48H390 8 requires C, 77.61; H, 5.16; O, 17.23).
(104)
Diethyl 5,5'-dihydroxy-4,4,-dimethoxy-8,8'-(5",5'"-dipyrimidylM6,6,-binaphthyl)-
2,2’-dicarboxylate (105)
To a solution (97) (150 mg, 205 pmol) in DCM 
(30 mL) was added dropwise boron trifluoride 
diethyl etherate (195 pL, 1.65 mmol) under N2, at 
0°C. The resulting solution was allowed to stir at 
room temperature for 24 hours, followed by the 
addition of methanol (10 mL). The solvent was 
removed under reduced pressure, and the residue 
extracted with chloroform (4 x 20 mL) and water.
The organic phase was dried (MgSCL), and concentrated in vacuo, before being 
subjected to flash column chromatography (80% ethyl acetate: hexane). 
Recrystallisation from isopropanol yielded (105) (87 mg, 65%) as a pale green solid: mp 
267.4-268.8 °C; ‘H NMR (CDC13, 300 MHz) 8 1.38 (t, 7 = 7.2 Hz, 6H, CH2CH3, 
CH’2CH’3), 4.18 (s, 6H, OCH3, OCH’3), 4.40 (q, 7 =  7.1 Hz, 4H, CH2CH3, CH’2CH’3), 
7.51 (d, 7 =  1.2 Hz, H-3, H-3’), 7.60 (s, 2H, H-7, H-T), 8.11 (d , J=  1.5 Hz, 2H, H-l, H- 
1’), 8.91 (s, 4H, 17-4” , 77-4’” , 17-6” , H-6’” ), 9.28 (s, 2H, 17-2” , 17-2” ’), 10.13 (s, 2H, 
OH, OH;); 13C NMR (CDC13, 75 MHz) 8 14.31 (CH2CH3, C’H2C’H3), 56.79 (OCH3, 
OC’H3), 61.58 (CH2CH3, C ’H2C’H3), 104.27 (C-3, C-3’), 117.38 (C-8a, C-8a’), 121.31 
(C-l, C -l’), 121.34 (C-4a, C-4a’), 124.55 (C-8, C-8’), 128.98 (C-6, C-6’), 133.14 (C-7, 
C-7’), 133.37 (C-2, C-2’), 134.08 (C-5” , C-5’” ), 152.46 (C-5, C-5’), 156.93 (C-2” , C- 
2” ’), 157.52 (C-4, C-4’, C-4” , C-4’” , C-5” , C-5’” ), 165.95 (COO, C’OO); m/z (ES+) 
647 (M+l, 33), 633 (4), 324 (100); HRMS (ES+) calcd for C36H3iN40 8: 647.2142, found 
647.2132.
Diethyl 5,5,-dihydroxy-4,4,-dimethoxy-8,8,-dimethyl-(6,6'-binaphthyl)-2,2'-
dicarboxylate (106)
To a solution of (98) (85 mg, 141 pmol) in DCM 
(15 mL) was added dropwise boron trifluoride 
diethyl etherate (135 pL, 1.14 mmol) under N2, at 
0°C. The resulting solution was allowed to stir at 
room temperature for 24 hours, followed by the 
addition of methanol (5 mL). The solvent was
(106)
N
(105)
removed under reduced pressure, and the residue extracted with chloroform (4 x 20 mL) 
and water. The organic phase was dried (M gS 04), and concentrated in vacuo, before 
being subjected to flash column chromatography (2 0 % ethyl acetate;hexane). 
Recrystallisation from isopropanol yielded (106) (52 mg, 71%) as a yellow solid: mp 
247.6-249.7 °C; !H NMR (CDC13, 400 MHz) 5 1.47 (t, J  = 7.2 Hz, 6 H, CH 2 C7 7 5, 
C H ^C H ’s), 2.67 (s, 6 H, Ar-CH3, A r’-CH*3\  4.11 (s, 6 H, OCH3, OC H ’3), 4.47 (q, J  =
7.3 Hz, 4H, C772 CH3, C7T2 C H ’3), 7.39 (s, 2H, 77-3, 77-3’), 7.43 (s, 2H, 77-7, 77-7’), 8.38 
(s, 2H, 77-1, 77-1’), 9.72 (s, 2H, 077, 0 /7 ’); 13C NMR (CDC13, 100 MHz) 5 14.43 
(CH 2 CH 3 , C ’H 2 C ’H 3), 19.42 (Ar-CH3, A r’-C ’H3), 56.41 (OCH3, O C ’H3), 61.30 
(CH 2 CH 3 , C ’H 2 C ’H 3), 103.35 (C-3, C-3’), 117.24 (C-4a, C-4a’), 121.51 (C -l, C - l’), 
122.22 (C-8 a, C-8 a’), 126.04 (C-6 , C-6 ’), 127.24 (C-2, C-2’), 131.89 (C -l, C - l’),
134.09 (C-8 , C-8 ’), 149.65 (C-5, C-5’), 156.85 (C-4, C-4 ’), 166.69 (COO, C ’OO); m/z 
(CR) 519 (Af+1, 100), 505 (8 ); HRMS (CT) ealed for C3oH310 8: 519.2019, found 
519.2018. (MA found: C, 69.57; H, 5.86; O, 24.57; C 3 0 H 3 1 O 8 requires C, 69.49; H, 
5.83; O, 24.68).
5-Isopropoxy-4-methoxy-8-phenylnaphthaIene-2-methanol (107)
To a solution of (6 8 ) (170 mg, 466 pmol) in dry THF (60 mL) 
was added a suspension of lithium aluminium hydride (18 mg,
474 pmol) in THF (5 mL) under N2, at 0 °C. The resulting 
solution was allowed to stir at room temperature for 1  hour 
followed by the addition of 1M HC1 (10 mL). The solvent was 
removed under reduced pressure, and the residue extracted with
(107)
DCM  (4 x 20 mL) and water. The organic phase was dried 
(M gS04), and concentrated in vacuo, before chromatography with a short silica plug 
(30% ethyl acetate:hexane). Recrystallisation from isopropanol afforded (107) (137 mg, 
91%) as yellow solid: mp 112.2-114.1 °C; !H NMR (CDC13, 400 MHz) 5 1.44 (d, J  = 
6.0 Hz, 6 H, CH(C775)2), 3.98 (s, 3H, OCT/?), 4.58 (p, J  = 6.1 Hz, 1 H, C77(CH3)2), 4.67
(s, 2H, C772 OH), 6.89 (s, 1H, 77-3), 6.97 (d, J  = 8.0 Hz, 1H, 77-6), 7.28 (d, J  = 8.0 Hz, 
1H, 11-1), 7.34 (d, J  = 1.6 Hz, 1H, H -1), 7.43 (m, 5H, aryl); 13C NMR (CDC13, 100 
MHz) 8  22.15 (CH(CH3)2), 56.43 (OCH3), 65.71 (CH 2 OH), 73.21 (CH(CH3)2), 105.51 
(C-3), 112.71 (C-6 ), 116.70 (C -l), 119.09 (C-4a), 126.88 (C-4’), 127.99 (C -l), 128.20 
(C-2’, 6 ’), 130.23 (C-3’, 5 ’), 133.72 (C - l’), 135.37 (C-8 ), 138.64 (C-2), 141.44 (C-8 a),
154.51 (0-5), 157.75 (0-4); m/z (C f ) 323 (M+l, 100), 305 (79), 281 (49); HRMS (C f) 
calcd for C21H23O3: 323.1647, found 323.1641.
5-Isopropoxy-4-methoxy-2-methylbromide-8-phenyInaphthalene (108)
To a solution of (107) (140 mg, 434 pmol) in dry distilled ether
(30 mL) was added triphenylphosphine (115 mg, 438 pmol) and
carbon tetrabromide (145 mg, 437 pmol) under N2, at room
temperature. The resulting solution was allowed to stir for 4
hours. The solvent was removed under reduced pressure, and the
extracted with chloroform (4 x 30 mL) and water. The organic
. (108) 
phase was dried (MgSCL), and concentrated in vacuo, before
being subjected to flash column chromatography (20% ethyl acetate:hexane).
Recrystallisation in isopropanol yielded (108) (158 mg, 94%) as a yellow solid: mp
92.9-94.8 °C; ‘H NMR (CDC13, 400 MHz) 8 1.43 (d, J  = 6.0 Hz, 6H, CH(Cfl))2), 3.99
(s, 3H, OCHs), 4.50 (s, 2H, CH2Br), 4.58 (p, J  = 6.1 Hz, 1H, CH(CH3)2), 6.86 (d, J  =
1.6 Hz, 1H, H-3), 6.99 (d, J  = 8.0 Hz, 1H, H-6), 7.29 (d, J  = 8.0 Hz, 1H, H-7), 7.39 (d, J 
= 1.6 Hz, 1H, H-1), 7.44 (m, 5H, aryl); 13C NMR (CDC13, 100 MHz) 8 22.14 
(CH(CH3)2), 34.64 (CH2Br), 56.41 (OCH3), 73.24 (CH(CH3)2), 106.84 (C-3), 113.36 
(C-6), 119.03 (C-7), 126.98 (C-4’), 128.26 (C-2\ C-6’), 128.30 (C-l), 128.40 (C-4a), 
130.40 (C -l’), 130.24 (C-3’, C-5’), 133.84 (C-2), 135.26 (C-8), 141.16 (C-8a), 154.53 
(C-5), 157.90 (C-4); m/z ( C f ) 387 (M+l, Br81, 98), 385 (M+l, Br79, 100), 345 (Br81, 
52), 343 (Br79, 56), 305 (52), 265 (9); HRMS (C f) calcd for C2iH22BrQ2: 385.0803,
found 385.0799.
5-Isopropoxy-4-methoxy-2-methyl-8-phenylnaphthalene (109)
To a solution of (108) (25 mg, 65 pmol) in dry DCM (15 mL) was 
added a 1.0 M solution of L-selectride in THF (15 pL, 70 pmol) 
under N2, at 0 °C. The resulting solution was allowed to stir at 
room temperature for 2 hours followed by the addition of a second 
equivalent of L-selectride (15 pL, 70 pmol) under N2, at 0 °C. The 
solution was allowed to stir for 1 hour, followed by the addition of 
ethanol (5 mL). The solvent was removed under reduced pressure, 
and the residue was extracted with chloroform (4 x 20 mL). The organic phase was
dried (MgS04), and concentrated in vacuo , before being subjected to flash column 
chromatography (10% ethyl acetate:hexane). Recrystallisation from isopropanol
yielded (109) (19 mg, 96%) as a yellow solid: mp 70.9-73.7 °C; !H NMR (CDC13, 400 
MHz) 5 1.44 (d, J  = 6.0 Hz, 6H, CH(CH5)2), 2.36 (s, 3H, CH3), 3.96 (s, 3H, OCH3), 
4.58 (p, J = 6.0 Hz, 1H, CH(CH3)2), 6.70 (d, J = 1.2 Hz, 1H, H-3), 6.91 (d, J = 8.0 Hz, 
1H, H-6), 7.19 (d, J = 1.2 Hz, 1H, H-1), 7.24 (d, J = 8.0 Hz, 1H, H-l), 7.45 (m, 5H, 
aryl)- l3C NMR (CDC13, 100 MHz) § 22.02 (CH3), 22.17 (CH(CH3)2), 56.57 (OCH3),
73.04 (CH(CH3)2), 108.99 (C-3), 111.78 (C-6), 117.86 (C-2), 118.33 (C-7), 126.69 (C- 
4’), 127.69 (C-l), 128.10 (C-2’, 6’), 130.27 (C-3’, 5’), 133.06 (C -l’), 135.62 (C-4a), 
135.87 (C-8), 141.78 (C-8a), 154.45 (C-5), 157.07 (C-4); m/z (CI+) 307 (M+l, 100), 265 
(38); HRMS (CR) calcd for C2,H230 2: 307.1698, found 307.1698.
5-Hydroxy-4-methoxy-8-phenylnaphthalene-2-methanol (110)
To a solution of (107) (100 mg, 310 pmol) in dry THF (40 mL) 
was added a suspension of lithium aluminium hydride (12 mg, 316 
umol) in THF (5 mL) under N2, at 0 °C. The resulting mixture 
was allowed to stir at room temperature for 1 hour followed by the 
addition of 1M HC1 (10 mL). The solvent was removed under 
reduced pressure, and the residue extracted with DCM (4 x 20 
mL) and water. The organic phase was dried (MgS04), and concentrated in vacuo, 
before chromatography with a short silica plug (50% ethyl acetate:hexane). 
Recrystallisation from isopropanol afforded (110) (46 mg, 53%) as yellow solid: mp 
152.0-154.4 °C; 'H NMR (CDC13, 400 MHz) 8 4.08 (s, 2H, CH2OH), 4.67 (s, 3H, 
OCHj), 6.87 (s, 1H, H-3), 6.93 (d, J  = 7.6 Hz, 1H, H-6), 7.30 (d, J  = 8.0 Hz, 1H, H-7), 
7.39 (s, 1H, H-l), 7.43 (m, 5H, aryl), 9.48 (s, 1H, OH); 13C NMR (CDC13, 100 MHz) 8 
56.23 (OCH3), 65.56 (CH2OH), 103.22 (C-3), 110.25 (C-6), 114.47 (C-4a), 117.530 (C- 
7), 126.84 (C-l), 128.25 (C-2’, C-6’), 129.42 (C-4’), 130.21 (C-3’, C-5’), 131.36 (C -l’),
134.35 (C-8), 138.43 (C-2), 141.12 (C-8a), 154.05 (C-5), 156.77 (C-4); m/z (CT) 281 
(M+l, 100), 263 (68); HRMS (CC) calcd for C18Hn 0 3: 281.117770, found 281.118046.
(H O )
6.2 Computer modelling
Atomic coordinates for all three-dimensional x-ray crystal structures were obtained 
from the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data 
Bank. A total of 23 x-ray crystallographic files were used, and some statistics 
relevant to the structures are tabulated in Appendix 7.3. Three additional crystal 
structures were used for only selected purposes, such as pharmacophore validation 
(Chapter 4), and these are tabulated in Appendix 7.3.1.
All computer modelling was performed on Silicon Graphics 02  workstations (Irix 
Release 6.5), with software as mentioned in the text.
6.2.1 Modelling of protein conformational changes
The superimposition subset for the conformational studies of reverse transcriptase was 
derived using the ProFlex program to calculate DMs and DDMs of different x-ray 
crystal structures of RT.147,151 The final superimposition subset is listed in Table 3.1 of 
Section 3.2.2. Superimposition was performed in the Insightll® program,152 by 
overlaying the second unliganded structure (lhmv), both DNA-bound structures (lrtd 
and 2hmi) and all of the inhibitor-bound structures onto the chosen unliganded 
structure, ldlo, with this subset. RMSD values were obtained from Insightll for the 
individual superimpositions and are listed in Table 3.2 of Section 3.2.2. The distance 
between corresponding atoms of equivalent residues in each individual crystal structure 
and the unliganded ldlo was measured once the crystal structure had been superimposed 
onto ldlo. Only the atoms of those residues in the active sites and motifs listed in 
Appendix 7.6, Subset definitions, were analysed. These distances were tabulated and 
graphed in Excel®.153
6.2.2 Ligand-based pharmacophore generation with Catalyst
The ligand-based pharmacophore was generated using the Catalyst® software program 
(Molecular Simulations Inc.).291,307
The inhibitor heteroatom coordinates of all selected liganded PDB files were saved in 
Sybyl mol2 file format after the correct atom types were applied in Insightll® 
(Molecular Simulations Inc.).152 These were imported into Catalyst in their original 
crystal conformations. Conformational models were generated in the Best-quality
mode, with the default energy range of 20 kcal.mol"1 from the minimum, based on the 
CHARMm forcefield.
Catalyst pharmacophores were generated using hydrogen bond acceptors, hydrogen 
bond donors, hydrophobic aliphatic, positive ionisable, and ring aromatic groups as the 
five possible feature types. All standard HypoGen parameters297,298 were used with the 
exception of the Minimum Total Features parameter and the 
forceAbsoluteSterochemistry option. The Minimum Total Features parameter was set at 
varying values as discussed in the text (see Section 4.2.3 Hypothesis generation) and 
increased until such a value where the hypothesis generation failed due to unfavourable 
cost values. The forceAbsoluteSterochemistry option was turned off by adding 
‘catHypo.forceAbsohiteStereochemistry=r to the .Catalyst file.
Database searching was performed with the Best Flexible Searching Tool, with the 
Maximum Search Hits option set at 10 000. The results from database searches can be 
saved in a spreadsheet format, or as a database, to be searched by subsequent 
pharmacophores.
6.2.3 Structure-based pharmacophore generation with Unity 3D
A set of residues within a 25 A radius of the inhibitor was defined for each of the 
nineteen liganded crystal structures of Appendix 7.3, except 3hvt, and all other protein 
residues were deleted. Using the Biopolymer module of Sybyl, hydrogens and charges 
(Kollman_All charge set) were added before the hydrogens were minimised. 
Minimisation calculations were carried out with the Powell method, using the Tripos 
forcefield, and were terminated once the RMS reached 0.05 kcal.mol \A  or after 500 
iterations.
Binding pocket residues were identified using the SitelD® module of Sybyl.309 The 
entire structure of each of the truncated crystal structures was selected for the initial 
solvation in SitelD. All standard parameters were used with the exception of the 
Minimum Pocket Concavity and the van der Waals bump scaling factor. Solvation of 
each crystal structure was performed with the Minimum Pocket Concavity and the van 
der Waals bump scaling factor set at 2 and 0.8 A, respectively, and 10 and 0.7 A, 
respectively.
The ‘largest’ and ‘smallest’ modified binding pockets, based on the position of the 
backbone and sidechain, were generated in InsightE by initially superimposing all the 
RT-inhibitor crystal structures onto the unliganded ldlo structure (Section 6.2.1). All 
residues, excepting those identified as binding pocket residues by SitelD, were deleted. 
The coordinates of the remaining liganded crystal structures were transformed, so that 
they were relative to each other, and were saved in PDB format. The average point for 
the backbone and sidechain of each residue of each individual binding pocket was 
calculated and its distance from a central inhibitor reference point was determined. The 
crystal structure with the minimum and maximum distance values for the backbone and 
sidechain of each residue was noted in the Table 6.1, and the complete coordinates for 
this residue from this crystal structure were then used for the modified pockets. The file 
was saved in PDB format for use with Unity 3D.
Residue Details Backbone Sidechain
minimum maximum minimum maximum
Trp 88 hni
Glu 89 rth
Val 90 bqm
Gin 91 klm
Leu 92 rt7
Gly 93 rt5
lie 94 rti
Pro 95 iti
His 96 klm
Pro 97 vru
Gly 99 vru
Leu 100 rev
Lys 101 bqn
Lys 102 tvr
Lys 103 bqm
Val 106 tvr
Gin 161 rt7
Ser 162 rt7
Met 164 klm
Thr 165 hni
Leu 168 rt3
Arg 172 rt3
Val 179 hni
Ile 180 hni
Tyr 181 rti
Gin 182 rt3
Tyr 183 rt3
Met 184 rt3
Asp 186 rti
rti hni rev
rt2 vru rev
rt3 rev rt2
rt3 klm rev
uwb rt4 uwb
hni rt5 hni
hni rt5 hni
hni rt4 hni
uwb vru tvr
rt6 hni rti
rt6 vru rt6
rt6 vru hni
klm rev tvr
rti tvr rti
rt4 hni klm
vru rti vru
uwb rti uwb
bqm rti tvr
tvr klm bqm
rti hni rt4
rth rt3 rev
rth rt3 uwb §
rth hni rt6
rt3 rti bqn
tvr f rti hnv
hnv rti tvr
bqm rt3 bqn
bqm rt3 tvr
hnv rti uwb
Leu 187 klm hnv rti tvr
Tyr 188 klm rev rti hnv
Val 189 rt3 vru rt3 bqn
Gly 190 uwb rth uwb rth
Glu 224 rt4 t hni rt6 f rt3
Pro 225 bqn klm rt4 tvr
Pro 226 rt6 hni rt6 uwb
Phe 227 klm bqm rt2 bqn
Trp 229 klm tvr klm uwb
Met 230 rth tvr klm tvr
Tyr 232 hni tvr hni rti
Leu 234 rt3 bqn rt3 bqn
His 235 hnv klm uwb klm
Pro 236 uwb klm uwb klm
Tyr 318 uwb rt6 uwb klm
lie 380 vru tvr bqn tvr
Val 381 vru tvr klm tvr
lie 382 vru hnv vru rt7
Pro 25 bqn rev bqn rti
Leu 26 rth uwb rth uwb
He 31 bqn rt3 tvr rt3
Thr 131 rt4 uwb rth hni
He 132 rt7 hni rt7 bqn
Pro 133 rt5 hni rt5 hni
Ser 134 rt5 rt3 rt7 hni
He 135 rti tvr rti rt3
Asn 136 rt4 uwb rti uwb
Asn 137 rt4 uwb rt4 uwb
Glu 138 rt4 hni klm rti
Thr 139 rth hni rti hni
Pro 140 rth vru tvr vru
Gly 141 tvr rt2 tvr rt2
He 142 rth hni rth uwb
Arg 143 rt2 tvr hnv bqm
T a b l e  6 .1  L i s t s  o f  t h e  c r y s t a l  s t r u c t u r e s  f r o m  w h ic h  e a c h  c o m p l e t e  r e s id u e  
o f  t h e  m o d i f i e d  b i n d i n g  p o c k e t s  w a s  d e r i v e d .
§ l u w b  h a s  a  l y s i n e  s i d e c h a i n  i n s t e a d  o f  a r g i n i n e
f T h e  s i d e c h a i n  o f  t h e  r e s i d u e  w h o s e  d i s t a n c e  s h o w e d  m a x i m a l  o r  m i n im a l  
d i s t a n c e  f r o m  t h e  i n h i b i t o r  r e f e r e n c e  p o i n t  w a s  m is s in g .  T h e  c r y s t a l  
s t r u c t u r e  w i t h  t h e  n e x t  g r e a t e s t  m a x i m u m  o r  m i n i m u m  d i s t a n c e  w a s  u s e d
Structural queries were generated in Unity 3D280 by using the Constraints and Select
Donor/Acceptor tools. The Constraints tool was used to define excluded volumes, and
standard parameters were selected, with the exception of the van der Waals scaling
factor that was used with the default of 1.0 and set at 0.5. The Select Donor/Acceptor
tool was used to perform an automated search for all donor and acceptor sites on the
protein. Only those sites that projected the potential feature of the ligand into the
binding pocket were chosen. All of the donor and acceptor sites on the protein chosen
as features in the structural query were selected for Unity’s Partial Match Constraint 
Dialog by typing ‘define unity_feature partial_match_constraint m2 
%unity_feature_names(m2 macro) |’ at the Sybyl prompt. Structural queries can be 
saved in the Sybyl mol2 file format, and provide Cartesian coordinates and spatial 
information of the features of the query that can be used in other programs such as 
Catalyst (see Section 4.3.6 Structural queries in Catalyst).
A Flex Query search using the Partial Match Constraint Dialog was performed in Unity 
3D using standard parameters with the exception of the minimum and maximum 
features to be accepted as a hit. These were set at varying valuables as noted in the text 
(see Section 4.3.4 Database searching with Unity queries). The time spent attempting to 
fit each compound to the structural query was set at 90 seconds. Search results were 
saved in a database format.
Unity 3D structural queries were converted to Catalyst pharmacophores by saving the 
queries in the Sybyl mol2 file format. The coordinates of the features were expressed in 
angstroms and needed to be multiplied by 100 to convert them to picometres, the units 
used for the Hypoedit utility (see Appendix 7.14). The Hypoedit file was modified to 
include the features and excluded volumes data from the structural query, and a 
pharmacophore was generated by typing ‘hypoedit’ at the unix prompt and pasting the 
modified Hypoedit file (see Appendix 7.14.1 Hypoedit file of activity ‘weighted’ 
structural query).
♦ ♦
References
4--------------------------------------------------------------------------------------------------------------------------------------------------- — -------------------------------------------------------------------------------------------------------------------------------------------------------- ♦
1. Tang, H. L., Kuhen, K. L. & Wong-Staal, F. Lentivirus replication and 
regulation. Ann. Rev. Gen.33, 133-170 (1999).
2. Pavlakis, G. N. “The molecular biology of human immunodeficiency virus type
I. ” in AIDS: Biology, Diagnosis, Treatment and Prevention (eds. DeVita, J. V. 
T., Heilman, S. & Rosenberg, S. A.) (Lippincott-Raven, Philadelphia, 1996).
3. Turner, B. G. & Summers, M. F. Structural biology of HIV. J. Mol. Biol. 285, 1­
32 (1999).
4. Wilk, T. & Fuller, S. D. Towards the structure of the human immunodeficiency 
virus: divide and conquer? Curr. Opin. Struct. Biol. 9, 231-243 (1999).
5. Hottiger, M. & Hubscher, U. Human immunodeficiency virus type 1 reverse 
transcriptase. Biol. Chem. Hoppe-Seyler 377, 97-120 (1996).
6. Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M. & 
Markowitz, M. Rapid turnover of plasma virions and CD4 lymphocytes in HTV- 
1 infection. Nature 373, 123-126 (1995).
7. Wei, X. P., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, 
P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., Saag, M. S. & 
Shaw, G. M. Viral dynamics in human immunodeficiency virus type 1 infection. 
Nature 373, 117-122 (1995).
8. Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M. & Ho, D. D. 
HIV-1 dynamics in vivo - Virion clearance rate, infected cell life-span, and viral 
generation time. Science 271, 1582-1586 (1996).
9. Stewart, G. (ed.) Managing HIV  (Australasian Medical Publishing Company 
Limited, Sydney, 1997).
10. Wodarz, D. & Nowak, M. A. Evolutionary dynamics of HIV-induced subversion 
of the immune response. Immun. Rev. 168, 75-89 (1999).
11. Ho, W., Kukla, M. J., Breslin, H. J., Ludovici, D. W., Grous, P. P., Diamond, C.
J. , Miranda, M., Rodgers, J. D„ Ho, C. Y„ Declercq, E., Pauwels, R„ Andries,
K. , Janssen, M. A. C. & Janssen, P. A. J. Synthesis and anti-HIV-1 activity of
4,5,6,7-tetrahydro-5-methylimidazo-[4,5,l-y7:][l,4]benzodiazepin-2(lH)-one
(TIBO) derivatives .4. J. Med. Chem. 38, 794-802 (1995).
12. Chun, T. W., Stuyver, L., Mizell, S. B., Ehler, L. A., Mican, J. A. M., Baseler, 
M., Lloyd, A. L., Nowak, M. A. & Fauci, A. S. Presence of an inducible HIV-1 
latent reservoir during highly active antiretroviral therapy. Proceed. Natl Acad. 
Sci. USA. 94, 13193-13197 (1997).
13. Chun, T. W., Engel, D., Berrey, M. M., Shea, T., Corey, L. & Fauci, A. S. Early 
establishment of a pool of latently infected, resting CD4(+) T cells during 
primary HIV-1 infection. Proceed. Natl. Acad. Sci. USA. 95, 8869-8873 (1998).
14. Pantaleo, G., Graziosi, C., Demarest, J. F., Butini, L., Montroni, M., Fox, C. H., 
Orenstein, J. M., Kotler, D. P. & Fauci, A. S. HIV infection is active and 
progressive in lymphoid tissue during the clinically latent stage of disease. 
Nature 362, 355-358 (1993).
15. Embretson, J., Zupancic, M., Ribas, J. L., Burke, A., Racz, P., Tenner-Racz, K. 
& Haase, A. T. Massive covert infection of helper T-lymphocytes and 
macrophages by HIV during incubation period of AIDS. Nature 362, 359-362
(1993).
16. Orenstein, J. M., Fox, C. & Wahl, S. M. Macrophages as a source of HIV during 
opportunistic infections. Science 276, 1857-1861 (1997).
17. Knight, S. C. & Patterson, S. Bone marrow-derived dendritic cells, infection 
with human immunodeficiency virus, and immunopathology. Ann. Rev. Immum. 
15, 593-615 (1997).
18. Chun, T. W., Carruth, L., Finzi, D., Shen, X. F., Digiuseppe, J. A., Taylor, H., 
Hermankova, M., Chadwick, K., Margolick, J., Quinn, T. C., Kuo, Y. H., 
Brookmeyer, R., Zeiger, M. A., Barditchcrovo, P. & Siliciano, R. F. 
Quantification of latent tissue reservoirs and total body viral load in HIV-1 
infection. Nature 387, 183-188 (1997).
19. Finzi, D. & Siliciano, R. F. Viral dynamics in HIV-1 infection. Cell 93, 665-671 
(1998).
20. Nowak, M. A. & McMichael, A. J. How HIV defeats the immune system. Sci. 
Am. 273, 58-65 (1995).
21. Wain-Hobson, S. The fastest genome evolution ever described: HIV variation in 
situ. Curr. Opin. Gen. Develop. 3, 878-883 (1993).
22. Sala, M. & Vartanian, J. P. HIV-1 reverse transcriptase - An out-of-the-ordinary 
enzyme. Bulletin de L'Institut Pasteur 96, 49-63 (1998).
23. Coffin, J. M. HTV population dynamics in vivo - implications for genetic 
variation, pathogenesis, and therapy. Science 267, 483-489 (1995).
24. De Clercq, E. Toward improved anti-HIV chemotherapy: Therapeutic strategies 
for intervention with HIV infections. J. Med. Chem. 38, 2491-2517 (1995).
25. Stem, A. M. “The development of human immunodeficiency vims type 1 
reverse transcriptase inhibitors.” in Chemical and Structural Approaches to 
Rational Drug Design (eds. Weiner, D. B. & Williams, W. B.) 35-61 (CRC 
Press Inc, Boca Raton, Florida, 1995).
26. De Clercq, E. The role of non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) in the therapy of HIV-1 infection. Antiviral Res. 38, 153-179 (1998).
27. De Clercq, E. Perspectives of non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) in the therapy of HIV-1 infection. II Farmaco 54, 26-45 (1999).
28. Pedersen, O. S. & Pedersen, E. B. Non-nucleoside reverse transcriptase 
inhibitors: the NNRTI boom. Antiviral Chem. Chemother. 10, 285-314 (1999).
29. Esnouf, R., Ren, J. S., Ross, C., Jones, Y., Stammers, D. & Stuart, D. 
Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside 
inhibitors. Nat. Struct. Biol.2, 303-308 (1995).
30. Ding, J. P., Das, K., Moereels, H., Koymans, L., Andries, K., Janssen, P. A. J., 
Hughes, S. H. & Arnold, E. Structure of HIV-1 RT/TIBO R 86183 complex 
reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat. Struct. 
Biol.2, 407-415 (1995).
31. Smith, M. B. K., Rouzer, C. A., Taneyhill, L. A., Smith, N. A., Hughes, S. H., 
Boyer, P. L., Janssen, P. A. J., Moereels, H., Koymans, L., Arnold, E., Ding, J. 
P., Das, K., Zhang, W. Y., Michejda, C. J. & Smith, R. H. Molecular modeling 
studies of HIV-1 reverse transcriptase nonnucleoside inhibitors - Total energy of 
complexation as a predictor of drug placement and activity. Prot. Sci.4, 2203­
2222 (1995).
32. Witvrouw, M., Pannecouque, C., Van Laethem, K., Desmyter, J., De Clercq, E. 
& Vandamme, A. M. Activity of non-nucleoside reverse transcriptase inhibitors 
against HIV-2 and SIV. AIDS 13, 1477-1483 (1999).
33. Tantillo, C., Ding, J. P., Jacobomolina, A., Nanni, R. G., Boyer, P. L., Hughes, 
S. H., Pauwels, R., Andries, K., Janssen, P. A. J. & Arnold, E. Locations of anti­
AIDS drug binding sites and resistance mutations in the three-dimensional 
structure of HIV-1 reverse transcriptase - Implications for mechanisms of drug 
inhibition and resistance. J. Mol. Biol. 243, 369-387 (1994).
34. Pedersen, O. S. & Pedersen, E. B. The flourishing syntheses of non-nucleoside 
reverse transcriptase inhibitors. Synthesis 4, 479-495 (2000).
35. Ng, T. B., Huang, B., Fong, W. P. & Yeung, H. W. Anti-human 
immunodeficiency virus (anti-HIV) natural products with special emphasis on 
HIV reverse transcriptase inhibitors. Life Sci. 61, 933-949 (1997).
36. Matthee, G., Wright, A. D. & Konig, G. M. HIV reverse transcriptase inhibitors 
of natural origin. Planta Medica. 65, 493-506 (1999).
37. Lee, K. H. & Morris-Natschke, S. L. Recent advances in the discovery and 
development of plant-derived natural products and their analogs as anti-HIV 
agents. Pure Appl. Chem. 71, 1045-1051 (1999).
38. Jung, M., Lee, S. & Kim, H. Recent studies on natural products as anti-HIV 
agents. Curr. Med. Chem. 7, 649-661 (2000).
39. Manfredi, K. P., Blunt, J. W., Cardellina, J. H., McMahon, J. B., Panned, L. L., 
Cragg, G. M. & Boyd, M. R. Novel alkaloids from the tropical plant 
Ancistrocladus abbreviatus inhibit cell killing in HIV-1 and HIV-2. J. Med. 
Chem. 34, 3402-3405 (1991).
40. Tan, G. T., Miller, J. F., Kinghom, A. D., Hughes, S., H, & Pezzuto, J. M. HIV- 
1 and HIV-2 reverse transcriptases: A comparative study of sensitivity to 
inhibition by selected natural products. Biochem. Biophys. Res. Comm. 185, 
370-378 (1992).
41.
Rejfkrmoes
Lin, T. S., Schinazi, R., Griffith, B. P., August, E. M., Eriksson, B. F. H., Zheng,
D. K., Huang, L. & Prusoff, W. H. Selective inhibition of human 
immunodeficiency virus type I replication by the (-) but not the (+) enantiomer 
of Gossypol. Antimicrob. Agents Chemother. 33, 2149-2151 (1989).
42. Keller, P. A., Leach, S. P., Birch, C., Tyssen, D. & Griffith, R. J. Med. Chem. 
(submitted) (2000).
43. Royer, R. E., Deck, L. M., Vanderjagt, T. J., Martinez, F. J., Mills, R. G., 
Young, S. A. & Vanderjagt, D. L. Synthesis and anti-HIV activity of 1,1'- 
dideoxygossypol and related compounds. J. Med. Chem. 38, 2427-2432 (1995).
44. Xie, L., Xie, J. X., Kashiwada, Y., Cosentino, L. M., Liu, S. H., Pai, R. B., 
Cheng, Y. C. & Lee, K. H. Anti-AIDS (Acquired Immune Deficiency 
Syndrome) agents .17. New brominated hexahydroxybiphenyl derivatives as 
potent anti-HIV agents. J. Med. Chem. 38, 3003-3008 (1995).
45. Gustafson, K. R., Cardellina, J. H., McMahon, J. B., Panned, L. K., Cragg, G. 
M. & Boyd, M. R. The Peltatols, novel HIV-inhibitory catechol derivatives from 
Pothomorphe peltata. J. Org. Chem. 57, 2809-2811 (1992).
46. Decosterd, L. A., Parsons, I. C., Gustafson, K. R., Cardellina, J. H., McMahon,
J. B., Cragg, G. M., Murata, Y., Panned, L. K., Steiner, J. R., Clardy, J. & Boyd, 
M. R. HIV inhibitory natural products .11. Structure, absolute stereochemistry, 
and synthesis of Conocurvone, a potent, novel HIV-inhibitory naphthoquinone 
trimer from a Conospermum Sp. J. Am. Chem. Soc. 115, 6673-6679 (1993).
47. Boyd, M. R., Hallock, Y. F., Manfredi, K. P., Blunt, J. W., McMahon, J. B., 
Buckheit, R. W., Bringmann, G., Schaffer, M., Cragg, G. M., Thomas, D. W., 
Jato, J. G. & Cardellina, J. H. Anti-HIV michellamines from Ancistrocladus 
korupensis. J. Med. Chem. 37, 1740-1745 (1994).
48. Supko, J. G. & Malspeis, L. Pharmacokinetics of Michellamine B, a 
naphthylisoquinoline alkaloid with in vitro activity against human 
immunodeficiency virus types 1 and 2, in the mouse and dog. Antimicrob. 
Agents Chemother. 39, 9-14 (1995).
49. McMahon, J. B., Currens, M. J., Gulakowski, R. J., Buckheit, R. W., 
Lackmansmith, C., Hallock, Y. F. & Boyd, M. R. Michellamine B, a novel plant 
alkaloid, inhibits human immunodeficiency virus-induced cell killing by at least 
two distinct mechanisms. Antimicrob. Agents Chemother. 39, 484-488 (1995).
50. White, E. L., Chao, W. R., Ross, L. J., Borhani, D. W., Hobbs, P. D., Upender, 
V. & Dawson, M. I. Michellamine alkaloids inhibit protein kinase C. Arch. 
Biochem. Biophys. 365, 25-30 (1999).
51. White, E. L., Ross, L. J., Hobbs, P. D., Upender, V. & Dawson, M. I. 
Antioxidant activity of michellamine alkaloids. Anticancer Res.. 19, 1033-1035 
(1999).
52. Bringmann, G., Zagst, R., Reuscher, H. & Assi, L. A. Ancistrobrevine B, the 
first naphthylisoquinoline alkaloid with a 5,8'-coupling site, and related 
compounds from Ancistrocladus abbreviatus. Phytochemistry 31, 4011-4014
(1992).
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
Bringmann, G., Gotz, R., Keller, P. A., Walter, R., Henschel, P., Schaffer, M., 
Stablein, M., Kelly, T. R. & Boyd, M. R. Acetogenic isoquinoline alkaloids .66. 
First total synthesis of Korupensamines A and B. Heterocycles 39 503-508
(1994). ’
Bringmann, G., Zagst, R., Schaffer, M., Hailock, Y. F., Cardellina, J. H. & 
Boyd, M. R. The absolute configuration of Michellamine-B, a 'dimeric', anti­
HIV-active naphthylisoquinoline alkaloid. Angew. Chem. Int Ed Engl 32 
1190-1191 (1993). ’
Kalsi, P. S. Sterochemistry: conformation and mechanism (Wiley Eastern 
Limited, New Delhi, India, 1990).
Sterochemistry, hydrocarbons, halo compounds, oxygen compounds.” in 
Comprehensive Organic Chemistry: The Synthesis and Reactions o f Organic 
Compounds (ed. Stoddart, J. F.) (Pergamon Press, Oxford, England, 1979).
Stereochemistry.” in Nomenclature o f Organic Chemistry (eds. Rigaudy, J. & 
Klesney, S. P.) (Pergamon Press, Oxford, England, 1979).
Hallock, Y. F., Manfredi, K. P., Dai, J. R., Cardellina, J. H., Gulakowski, R. J., 
McMahon, J. B., Schaffer, M., Stahl, M., Gulden, K. P., Bringmann, G., 
Francois, G. & Boyd, M. R. HIV-Inhibitory natural products .36. Michellamines 
D-F, new HIV-inhibitory dimeric naphthylisoquinoline alkaloids, and 
Korupensamine E, a new antimalarial monomer, from Ancistrocladus 
korupensis. J. Nat. Prod. 60, 677-683 (1997).
Bringmann, G., Harmsen, S., Holenz, J., Geuder, T., Gotz, R., Keller, P. A., 
Walter, R., Hallock, Y. F., Cardellina, J. H. & Boyd, M. R. Acetogenic 
isoquinoline alkaloids .69. 'Biomimetic' oxidative dimerization of 
korupensamine A - Completion of the first total synthesis of Michellamines A, 
B, and C. Tetrahedron 50, 9643-9648 (1994).
Hallock, Y. F., Manfredi, K. P., Blunt, J. W., Cardellina, J. H., Schaffer, M., 
Gulden, K. P., Bringmann, G., Lee, A. Y., Clardy, J., Francois, G. & Boyd, M.
R. Korupensamines A-D, novel antimalarial alkaloids from Ancistrocladus 
korupensis. J. Org. Chem. 59, 6349-6355 (1994).
Hoye, T. R. & Mi, L. Total syntheses of Korupensamine C and Ancistrobrevine
B. Tet. Lett. 37, 3097-3098 (1996).
Bringmann, G., Gotz, R., Harmsen, S., Holenz, J. & Walter, R. Acetogenic 
isoquinoline alkaloids .82. Biomimetic total synthesis of Michellamines A-C. 
Liebigs Ann. 2045-2058 (1996).
Hoye, T. R., Chen, M. Z., Mi, L. & Priest, O. P. Total synthesis of 
Michellamines A-C - Important anti-HIV agents. Tet. Lett. 35, 8747-8750 
(1994).
Hoye, T. R., Chen, M. Z., Hoang, B., Mi, L. & Priest, O. P. Total synthesis of 
Michellamines A-C, Korupensamines A-D, and Ancistrobrevine B. J. Org. 
Chem. 64, 7184-7201 (1999).
Hobbs, P. D., Upender, V., Liu, J. W., Pollart, D. J., Thomas, D. W. & Dawson, 
M. I. The first stereospecific synthesis of Michellamine B. Chem. Comm. 923­
924 (1996).
m
66. Hobbs, P. D., Upender, V. & Dawson, M. I. Stereospecific syntheses of 
Michellamines A and C. Synlett, 965 ff. (1997).
67. Kelly, T. R., Garcia, A., Lang, F. R., Walsh, J. J., Bhaskar, K. V., Boyd, M. R., 
Gotz, R., Keller, P. A., Walter, R. & Bringmann, G. Convergent total synthesis 
of the michellamines. Tet. Lett. 35, 7621-7624 (1994).
68. Bringmann, G., Gotz, R., Keller, P. A., Walter, R., Boyd, M. R., Lang, F. R., 
Garcia, A., Walsh, J. J., Tellitu, I., Bhaskar, K. V. & Kelly, T. R. A convergent 
total synthesis of the michellamines. J. Org. Chem. 63, 1090-1097 (1998).
69. Bringmann, G., Ortmann, T., Feineis, D., Peters, E. M. & Peters, K. A new 
central binaphthalene building block for michellamine syntheses. Synthesis 3, 
383-388 (2000).
70. Upender, V., Pollart, D. J., Liu, J., Hobbs, P. D., Olsen, C., Chao, W. R., 
Bowden, B., Crase, J. L., Thomas, D. W., Pandey, A., Lawson, J. A. & Dawson, 
M. I. The synthesis and biological activity of two analogs of the anti-HIV 
alkaloid Michellamine B. Journal o f Heterocyclic Chemistry 33, 1371-1384
(1996).
71. Zhang, H. P., Zembower, D. E. & Chen, Z. D. Structural analogues of the 
michellamine anti-HIV agents - Importance of the tetrahydroisoquinoline rings 
for biological activity. Bioorg. Med. Chem. Lett. 7, 2687-2690 (1997).
72. Bringmann, G. Mono- and dimeric naphthylisoquinoline alkaloids - 
Pharmaceutically and structurally exciting natural heterocycles with axial 
chirality. Bulletin des Societes Chimiques Beiges 105, 601-613 (1996).
73. Bringmann, G., Ortmann, T., Zagst, R., Schöner, B., Assi, L. A. & Burschka, C. 
(±)-Dioncophyllacine A, a naphthylisoquinoline alkaloid with a 4-methoxy 
substituent from the leaves of Triphyophyllum peltatum. Phytochemistry 31, 
4015-4018 (1992).
74. Bringmann, G., Rübenacker, M., Weirich, R. & Assi, L. A. Dioncophylline C 
from the roots of Triphyophyllum peltatum, the first 5,1'-coupled 
dioncophyllaceae alkaloid. Phytochemistry 31, 4019-4024 (1992).
75. Bringmann, G., Holenz, J., Weirich, R., Rubenacker, M., Funke, C., Boyd, M. 
R., Gulakowski, R. J. & Francois, G. First synthesis of the antimalarial 
naphthylisoquinoline alkaloid Dioncophylline C, and its unnatural anti-HIV 
dimer, Jozimine C. Tetrahedron 54, 497-512 (1998).
76. Bringmann, G., Saeb, W., Koppler, D. & Francois, G. Jozimine A ('dimeric' 
Dioncophylline A), a non-natural michellamine analog with high antimalarial 
activity. Tetrahedron 52, 13409-13418 (1996).
77. Greer, J., Erickson, J. W., Baldwin, J. J. & Varney, M. D. Application of the 
three-dimensional structures of protein target molecules in structure-based drug 
design. J. Med. Chem. 37, 1035-1054 (1994).
78. Boyd, D. B. “Drug design.” in Encyclopedia o f Computational Chemistry (eds. 
Schleyer, P. v. R. et al.) 795-804 (John Wiley & Sons Ltd, Chichester, UK, 
1998).
79. Sarafianos, S. G., Das, K., Ding, J. P., Hsiou, Y., Hughes, S. H. & Arnold, E. 
“Current perspectives on mechanisms of HIV-1 reverse transcriptase inhibition 
by nonucleoside inhibitors.” in Anti-infectives: Recent Advances in Chemistry 
and Structure-Activity Relationships (eds. Bentley, P. H. & O'Hanlon, P. J.) 328­
334 (The Royal Society of Chemistry, Cambridge, 1997).
80. Stanforth, S. P. Catalytic cross-coupling reactions in biaryl synthesis. 
Tetrahedron 54, 263-303 (1998).
81. Fanta, P. E. The Ullmann synthesis of biaryls. Synthesis, 9-21 (1974).
82. Negishi, E., King, A. O. & Okukado, N. Selective carbon-carbon bond 
formation via transition metal catalysis. 3. A highly selective synthesis of 
unsymmetrical biaryls and diarylmethanes by the nickel- or palladium-catalyzed 
reaction of aryl- and benzylzinc derivatives with aryl halides. J. Org. Chem. 42, 
1821 (1977).
83. Hoye, T. R. & Chen, M. Z. Studies of palladium-catalyzed cross-coupling 
reactions for preparation of highly hindered biaryls relevant to the 
Korupensamine/Michellamine problem. J. Org. Chem. 61, 7940-7942 (1996).
84. Stille, J. K. The palladium-catalyzed cross-coupling reactions of organotin 
reagents with organic electrophiles. Angew. Chem. Int. Ed. Engl. 25, 508-524 
(1986).
85. Suzuki, A. New synthetic transformations via organoboron compounds. Pure 
Appl. Chem. 66, 213-222 (1994).
86. Miyaura, N. & Suzuki, A. Palladium-catalyzed cross-coupling reactions of 
organoboron compounds. Chem. Rev. 95, 2457-2483 (1995).
87. Suzuki, A. Recent advances in the cross-coupling reactions of organoboron 
derivatives with organic electrophiles, 1995-1998. J. Organomet. Chem. 576, 
147-168 (1999).
88. Mitchell, T. N. Palladium-catalysed reactions of organotin compounds. 
Synthesis, 805-815 (1992).
89. Duncton, M. A. J. & Pattenden, G. The intramolecular Stille reaction. J. Chem. 
Soc. Perkin Trans. I. 1235-1246 (1999).
90. Farina, V., Kapadia, S., Krishnan, B., Wang, C. J. & Liebeskind, L. S. On the 
nature of the 'copper effect' in the Stille cross-coupling. J. Org. Chem. 59, 5905­
5911 (1994).
91. Roth, G. P., Farina, V., Liebeskind, L. S. & Penacabrera, E. Optimized stille 
coupling reactions catalyzed by palladium on carbon with Cul as cocatalyst. Tet. 
Lett. 36, 2191-2194 (1995).
92. Tamayo, N., M., E. A., C., P. M., Farina, F. & Noheda, P. Synthesis of 
anthraquinone derivatives by palladium-catalysed coupling of inflates with 
stannanes. Tet. Lett. 31, 5189-5192 (1990).
93. Kelly, T. R. & Kim, M. H. Synthesis of schumanniophytine and 
isoschumanniophytine. J. Org. Chem. 57, 1593-1597 (1992).
94. Ohe, T., Miyaura, N. & Suzuki, A. Palladium-catalyzed cross-coupling reaction 
of organoboron compounds with organic inflates. /. Org. Chem. 58, 2201-2208
(1993).
95. Watanabe, T., Miyaura, N. & Suzuki, A. Synthesis of sterically hindered biaryls 
via the palladium-catalyzed cross-coupling reaction of arylboronic acids or their 
esters with haloarenes. Synlett 8, 207-210 (1992).
96. Zhang, H. C., Kwong, F. Y., Tian, Y. & Chan, K. S. Base and cation effects on 
the Suzuki cross-coupling of bulky arylboronic acid with halopyridines - 
Synthesis of pyridylphenols. J. Org. Chem. 63, 6886-6890 (1998).
97. Moreno-Manas, M., Perez, M. & Pleixats, R. Palladium-catalyzed suzuki-type 
self-coupling of arylboronic acids - A mechanistic study. J. Org. Chem. 61, 
2346-2351 (1996).
98. Miller, R. B. & Dugar, S. Stoichiometric synthesis of unsymmetrical 
mononitrobiphenyls via the palladium-catalyzed cross-coupling of arylboronic 
acids with aryl bromides. Organometallics 3, 1261-1263 (1984).
99. Andersen, N. G., Maddaford, S. P. & Keay, B. A. A modified in situ Suzuki 
cross-coupling of haloarenes for the preparation of C2-symmetrical biaryls. J. 
Org. Chem. 61, 9556-9559 (1996).
100. Benbow, J. W. & Martinez, B. L. Biaryl formation using the Suzuki protocol - 
Considerations of base, halide, and protecting group. Tet. Lett. 37, 8829-8832
(1996) .
101. Giroux, A., Han, Y. X. & Prasit, P. One pot biaryl synthesis via in situ boronate 
formation. Tet. Lett. 38, 3841-3844 (1997).
102. Ishiyama, T., Itoh, Y., Kitano, T. & Miyaura, N. Synthesis of arylboronates via 
the palladium(0)-catalyzed cross-coupling reaction of tetra(alkoxo)diborons with 
aryl triflates. Tet. Lett. 38, 3447-3450 (1997).
103. Ishiyama, T., Murata, M. & Miyaura, N. Palladium(0)-catalyzed cross-coupling 
reaction of alkoxydiboron with haloarenes - A direct procedure for arylboronic 
esters. J. Org. Chem. 60, 7508-7510 (1995).
104. Kong, K. C. & Cheng, C. H. Facile aryl-aryl exchange between the palladium 
center and phosphine ligands in palladium(II) complexes. J. Am. Chem. Soc. 
113, 6313-6315 (1991).
105. O'Keefe, D. F., Dannock, M. C. & Marcuccio, S. M. Palladium catalysed 
coupling of halobenzenes with arylboronic acids: Role of the triphenylphosphine 
ligand. Tet. Lett. 33, 6679-6680 (1992).
106. Smith, K. A., Campi, E. M., Jackson, W. R., Marcuccio, S., Naeslund, C. G. M. 
& Deacon, G. B. High yields of symmetrical biaryls from palladium catalysed 
homocoupling of arylboronic acids under mild conditions. Synlett, 131 ff.
(1997) .
107. Koyama, H. &  Kamikawa, T. Total syntheses of 0 4'9-dimethyl stealthins A and
C. Tet. Lett. 38, 3973-3976 (1997).
108. Marck, G., Villiger, A. &  Buchecker, R. Aryl couplings with heterogeneous 
palladium catalysts. Tet. Lett. 35, 3277-3280 (1994).
109. Owton, W. M., Gallagher, P. T. & Juanmontesinos, A. Tert-butyl 3- 
carboxyethyl-3-phosphonodiethylpropionate - A novel reagent for Stobbe-like 
condensations. Synth. Comm. 23, 2119-2125 (1993).
110. Aliprantis, A. O. & Canary, J. W. Observation of catalytic intermediates in the 
suzuki reaction by electrospray mass spectrometry. J. Am. Chem. Soc. 116, 
6985-6986 (1994).
111. Hayashi, T., Konishi, M., Kobori, Y., Kumada, M., Higuchi, T. & Hirotsu, K.
Dichloro[l. r-bis(diphenylphosphino)ferrocene]palladium(II): An effective
catalyst for cross-coupling of secondary and primary alkyl Grignard and 
alkylzinc reagents with organic halides. J. Am. Chem. Soc. 106, 158-163 (1984).
112. Coulson, D. R. Tetrakis(triphenylphosphine) palladium (0). Inorg. Synth. 13, 
121-123 (1972).
113. Malan, C. & Morin, C. A concise preparation of 4-borono-L-phenylalanine (L- 
BPA) from L-phenylalanine. J. Org. Chem. 63, 8019-8020 (1998).
114. Segelstein, B. E., Butler, T. W. & Chenard, B. L. Equilibration of the oxidative 
addition product of tetrakis(triphenylphosphine) palladium and electron-rich aryl 
halides leads to product scrambling in the stille reaction. J. Org. Chem. 60, 12­
13 (1995).
115. Hitchcock, S. A., Mayhugh, D. R. & Gregory, G. S. Selectivity in palladium(O)- 
catalyzed cross-coupling reactions - Application to a tandem Stille reaction. Tet. 
Lett. 36, 9085-9088 (1995).
116. Brimble, M. A., Neville, D. & Duncalf, L. J. Synthesis of a dimeric 
pyranonaphthoquinone via a novel double furofuran annulation strategy. Tet. 
Lett. 39, 5647-5650 (1998).
117. Lan, A. J. Y., Heuckeroth, R. O. & Mariano, P. S. Electron-transfer-induced 
photocyclization reactions of arene-iminium salt systems. Effects of cation 
diradical deprotonation and desilylation on the nature and efficiencies of 
reaction pathways followed. J. Am. Chem. Soc. 109, 2738-2745 (1987).
118. AMRAD Operations (AMRAD, 2000). http://www.amrad.com.au.
119. Paitayatat, S., Tamchompoo, B., Thebtaranonth, Y. & Yuthavong, Y. 
Correlation of antimalarial activity of Artemisinin derivatives with binding 
affinity with ferroprotoporphyrin IX. J. Med. Chem. 40, 633-638 (1997).
120. Baltimore, D. Viral RNA-dependent DNA polymerase. Nature 226, 1209-1211 
(1970).
121. Temin, H. M. & Mizutani, S. RNA-dependant DNA polymerase in virions of 
Rous Sarcoma Virus. Nature 226, 1211-1213 (1970).
122. Telesnitsky, A. & Goff, S. P. “Reverse transcriptase and the generation of 
retroviral DNA.” in Retroviruses (eds. Coffin, J. M., Hughes, S. H. & Varmus, 
H. E.) 121-160 (Cold Spring Harbor Laboratory Press, New York, 1997).
123. Furman, P. A., Painter, G. R. & Anderson, K. S. An analysis of the catalytic 
cycle of HIV-1 reverse transcriptase: Opportunities for chemotherapeutic 
intervention based on enzyme inhibition. Curr. Pharm. Des. 6, 547-567 (2000).
124. Nanni, R. G., Ding, J. P., Jacobo-Molina, A., Hughes, S. H. & Arnold, E. 
Review of HIV-1 reverse transcriptase three-dimensional structure: Implications 
for drug design. Perspect. Drug Discov. Design 1, 129-150 (1993).
125. Arts, E. J. & Wainberg, M. A. Human immunodeficiency virus type 1 reverse 
transcriptase and early events in reverse transcription. Adv. Virus Res. 46, 97­
163 (1996).
126. Litvak, S. Retroviral Reverse Transcriptases (R. G. Landes Company, 
Heidelberg, Germany, 1996).
127. Gotte, M., Li, X. G. & Wainberg, M. A. HIV-1 reverse transcription: A brief 
overview focused on structure-function relationships among molecules involved 
in initiation of the reaction. Arch. Biochem. Biophys.. 365, 199-210 (1999).
128. Jonckheere, H., Anne, J. & De Clercq, E. The HIV-1 reverse transcription (RT) 
process as target for RT inhibitors. Med. Res. Rev. 20, 129-154 (2000).
129. Hostomsky, Z., Hughes, S. H., Goff, S. P. & Legrice, S. F. J. Redesignation of 
the RNase D activity associated with retroviral reverse transcriptase as RNase 
H*. /. Virol. 68, 1970-1971 (1994).
130. Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A. & Steitz, T. A. Crystal
o
structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an 
inhibitor. Science 256, 1783-1790 (1992).
131. Harris, D., Lee, R., Misra, H. S., Pandey, P. K. & Pandey, V. N. The p51 subunit 
of human immunodeficiency virus type 1 reverse transcriptase is essential in 
loading the p66 subunit on the template primer. Biochemistry 37, 5903-5908
(1998).
132. Jacobo Molina, A., Ding, J. P., Nanni, R. G., Clark, A. D., Lu, X. D., Tantillo, 
C., Williams, R. L., Kamer, G., Ferris, A. L., Clark, P., Hizi, A., Hughes, S. H. 
& Arnold, E. Crystal structure of human immunodeficiency virus type-1 reverse 
transcriptase complexed with double-stranded DNA at 3.0 Â resolution shows 
bent DNA. Proceed. Natl. Acad. Sci. USA. 90, 6320-6324 (1993).
133. Ren, J. S., Esnouf, R., Garman, E., Somers, D., Ross, C., Kirby, I., Keeling, J., 
Darby, G., Jones, Y., Stuart, D. & Stammers, D. High resolution structures of 
HIV-1 RT from four RT-inhibitor complexes. Nat. Struct. Biol.2, 293-302
(1995).
134. Ding, J., Das, K., Tantillo, C., Zhang, W., Clark, A. D., lessen, S., Lu, X., 
Hsiou, Y., Jacobomolina, A., Andries, K., Pauwels, R., Moereels, H., Koymans,
L., Janssen, P. A. J., Smith, R. H., Koepke, M. K., Michejda, C. J., Hughes, S. 
H. & Arnold, E. Structure of HIV-1 reverse transcriptase in a complex with the 
non-nucleoside inhibitor ct-APA R 95845 at 2.8 Â resolution. Structure 3, 365­
379 (1995).
135. Rodgers, D. W., Gamblin, S. J., Harris, B. A., Ray, S., Culp, J. S., Hellmig, B., 
Woolf, D. J., Debouck, C. & Harrison, S. C. The structure of unliganded reverse 
transcriptase from the human immunodeficiency virus type 1. Proceed. Natl. 
Acad. Sci. USA. 92, 1222-1226 (1995).
136. Huang, H. F., Chopra, R., Verdine, G. L. & Harrison, S. C. Structure of a 
covalently trapped catalytic complex of HIV-1 reverse transcriptase - 
Implications for drug resistance. Science 282, 1669-1675 (1998).
137. Bahar, L, Erman, B., Jemigan, R. L., Atilgan, A. R. & Coveil, D. G. Collective 
motions in HTV-1 reverse transcriptase: Examination of flexibility and enzyme 
function. J. Mol. Biol. 285, 1023-1037 (1999).
138. Ren, J. S., Esnouf, R., Hopkins, A., Ross, C., Jones, Y., Stammers, D. & Stuart,
D. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: 
lessons for inhibitor design. Structure 3, 915-926 (1995).
139. Ding, J. P., Das, K., Hsiou, Y., Sarafianos, S. G., Clark, A. D., Jacobo-Molina, 
A., Tantillo, C., Hughes, S. H. & Arnold, E. Structure and functional 
implications of the polymerase active site region in a complex of HTV-1 RT with 
a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 Ä 
resolution. J. Mol. Biol. 284, 1095-1111 (1998).
140. May, A. C. W. Pairwise iterative superposition of distantly related proteins and 
assessment of the significance of 3-D structural similarity. Prot. Eng. 9, 1093­
1101 (1996).
141. May, A. C. W. & Johnson, M. S. Improved genetic algorithm-based protein 
structure comparisons - Pairwise and multiple superpositions. Prot. Eng. 8, 873­
882 (1995).
142. Ren, J. S., Esnouf, R. M., Hopkins, A. L., Warren, J., Balzarini, J., Stuart, D. I. 
& Stammers, D. K. Crystal structures of HIV-1 reverse transcriptase in complex 
with carboxanilide derivatives. Biochemistry 37, 14394-14403 (1998).
143. Jäger, J., Smerdon, S. J., Wang, J. M., Boisvert, D. C. & Steitz, T. A. 
Comparison of three different crystal forms shows HIV-1 reverse transcriptase 
displays an internal swivel motion. Structure 2, 869-876 (1994).
144. Das, K., Ding, J. P., Hsiou, Y., Clark, A. D., Moereels, H , Koymans, L., 
Andries, K., Pauwels, R., Janssen, P. A. J., Boyer, P. L., Clark, P., Smith, R. H , 
Smith, M. B. K., Michejda, C. J., Hughes, S. H. & Arnold, E. Crystal structures 
of 8-C1 and 9-C1 TIBO complexed with wild-type HIV-1 RT and 8-C1 TIBO 
complexed with the Tyrl81Cys HIV-1 RT drug-resistant mutant. J. Mol. Biol. 
264, 1085-1100(1996).
145. Lesk, A. M. Extraction of well-fitting substructures - Root-mean-square 
deviation and the difference distance matrix. Folding Des. 2, S12-S14 (1997).
146. Lesk, A. M. Extraction of geometrically similar substructures - Least-squares 
and Chebyshev fitting and the difference distance matrix. Proteins 33, 320-328 
(1998).
147. Keller, P. A., Leach, S. P., Luu, T. T. T., Titmuss, S. J. & Griffith, R. 
Development of computational and graphical tools for the analysis of movement 
and flexibility in large molecules. J. Mol. Graph. Mod. 18, 235-241 (2000).
148. Paakkonen, K., Annila, A., Sorsa, T., Pollesello, P., Tilgmann, C., Kilpelainen,
I. , Karisola, P., Ulmanen, I. & Drakenberg, T. Solution structure and main chain 
dynamics of the regulatory domain (residues 1-91) of human cardiac troponin C.
J. Biol. Chem. 273, 15633-15638 (1998).
149. Nichols, W. L., Rose, G. D., Teneyck, L. F. & Zimm, B. H. Rigid domains in 
proteins - An algorithmic approach to their identification. Proteins 23, 38-48 
(1995).
~  2 9 8
150. Akke, M., Forsen, S. & Chazin, W. J. Solution structure of (Cd2+)i-calbindin D9k 
reveals details of the stepwise structural changes along the 
apo—>(Ca2+) in—KCa2+)2I,n binding pathway. J. Mol. Biol. 252, 102-121 (1995).
151. Leach, S. (1999). “ProFlex: A computational tool for the investigation and 
analysis of movement and flexibility in large molecules,” Honours, University of 
Wollongong, Wollongong.
152. Insightll® 97.0 (Molecular Simulations Inc., San Diego, CA, USA, 1997).
153. Excel® 97 (Microsoft Corporation, 1997).
154. Patel, P. H., Jacobomolina, A., Ding, J. P., Tantillo, C., Clark, A. D., Raag, R., 
Nanni, R. G., Hughes, S. H. & Arnold, E. Insights into DNA polymerization 
mechanisms from structure and function analysis of HIV-1 reverse transcriptase. 
Biochemistry 34, 5351-5363 (1995).
155. Divita, G., Muller, B., Immendorfer, U., Gautel, M., Rittinger, K., Restle, T. & 
Goody, R. S. Kinetics of interaction of HIV reverse transcriptase with 
primer/template. Biochemistry 32, 7966-7971 (1993).
156. Kati, W. M., Johnson, K. A., Jerva, L. F. & Anderson, K. S. Mechanism and 
fidelity of HIV reverse transcriptase. J. Biol Chem. 267, 25988-25997 (1992).
157. Hsieh, J. C., Zinnen, S. & Modrich, P. Kinetic mechanism of the DNA- 
dependent DNA polymerase activity of human immunodeficiency virus reverse 
transcriptase. J. Biol Chem. 268, 24607-24613 (1993).
158. Reardon, J. E. Human immunodeficiency virus reverse transcriptase: Steady- 
state and pre-steady-state kinetics of nucleotide incorporation. Biochemistry 31, 
4473-4479 (1992).
159. Huang, H. F., Harrison, S. C. & Verdine, G. L. Trapping of a catalytic HIV 
reverse transcriptase center*template : primer complex through a disulfide bond. 
Chem. Biol. 7, 355-364 (2000).
160. Sarafianos, S. G., Das, K., Ding, J. P., Boyer, P. L., Hughes, S. H. & Arnold, E. 
Touching the heart of HIV-1 drug resistance: the fingers close down on the 
dNTP at the polymerase active site. Chem. Biol.. 6, R137-R146 (1999).
161. Kaushik, N., Rege, N., Yadav, P. N. S., Sarafianos, S. G., Modak, M. J. & 
Pandey, V. N. Biochemical analysis of catalytically crucial aspartate mutants of 
human immunodeficiency virus type 1 reverse transcriptase. Biochemistry 35, 
11536-11546(1996).
162. Jonckheere, H., De Clercq, E. & Anne, J. Fidelity analysis of HIV-1 reverse 
transcriptase mutants with an altered amino-acid sequence at residues Leu74, 
Glu89, Tyrll5 , Tyrl83 andMetl84. Eur. J. Biochem. 267, 2658-2665 (2000).
163. Harris, D., Yadav, P. N. S. & Pandey, V. N. Loss of polymerase activity due to 
Tyr to Phe substitution in the YMDD motif of human immunodeficiency virus 
type-1 reverse transcriptase is compensated by Met to Val substitution within the 
same motif. Biochemistry 37, 9630-9640 (1998).
164. Pandey, V. N., Kaushik, N., Rege, N., Sarafianos, S. G., Yadav, P. N. S. & 
Modak, M. J. Role of methionine 184 of human immunodeficiency virus type-1 
reverse transcriptase in the polymerase function and fidelity of DNA synthesis. 
Biochemistry 35, 2168-2179 (1996).
299
165. Harris, D., Kaushik, N., Pandey, P. K., Yadav, P. N. S. & Pandey, V. N. 
Functional analysis of amino acid residues constituting the dNTP binding pocket 
of HIV-1 reverse transcriptase. J. Biol. Chem. 273, 33624-33634 (1998).
166. Boyer, P. L., Ferris, A. L. & Hughes, S. H. Cassette mutagenesis of the reverse 
transcriptase of human immunodeficiency virus type 1. J. Virol 66, 1031-1039
(1992).
167. Spence, R. A., Kati, W. M., Anderson, K. S. & Johnson, K. A. Mechanism of 
inhibition of HTV-1 reverse transcriptase by nonnucleoside inhibitors. Science 
267, 988-993 (1995).
168. Arnold, E., Ding, J. P., Hughes, S. H. & Hostomsky, Z. Structures of DNA and 
RNA polymerases and their interactions with nucleic acid substrates. Curr. 
Opin. Struct. Biol 5, 27-38 (1995).
169. Jacques, P. S., Wohrl, B. M., Ottmann, M., Darlix, J. L. & Legrice, S. F. J. 
Mutating the primer grip of p66 HIV-1 reverse transcriptase implicates 
tryptophan-229 in template-primer utilization. J. Biol Chem. 269, 26472-26478
(1994).
170. Ghosh, M., Jacques, P. S., Rodgers, D. W., Ottman, M., Darlix, J. L. & Legrice,
S. F. J. Alterations to the primer grip of p66 HIV-1 reverse transcriptase and 
their consequences for template-primer utilization. Biochemistry 35, 8553-8562
(1996).
171. Powell, M. D., Ghosh, M., Jacques, P. S., Howard, K. J., Legrice, S. F. J. & 
Levin, J. G. Alanine-scanning mutations in the primer grip of p66 HIV-1 reverse 
transcriptase result in selective loss of RNA priming activity. J. Biol. Chem. 272, 
13262-13269 (1997).
172. Palaniappan, C., Wisniewski, M., Jacques, P. S., Legrice, S. F. J., Fay, P. J. & 
Bambara, R. A. Mutations within the primer grip region of HIV-1 reverse 
transcriptase result in loss of RNase H function. J. Biol. Chem. 272, 11157- 
11164(1997).
173. Ghosh, M., Williams, J., Powell, M. D., Levin, J. G. & Legrice, S. F. J. Mutating 
a conserved motif of the HIV-1 reverse transcriptase palm subdomain alters 
primer utilization. Biochemistry 36, 5758-5768 (1997).
174. Fedoroff, O. Y., Ge, Y. & Reid, B. R. Solution structure of R(GAGGACUG)- 
D(CAGTCCTC) hybrid - Implications for the initiation of HIV-1 (+)-strand 
synthesis. J. Mol. Biol. 269, 225-239 (1997).
175. Szyperski, T., Gotte, M., Billeter, M., Perola, E., Cellai, L., Heumann, H. &
Wuthrich, K. NMR structure of the chimeric hybrid duplex
r(gcaguggc).r(gcca)d(CTGC) comprising the tRNA-DNA junction formed 
during initiation of HIV-1 reverse transcription. J. Biomol. NMR. 13, 343-355
(1999).
176. Elgavish, T., VanLoock, M. S. & Harvey, S. C. Exploring three-dimensional 
structures of the HIV-1 RNA/tRNALys3 initiation complex. J. Mol. Biol. 285, 
449-453 (1999).
177. Wisniewski, M., Palaniappan, C., Fu, Z. P., Le Grice, S. F. J., Fay, P. &
Bambara, R. A. Mutations in the primer grip region of HIV reverse transcriptase
can increase replication fidelity. J. Biol. Chem. 274, 28175-28184 (1999).
178. Lanchy, J. M., Keith, G., Legrice, S. F. J., Ehresmann, B., Ehresmann, C. & 
Marquet, R. Contacts between reverse transcriptase and the primer strand govern 
the transition from initiation to elongation of HIV-1 reverse transcription. J. 
Biol. Chem. 273, 24425-24432 (1998).
179. Pelemans, H., Esnouf, R., De Clercq, E. & Balzarini, J. Mutational analysis of 
Trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) 
identifies this amino acid residue as a prime target for the rational design of new 
non-nucleoside RT inhibitors. M ol Pharm. 57, 954-960 (2000).
180. Boyer, P. L., Ferris, A. L. & Hughes, S. H. Mutational analysis of the fingers 
domain of human immunodeficiency virus type 1 reverse transcriptase. J. Virol 
66, 7533-7537 (1992).
181. Boyer, P. L., Ferris, A. L., Clark, P., Whitmer, J., Frank, P., Tantillo, C., Arnold,
E. & Hughes, S. H. Mutational analysis of the fingers and palm subdomains of 
human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. J. Mol 
Biol 243, 472-483 (1994).
182. Chao, S. F., Chan, V. L., Juranka, P., Kaplan, A. H., Swanstrom, R. & 
Hutchison, C. A. Mutational sensitivity patterns define critical residues in the 
palm subdomain of the reverse transcriptase of human immunodeficiency virus 
type 1. Nucleic Acids Res. 23, 803-810 (1995).
183. Kew, Y., Olsen, L. R., Japour, A. J. & Prasad, V. R. Insertions into the (33-|34 
hairpin loop of HIV-1 reverse transcriptase reveal a role for fingers subdomain 
in processive polymerization. J. Biol Chem. 273, 7529-7537 (1998).
184. Kim, B., Ayran, J. C., Sagar, S. G., Adman, E. T., Fuller, S. M., Tran, N. H. & 
Horrigan, J. New human immunodeficiency virus, type 1 reverse transcriptase 
(HIV-1 RT) mutants with increased fidelity of DNA synthesis - Accuracy, 
template binding, and processivity. J. Biol. Chem. 274, 27666-27673 (1999).
185. Kim, B., Hathaway, T. R. & Loeb, L. A. Fidelity of mutant HIV-1 reverse 
transcriptases - Interaction with the single-stranded template influences the 
accuracy of DNA synthesis. Biochemistry 37, 5831-5839 (1998).
186. Sarafianos, S. G., Pandey, V. N., Kaushik, N. & Modak, M. J. Site-directed 
mutagenesis of arginine 72 of HIV-1 reverse transcriptase - Catalytic role and 
inhibitor sensitivity. J. Biol. Chem. 270, 19729-19735 (1995).
187. Kaushik, N., Harris, D., Rege, N., Modak, M. J., Yadav, P. N. S. & Pandey, V. 
N. Role of glutamine-151 of human immunodeficiency virus type-1 reverse 
transcriptase in RNA-directed DNA synthesis. Biochemistry 36, 14430-14438
(1997).
188. Kaushik, N., Talele, T. T., Pandey, P. K., Harris, D., Yadav, P. N. S. & Pandey, 
V. N. Role of glutamine 151 of human immunodeficiency virus type-1 reverse 
transcriptase in substrate selection as assessed by site-directed mutagenesis. 
Biochemistry 39, 2912-2920 (2000).
189. Sarafianos, S. G., Pandey, V. N., Kaushik, N. & Modak, M. J. Glutamine 151 
participates in the substrate dNTP binding function of HTV-1 reverse 
transcriptase. Biochemistry 34, 7207-7216 (1995).
190. Davies, J. F., Hostomsky, Z., Jordan, S. R. & Matthews, D. A. Crystal structure 
of the ribonucléase H domain of fflV-1 reverse transcriptase. Science 252, 88-95 
(1991).
191. Hughes, S. H., Arnold, E. & Hostomsky, Z. “RNase H of retroviral reverse 
transcriptases.” in Ribonucleases H  (eds. Crouch, R. J. & Toulme, J. J.) 195-224 
(Paris, 1998).
192. Gotte, M., Maier, G., Gross, H. J. & Heumann, H. Localization of the active site 
of HIV-1 reverse transcriptase-associated RNase H domain on a DNA template 
using site-specific generated hydroxyl radicals. J. Biol. Chem. 273, 10139-10146
(1998).
193. Destefano, J. J., Wu, W. M., Seehra, J., McCoy, J., Laston, D., Albone, E., Fay, 
P. J. & Bambara, R. A. Characterization of an RNase H deficient mutant of 
human immunodeficiency virus-1 reverse transcriptase having an aspartate to 
asparagine change at position 498. Biochim. Biophys. Acta - Gene Structure & 
Expression 1219, 380-388 (1994).
194. Mizrahi, V., Usdin, M. T., Harington, A. & Dudding, L. R. Site-directed 
mutatgenesis of the conserved Asp-443 and Asp-498 carboxy-terminal residues 
of HIV-1 reverse transcriptase. Nucleic Acids Res. 18, 5359-5363 (1990).
195. Smith, C. M., Smith, J. S. & Roth, M. J. RNase H requirements for the second 
strand transfer reaction of human immunodeficiency virus type 1 reverse 
transcription. J. Virol.. 73, 6573-6581 (1999).
196. Furfine, E. S. & Reardon, J. E. Human immunodeficiency virus reverse 
transcriptase ribonucléase H: Specificity of tRNALys3-primer excision. 
Biochemistry 30, 7041-7046 (1991).
197. Furfine, E. S. & Reardon, J. E. Reverse transcriptase RNase H from the human 
immunodeficiency virus: Relationship of the DNA polymerase and RNA 
hydrolysis activities. J. Biol. Chem. 266, 406-412 (1991).
198. Schatz, O., Mous, J. & Legrice, S. F. J. HIV-1 RT-associated ribonucléase H 
displays both endonuclease and 3'-5' exonuclease activity. EMBO Journal, 4 
(1990).
199. Gopalakrishnan, V., Peliska, J. A. & Benkovic, S. J. Human immunodeficiency 
virus type 1 reverse transcriptase: Spatial and temporal relationship between the 
polymerase and RNase H activities. Proceed. Natl. Acad. Sci. USA. 89, 10763­
10767 (1992).
200. Artzi, H. B., Shemesh, J., Zeelon, E., Amit, B., Kleiman, L., Górecki, M. & 
Panet, A. Ribonucléase H activity during initiation of reverse transcription using 
tRNALys/RNA primer/template of human immunodeficiency virus. Arch. 
Biochem. Biophys. 325, 209-216 (1996).
201. Smith, J. S. & Roth, M. J. Specificity of human immunodeficiency virus-1 
reverse rranscriptase-associated ribonucléase H in removal of the minus-strand 
primer, tRNALys3. J. Biol. Chem. 267, 15071-15079 (1992).
202. Wohrl, B. & Moelling, K. Interaction of HIV-1 ribonucléase H with polypurine 
tract containing RNA-DNA hybrids. Biochemistry 29, 10141-10147 (1990).
203. Zhan, X. Y., Tan, C. K., Scott, W. A., Mian, A. M., Downey, K. M. & So, A. G. 
Catalytically distinct conformations of the ribonucléase H of HIV-1 reverse 
transcriptase by substrate cleavage patterns and inhibition by azidothymidylate 
and/V-ethylmaleimide. Biochemistry 33, 1366-1372 (1994).
204. Cowan, J. A., Ohyama, T., Howard, K., Rausch, J. W., Cowan, S. M. L. & Le 
Grice, S. F. J. Metal-ion stoichiometry of the HIV-1 RT ribonucléase H domain: 
evidence for two mutually exclusive sites leads to new mechanistic insights on 
metal-mediated hydrolysis in nucleic acid biochemistry. J. Biol. Inorg. Chem. 5, 
67-74 (2000).
205. Ohtani, N., Haruki, M., Morikawa, M. & Kanaya, S. Molecular diversities of 
RNases H. J. Biosci. Bio eng. 88, 12-19 (1999).
206. Ding, J. P., Hughes, S. H. & Arnold, E. Protein-nucleic acid interactions and 
DNA conformation in a complex of human immunodeficiency virus type 1 
reverse transcriptase with a double-stranded DNA template-primer. Biopolymers 
44, 125-138 (1997).
207. Fan, N. S., Rank, K. B., Slade, D. E., Poppe, S. M., Evans, D. B., Kopta, L. A., 
Olmsted, R. A., Thomas, R. C., Tarpley, W. G. & Sharma, S. K. A drug 
resistance mutation in the inhibitor binding pocket of human immunodeficiency 
virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation. 
Biochemistry 35, 9737-9745 (1996).
208. Gao, H. Q., Boyer, P. L., Arnold, E. & Hughes, S. H. Effects of mutations in the 
polymerase domain on the polymerase, RNase H and strand transfer activities of 
human immunodeficiency virus type 1 reverse transcriptase. J. Mol. Biol. 277, 
559-572 (1998).
209. Palaniappan, C., Fay, F. J. & Bambara, R. A. Nevirapine alters the cleavage 
specificity of ribonucléase H of human immunodeficiency virus 1 reverse 
transcriptase. J. Biol. Chem. 270, 4861-4869 (1995).
210. Isel, C., Keith, G., Ehresmann, B., Ehresmann, C. & Marquet, R. Mutational 
analysis of the tRNALys3/HIV-l RNA (primer/template) complex. Nucleic Acids 
Res. 26, 1198-1204(1998).
211. Isel, C., Westhof, E., Massire, C., Le Grice, S. F. J., Ehresmann, B., Ehresmann, 
C. & Marquet, R. Structural basis for the specificity of the initiation of HIV-1 
reverse transcription. EMBO Journal 18, 1038-1048 (1999).
212. Wohrl, B. M., Krebs, R., Goody, R. S. & Restle, T. Refined model for 
primer/template binding by HIV-1 reverse transcriptase: Pre-steady-state kinetic 
analyses of primer/template binding and nucleotide incorporation events 
distinguish between different binding modes depending on the nature of the 
nucleic acid substrate. J. Mol. Biol.. 292, 333-344 (1999).
213. Yusupova, G., Lanchy, J. M., Yusupov, M., Keith, G., Legrice, S. F. J., 
Ehresmann, C., Ehresmann, B. & Marquet, R. Primer selection by HIV-1 reverse 
transcriptase on RNA-tRNALys3 and DNA-tRNALys3 hybrids. J. Mol. Biol. 261, 
315-321 (1996).
214. Smith, R. H., Michejda, C. J., Hughes, S. H., Arnold, E., Janssen, P. A. J. & 
Smith, M. B. K. Structure and mechanism of action of nonnucleoside inhibitors 
of HIV-1 reverse transcriptase - Strategies to combat drug resistance. Theochem- 
J. Mol. Struc. 423, 67-77 (1998).
215. Hsiou, Y., Das, K. Y., Ding, J. P., Clark, A. D., Kleim, J. P., Rosner, M., 
Winkler, I., Riess, G., Hughes, S. H. & Arnold, E. Structures of Tyrl88Leu 
mutant and wild-type HIV-1 reverse transcriptase complexed with the non­
nucleoside inhibitor HBY 097 - Inhibitor flexibility is a useful design feature for 
reducing drug resistance. J. M ol Biol 284, 313-323 (1998).
216. Hopkins, A. L., Ren, J. S., Esnouf, R. M., Willcox, B. E., Jones, E. Y., Ross, C., 
Miyasaka, T., Walker, R. T., Tanaka, H., Stammers, D. K. & Stuart, D. I. 
Complexes of HTV-1 reverse transcriptase with inhibitors of the HEPT series 
reveal conformational changes relevant to the design of potent non-nucleoside 
inhibitors. J. Med. Chem. 39, 1589-1600 (1996).
217. Esnouf, R. M., Ren, J. S., Hopkins, A. L., Ross, C. K., Jones, E. Y., Stammers, 
D. K. & Stuart, D. I. Unique features in the structure of the complex between 
HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 
explain resistance mutations for this nonnucleoside inhibitor. Proceed. Natl. 
Acad. Sei. USA. 94, 3984-3989 (1997).
218. Ren, J. S., Esnouf, R. M., Hopkins, A. L., Jones, E. Y., Kirby, I., Keeling, J., 
Ross, C. K., Larder, B. A., Stuart, D. I. & Stammers, D. K. 3'-Azido-3'- 
deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can 
induce long range conformational changes. Proceed. Natl. Acad. Sei. USA. 95, 
9518-9523 (1998).
219. Smerdon, S. J., Jäger, J., Wang, J., Kohlstaedt, L. A., Chirino, A. J., Friedman, J.
M., Rice, P. A. & Steitz, T. A. Structure of the binding site for nonnucleoside 
inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. 
Proceed. Natl. Acad. Sei. USA. 91, 3911-3915 (1994).
220. Maga, G., Amacker, M., Ruel, N., Hubscher, U. & Spadari, S. Resistance to 
nevirapine of HIV-1 reverse transcriptase mutants - Loss of stabilizing 
interactions and thermodynamic or steric barriers are induced by different single 
amino acid substitutions. J. Mol. Biol. 274, 738-747 (1997).
221. Bacheier, L. T. Resistance to non-nucleoside inhibitors of HIV-I reverse 
transcriptase. Drug Resistance Updates. 2, 56-67 (1999).
222. Hsiou, Y., Ding, J., Das, K., Clark, A. D., Hughes, S. H. & Arnold, E. Structure 
of unliganded HIV-1 reverse transcriptase at 2.7 Â resolution - Implications of 
conformational changes for polymerization and inhibition mechanisms. 
Structure 4, 853-860 (1996).
223. Ding, J. P., Das, K., Hsiou, Y., Zhang, W., Arnold, E., Yadav, P. N. S. & 
Hughes, S. H. “Structural studies of HIV-1 reverse transcriptase and 
implications for drug design.” in Structure-Based Drug Design 41-82 (Marcel 
Dekker, New York, 1997).
224. Doublie, S., Sawaya, M. R. & Ellenberger, T. An open and closed case for all 
polymerases. Structure 7, R31-R35 (1999).
m
225. Smith, M. B. K., Michejda, C. J., Hughes, S. H., Boyer, P. L., Janssen, P. A. J., 
Andries, K., Buckheit, R. W. & Smith, R. H. Molecular modeling of HIV-1 
reverse transcriptase drug-resistant mutant strains - Implications for the 
mechanism of polymerase action. Prot. Eng. 10, 1379-1383 (1997).
226. Fedoroff, O. Y., Salazar, M. & Reid, B. R. Structure of a DNA-RNA hybrid 
duplex - Why RNase H does not cleave pure RNA. /. Mol. Biol. 233, 509-523
(1993).
227. Isel, C., Ehresmann, C., Keith, G., Ehresmann, B. & Marquet, R. Initiation of 
reverse transcription of HIV-1 - Secondary structure of the HIV-1 
RNA/tRNALys3 (template/primer) complex. J. Mol. Biol. 247, 236-250 (1995).
228. Suo, Z. C. & Johnson, K. A. Effect of RNA secondary structure on the kinetics 
of DNA synthesis catalyzed by HIV-1 reverse transcriptase. Biochemistry 36, 
12459-12467 (1997).
229. Lu, X. J., Shakked, Z. & Olson, W. K. A-form conformational motifs in ligand- 
bound DNA structures. J. Mol. Biol. 300, 819-840 (2000).
230. Barat, C., Lullien, V., Schatz, O., Keith, G., Nugeyre, M. T., Gruninger-Leitch,
F., Barre-Sinoussi, F., LeGrice, S. F. & Darlix, J. L. HIV-1 reverse transcriptase 
specifically interacts with the anticodon domain of its cognate primer tRNA. 
EMBO Journal 8, 3279-3285 (1989).
231. Powell, M. D. & Levin, J. G. Sequence and structural determinants required for 
priming of plus-strand DNA synthesis by the human immunodeficiency virus 
type 1 polypurine tract. J. Virol. 70, 5288-5296 (1996).
232. Huber, H. E., McCoy, J. M., Seehra, J. S. & Richardson, C. C. Human 
immunodeficiency virus 1 reverse transcriptase: Template binding, processivity, 
strand displacement synthesis, and template switching. J. Biol. Chem. 264, 
4669-4678 (1989).
233. Reardon, J. E. Human immunodeficiency virus reverse transcriptase: A kinetic 
analysis of RNA-dependent and DNA-dependent polymerization. J. Biol. Chem. 
268, 8743-8751 (1993).
234. Lanchy, J. M., Ehresmann, C., Legrice, S. F. J., Ehresmann, B. & Marquet, R. 
Binding and kinetic properties of HIV-1 reverse transcriptase markedly differ 
during initiation and elongation of reverse transcription. EMBO Journal 15, 
7178-7187 (1996).
235. Thrall, S. H., Krebs, R., Wohrl, B. M., Cellai, L., Goody, R. S. & Restle, T. Pre­
steady-state kinetic characterization of RNA-primed initiation of transcription by 
HTV-1 reverse transcriptase and analysis of the transition to a processive DNA- 
primed polymerization mode. Biochemistry 37, 13349-13358 (1998).
236. Boyer, J. C., Bebenek, K. & Kunkel, T. A. Unequal human immunodeficiency 
virus type 1 reverse transcriptase error rates with RNA and DNA templates. 
Proceed. Natl. Acad. Sci. USA. 89, 6919-6923 (1992).
237. Essink, B. B. O. & Berkhout, B. The fidelity of reverse transcription differs in 
reactions primed with RNA versus DNA primers. J. Biomed. Sci. 6, 121-132
(1999).
238. Destefano, J. J., Mallaber, L. M., Fay, P. J. & Bambara, R. A. Determinants of 
the RNase H cleavage specificity of human immunodeficiency virus reverse 
transcriptase. Nucleic Acids Res. 21, 4330-4338 (1993).
239. Destefano, J. J., Mallaber, L. M., Fay, P. J. & Bambara, R. A. Quantitative 
analysis of RNA cleavage during RNA-directed DNA synthesis by human 
immunodeficiency and avian myeloblastosis virus reverse transcriptases. Nucleic 
Acids Res. 22, 3793-3800 (1994).
240. Gotte, M., Fackler, S., Hermann, T., Perola, E., Cellai, L., Gross, H. J., Legrice, 
S. F. J. & Heumann, H. HIV-1 reverse transcriptase-associated RNase H cleaves 
RNA/RNA in arrested complexes - Implications for the mechanism by which 
RNase H discriminates between RNA/RNA and RNA/DNA. EMBO Journal 14, 
833-841 (1995).
241. Reddy, M. R. & Parrill, A. L. “Overview of rational drug design.” in Rational 
Drug Design: Novel Methodology and Practical Applications (eds. Reddy, M. 
R. & Parrill, A. L.) 1-11 (American Chemical Society, Washington, 1999).
242. Lunney, E. A. & Humblet, C. “Structure-based design: From renin to HIV-1 
protease.” in Structure-Based Ligand Design (eds. Gubemator, K. & Boehm, H. 
J.) 37-71 (Wiley-VCH, Weinheim, 1998).
243. Schafer, W. “Rational design of inhibitors of HIV-1 reverse transcriptase.” in 
Structure-Based Ligand Design (eds. Gubemator, K. & Boehm, H. J.) 122-127 
(Wiley-VCH, Weinheim, 1998).
244. Gubemator, K., Heinze-Krauss, I., Angehm, P., Chamas, R. L., Hubschwerlen,
C. , Oefner, C., Page, M. G. P. & Winkler, F. K. “Structure-based design of 
potent beta-lactamase inhibitors.” in Structure-Based Ligand Design (eds. 
Gubemator, K. & Boehm, H. J.) 89-103 (Wiley-VCH, Weinheim, 1998).
245. Taylor, N. R. “Inhibition of sialidase.” in Structure-Based Ligand Design (eds. 
Gubemator, K. & Boehm, H. J.) 105-119 (Wiley-VCH, Weinheim, 1998).
246. Sprague, P. W. Automated chemical hypothesis generation and database 
searching with Catalyst®. Perspectives in Drug Discovery & Design 3, 1-20
(1995).
247. Clark, D. E., Murray, C. W. & Li, J. “Current issues in de novo molecular 
design.” in Reviews in Computational Chemistry (eds. Lipkowitz, K. B. & Boyd,
D. B.) 67-125 (Wiley-VCH, New York, 1997).
248. Gubemator, K. & Boehm, H. J. “Examples of active areas of structure based- 
design.” in Structure-Based Ligand Design (eds. Gubemator, K. & Boehm, H. 
J.) 15-36 (Wiley-VCH, Weinheim, 1998).
249. Gubemator, K. & Boehm, H. J. “Rational design of bioactive molecules.” in 
Structure-Based Ligand Design (eds. Gubemator, K. & Boehm, H. J.) 1-13 
(Wiley-VCH, Weinheim, 1998).
250. Sprague, P. W. & Hoffmann, R. “CATALYST pharmacophore models and their 
utility as queries for searching 3D databases.” in Computer-Assisted Lead 
Binding and Optimization: Current Tools for Medicinal Chemistry (eds. van de 
Waterbeemd, H., Testa, B. & Folkers, G.) 225-240 (VHCA Wiley-VCH, 
Weinheim, 1997).
m
*♦ Rdferertczs
251. Kubinyi, H. “Comparative molecular field analysis (COMFA).” in Encyclopedia 
o f Computational Chemistry (eds. Schleyer, P. v. R. et al.) 448-460 (John Wiley 
& Sons Ltd, Chichester, UK, 1998).
252. Kubinyi, H. Quantitative structure-activity relationships in drug design.” in 
Encyclopedia o f Computational Chemistry (eds. Schleyer, P. v. R. et a l)  2309­
2320 (John Wiley & Sons Ltd, Chichester, UK, 1998).
253. Greco, G., Novellino, E. & Martin, Y. C. “Approaches to three-dimensional 
quantitative structure-activity relationships.” in Reviews in Computational 
Chemistry (eds. Lipkowitz, K. B. & Boyd, D. B.) 183-240 (Wiley-VCH New 
York, 1997).
254. Oprea, T. I. & Waller, C. L. “Theoretical and practical aspects of three- 
dimemensional quantitative structure-activity relationships.” in Reviews in 
Computational Chemistry (eds. Lipkowitz, K. B. & Boyd, D. B.) 127-182 
(Wiley-VCH, New York, 1997).
255. Hogberg, T. & Norinder, U. “Theoretical and experimental methods in drug 
design applied on antipsychotic dopamine antagonists.” in A Textbook o f Drug 
Design and Development (eds. Krogsgaard-Larsen, P. & Bundgaard, H.) 55-91 
(Harwood Academic Publishers, Chur, Switzerland, 1991).
256. Cramer, R. D. I., Patterson, D. E. & Bunce, J. D. Comparative molecular field 
analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. 
J. Am. Chem. Soc. 110, 5959-5967 (1988).
257. Barreca, M. L., Carotti, A., Carrieri, A., Chimirri, A., Monforte, A. M., Calace, 
M. P. & Rao, A. Comparative molecular field analysis (CoMFA) and docking 
studies of non-nucleoside HIV-1 RT inhibitors (NNIs). Bioorg. Med. Chem. 7, 
2283-2292 (1999).
258. Clark, R. D., Leonard, J. M. & Strizhev, A. “Pharmacophore models and 
comparative molecular field analysis (CoMFA).” in Pharmacophore Perception, 
Development and Use in Drug Design (ed. Guner, O. F.) 153-169 (International 
University Line, La Jolla, California, 2000).
259. Diana, G. D., Kowalczyk, P., Treasurywala, A. M., Oglesby, R. C., Pevear, D. 
C. & Dutko, F. J. CoMFA analysis of the interaction of antipicomavirus 
compounds in the binding pocket of human rhinovirus-14. J. Med. Chem. 35, 
1002-1008 (1992).
260. Klebe, G. & Abraham, U. On the prediction of binding properties of drug 
molecules by comparative molecular field analysis. J. Med. Chem. 35, 70-80 
(1993).
261. Depriest, S. A., Mayer, D., Naylor, C. B. & Marshall, G. R. 3D-QSAR of 
angiotensin-converting enzyme and thermolysin inhibitors - A comparison of 
CoMFA models based on deduced and experimentally determined active site 
geometries. J. Am. Chem. Soc. 115, 5372-5384 (1993).
262. Klebe, G., Abraham, U. & Mietzner, T. Molecular similarity indices in a 
comparative analysis (CoMSIA) of drug molecules to correlate and predict their 
biological activity. J. Med. Chem. 37, 4130-4146 (1994).
W !
263.
Rdf&mm&s
Silverman, B. D. & Platt, D. E. Comparative molecular moment analysis 
(CoMMA) - 3D-QSAR without molecular superposition. J. Med. Chem 39 
2129-2140 (1996). ’
264. Milne, G. W. A. “Pharmacophore and drug discovery.” in Encyclopedia o f 
Computational Chemistry (eds. Schleyer, P. v. R. et al.) 2046-2056 (John Wiley 
& Sons Ltd, Chichester, UK, 1998).
265. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., 
Shindyalov, I. N. & Bourne, P. E. The protein data bank. Nucleic Acids Res. 28 
(2000).
266. Beddell, C. R. Designing drugs to fit a macromolecular receptor. Chem. Soc. 
Rev. 13, 279-319(1984).
261. Blaney, J. m. & Dixon, J. S. A good ligand is hard to find: Automated docking 
methods. Perspectives in Drug Discovery & Design 1, 301-319 (1993).
268. Joseph-McCarthy, D. Computational approaches to structure-based ligand 
design. Pharmacol. Ther.. 84, 179-191 (1999).
269. Koehler, K. F., Rao, S. N. & Snyder, J. P. “Modelling drug-receptor 
interactions.” in Guidebook on Molecular Modelling in Drug Design (ed. Cohen,
N. C.) 235-336 (Academic Press, San Diego, 1996).
270. Jones, G. & Willet, P. Docking small-molecule ligands into active sites. Curr. 
Opin. Biotech. 213, 627-630 (1995).
271. Rosenfeld, R., Vajda, S. & Delisi, C. Flexible docking and design. Ann. Rev. 
Biophys. Biomol. Struct. 24, 677-700 (1995).
272. Oshiro, C. M., Kuntz, I. D. & Dixon, J. S. Flexible ligand docking using a 
genetic algorithm. J. Comp. Aided. Mol. Des. 9, 113-130 (1995).
273. Lybrand, T. P. Ligand protein docking and rational drug design. Curr. Opin. 
Struct. Biol. 5, 224-228 (1995).
274. Leach, A. R. & Kuntz, I. D. Conformational analysis of flexible ligands in 
macromolecular receptor sites. J. Comp. Chem. 13, 730-748 (1992).
275. Leach, A. R. Ligand docking to proteins with discrete side-chain flexibility. J. 
Mol. Biol. 235, 345-356 (1994).
276. Goodford, P. A computational procedure for determining energetically favorable 
binding sites on biologically important macromolecules. J. Med. Chem. 28, 849­
857 (1985).
277. Bohm, H. J. LUDI: Rule-based automatic design of new substituents for enzyme 
inhibitor leads. J. Comp. Aided. Mol. Des. 6, 593-606 (1992).
278. Bohm, H. J. Site-directed structure generation by fragment-joining. Perspectives 
in Drug Discovery & Design 3, 21-33 (1995).
279. Bohm, H. J. & Fisccher, S. “De novo ligand design.” in Encyclopedia of 
Computational Chemistry (eds. Schleyer, P. v. R. et al.) 657-663 (John Wiley & 
Sons Ltd, Chichester, UK, 1998).
Unity 3D® 4.1 (Tripos, St. Louis, Missouri, 1999).280.
281. Cerius2 Structure Based Focusing® 4.5 (Molecular Simulations Inc., San Diego, 
CA, USA, 2000).
282. Venkatachalam, C. M., Kirchhoff, P. & Waldman, M. “Receptor-based 
pharmacophore perception and modeling.” in Pharmacophore Perception, 
Development and Use in Drug Design (ed. Guner, O. F.) 342-350 (International 
University Line, La Jolla, California, 2000).
283. Vedani, A., Dobler, M. & Zbinden, P. Quasi-atomistic receptor surface models - 
A bridge between 3-D QSAR and receptor modeling. J. Am. Chem. Soc. 120, 
4471_4477 (1998).
284. Griffith, R., Bremner, J. B. & Coban, B. “Docking-derived pharmacophores 
from models of receptor-ligand complexes.” in Pharmacophore Perception, 
Development and Use in Drug Design (ed. Guner, O. F.) 387-408 (International 
University Line, La Jolla, California, 2000).
285. Bremner, J. B., Coban, B., Griffith, R., Groenewoud, K. M. & Yates, B. F. 
Ligand design for cq adrenoceptor subtype selective antagonists. Bioorg. Med. 
Chem. 8, 201-214 (2000).
286. Thomas IV, B. E., Joseph-McCarthy, D. & Alvarez, J. C. “Pharmacophore- 
based molecular docking.” in Pharmacophore Perception, Development and Use 
in Drug Design (ed. Guner, O. F.) 353-367 (International University Line, La 
Jolla, California, 2000).
287. Schleifer, K. J., Tot, E. & Holtje, H. D. Pharmacophore and pseudoreceptor 
modelling of class lb antiarrhythmic and local anaesthetic lidocaine analogues. 
Pharmazie 53, 596-602 (1998).
288. Zbinden, P., Dobler, M., Folkers, G. & Vedani, A. PrGen - Pseudoreceptor 
modeling using receptor-mediated ligand alignment and pharmacophore 
equilibration. Quantit. Struct. Act. Relat. 17, 122-130 (1998).
289. Greenidge, P. A., Carlsson, B., Bladh, L. G. & Gillner, M. Pharmacophores 
incorporating numerous excluded volumes defined by x-ray crystallographic 
structure in three-dimensional database searching - Application to the thyroid 
hormone receptor. J. Med. Chem. 41, 2503-2512 (1998).
290. Gillner, M. & Greenidge, P. “The use of multiple excluded volumes derived 
from x-ray crystallographic structures in 3D database searching and 3D QSAR.” 
in Pharmacophore Perception, Development and Use in Drug Design (ed. 
Guner, O. F.) 373-384 (International University Line, La Jolla, California, 
2000).
291. Catalyst® 4.0 (Molecular Simulations Inc., San Diego, CA, USA, 1998).
292. LeapFrog® 4.1 (Tripos, St. Louis, Missouri, 1999).
293. Cerius2 LUDI® 4.5 (Molecular Simulations Inc., San Diego, CA, USA, 2000).
294. Garg, R., Gupta, S. P., Gao, H., Babu, M. S., Debnath, A. K. & Hansch, C. 
Comparative quantitative structure-activity relationship studies on anti-HIV 
drugs. Chem. Rev. 99, 3525-3601 (1999).
295. Clement, O. O. & Mehl, A. T. “HipHop: Pharmacophores based on multiple 
common feature alignments.” in Pharmacophore Perception, Development and 
Use in Drug Design (ed. Guner, O. F.) 71-84 (International University Line, La 
Jolla, California, 2000).
296. Li, H., Sutter, J. & Hoffmann, R. “HypoGen: An automated systems for 
generating 3D predictive pharmacophore models.” in Pharmacophore 
Perception, Development and Use in Drug Design (ed. Guner, O. F.) 173-189 
(International University Line, La Jolla, California, 2000).
297. Catalyst notes 4.0 (Molecular Simulations Inc., 1998). 
http://www.msi.com/support/catalyst.
298. Catalyst tutorials 4.0 (Molecular Simulations Inc., 1998). 
http://www.msi.com/doc/catalyst40/tutorials.
299. Sober, E. “Simplicity.” in A companion to the philosophy of science (ed. 
Newton-Smith, W. H.) (Blackwell Publishers Ltd, Oxford, UK, 2000).
300. Greene, J., Kahn, S., Savoj, H., Sprague, P. & Teig, S. Chemical function 
queries for 3D database search. J. Chem. Inform. Comp. Sci. 34, 1297-1308
(1994).
301. Archive of catalyst mailing list (Molecular Simulations Inc., 2000). 
http://www.msi.com/user/groups/catalyst/cat-archive-dir/index.html.
302. Catalyst 4.6® (Molecular Simulations Inc., San Diego, CA, USA, 2000).
303. Ren, J. S., Esnouf, R. M., Hopkins, A. L., Stuart, D. I. & Stammers, D. K. 
Crystallographic analysis of the binding modes of thiazoloisoindolinone non­
nucleoside inhibitors to HIV-1 reverse transcriptase and comparison with 
modeling studies. J. Med. Chem. 42, 3845-3851 (1999).
304. Ren, J. S., Nichols, C., Bird, L. E., Fujiwara, T., Sugimoto, H., Stuart, D. I. & 
Stammers, D. K. Binding of the second generation non-nucleoside inhibitor S- 
1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen 
bonding. J. Biol. Chem. 275, 14316-14320 (2000).
305. Fujiwara, T., Sato, A., Elfarrash, M., Miki, S., Abe, K., Isaka, Y., Kodama, M., 
Wu, Y. M., Chen, L. B., Harada, H., Sugimoto, H., Hatanaka, M. & Hinuma, Y. 
S-1153 inhibits replication of known drug-resistant strains of human 
immunodeficiency virus type 1. Antimicrob. Agents Chemother. 42, 1340-1345 
(1998).
306. Mertens, A., Zilch, H., Konig, B., Schafer, W., Poll, T., Kampe, W., Seidel, H., 
Lesser, U. & Leinert, H. Selective non-nucleoside HIV-1 reverse transcriptase 
inhibitors. New 2,3-dihydrothiazolo[2,3-a]isoindol-5(9b#)-ones and related 
compounds with anti-HIV activity. J. Med. Chem. 36, 2526-2535 (1993).
307. Catalyst® 4.5 (Molecular Simulations Inc., San Diego, CA, USA, 1999).
308. SitelD® 4.1 (Tripos, St. Louis, Missouri, 1999).
309. Sybyl® 6.6 (Tripos, St. Louis, Missouri, 1999).
310. SitelD Design Manual 6.6 (Tripos, 1999). http://www.tripos.com.
311. Carlson, H. A. & McCammon, J. A. Accommodating protein flexibility in 
computational drug design. Mol. Pharm. 57, 213-218 (2000).
310
312. Sudbeck, E. A., Mao, C., Vig, R., Venkatachalam, T. K., Tuel-Ahlgren, L. & 
Uckun, F. M. Structure-based design of novel 
dihydroalkoxybenzyloxopyrimidine derivatives as potent nonnucleoside 
inhibitors of the human immunodeficiency virus reverse transcriptase. 
Antimicrob. Agents Chemother. 42, 3225-3233 (1998).
313. Carlson, H. A., Masukawa, K. M. & McCammon, J. A. Method for including the 
dynamic fluctuations of a protein in computer-aided drug design. J. Phys. Chem. 
103, 10213-10219 (1999).
314. Masukawa, K. M., Carlson, H. A. & McCammon, J. A. “Technique for 
developing a pharmacophore model that accommodates inherent protein 
flexibility: An application to HIV-1 integrase.” in Pharmacophore Perception, 
Development and Use in Drug Design (ed. Guner, O. F.) 412-427 (International 
University Line, La Jolla, California, 2000).
315. Carlson, H. A., Masukawa, K. M., Rubins, K., Bushman, F. D., Jorgensen, W. 
L., Lins, R. D., Briggs, J. M. & McCammon, J. A. Developing a dynamic 
pharmacophore model for HIV-1 integrase. J. Med. Chem. 43, 2100-2114 
(2000).
316. Marriott, D. P., Dougall, I. G., Meghani, P., Liu, Y. J. & Flower, D. R. Lead 
generation using pharmacophore mapping and three-dimensional database 
searching: Application to muscarinic M3 receptor antagonists. J. Med. Chem. 42, 
3210-3216 (1999).
317. Fox, T. & Haaksma, E. E. J. Computer based screening of compound databases: 
1. Preselection of benzamidine-based thrombin inhibitors. J. Comp. Aided. Mol. 
Des. 14,411-425 (2000).
318. Unity User Guide 4.1 (Tripos, 1999). http://www.tripos.com.
319. Development Therapeutics Program (National Cancer Institute, 2000). 
http://dtp.nci.nih.gov/main.html and http://dtp.nci.nih.gov/docs/dtp_search.html.
320. Protein Data Bank (Research Collaboratory for Structural Bioinformatics, 2000). 
http://www.rcsb.org.
321. Genin, M. J., Poel, T. J., Yagi, Y., Biles, C., Althaus, I., Keiser, B. J., Kopta, L. 
A., Friis, J. M., Reusser, F., Adams, W. J., Olmsted, R. A., Voorman, R. L., 
Thomas, R. C. & Romero, D. L. Synthesis and bioactivity of novel 
bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors - Structure- 
activity relationships and increased metabolic stability of novel substituted 
pyridine analogs. J. Med. Chem. 39, 5267-5275 (1996).
322. Baba, M., Balzarini, J., Pauwels, R. & De Clercq, E. “HIV-1 specific reverse 
transcriptase inhibitors.” in Anti-AIDS Drug Development Challenges, Strategies 
and Prospects (eds. Mohan, P. & Baba, M.) 239-267 (Harwood Academic, 
1995).
323. Pauwels, R., Andries, K., Desmyter, J., Schols, D., Kukla, M. J., Breslin, H. J., 
Raeymaeckers, A., Gelder, J. V., Woestenborghs, R., Heykants, J., Schellekens,
K., Janssen, M. A. C., De Clerq, E. & Janssen, P. A. J. Potent and selective 
inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. 
Nature 343, 470-474 (1990).
324. Balzarini, J., Perezperez, M. J., Velazquez, S., Sanfelix, A., Camarasa, M. J., 
Declercq, E. & Karlsson, A. Suppression of the breakthrough of human 
immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide 
derivatives when used individually or in combination with other HIV-1 specific 
Inhibitors (ie, TSAO derivatives). Proceed. Natl Acad. Sci. USA. 92, 5470-5474
(1995) .
325. McMahon, J. B., Buckheit, R. W., Gulakowski, R. J., Currens, M. J., Vistica, D. 
T., Shoemaker, R. H., Stinson, S. F., Russell, J. D., Bader, J. P., Narayanan, V.
L. , Schultz, R. J., Brouwer, W. G., Felauer, E. E. & Boyd, M. R. Biological and 
biochemical anti-human immunodeficiency virus activity of UC 38, a new non­
nucleoside reverse transcriptase inhibitor. J Pharmacol Exp Thers 276, 298-305
(1996) .
326. Hargrave, K. D., Proudfoot, J. R., Grozinger, K. G., Cullen, E., Kapadia, S. R., 
Patel, U. R., Fuchs, V. U., Mauldin, S. C., Vitous, J., Behnke, M. L., Klunder, J.
M. , Pal, K., Skiles, J. W., McNeil, D. W., Rose, J. M., Chow, G. C., Skoog, M.
T., Wu, J. C., Schmidt, G., Engel, W. W., Eberlein, W. G., Saboe, T. D., 
Campbell, S. J., Rosenthal, A. S. & Adams, J. Novel non-nucleoside inhibitors 
of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and 
dipyridodiazepinones. J. Med. Chem. 34, 2231-2241 (1991).
327. Miyasaka, T., Tanaka, H., Baba, M., Hayakawa, H., Walker, R. T., Balzarini, J. 
& De Clerq, E. A novel lead for specific anti-HIV agents: l-[(2- 
hydroxyethoxy)methyl]-6-(phenylthio)thymine. J. Med. Chem. 32, 2507-2509 
(1989).
328. Pauwels, R., Andries, K., Debyser, Z., Van Daele, P., Schols, D., Stoffels, P., De 
Vreese, K., Woestenborghs, R., Vandamme, A. M., Janssen, C. G. M., Anne, J., 
Cauwenbergh, G., Desmyter, J., Heykants, J., Janssen, M. A. C., De Clerq, E. & 
Janssen, P. A. J. Potent and highly selective human immunodeficiency virus 
type 1 (HIV-1) inhibition by a series of a-anilinophenylacetamide derivatives 
targeted at HIV-1 reverse transcriptase. Proc. Natl Acad. Sci. USA 90, 1711­
1715 (1993).
♦
Appendices
♦ ♦
Appendix 7.1 Subdomains of reverse transcriptase
Subdomain Residues (CABM124) Residues (OCMS133)
fingers 1-84 and 120-150 
1-85 and 119-149
1-88 and 121-146
palm 85- 119 and 151-243
86- 118 and 150-244
89-120 and 147-242
thumb 244- 322
245- 320
243-311
connection 323-437
321-427
312-425
RNase H 438-560 426-560
Subdomains of RT as defined by the CABM (Center for Advanced Biotechnology and 
Medicine, Rutgers University, New Jersey) and OCMS (Oxford Centre for Molecular
°  J . . |24  133
Sciences, Oxford) research groups and their associates. ’
Appendix 7.2 Secondary structure of reverse transcriptase
CABM 132 OCMS133
sequence secondary structure sequence secondary structure
p66 p51
7-24 7-22 p o - p i 28-43 a l
28-44 28-44 aA 47-75 P1-P3
49-77 49-76 P2-P4 78-83 a2
78-83 78-84 aB 105-110 P4
86-112 87-111 p5a-p6 112-128 a3-a4
114-127 112-127 aC-aD 130-146 P5-P6
128-147 128-147 P7-P8 156-174 a5
155-174 155-174 aE 179-191 P7-P8
178-191 179-191 p9-p 10 195-211 a6
195-212 198-212 aF 227-241 P9-P11
214-242 Plla-P14 254-311 a7-a9
214-219 p lia 326-355 P12-P14
239-242 P14 364-383 alO
255-311 254-310 aH-aJ 388-391 P15
316-358 316-358 P15-P18 395-404 a l l
364-382 364-381 aK 413-416 P16
388-391 386-392 pl9 421-428 a l2
395-404 395-404 aL 439-470 P17-P19
408-430 P20-P22 474-488 al3
410-416 p20 492-497 p20
438-470 p l ’-p3’ 500-527 a l4 -a l5
474-488 aA ’ 530-535 P21
492-497 P4’
500-508 aB ’
516-527 aD ’
530-536 P5’
544-555 aE ’
Secondary structure nomenclature/definition for HIV-1 RT from the CABM and OCMS
U 132,133research groups.
In the OCMS secondary structure assignation a3 and a4 are 3io-helices; a l3 -a l5 , (39- 
p l l ,  and pi7-|321 are only seen in the p66 subunit; and P12 is only present in the p51 
subunit.
| Appendix 7.3 X-ray crystallographic structures of reverse transcriptase
PDB file HIV-1 RT Structure Crystal
Form
Resolution 
Range (Â)
R-Factor/ Free 
R-Factor (%)
Data
Completeness
(%)
IC50 (nM)
§
Reference *
ldlo unliganded RT C2 8.0-2.7 24.9/33.6 99.5# - 222
lhmv unliganded RT C2 6.0-3.2 25.4/29.7 85 - 135„ - * lrtj unliganded RT P2\2\2\ 25.0-2.35 21.9 89.5 - 29
lrtd RT/DNA/dNTP P2\2\2\ 12.0-3.2 22.4/29.8 92.2 _ 136
2hmi RT/DNA/Fab P3212 8.0-2.8 27.1/35.2 74.8 - 132,139
lbqm RT-HBY 097 C2 10.0-3.1 25.8/36.2 99.1 45 215
lbqn RT-HBY 097 
Tyrl88Leu mutant
C2 10.0-3.3 24.5-36.2 95.1 600 215
lhni RT/Br-a-APA (R95845) C2 10.0-2.8 25.5/36 78.5 - 134
lhnv RT/8-C1TIBO (R86183) C2 10.0-3.0 24.9/35.6 81 4.6 30,144
lklm* RT/BHAP(U-90152) P2{2\2X 20.0-2.65 23.7/31.3 86.8 1100/260 217,321,322
lrev * RT/9-C1 TIBO (R82913) P2\2{2\ 25.0-2.6 22.4 80.7 600/1.5 138,323
lrtl RT/MKC-422 P2\2{2\ 25.0-2.55 19.7 95.5 8 216
lrt2 RT/TNK-651 P2{2\2\ 20.0-2.55 20.7 85.3 6 216
lrt3 RT/1051U91 
RTMC mutant
P2X2{2X 25.0-3.0 26.4/33.5 83.3 400 218
lrt4 RT/UC781 P2{2{2X 30.0-2.9 23.7/29.5 93.6 142
lrt5 RT/UC10 P2{2<2x 30.0-2.9 23.1/29.1 86.1 200 142,324
Irt6 RT/UC38 P2i2i2i 30.0-2.8 23.6/33.5 95.7 150 142,325
lrt7 RTAJC84 P2\2\2\ 30.0-3.0 25.8/33.4 87.3 280 142,325
lrth RT/1051U91 P2\2\2\ 25.0-2.2 21.4 81.4 400 133,326
lrti RT/HEPT P2\2\2\ 25.0-3.0 23.6 86.3 17 000 133,327
ltvr RT/9-C1 TEBO (R82913) C2 10.0-3.0 25.9 00 4̂ =
8:
33 144
luwb RT/8-C1 TIBO (R86183) C2 15.0-3.2 27.4/36.0 85 130 144
Tyrl81Cys mutant
lvrt RT/nevirapine P2{2\2\ 25.0-2.2 18.6 87.1 84 133,326
lvru RT/Cl-a-APA (R90385) P2l2l2l 25.0-2.4 18.7 86.5 5 133,328
3hvtf RT/nevirapine C2 8.0-2.9 26.6 95.6 84 130,219,326
Crystal structures of HIV-1 RT. (Adapted from223)
* Crystal structures were prepared by soaking out HEPT from a HEPT/RT complex, and then soaking in the new inhibitor, if applicable.
f Crystal structure was unsuitable for use in superposition because residues with poor or missing sidechain electron density were treated as 
alanine residues.
s IC50 values used were obtained preferably from the same publication that reported the crystallographic data. In cases where this was not 
possible, IC50 were obtained from publications reporting the synthesis of the inhibitors. Where more than one IC50 was obtained, the first one 
was used for graphical analysis.
* First (and second reference for lhnv.pdb) refers to the crystal structure and may also include the IC50 value. Following references are for IC50 
data.
* Data completeness overall for range.
Appendix 7.3.1 Additional-ray crystallographic structures of reverse transcriptase
PDB file HIV-1 RT Structure Crystal
Form
Resolution 
Range (À)
R-Factor/ Free 
R-Factor (%)
Data
Completeness
(%)
IC50 (nM)
§
Reference
lep4 RT/S-1153 P2\2\2\ 30.0-2.5 25.4/33.0 90.9* 450 304 305
IcOt RT/BM+21.1326 P2\2\2\ 20.0-2.7 21.4/27.6 81.2* 4100 303 306
IcOu RT/BM+50.0934 P2\2\2\ 15.0-2.52 23.2/29.8 88.8* 220 303 306 ?
Additional crystal structures of HIV-1 RT.
§ c
I IC50 values used were obtained preferably from the same publication that reported the crystallographic data. In cases where this was not
^  possible, IC50 were obtained from publications reporting the synthesis of the inhibitors. Where more than one IC50 was obtained, the first one
was used for graphical analysis.
j * First references refers to the crystal structure, the following references are for IC50 data.
| # Data completeness overall for range.
Appendix 7.4 Displacement data for comparison of superimposition techniques (I)
DDM derived superimposition Superimposition of Ding et
a l m
Residue unliganded a-APA unliganded a-APA
177 1.49 3.68 1.15 0.92
178 0.90 3.04 0.73 0.57
179 1.19 2.97 0.28 0.38
180 1.20 2.81 0.86 0.53
181 1.02 2.80 0.88 0.74
182 1.24 2.72 0.29 0.46
183 1.27 2.76 0.87 0.40
184 2.05 2.82 0.79 0.85
185 2.31 3.10 1.15 0.92
186 1.56 2.87 0.81 0.30
187 1.43 2.66 0.36 0.28
188 0.94 2.81 0.72 0.56
189 1.43 3.22 0.98 0.93
190 1.46 3.78 0.65 0.51
191 1.31 4.14 0.49 0.56
192 1.36 4.59 0.65 0.72
RMSD 0.997 1.897 0.774 0.638
Displacement of Ca atom of an unliganded and a liganded crystal structure 
superimposed onto 2hmi using difference distance matrices derived subset and a subset 
of Ding et al. Values for the Ca atom displacement using the Ding et al. subset have 
been generated following the reference procedure.
The DDM derived subset is composed of the backbone residues of 376 residues, a total 
of 1528 atoms. The Ding et al. subset is defined as being comprised of the Ca atoms of 
the p9-(310 hairpin (residues 177-192), a total of 16 atoms.
Crystal structure PDB file
unliganded ldlo
a-APA lvru
unliganded 2hmi
Appendix 7.5 Displacement data for comparison of superimposition techniques (II)
DDM derived superimposition Superimposition of Ren et al.138
Residue 1051U91 a-APA HEPT Cl-TIBO 1051U91 a-APA HEPT Cl-TIBO
Pro95 0.50 0.47 0.57 0.21 0.7 0.7 0.7 0.2
Leu100 0.27 0.40 0.26 0.34 0.3 0.2 0.7 0.6
LyslOl 0.46 0.32 0.63 0.34 0.4 0.2 0.5 0.5
Lysl03 0.65 0.43 1.50 0.22 0.3 0.4 0.3 0.4
Vall06 0.73 1.00 1.50 0.69 0.3 0.7 0.4 0.6
Vall79 0.43 0.38 1.69 1.01 0.3 0.3 0.7 0.6
Tyrl81 0.44 0.29 1.13 0.67 0.5 0.1 0.5 0.4
Tyrl83 0.18 0.40 0.56 0.53 0.5 0.2 0.6 0.5
Tyrl88 0.69 0.59 1.10 0.93 0.6 0.2 0.5 0.7
Vail 89 0.60 0.55 1.32 0.78 0.4 0.3 0.3 0.5
Glyl90 0.62 0.74 1.29 0.75 0.3 0.4 0.1 0.5
Pro225 0.92 0.29 1.46 0.33 0.4 0.3 0.4 0.2
Phe227 0.99 0.21 1.33 0.71 0.7 0.4 0.4 0.7
Trp229 1.27 0.22 1.30 0.25 0.9 0.1 0.2 0.3
Leu234 0.86 0.36 1.25 0.37 0.3 0.1 0.6 0.2
His235 0.83 0.36 1.75 0.38 0.3 0.1 1.8 0.2
Pro236 0.69 0.58 2.74 0.48 0.3 0.2 2.7 0.6
Tyr318 0.28 0.24 0.35 0.22 0.5 0.1 0.7 0.1
Glul38 0.51 0.73 0.32 0.30 0.4 1.5 0.8 0.2
No.
Atoms
1528 1528 1528 1528 102 109 96 109
RMSD 0.74 0.43 0.81 0.43 0.5 0.4 0.5 0.5
Displacement of Ca atom of liganded crystal structures superimposed onto lvrt using 
difference distance matrices derived subset and ‘core’ subset of Ren et a l m  The 
number of atoms used in each superimposition and the resultant RMSD are noted. 
Values for the Ca atom displacement using the ‘core’ subset have been taken directly 
from the reference paper.
The ‘core’ subset is defined as being comprised of the Ca atoms of residues 94-118, 
156-215 and 225-243 of the palm subdomain, and 317-319 of the connection subdomain 
of p66, and residues 137-139 from the fingers domain of p51.
Ligand PDB file
1051U91 lrth
a-APA lvru
HEPT lrti
Cl-TIBO lrev
nevirapine lvrt
Appendix 7.6 Subset definitions
Subset Residues
PAS 110, 183-186
primer grip 
template grip 
RNase H active site 
NNIBP
227-235
73-83, 86-93, 148-154 
443,478,498, 539, 549
100, 101, 103, 106, 179, 181, 188, 190, 227, 229, 
234, 235, 236,318, 138 (p51)
Residues defining subsets investigated. All residues are from the p66 subunit, unless 
otherwise stated.
Appendix 7.7 Displacement data for the PAS
\ lrtd 2hmi lhmv lbqm lbqn lhni lhnv Iklm lrev Irti lrt2
Aspi 10 N 0.60 1.98 0.79 2.58 2.62 2.29 2.86 1.46 2.39 2.22 2.21
\ Aspi 10 CA 0.61 2.09 0.75 2.79 2.71 2.53 3.06 1.64 2.63 2.42 2.38
1 Aspi 10 C 0.41 2.01 0.80 2.56 2.44 2.18 2.63 1.56 2.48 2.28 2.24i
Aspi 10 O 0.62 2.04 0.82 3.08 2.75 2.21 2.70 1.65 2.72 2.51 2.57! Aspi 10 CB 0.95 2.03 0.67 3.22 3.10 2.96 3.67 1.94 2.94 2.91 3.08
j Aspi 10 CG 1.22 3.53 0.83 3.67 3.71 3.67 4.56 2.82 2.18 2.75 3.34
Aspi 10 ODI 1.80 4.75 2.96 3.96 4.22 4.19 5.66 3.33 3.67 2.78 3.74
Aspi 10 OD2 2.99 4.65 1.54 3.78 3.75 2.85 4.33 3.18 0.73 2.61 3.28
Tyrl83 N 0.77 1.29 1.09 2.13 1.94 1.64 2.38 1.17 2.13 1.31 1.07
Tyrl83 CA 0.75 1.27 1.16 2.18 2.01 1.80 2.37 1.41 2.24 1.53 1.33
Tyrl83 C 1.00 1.38 0.97 2.38 2.14 1.98 1.34 2.30 1.51 1.32
g
Tyrl83 0 1.00 1.48 0.93 2.70 2.50 2.66 1.69 2.69 1.85 1.66
Tyrl83 CB 0.59 1.35 1.46 2.42 2.16 2.60 2.84 2.13 2.82 2.11 1.91
Tyrl83 CG 0.61 1.41 1.58 2.37 2.23 2.28 2.75 2.76 3.04 2.58 2.14
Tyrl83 CD1 1.51 1.82 1.85 1.90 1.84 1.76 2.45 3.05 2.95 2.71 2.23
Tyrl83 CD2 0.72 1.50 1.58 2.88 2.72 2.63 3.14 3.29 3.52 3.05 2.31
Tyrl83 CE1 1.53 1.80 1.91 1.92 2.00 1.47 2.36 3.71 3.26 3.17 2.46
Tyrl83 CE2 
Tyrl83 C2
0.69 1.56 1.64 2.93 2.89 2.35 3.06 3.86 3.72 3.48 2.55
Tyrl83 OH 0.56 1.43 1.73 2.57 2.78 1.41 2.44 4.63 3.84 3.95 2.84
Metl84 N 1.56 1.64 0.96 2.23 1.91 1.58 1.88 1.05 1.99 1.28 0.98
; Metl84 CA 2.16 2.05 0.88 2.52 2.08 2.22 2.09 1.03 2.10 1.27 1.07
Metl84 C 2.27 2.23 0.87 2.83 2.58 2.44 2.70 1.20 2.32 1.40 1.38
Metl84 0 2.45 2.42 0.88 3.99 3.84 3.15 3.53 1.57 2.52 1.89 2.09
Metl84 CB 2.31 1.99 0.95 3.00 2.12 3.25 2.72 1.47 2.59 1.70 1.43
Metl84 CG 2.87 3.02 0.99 3.08 2.32 3.57 2.70 2.81 2.75 3.28 1.76
Metl84 SD 6.05 5.40 1.17 3.80 4.47 5.13 4.56 2.03 3.96 2.44 2.23
j Metl84 CE 7.36 5.77 3.79 6.78 6.99 7.34 7.26 4.94 6.02 5.39 4.91
<#»
I
lrt3 lrt4 lrt5 lrt6 lrt7 lrth Irti ltvr luwb lvrt lvru j
1.70 1.84 2.13 1.26 1.79 2.49 1.44 2.61 2.78 1.95 2.55 j
1.91 2.14 2.38 1.42 1.98 2.73 1.61 2.90 2.95 2.26 2.80 \
1.53 2.09 2.30 1.39 1.85 2.50 1.47 2.23 2.48 2.16 2.60 I
1.86 2.12 2.38 1.53 2.02 2.60 1.52 1.90 2.48 2.12 2.64 if
2.51 2.42 2.65 1.50 2.09 3.29 2.10 3.79 3.61 2.59 3.22
l
Ì
2.50 3.40 3.42 2.19 1.95 3.66 2.60 4.55 4.43 3.07 4.27 \
3.84 4.01 4.38 2.59 3.95 4.02 2.70 5.02 5.16 3.60 4.91
j
1.85 3.71 3.29 2.46 0.87 3.66 2.97 4.73 4.48 3.09 4.60 1Í1
0.77 1.75 1.89 1.34 1.41 1.96 1.14 2.74 2.32 1.82 2.26 fi
0.91 1.84 1.94 1.36 1.58 1.97 1.47 2.69 2.25 1.95 2.33 I
0.90 1.84 2.00 1.43 1.58 1.95 1.42 2.72 2.31 1.89 2.27
1
1.29 2.24 2.43 1.81 1.94 2.27 1.79 3.33 2.82 2.39 2.60 !i
1.65 2.52 2.54 1.86 2.20 2.57 2.32 3.51 2.79 2.84 2.99 !
1.98 2.94 2.89 2.24 2.66 3.07 2.61 3.36 2.51 3.06 3.39 1
2.35 2.96 2.87 4.57 2.76 3.17 2.88 5.06 4.38 2.93 3.35 i
2.26 3.46 3.37 0.51 3.13 3.64 2.98 1.77 0.92 3.46 3.96 !
2.83 3.40 3.27 4.97 3.21 3.68 3.19 4.87 4.16 3.15 3.77
j
j
2.53 3.84 3.70 0.73 3.56 4.10 3.16 1.61 0.72 3.65 4.31 j
3.19 4.17 4.03 3.39 4.00 4.53 3.38 2.73 1.75 3.69 4.61
1
0.55 1.48 1.65 1.21 1.34 1.64 1.16 2.15 1.88 1.46 1.94 j
0.77 1.64 1.78 1.28 1.37 1.66 1.52 2.49 2.15 1.86 2.10 j
1.10 1.91 2.11 1.54 1.49 1.88 1.65 2.75 2.48 2.15 2.31
1.38 2.30 2.63 1.99 1.79 2.39 1.91 2.87 2.49 2.61 2.64 j
1.12 2.16 2.31 1.65 1.86 2.10 2.06 3.10 2.71 2.47 2.52
1.49 2.35 2.59 3.13 3.46 3.73 2.41 3.26 2.99 2.98 3.14
1.87 4.07 4.27 2.53 2.73 3.36 3.11 5.76 4.78 3.40 3.35 I4.91 6.34 6.25 5.66 5.59 6.22 3.81 7.92 7.42 4.97 6.04
Appendix 7.7 Displacement data for the PAS (cont.)
lrtd 2hmi lhmv lbqm lbqn lhni lhnv lklm lrev Irti lrt2 lrt3 lrt4 lrt5 lrt6 lrt7 lrth Irti ltvr luwb lvrt lvru
! Asp185 N 2.23 2.27 0.81 1.82 1.59 1.90 2.37 1.08 2.32 1.17 0.96 1.09 1.80 1.96 1.38 1.40 1.75 1.44 2.61 2.73 1.76 2.08
j Asp 185 CA 2.18 2.31 0.80 2.17 2.09 2.31 2.88 1.41 2.64 1.47 1.26 1.53 2.09 2.32 1.75 1.71 2.02 1.53 2.86 3.15 2.06 2.32
j Asp 185 C 1.88 2.10 0.93 2.26 2.23 2.46 3.18 1.64 2.83 1.80 1.68 1.72 2.36 2.63 1.98 1.90 2.35 1.70 3.10 3.33 2.43 2.56
! Asp 185 O 2.31 2.30 0.94 2.42 2.45 2.71 3.51 1.74 2.90 2.02 2.01 1.91 2.66 2.93 2.20 2.03 2.56 2.10 3.14 3.61 2.87 2.91
j Asp 185 CB 2.29 2.43 0.59 2.20 2.23 2.40 3.28 1.20 2.62 1.23 0.86 1.58 2.13 2.38 1.57 1.60 2.06 1.09 3.04 3.49 1.60 1.90
j Asp 185 CG 2.26 2.62 0.62 3.31 3.36 3.58 3.34 2.63 4.63 2.41 1.90 3.04 2.09 2.34 3.23 2.95 2.08 0.98 2.97 3.62 3.54 3.31
! Asp 185 ODI 2.57 3.56 0.84 4.75 4.94 5.88 3.93 5.10 6.59 4.86 4.33 4.96 2.30 2.87 5.68 5.37 2.77 1.09 3.00 5.13 5.77 5.50
| Aps 185 OD2 2.30 2.38 1.72 3.36 3.39 3.20 3.01 1.46 4.80 1.13 0.68 2.78 1.85 1.84 2.17 1.73 1.52 2.55 3.14 2.55 3.20 2.62
| Asp186 N 1.21 1.76 1.04 2.27 2.15 2.39 3.11 1.74 2.95 1.84 1.72 1.72 2.27 2.55 1.96 1.89 2.41 1.54 3.09 3.20 2.35 2.57
j Asp 186 CA 0.83 1.56 1.20 2.39 2.29 2.52 3.40 1.98 3.09 2.16 2.16 1.95 2.52 2.80 2.17 2.06 2.70 1.64 3.29 3.40 2.71 2.88
I Asp186 C 0.68 1.39 0.95 2.38 2.17 2.35 3.04 1.68 2.83 1.86 1.78 1.87 2.23 2.46 1.82 1.71 2.37 1.39 2.95 2.92 2.41 2.62
Asp 186 0 0.67 1.38 0.88 3.13 2.37 2.56 3.28 2.18 3.25 2.39 2.33 2.53 2.64 2.78 2.05 1.98 2.39 1.76 3.71 3.19 3.08 3.20
H  Asp 186 CB 0.94 1.39 1.49 2.39 2.44 2.63 3.75 2.16 3.26 2.42 2.56 2.05 2.80 3.09 2.38 2.36 3.04 1.87 3.51 3.78 3.12 3.36
i Aspl86CG 1.08 2.73 1.60 2.39 2.57 2.67 4.24 2.44 3.61 2.79 2.86 2.31 3.22 3.56 2.92 2.93 3.38 2.26 3.95 4.44 3.56 3.75
| Asp 186 ODI 0.97 4.04 1.71 3.19 3.44 3.30 4.86 2.36 3.90 3.11 3.36 2.94 3.68 4.11 3.18 2.80 3.84 2.27 4.82 5.37 4.11 4.37
! Asp 186 OD2 2.10 3.24 1.64 2.09 2.64 2.28 4.92 2.84 4.67 2.79 2.75 2.48 3.21 3.55 3.13 3.64 3.32 2.62 3.81 4.31 3.48 3.74
The measured distances between the unliganded (ldlo) structure and each RT structure for all the atoms of the residues of polymerase active site.
Appendix 7.8 Displacement data for the primer grip
1 lrtd 2hmi lhmv lbqm lbqn lhni lhnv lklm lrev Irti lrt2
Phe227 N 0.92 1.62 0.75 4.47 4.49 4.32 4.58 2.09 3.51 3.08 2.72
Phe227 CA 0.88 1.50 0.85 4.94 4.85 4.59 4.90 2.70 3.94 3.67 3.20
Phe227 C 0.91 1.45 0.70 4.88 4.80 4.47 4.80 2.73 3.83 3.67 3.10
1 Phe227 O 0.76 1.42 0.72 4.67 4.59 4.12 4.55 2.46 3.66 3.32 2.84
Phe227 CB 0.84 1.36 0.95 5.10 4.77 4.57 5.05 2.87 4.22 3.90 3.58
Phe227 CG 0.67 1.55 0.92 5.48 6.26 4.63 5.12 2.93 4.47 4.10 3.70
Phe227 CD1 0.87 1.78 1.00 6.09 6.01 4.87 5.28 3.12 4.76 4.45 3.70
Phe227 CD2 0.39 1.56 0.82 5.35 8.36 4.49 5.05 2.91 4.53 4.12 3.87
Phe227 CEI 0.75 1.96 0.97 6.51 7.60 4.99 5.36 3.19 5.01 4.70 3.80
Phe227 CE2 0.26 1.80 0.78 5.85 10.12 4.58 5.11 2.97 4.83 4.44 4.02
Phe227 CZ 0.42 1.97 0.85 6.39 9.67 4.84 5.26 3.07 5.01 4.67 3.94
Leu228 N 1.09 1.49 0.57 5.05 4.94 4.79 5.01 3.21 4.11 4.15 3.41
Leu228 CA 1.08 1.47 0.33 5.04 4.96 4.77 5.00 3.51 4.25 4.34 3.56
Leu228 C 1.05 1.31 0.27 5.21 5.14 5.01 5.40 4.10 4.78 4.96 4.06
Leu228 0 1.11 1.22 0.71 5.97 6.19 5.54 6.07 4.96 5.49 5.31 4.53
Leu228 CB 1.19 1.59 0.28 5.17 4.77 5.01 5.02 3.62 4.41 4.59 3.56
Leu228 CG 0.87 1.11 0.87 6.85 5.23 4.90 4.73 3.21 4.34 4.44 3.30
Leu228 CD1 0.75 3.03 1.89 7.54 5.45 5.92 5.34 3.94 5.67 5.69 2.08
Leu228 CD2 1.48 1.64 0.88 7.09 4.44 3.61 3.71 2.78 2.04 3.53 3.61
Trp229 N 0.99 1.21 0.81 4.59 4.22 4.71 5.12 3.67 4.44 5.14 3.89
Trp229 CA 0.97 1.13 0.81 4.65 4.21 4.88 5.36 4.11 4.85 5.71 4.32
Trp229 C 1.19 1.23 0.80 4.68 4.27 4.73 5.07 4.41 4.82 5.93 4.54
Trp229 0 1.45 1.35 0.82 4.65 4.44 4.36 4.75 4.23 4.59 5.72 4.38
Trp229 CB 0.85 1.10 0.77 4.58 4.29 4.77 5.32 4.10 4.80 5.71 4.33
Trp229 CG 0.99 1.07 0.75 4.77 4.52 4.98 5.44 4.19 5.21 5.25 4.50
Trp229 CD1 1.01 1.08 0.90 5.53 5.45 5.46 5.63 4.51 5.59 5.36 4.56
Trp229 CD2 1.20 1.14 0.74 5.14 4.77 4.72 5.45 4.05 5.26 5.06 4.60
Trp229 NEI 1.17 1.16 1.00 5.54 5.28 5.49 5.76 4.57 5.85 5.26 4.67
Trp229 CE2 1.26 1.20 0.88 4.98 4.64 5.06 5.66 4.29 5.67 5.08 4.70
Irt3 lrt4 lrt5 lrt6 lrt7 lrth Irti ltvr luwb lvrt lvru !
2.89 2.62 2.64 2.89 3.06 2.61 2.22 5.50 5.07 3.43 3.35 1
3.48 3.17 3.30 3.48 3.65 3.08 2.73 5.77 5.32 3.89 3.82 1
3.42 3.15 3.26 3.48 3.68 2.98 2.77 5.71 5.26 3.72 3.63 \
3.08 2.79 2.92 3.12 3.34 2.66 2.55 5.47 5.06 3.32 3.23 Î
3.85 3.39 3.59 3.66 3.83 3.35 3.07 5.61 5.27 4.16 4.12 1
3.98 3.76 3.95 3.95 4.03 3.92 3.26 5.75 5.41 4.38 4.31 f
4.18 4.24 4.56 4.47 4.53 4.68 3.53 6.23 5.78 4.70 4.67
ij
4.10 3.94 3.90 3.94 3.92 3.93 3.42 5.50 5.22 4.49 4.25
4.32 4.67 4.99 4.81 4.80 5.28 3.76 6.45 5.95 4.95 4.87 !
4.30 4.52 4.44 4.36 4.25 4.64 3.78 5.70 5.38 4.78 4.52 i
4.31 4.78 4.92 4.71 4.63 5.23 3.85 6.18 5.73 4.93 4.77 i
3.85 3.64 3.76 3.96 4.15 3.33 3.19 5.93 5.43 4.14 4.05 I
4.00 3.85 3.94 4.15 4.34 3.44 3.43 5.98 5.45 4.15 4.08 i
4.41 4.39 4.46 4.71 4.96 3.84 3.90 6.50 5.76 4.58 4.54 J
5.11 4.85 4.85 5.32 5.58 4.31 4.49 8.19 6.58 5.25 5.16 1
4.20 4.03 4.23 4.42 4.60 3.64 3.54 5.97 5.48 4.44 4.39
4.38 5.32 4.39 4.60 4.48 4.93 4.73 6.10 5.17 4.64 4.32
5.69 7.17 5.59 5.90 5.45 6.62 5.89 5.45 5.80 5.38 4.12 j
2.27 3.93 3.70 3.89 3.83 3.41 3.97 6.60 4.10 4.31 4.42
4.06 4.40 4.53 4.56 4.89 3.74 3.68 5.47 5.23 4.34 4.27
4.32 4.85 4.99 5.04 5.43 4.05 4.08 5.75 5.43 4.67 4.62
4.36 5.08 5.21 5.29 5.72 4.20 4.28 5.36 5.30 4.57 4.46 I
4.16 4.97 5.05 5.12 5.57 4.01 4.17 4.99 5.04 4.39 4.17 j
4.18 4.89 4.98 5.12 5.55 4.00 4.02 5.87 5.39 4.57 4.55
4.32 5.10 5.10 5.34 5.55 4.15 4.46 5.83 5.59 4.82 4.87
4.24 6.59 6.59 6.91 6.90 4.22 4.78 6.15 5.69 5.01 5.11
4.55 4.51 4.36 4.55 4.81 4.14 4.66 5.49 5.70 4.85 4.97
4.39 6.14 6.03 6.43 6.29 4.20 5.15 6.04 5.84 5.12 5.33 1
4.59 4.86 4.66 4.91 4.98 4.16 5.09 5.64 5.85 5.03 5.27
Appendix 7.8 Displacement data for the primer grip (cont.)
lrtd 2hmi lhmv lbqm lbqn lhni lhnv lklm lrev Irti lrt2
! Trp229 CE3 1.38 1.24 0.73 6.58 6.19 4.24 5.31 3.77 5.00 5.15 4.64
; Trp229 CZ2 1.46 1.33 0.93 5.26 4.98 4.94 5.74 4.29 5.82 5.22 4.85
; Trp229 CZ3 1.58 1.36 0.82 7.48 7.27 4.11 5.38 3.75 5.15 5.26 4.77
j Trp229 CH2 1.61 1.41 0.89 6.50 6.38 4.46 5.60 4.01 5.56 5.30 4.88
I Met230 N 1.16 1.22 0.79 4.74 4.11 5.01 5.24 4.91 5.04 6.45 4.95
; Met230 CA 1.31 1.26 0.87 4.81 4.21 4.98 5.12 5.32 5.12 6.86 5.34
i  Met230 C 1.25 1.42 1.27 4.41 3.93 4.52 4.64 4.97 4.71 6.47 4.69
; Met230 0 1.26 1.51 1.44 4.03 3.53 3.99 4.02 4.53 4.27 5.99 3.77
; Met230 CB 1.46 1.34 0.78 5.07 4.47 4.89 5.02 5.58 5.22 7.23 6.05
:  Met230 CG 1.65 1.47 0.66 4.78 4.62 4.65 5.25 6.04 6.05 7.75 5.79
1 Met230 SD 1.81 0.71 1.24 6.29 6.44 5.89 6.79 5.16 6.03 6.64 5.01
^ Met230 CE 2.46 3.43 1.90 8.11 8.26 7.29 7.81 4.29 7.79 5.89 5.05
£  Gly231N 1.20 1.61 1.49 4.44 4.03 4.67 4.90 5.29 4.89 6.81 5.30
i Gly231 CA 1.16 1.83 1.83 4.09 3.72 4.28 4.51 5.20 4.60 6.69 5.14
1 Gly231C 1.25 2.20 1.92 3.41 3.19 3.39 3.68 4.45 3.78 5.62 4.23
j  Gly231 O 1.64 3.49 2.60 3.00 2.94 2.99 3.14 4.70 3.64 5.71 4.27
] Tyr232 N 1.04 1.48 1.32 3.81 3.86 3.50 4.01 3.75 3.45 4.85 3.66
¡ Tyr232 CA 1.17 1.53 1.27 3.34 3.52 2.87 3.42 3.07 2.80 3.89 2.96
; Tyr232 C 1.15 1.61 1.27 3.57 3.75 3.04 3.68 2.65 3.00 3.41 2.68
! Tyr232 O 1.26 1.82 1.81 3.57 3.79 3.04 4.14 2.60 3.74 3.74 2.99
] Tyr232 CB 1.38 1.51 1.19 3.08 3.16 2.64 3.09 3.08 2.51 3.84 3.08
1 Tyr232 CG 1.43 1.41 1.25 2.82 2.75 2.45 2.86 3.65 2.32 4.41 2.81
Tyr232 CD1 1.48 1.81 1.51 3.92 3.77 1.99 3.71 3.84 2.06 3.14 1.54
i  Tyr232 CD2 1.43 3.40 1.50 3.25 3.10 2.84 3.50 4.13 2.51 6.68 4.84
; Tyr232 CEI 1.53 1.81 1.83 3.76 3.47 1.91 3.51 4.49 2.02 3.58 1.46
j  Tyr232 CE2 1.43 3.36 1.40 3.31 3.10 2.76 3.53 4.73 2.46 7.36 4.63
; Tyr232 CZ 1.49 1.27 1.52 2.65 2.28 2.30 2.62 4.90 2.22 5.65 2.34
! Tyr232 OH 1.60 1.36 1.81 2.67 2.16 2.30 2.55 5.58 2.23 6.32 2.07
Glu233 N 1.11 1.48 1.24 3.85 3.90 3.28 3.42 2.46 2.38 2.74 2.22
lrt3 lrt4 lrt5 lrt6 lrt7 lrth Irti ltvr luwb lvrt lvru í1
4.74 5.09 4.87 4.89 5.28 4.13 4.52 5.16 5.68 4.75 4.86 !
4.81 4.89 4.61 4.66 4.83 4.15 5.39 5.45 5.99 5.12 5.44 J
4.96 6.24 6.00 5.82 6.26 4.12 4.81 4.97 5.82 4.85 5.04 !
5.00 5.81 5.55 5.30 5.73 4.12 5.24 5.11 5.97 5.03 5.33 i
4.63 5.41 5.61 5.76 6.19 4.63 4.60 5.49 5.42 4.73 4.73 j
4.73 5.72 5.91 6.16 6.64 4.94 4.87 5.34 5.38 4.71 4.74 1
4.36 5.42 5.64 5.84 6.25 4.43 4.42 5.01 4.89 4.44 4.41 J
3.81 5.08 5.36 5.37 5.78 3.77 3.88 5.04 4.39 4.22 3.93
4.69 5.86 5.97 6.40 7.03 5.24 5.07 5.18 5.31 4.60 4.60 1
4.67 6.51 6.39 6.98 7.70 5.26 5.27 5.24 5.16 4.48 6.07 1
6.07 5.71 5.57 5.99 6.52 5.11 5.22 6.46 6.30 5.99 6.07 í
7.73 5.47 5.49 4.97 5.66 4.30 7.52 8.29 7.84 7.14 8.24 1
4.75 5.62 5.84 6.27 6.55 4.82 4.72 4.72 4.91 4.45 4.67
4.55 5.55 5.74 6.19 6.45 4.68 4.49 4.38 4.47 4.28 4.42 J
3.79 4.66 4.78 5.23 5.42 3.92 3.80 3.86 3.60 3.58 3.67
3.78 4.75 4.91 5.38 5.60 4.13 4.02 3.49 3.01 3.42 3.57
{
3.46 4.23 4.19 4.55 4.61 3.40 3.32 3.94 4.05 3.32 3.28 f
2.82 3.45 3.33 3.70 3.67 2.78 2.71 3.65 3.43 2.77 2.80 1
2.95 3.10 2.99 3.19 3.20 2.57 2.70 3.99 3.75 2.99 3.00
3.66 3.39 3.25 3.31 3.35 2.80 3.05 4.63 4.19 3.46 3.49
2.50 3.42 3.27 3.73 3.60 2.76 2.51 3.36 3.04 2.45 2.50 |
2.38 4.00 3.91 4.37 4.25 3.13 2.65 2.92 2.72 2.25 2.35
2.29 2.54 2.50 2.93 2.95 1.98 2.57 2.51 3.65 2.03 2.14 j
2.43 6.37 6.31 6.71 6.55 5.24 2.99 3.13 3.30 2.44 2.57
2.28 2.98 3.01 3.38 3.44 2.12 2.85 2.37 3.45 2.05 2.18
2.42 7.02 7.04 7.39 7.26 5.70 3.23 3.01 3.22 2.44 2.59
■It*2.36 5.20 5.27 5.60 5.56 3.90 3.16 2.66 2.29 2.26 2.41
2.42 5.85 5.99 6.25 6.24 4.35 3.49 2.71 2.13 2.37 2.49 1
2.31 2.62 2.51 2.75 2.79 2.25 2.34 3.71 3.54 2.65 2.54
Appendix 7.8 Displacement data for the primer grip (cont.)
lrtd 2hmi lhmv lbqm lbqn lhni lhnv lklm lrev
Glu233 CA 1.20 1.61 1.17 4.05 4.07 3.39 3.61 2.13 2.47
Glu233 C 1.13 1.61 1.22 3.77 3.83 3.11 3.37 1.82 2.14
Glu233 O 1.15 1.86 1.45 3.35 3.57 2.69 2.98 1.84 1.59
Glu233 CB 1.24 1.74 1.17 4.19 4.24 3.42 3.67 2.01 2.42
Glu233 CG 1.46 3.38 0.59 2.79 2.62 2.95 2.01
Glu233 CD 1.80 4.20 1.49 2.50 1.94 2.87 2.26
Glu233 OE1 2.03 3.92 2.63 2.65 2.25 2.53 2.13
Glu233 OE2 2.32 5.20 2.02 2.53 3.18 3.67 2.92
Leu234 N 0.96 1.32 1.06 4.03 3.94 3.40 3.63 1.69 2.73
Leu234 CA 0.90 1.36 1.08 3.87 3.76 3.32 3.48 1.47 2.70
Leu234 C 0.80 1.38 1.07 3.97 3.81 3.34 3.63 1.11 2.70
Leu234 0 0.81 1.11 1.07 4.73 4.68 4.15 4.44 1.38 3.26
Leu234 CB 0.87 1.30 1.08 4.13 3.96 3.71 3.75 1.74 3.19
Leu234 CG 0.84 1.67 1.18 3.71 4.03 3.49 3.69 2.04 2.81
Leu234 CD1 0.97 1.82 0.86 4.40 5.11 3.85 4.84 3.98 3.97
Leu234 CD2 0.72 2.15 1.37 2.64 3.23 2.83 2.72 0.53 4.44
His235 N 1.01 1.92 1.24 3.20 2.91 2.74 3.10 0.54 2.30
His235 CA 1.16 2.07 1.27 3.25 2.99 2.98 3.33 0.11 2.50
His235 C 0.92 2.11 0.92 3.44 3.16 3.19 3.62 0.39 2.95
His235 O 0.63 2.19 0.80 3.31 2.96 2.94 3.62 0.56 3.01
His235 CB 1.58 2.30 1.43 2.82 2.58 2.67 3.00 0.44 2.13
His235 CG 1.74 2.42 1.38 2.65 2.42 2.46 2.72 0.69 1.58
His235 ND1 1.63 2.50 1.34 1.98 1.84 2.46 2.38 2.40 2.65
His235 CD2 2.08 2.54 1.35 3.11 2.88 2.18 2.70 1.31 2.02
His235 CEI 1.86 2.71 1.29 2.07 2.06 2.19 2.15 2.23 2.15
His235 NE2 2.17 2.75 1.30 2.74 2.67 2.02 2.35 1.17 0.73
Irti lrt2 lrt3 lrt4 lrt5 lrt6 lrt7 lrth Irti ltvr luwb lvrt lvru
2.33 1.99 2.36 2.40 2.30 2.35 2.43 2.20 2.33 3.92 3.75 2.76 2.61
1.98 1.69 1.97 1.91 1.83 1.93 2.04 1.83 2.05 3.73 3.53 2.48 2.30
1.80 1.39 1.45 1.74 1.72 1.79 1.91 1.65 1.97 3.41 3.17 2.07 1.83
1.95 1.67 2.32 2.27 2.19 2.06 2.21 2.11 2.31 4.11 3.86 2.68 2.52
3.10 2.84 2.14 2.11 2.09 2.93 2.92 2.08 2.07 4.27 2.93 2.06 2.06
2.79 2.32 2.71 2.59 2.65 2.56 2.76 2.63 2.59 3.74 2.17 2.07 2.18
2.76 1.40 1.78 1.70 1.75 2.23 2.67 2.12 2.21 3.07 1.53 1.80 1.91
3.15 3.99 4.82 4.63 4.74 3.21 3.16 4.53 3.87 4.04 2.37 3.17 3.23
2.17 1.99 2.39 2.12 2.06 2.04 2.05 2.08 2.14 3.99 3.77 2.83 2.63
1.93 1.89 2.33 1.84 1.80 1.78 1.78 1.98 1.94 3.86 3.64 2.72 2.59
1.76 1.85 2.30 1.67 1.65 1.52 1.45 1.90 1.83 3.98 3.75 2.71 2.57
2.48 2.32 2.81 2.36 2.38 2.32 2.12 2.54 2.39 4.70 4.53 3.33 3.11
2.30 2.23 2.88 2.39 2.34 2.29 2.33 2.60 2.17 4.13 3.94 3.13 3.13
2.53 2.17 2.60 2.13 2.01 2.60 2.59 2.10 2.03 4.09 4.04 2.78 3.24
5.06 4.34 4.90 4.75 4.66 5.14 4.85 4.59 3.90 5.00 5.50 4.55 3.60
3.10 3.41 3.00 2.36 2.30 3.11 3.49 2.85 3.68 3.34 3.37 4.33 3.06
0.95 1.37 1.82 1.05 1.10 0.97 0.69 1.43 1.05 3.33 3.19 2.15 2.03
1.10 1.45 2.11 1.47 1.58 1.64 1.36 2.01 0.95 3.38 3.43 2.45 2.32
1.44 1.73 2.71 1.92 2.07 2.11 1.77 2.53 1.14 3.48 3.69 3.06 2.81
1.23 1.90 2.60 1.57 1.90 1.49 1.14 2.24 1.24 3.35 3.35 3.19 2.75
0.79 1.08 1.79 1.42 1.56 1.77 1.66 2.05 0.61 3.00 3.10 2.08 1.99
0.22 0.78 1.36 1.11 1.22 1.30 1.31 1.62 0.48 2.82 2.78 1.45 1.50
2.11 1.46 3.50 2.20 1.81 3.01 3.38 2.26 1.00 2.12 2.76 2.94 3.39
2.23 0.72 0.92 1.06 1.04 1.78 1.20 1.23 1.28 3.22 2.51 1.69 1.21
1.19 0.93 3.22 2.05 1.86 2.16 2.67 2.18 0.54 2.12 2.44 2.31 2.83
1.62 0.68 0.86 0.56 0.92 1.22 0.86 1.07 1.18 2.79 2.31 0.39 0.33
The measured distances between the unliganded (ldlo) structure and each RT structure for all the atoms of the residues of primer grip.
Appendix 7.9 Distance between the primer grip and the PAS
PDB file A spi10 Aspl85 Aspl86
1 dio
_ _  -
.  12.19
ia Q 7
lrtd 13.59 14.59 11.62
2hmi 14.02 13.96 11.34
lhmv 12.41 12.29 10.34
lbqm 17.74 15.50 14.42
lbqn 16.71 14.65 13.32
lhni 18.25 16.59 14.97
lhnv 18.74 17.27 15.78
lklm 19.71 18.55 17.10
lrev 19.68 18.24 16.85
Irti 22.13 20.04 18.70
lrt2 20.57 18.08 17.12
lrt3 18.76 17.06 15.83
lrt4 20.58 19.62 17.67
lrt5 21.01 20.02 18.12
lrt6 20.54 19.88 18.18
lrt7 21.35 20.14 18.29
lrth 20.31 18.50 16.98
Irti 18.90 17.81 15.89
ltvr 18.09 16.78 15.54
luwb 18.28 17.50 15.86
lvrt 19.00 17.43 16.17
lvru 19.65 17.83 16.34
The measured distance between Ca of Gly231 of the primer grip and Ca of the residues 
of the catalytic triad in each of the crystal structures.
Appendix 7.10 Displacement of the thumb
PDB file 286:Ca 296:Ca 306:Ca
lrtd 18.37 19.13 12.99
2hmi 21.40 19.13 14.11
lhmv 3.10 3.43 2.63
lbqm 18.77 19.30 13.18
lbqn 19.19 19.49 13.37
lhni 19.94 21.46 13.60
lhnv 19.60 20.96 13.54
lklm 24.10 23.79 15.37
lrev 25.40 25.33 15.70
Irti 24.40 24.10 15.69
lrt2 24.00 22.86 14.26
lrt3 24.91 25.23 15.90
lrt4 24.12 23.81 15.75
lrt5 24.15 23.86 15.80
lrt6 24.33 24.31 16.16
lrt7 24.54 24.55 16.24
lrth 24.36 23.86 15.40
Irti 23.90 23.45 15.05
ltvr 19.38 19.78 13.24
luwb 20.29 20.70 13.64
lvrt 25.73 25.59 15.94
lvru 25.53 25.15 16.12
The measured distances between the unliganded (ldlo) structure and each RT structure 
at three residues (Ca atoms of 286, 296 and 306) representing three different parts of the 
thumb (Figure 3.29).
Appendix 7.11 Displacement data for the template grip
lrtd 2hmi lhmv lbqm lbqn lhni lhnv lklm lrev Irti lrt2
Lys73 N 4.15 1.37 4.80 4.73 3.07 5.03 3.23 6.81 3.26 3.94
Lys73 CA 3.82 2.24 4.52 4.57 3.48 5.21 3.27 7.04 3.28 4.05
Lys73 C 3.52 3.06 4.48 4.58 3.28 4.81 3.23 6.72 3.22 3.77
Lys73 0 3.60 4.03 3.80 3.82 2.72 3.74 2.81 6.08 2.94 3.23
Lys73 CB 3.68 2.80 4.48 4.57 3.48 5.07 3.27 6.99 3.23 4.06
Lys73 CG 2.75 4.74 4.78 3.86 5.08 4.19 7.22 4.18 4.07
Lys73 CD 2.06 4.46 4.32 3.83 4.75 3.34 7.27 3.26 4.06
Lys73 CE 1.24 5.18 4.92 4.87 5.94 3.98 7.82 3.40 4.35
Lys73 NZ 1.98 5.08 4.92 4.04 5.17 2.25 5.96 1.82 2.71
Leu74 N 3.22 3.00 5.39 5.61 3.78 5.84 3.81 7.18 3.71 4.31
Leu74 CA 2.98 3.83 5.52 5.85 3.67 5.67 3.82 6.97 3.70 4.17
Leu74 C 2.54 3.28 5.37 5.64 3.84 5.92 3.86 6.99 3.82 4.12
Leu74 0 2.79 3.25 5.12 5.73 4.01 6.88 4.12 7.44 4.13 4.18
Leu74 CB 3.17 4.65 5.54 5.92 4.05 6.33 3.83 7.09 3.72 4.24
Leu74 CG 3.56 6.20 6.38 3.80 6.18 3.80 6.84 3.75 4.71
Leu74 CD1 2.02 5.41 7.69 3.68 5.91 4.54 7.10 3.96 5.81
Leu74 CD2 6.15 7.60 6.44 3.92 6.63 3.86 6.80 3.67 4.81
Val75 N 2.32 2.84 0.71 5.54 5.27 3.83 5.09 3.58 6.52 3.61 4.06
Val75 CA 1.87 2.27 0.63 5.46 5.01 3.98 5.21 3.55 6.45 3.63 3.95
Val75 C 1.80 2.20 0.71 5.60 5.01 4.52 5.44 3.57 6.34 3.62 3.90
Val75 0 2.28 2.41 1.08 6.31 5.49 5.79 5.76 3.79 6.28 3.68 3.96
Val75 CB 1.71 2.16 0.51 5.53 5.08 4.14 5.33 3.56 6.27 3.58 3.82
Val75 CGI 1.18 1.41 0.51 5.40 4.75 4.16 5.19 3.40 6.18 3.42 3.67
Val75 CG2 1.93 2.62 0.64 5.54 5.31 3.99 5.59 3.62 6.40 3.63 3.90
Asp76N 1.26 1.97 0.69 5.02 4.47 3.64 5.17 3.38 6.31 3.54 3.79
Asp76 CA 1.06 1.96 0.67 5.08 4.49 4.16 5.51 3.36 6.23 3.52 3.74
Asp76 C 0.91 1.76 0.51 4.99 4.52 3.75 5.41 3.25 5.89 3.28 3.55
Asp76 0 0.75 1.36 0.18 4.99 4.45 3.04 4.97 3.10 5.71 3.05 3.62
Asp76 CB 0.78 2.06 0.67 4.77 4.17 4.20 5.14 3.50 6.66 3.76 3.93
Irt3 lrt4 lrt5 lrt6 lrt7 lrth Irti ltvr luwb lvrt lvru
6.13 4.53 4.75 3.18 3.13 4.26 4.00 5.97 4.90 6.68 6.72
6.37 4.39 4.68 3.26 3.15 4.09 4.06 6.31 5.23 6.87 6.89
6.07 4.26 4.52 3.09 3.10 3.95 3.96 5.95 5.00 6.60 6.54
5.28 3.86 4.01 2.57 2.75 3.60 3.53 4.78 4.03 6.07 5.74
6.38 4.27 4.58 3.26 3.15 3.91 4.04 6.13 5.23 6.85 6.85
6.60 5.21 5.43 3.34 4.19 5.04 4.89 6.64 5.45 6.94 6.89
6.66 4.52 4.69 3.36 2.97 4.22 4.13 6.54 4.66 6.98 6.73
7.01 4.56 4.84 3.37 3.09 4.32 3.98 7.28 5.65 7.37 6.99
5.13 2.42 2.69 1.15 1.66 2.55 3.49 5.79 4.80 5.74 6.60
6.74 4.80 5.09 3.76 3.70 4.48 4.58 7.09 6.01 7.01 7.19
6.57 4.73 5.01 3.70 3.73 4.41 4.57 6.89 5.93 6.86 6.98
6.68 4.83 5.07 3.84 3.86 4.45 4.56 6.97 6.10 7.04 7.20
7.42 5.22 5.46 4.41 4.31 4.68 4.81 7.56 6.72 7.88 8.14
6.67 4.79 5.08 3.74 3.74 4.49 4.58 7.22 6.08 7.01 7.23
6.47 5.22 5.14 3.66 3.72 4.71 4.64 7.14 6.19 7.05 8.06
6.75 6.57 6.04 4.02 4.17 5.60 5.25 7.06 6.33 8.31 9.00
6.41 5.09 5.22 3.60 3.64 4.93 4.65 7.23 6.98 6.86 8.21
5.93 4.45 4.72 3.32 3.45 4.22 4.27 6.35 5.49 6.30 6.38
5.91 4.45 4.70 3.38 3.47 4.18 4.20 6.32 5.51 6.34 6.44
5.86 4.46 4.69 3.48 3.52 4.17 4.17 6.73 5.94 6.28 6.39
5.94 4.55 4.78 3.74 3.75 4.19 4.21 8.01 6.76 6.27 6.29
5.78 4.43 4.66 3.46 3.52 4.12 4.13 6.50 5.73 6.20 6.25
5.84 4.36 4.58 3.49 3.55 3.92 4.08 6.28 5.56 6.21 6.42
5.77 4.46 4.69 3.40 3.45 4.19 4.15 6.46 5.71 6.22 6.16
5.71 4.39 4.59 3.32 3.35 4.15 4.10 5.71 5.31 6.19 6.44
5.66 4.39 4.55 3.38 3.34 4.12 4.06 6.15 5.79 6.14 6.43
5.53 4.23 4.36 3.29 3.17 3.88 3.89 5.86 5.63 5.95 6.11
5.49 4.08 4.17 3.29 2.98 3.69 3.73 5.42 5.21 6.17 6.15
5.91 4.56 4.75 3.46 3.50 4.38 4.29 5.92 5.51 6.49 6.96
Appendix 7.11 Displacement data for the template grip (cont.)
lrtd 2hmi lhmv lbqm lbqn lhni lhnv lklm lrev lrtl lrt2
1 Asp76 CG 0.53 2.25 0.62 4.61 3.94 5.06 5.86 3.30 6.45 3.86 3.93
j Asp76 OD1 0.65 2.25 0.82 5.11 4.27 5.58 6.79 3.33 6.22 3.81 3.69
j Asp76 OD2 0.31 2.55 0.56 4.27 3.86 5.33 5.80 3.17 6.60 4.13 4.30
| Phe77 N 1.15 2.16 0.77 4.91 4.73 4.26 5.88 3.29 5.75 3.22 3.22
j Phc77 CA 1.20 2.13 0.71 4.73 4.72 4.15 5.91 3.15 5.42 3.00 3.00
| Phc77 C 1.26 2.16 0.70 4.44 4.54 4.15 5.95 3.15 5.38 3.00 3.01
j Phc77 0 1.31 2.20 0.81 3.50 3.82 3.99 6.07 3.11 5.25 3.04 2.97
j Phe77 CB 1.38 2.09 0.71 4.78 4.79 4.85 6.06 2.93 5.19 2.87 2.78
| Phc77 CG 1.53 2.12 0.63 4.95 4.86 4.43 5.74 2.98 5.38 2.90 2.81
j Phe77 CD1 1.44 2.04 0.51 5.02 4.85 3.18 4.33 3.03 5.31 2.85 2.89
! Phe77 CD2 1.90 2.28 0.74 5.06 4.93 6.10 7.40 2.98 5.64 2.99 2.80
, Phe77 CE1 1.61 2.10 0.54 5.16 4.88 3.04 4.19 3.07 5.52 2.88 2.93
U  Phe77 CE2 2.07 2.29 0.74 5.20 4.96 5.70 7.06 3.02 5.83 3.02 2.83
1 Phe77 CZ 1.88 2.19 0.67 5.23 4.93 3.75 5.18 3.06 5.78 2.97 2.90
j Arg78 N 1.27 2.15 0.62 5.35 5.14 4.39 5.86 3.20 5.51 2.99 3.08
j Arg78 CA 1.27 2.18 0.66 5.14 5.03 4.33 5.84 3.15 5.45 2.96 3.09
J Arg78 C 1.27 2.16 0.71 5.00 4.97 4.24 5.76 3.03 5.42 2.91 3.11
| Arg78 0 1.42 2.27 0.82 4.81 5.13 4.34 5.67 3.03 5.53 2.88 3.14
j Arg78 CB 1.15 2.40 0.80 5.52 5.70 4.25 5.79 3.57 5.77 3.15 3.28
j Arg78 CG 1.20 1.33 7.70 8.18 4.30 5.77 3.97 6.34 3.36 3.74
Arg78 CD 1.06 1.72 9.58 8.76 6.35 7.37 3.86 6.67 3.52 3.87
Arg78 NE 0.90 0.83 9.61 8.96 6.67 7.80 3.77 5.97 3.66 3.90
j Arg78 CZ 0.70 1.08 9.63 9.33 9.03 10.12 3.71 6.72 3.82 3.95
j Arg78 NH1 0.64 1.93 9.62 9.58 10.78 11.67 3.79 8.18 3.86 3.97
Arg78 NH2 0.61 2.35 9.68 9.46 10.07 11.28 3.71 6.19 3.95 4.00
i Glu79 N 1.08 2.07 0.57 5.12 4.90 3.98 5.75 2.99 5.27 2.87 3.12
j Glu79 CA 1.09 2.07 0.66 5.10 4.88 3.94 5.64 2.93 5.25 2.89 3.16
| Glu79 C 1.21 1.90 0.64 4.91 4.65 3.84 5.50 2.77 5.01 2.70 2.95
i Glu79 0 1.27 1.77 0.73 4.94 4.59 3.69 5.40 2.53 4.67 2.45 2.70
Irt3 lrt4 lrt5 lrt6 lrt7 lrth Irti ltvr luwb lvrt lvru
5.72 4.53 4.65 3.42 3.47 4.36 4.21 6.91 6.33 6.61 6.75
5.46 4.39 4.57 3.34 3.39 4.27 4.16 7.71 7.29 6.37 6.50
5.85 4.68 4.65 3.80 3.78 4.47 4.24 7.29 6.31 6.95 6.84
5.46 4.18 4.34 3.16 3.15 3.80 3.87 6.27 6.06 5.53 5.71
5.31 4.01 4.13 3.02 2.98 3.57 3.70 6.17 6.11 5.32 5.38
5.30 4.04 4.10 3.02 3.04 3.55 3.72 6.03 6.12 5.36 5.35
5.19 4.06 4.02 3.03 3.17 3.46 3.69 5.91 6.23 5.26 5.27
5.08 3.77 3.96 2.84 2.73 3.41 3.48 6.70 6.68 5.12 5.01
5.22 3.78 3.99 2.89 2.74 3.42 3.50 6.51 6.04 5.20 5.02
5.20 3.81 4.00 2.85 2.77 3.39 3.55 5.06 4.39 5.31 5.16
5.39 3.77 4.01 2.99 2.73 3.48 3.46 8.23 7.56 5.21 4.90
5.33 3.81 4.02 2.89 2.77 3.39 3.55 4.91 3.98 5.45 5.18
5.52 3.80 4.04 3.05 2.74 3.51 3.47 8.02 6.91 5.30 4.91
5.49 3.82 4.05 3.00 2.77 3.46 3.52 6.13 4.85 5.42 5.06
5.43 4.05 4.17 3.00 2.99 3.65 3.81 6.03 6.00 5.53 5.41
5.37 4.05 4.13 2.94 2.99 3.63 3.82 5.98 5.94 5.59 5.36
5.33 3.95 4.02 2.90 2.97 3.54 3.85 5.67 5.88 5.64 5.37
5.36 4.00 4.11 2.90 3.11 3.66 4.05 5.31 6.02 5.61 5.30
5.63 4.30 4.38 3.19 3.19 3.89 4.12 5.83 5.90 5.95 5.55
6.68 4.40 4.67 3.44 3.35 4.13 4.53 6.47 5.88 6.35 7.62
6.47 4.33 4.23 3.58 3.45 3.98 4.90 8.42 7.46 6.77 8.13
6.04 4.27 3.67 3.69 3.54 3.86 3.89 9.71 7.99 6.06 6.35
5.84 4.98 4.76 3.81 3.63 4.69 4.73 12.07 10.31 6.93 6.75
6.06 6.11 6.72 3.83 3.65 5.96 6.46 13.10 11.82 8.52 9.08
5.40 4.81 4.09 3.89 3.71 4.44 4.34 13.62 11.48 6.44 5.14
5.23 3.81 3.84 2.87 2.83 3.32 3.66 5.80 5.71 5.72 5.46
5.19 3.75 3.79 2.91 2.87 3.29 3.73 5.64 5.69 5.74 5.49
5.05 3.61 3.66 2.85 2.79 3.23 3.56 5.41 5.57 5.53 5.30
4.91 3.39 3.45 2.66 2.63 3.12 3.44 4.85 5.40 5.36 5.23
Appendix 7.11 Displacement data for the template grip (cont.)
lrtd 2hmi lhmv lbqm lbqn lhni lhnv lklm lrev lrtl lrt2
1 Glu79 CB 0.74 2.20 0.77 5.35 5.10 4.04 5.81 3.08 5.50 3.13 3.35
| Glu79 CG 1.71 2.77 1.25 5.62 4.67 5.27 6.57 3.50 5.86 3.87 3.51
| Glu79 CD 2.68 2.97 0.88 6.32 6.81 6.19 7.01 3.34 6.01 3.53 4.29
1 Glu79 OE1 2.94 3.54 2.93 5.99 8.84 6.18 6.90 3.85 6.04 3.55 6.07
S Glu79 OE2 3.54 3.07 1.50 7.47 6.98 7.09 7.50 4.06 6.12 4.50 3.79
Leu80 N 1.24 1.90 0.83 4.75 4.52 3.89 5.52 2.93 5.20 2.85 3.05
| Leu80 CA 1.38 1.72 0.77 4.55 4.28 3.70 5.35 2.77 4.99 2.67 2.83
Leu80 C 1.58 1.65 0.72 4.27 3.99 3.49 5.09 2.61 4.76 2.55 2.61
Leu80 0 1.84 1.77 0.69 4.03 3.76 3.30 4.80 2.38 4.53 2.31 2.32
; Leu80 CB 1.33 1.43 0.67 4.45 4.21 3.72 5.30 2.73 5.04 2.65 2.74
; Leu80 CG 1.36 1.87 0.43 4.35 4.01 3.48 4.98 2.48 4.87 2.40 2.58
Leu80 CD1 1.39 2.89 0.59 4.44 4.11 3.56 5.15 2.58 4.90 2.52 2.54
& Leu80 CD2 
125 Asn81 N
1.25 2.31 0.82 4.29 4.07 3.52 4.86 2.49 4.91 2.37 2.71
1.49 1.68 0.77 4.32 4.03 3.50 5.18 2.76 4.84 2.74 2.81
| Asn81 CA 1.64 1.62 0.76 4.11 3.82 3.32 4.96 2.66 4.67 2.69 2.67
j Asn81 C 1.83 1.87 0.76 4.23 3.87 3.34 4.94 2.68 4.58 2.72 2.69
Asn81 0 2.27 2.29 1.07 4.19 3.75 3.19 4.90 3.14 4.71 3.17 2.97
Asn81 CB 1.75 1.51 0.73 4.09 3.81 3.30 4.97 2.64 4.76 2.71 2.72
Asn81 CG 1.60 1.04 0.70 3.59 3.39 3.03 4.86 2.54 4.75 2.61 2.58
Asn81 OD1 1.64 1.22 1.20 2.47 3.02 3.27 4.69 2.61 4.69 2.58 2.66
Asn81 ND2 2.01 2.86 1.71 5.33 3.81 3.08 5.34 2.66 5.12 2.86 2.53
Lys82 N 1.64 1.79 0.59 4.43 4.01 3.52 4.99 2.30 4.39 2.44 2.54
! Lys82 CA 1.80 1.99 0.60 4.52 4.05 3.51 4.96 2.25 4.28 2.42 2.51
Lys82 C 1.86 2.02 0.38 4.53 3.91 3.47 4.86 2.20 4.11 2.36 2.44
Lys82 0 1.83 2.67 0.42 4.56 3.82 3.35 4.71 2.21 3.92 2.55 3.06
j Lys82 CB 1.72 2.08 0.70 4.73 4.55 3.52 4.95 1.95 4.40 2.22 2.25
| Lys82 CG 1.75 1.57 1.51 5.03 4.78 3.51 4.84 3.85 4.43 3.73 4.00
| Lys82 CD 1.63 1.55 1.45 5.44 5.29 3.43 4.91 3.79 4.86 3.55 3.67
| Lys82 CE 1.61 3.43 1.64 5.88 5.78 3.30 5.16 5.70 4.90 5.00 4.84
lrt3 lrt4 lrt5 lrt6 lrt7 lrth Irti ltvr luwb lvrt lvru
5.35 3.86 3.92 3.06 3.02 3.34 3.97 5.98 5.87 5.95 5.70
6.13 4.16 4.19 3.18 3.49 3.55 4.27 7.24 6.74 6.45 6.17
6.51 4.16 4.25 3.37 3.27 3.56 4.34 8.06 7.26 6.66 6.31
6.36 5.04 4.13 4.81 3.76 3.43 4.34 8.74 7.38 6.87 6.25
7.12 4.38 4.42 3.23 3.95 3.71 4.40 8.27 7.64 6.69 6.53
5.11 3.74 3.78 3.05 2.93 3.33 3.55 5.83 5.66 5.57 5.28
4.94 3.60 3.62 2.96 2.82 3.18 3.35 5.66 5.51 5.33 5.04
4.69 3.49 3.49 2.88 2.72 3.03 3.16 5.48 5.31 4.97 4.68
4.41 3.29 3.22 2.72 2.53 2.72 2.87 5.27 5.05 4.62 4.22
4.94 3.54 3.59 2.84 2.75 3.13 3.30 5.85 5.47 5.15 5.07
4.71 3.22 3.25 2.53 2.48 2.74 3.03 5.47 4.67 5.04 4.95
4.67 3.11 3.22 2.67 2.57 2.54 2.96 5.31 4.90 4.91 4.86
4.86 3.30 3.31 2.52 2.48 2.86 3.14 5.82 4.58 5.28 5.17
4.79 3.66 3.72 3.03 2.90 3.26 3.36 5.61 5.50 5.08 4.92
4.60 3.60 3.64 2.98 2.85 3.21 3.24 5.51 5.36 4.79 4.65
4.64 3.61 3.62 2.99 2.89 3.18 3.21 5.56 5.37 4.70 4.67
4.88 3.84 3.73 3.48 3.39 3.28 3.17 6.06 5.62 4.73 4.91
4.57 3.62 3.68 2.97 2.81 3.30 3.32 5.47 5.31 4.87 4.69
4.37 3.61 3.63 2.96 2.76 3.25 3.33 5.33 5.23 4.85 4.62
4.35 3.60 3.66 3.03 2.80 3.23 3.34 5.43 5.28 4.88 4.50
4.61 3.84 3.75 3.17 2.90 3.44 3.59 5.39 5.38 5.08 5.09
4.47 3.45 3.50 2.54 2.50 3.08 3.24 5.12 5.09 4.58 4.56
4.47 3.42 3.45 2.47 2.46 3.03 3.21 5.14 5.07 4.48 4.58
4.33 3.25 3.27 2.39 2.41 2.82 2.97 5.13 5.08 4.24 4.37
4.21 3.13 3.21 2.37 2.40 2.82 2.81 5.11 5.23 4.01 4.18
4.69 3.47 3.50 2.12 2.16 3.11 3.34 4.72 4.95 4.72 4.92
4.47 3.53 3.38 3.83 3.83 3.29 3.31 5.68 4.85 4.86 5.00
4.80 3.79 4.04 3.62 3.62 3.49 3.34 5.17 5.14 5.39 5.27
4.86 3.92 4.62 3.29 5.18 3.72 3.28 6.73 5.19 6.27 5.39
C-S
Appendix 7.11 Displacement data for the template grip (cont.)
lrtd 2hmi lhmv lbqm lbqn lhni lhnv lklm lrev lrtl lrt2
Lys82 NZ 2.40 2.92 2.40 6.01 5.96 3.51 4.72 5.99 4.84 5.29 4.50
Arg83 N 1.95 1.33 0.32 4.58 4.04 3.59 4.98 2.19 4.19 2.17 1.96
Arg83 CA 2.01 1.14 0.22 4.54 3.96 3.52 4.86 2.03 4.03 1.96 1.66
Arg83 C 2.05 1.00 0.16 4.33 3.64 3.35 4.65 1.98 3.78 1.92 1.82
Arg83 0 2.12 0.69 0.41 4.08 3.08 3.27 4.71 1.98 3.67 1.96 2.18
Arg83 CB 1.95 1.19 0.42 4.79 4.32 3.81 5.19 2.09 4.31 1.97 1.58
Arg83 CG 1.94 1.48 0.10 5.17 4.78 3.71 5.71 2.16 4.52 2.12 3.14
Arg83 CD 1.52 1.81 0.65 4.72 4.62 4.49 4.77 2.54 5.20 2.33 3.30
Arg83 NE 2.98 2.35 0.95 5.82 6.24 6.14 6.07 3.37 6.35 2.97 3.74
Arg83 CZ 2.67 1.65 1.06 4.69 5.60 6.13 6.21 2.63 5.34 2.67 3.19
Arg83 NH1 1.28 0.45 0.90 2.71 3.79 5.20 5.80 2.96 3.53 3.65 3.84
Arg83 NH2 4.22 2.20 1.35 5.85 7.20 7.59 7.40 3.30 6.50 2.99 3.54
Asp86 N 1.84 1.05 0.69 3.49 3.34 2.52 3.39 1.54 2.55 1.58 1.46
Asp86 CA 1.76 1.12 0.90 3.38 3.24 2.55 3.35 1.60 2.71 1.57 1.57
Asp86 C 1.70 0.88 0.22 3.11 2.98 2.42 3.22 1.40 2.52 1.29 1.32
Asp86 0 1.63 0.89 1.10 2.96 2.92 2.34 2.94 1.18 2.25 0.95 0.99
Asp 8 6 CB 1.58 1.41 2.10 3.10 2.94 2.21 2.98 1.42 2.46 1.57 1.56
Asp86 CG 1.85 0.90 0.70 3.67 3.21 2.81 3.76 1.84 3.14 1.97 2.34
Asp86 OD1 2.69 1.62 2.20 3.31 3.12 2.60 4.38 1.39 2.72 2.07 3.10
Asp86 OD2 1.39 3.03 1.50 4.55 3.58 3.63 3.85 3.15 4.25 3.01 3.13
Phe87 N 1.72 0.72 0.73 3.06 2.83 2.43 3.58 1.52 2.67 1.42 1.59
Phe87 CA 1.62 0.77 0.45 2.79 2.55 2.31 3.49 1.38 2.52 1.23 1.49
Phe87 C 1.68 0.91 0.40 2.59 2.43 2.27 3.42 1.37 2.39 1.18 1.43
Phe87 O 2.20 1.49 0.47 2.62 2.45 2.28 3.42 1.36 2.44 1.22 1.54
Phe87 CB 1.56 0.60 0.78 2.95 2.70 2.66 3.85 1.66 2.87 1.42 1.97
Phe87 CG 1.51 0.49 0.64 3.13 2.80 2.52 3.74 1.58 2.83 1.39 1.86
Phe87 CD1 1.67 2.16 0.68 5.03 4.72 4.38 5.51 3.30 2.66 3.01 1.49
Irt3 lrt4 lrt5 lrt6 lrt7 lrth Irti ltvr luwb lvrt lvru
3.70 3.11 3.84 2.31 5.43 2.90 3.56 6.56 4.97 6.33 5.00
4.39 3.23 3.23 2.38 2.39 2.71 2.93 5.14 5.04 4.33 4.42
4.21 2.99 2.99 2.20 2.23 2.47 2.61 5.10 4.99 4.10 4.19
3.89 2.79 2.85 2.16 2.15 2.33 2.35 5.07 4.69 3.83 3.81
3.75 2.72 2.92 2.11 2.04 2.43 2.04 5.28 4.61 3.74 3.60
4.55 3.13 3.13 2.26 2.27 2.54 2.79 5.15 5.29 4.47 4.59
4.96 3.36 3.34 2.31 2.36 2.78 3.06 5.19 6.04 4.81 5.80
5.69 3.76 3.82 2.66 2.56 3.24 3.54 5.77 4.85 5.71 4.79
6.95 4.55 4.61 3.74 3.25 4.05 4.38 6.88 6.19 7.01 6.43
6.04 3.87 3.88 2.86 2.68 3.58 3.76 7.05 6.37 6.15 5.89
4.27 3.63 3.55 2.25 3.31 3.73 3.60 6.80 5.97 4.37 4.11
7.27 4.56 4.60 3.92 3.18 4.27 4.48 8.04 7.59 7.41 7.53
2.68 2.23 2.36 1.86 1.91 1.99 1.76 3.82 3.81 2.77 2.68
2.67 2.39 2.54 1.90 1.95 2.20 1.82 3.67 3.82 2.88 2.92
2.50 2.06 2.24 1.72 1.76 1.87 1.39 3.35 3.65 2.72 2.67
2.29 1.71 1.90 1.46 1.60 1.54 0.88 3.10 3.52 2.47 2.36
2.44 2.32 2.40 1.74 1.82 2.21 1.84 3.31 3.27 2.58 2.71
3.05 2.89 2.99 2.01 2.23 2.74 2.56 4.37 3.95 3.16 3.22
3.94 2.40 2.86 1.41 2.66 3.00 2.01 4.48 4.70 2.61 3.01
3.33 4.26 3.95 3.55 2.69 3.08 3.90 5.16 3.83 4.35 3.98
2.62 2.25 2.45 1.93 1.76 1.89 1.71 3.45 3.72 2.88 2.67
2.46 1.99 2.23 1.81 1.62 1.65 1.41 3.17 3.53 2.75 2.48
2.32 1.87 2.06 1.70 1.51 1.52 1.28 3.10 3.35 2.64 2.41
2.37 2.02 2.22 1.73 1.57 1.65 1.50 3.20 3.55 2.68 2.48
2.77 2.34 2.56 2.07 1.84 1.87 1.71 3.38 3.80 3.08 2.83
2.81 2.34 2.48 2.01 1.71 1.83 1.68 3.48 3.50 3.17 2.95
2.73 2.31 2.38 1.78 3.42 1.82 1.63 5.37 3.07 4.97 3.06
Appendix 7.11 Displacement data for the template grip (cont.)
lrtd 2hmi lhmv lbqm lbqn lhni lhnv lklm lrev lrtl lrt2
; Phe87 CD2 1.37 2.54 0.67 2.53 2.14 1.94 2.79 2.23 2.99 2.41 2.21
| Phc87 CE1 1.69 2.04 0.70 5.18 4.74 4.22 5.37 3.14 2.59 2.85 1.38
j Phe87 CE2 1.39 2.64 0.59 2.57 2.19 2.10 2.90 2.48 2.98 2.63 2.17
| Phc87 CZ 1.56 0.39 0.57 3.38 2.86 2.34 3.60 1.56 2.76 1.41 1.71
j Trp88 N 1.35 0.73 0.40 2.47 2.35 2.29 3.41 1.43 2.27 1.12 1.38
5 Trp88 CA 1.29 0.62 0.50 2.45 2.36 2.47 3.47 1.55 2.23 1.10 1.42
1 Trp88 C 1.40 0.69 0.62 2.11 2.13 2.05 2.74 1.29 2.08 1.24 1.51
! Trp88 0 1.80 0.73 0.68 2.59 2.29 2.45 3.21 2.55 1.97 2.13 2.05
j  Trp88 CB 1.20 0.57 0.42 3.06 2.93 3.31 4.35 2.53 2.95 1.51 1.99
| Trp88 CG 1.36 0.56 0.51 3.28 3.19 3.61 4.52 2.59 2.98 1.38 2.28
I Trp88 CD1 1.40 0.59 0.67 3.45 3.41 3.83 4.65 2.64 3.01 1.19 2.57
Trp88 CD2 1.46 0.49 0.56 3.36 3.24 3.77 4.60 2.62 2.99 1.43 2.34
<g Trp88 NE1 1.49 0.54 0.88 3.62 3.62 4.10 4.81 2.64 3.02 1.13 2.76
10 Trp88 CE2 1.51 0.47 0.80 3.56 3.52 4.07 4.78 2.62 3.01 1.28 2.62
Trp88 CE3 1.53 0.46 0.47 3.29 3.10 3.72 4.55 2.70 3.02 1.60 2.28
| Trp88 CZ2 1.63 0.40 0.95 3.67 3.64 4.30 4.91 2.67 3.04 1.31 2.76
| Trp88 CZ3 1.65 0.38 0.60 3.44 3.26 3.99 4.70 2.83 3.09 1.62 2.50
j  Trp88 CH2 1.70 0.35 0.84 3.62 3.52 4.26 4.88 2.79 3.10 1.50 2.69
Glu89 N 1.23 0.87 0.66 1.80 2.10 1.73 2.44 0.65 3.77 0.86 1.27
Glu89 CA 1.35 1.37 0.66 1.76 2.35 1.77 2.09 1.00 4.11 1.33 1.72
j Glu89 C 1.45 2.23 0.76 2.58 2.85 2.98 2.89 1.78 4.39 2.41 2.37
j Glu89 0 1.71 4.34 0.84 2.97 3.13 3.43 3.20 2.19 4.71 2.96 3.44
Glu89 CB 1.14 1.16 0.56 1.63 2.24 1.35 2.30 1.72 4.60 1.40 2.87
j Glu89 CG 1.20 0.77 0.30 1.64 0.85 2.36 1.21 3.13 4.89 3.83 3.17
| Glu89 CD 1.56 1.72 0.22 2.48 2.38 4.37 3.50 5.31 4.58 5.51 3.43
| Glu89 OE1 1.71 2.33 0.25 3.76 3.88 5.01 5.37 7.10 5.44 4.87 5.35
j  Glu89 OE2 1.74 2.12 0.64 2.74 3.19 5.87 4.59 5.24 4.45 7.72 2.73
| Val90 N 1.86 1.25 0.78 3.55 3.63 4.10 3.88 3.38 5.07 4.01 2.24
Irt3 lrt4 lrt5 lrt6 lrt7 lrth Irti ltvr luwb lvrt lvru
2.93 2.38 2.53 2.23 2.19 1.80 1.80 2.69 3.69 2.70 2.95
2.74 2.29 2.28 1.70 3.19 1.72 1.55 5.48 2.79 5.07 3.16
2.97 2.38 2.46 2.21 2.45 1.76 1.80 2.78 3.50 2.78 3.07
2.86 2.32 2.31 1.91 1.57 1.69 1.61 3.69 3.03 3.37 3.17
2.21 1.68 1.81 1.61 1.39 1.31 1.05 3.05 3.14 2.56 2.36
2.17 1.64 1.73 1.58 1.35 1.20 0.97 3.15 3.24 2.59 2.46
2.27 1.53 1.47 1.48 1.39 0.89 1.13 2.57 2.43 2.41 2.19
2.19 2.75 2.46 2.62 2.54 2.86 3.24 3.21 2.90 3.02 2.80
2.47 2.11 2.25 2.12 1.81 1.69 1.39 4.05 4.21 3.24 3.21
2.63 1.92 2.02 1.98 1.66 1.38 1.23 4.25 4.39 3.34 3.31
2.79 1.72 1.78 1.79 1.46 1.08 1.03 4.39 4.39 3.42 3.38
2.64 1.93 2.03 2.03 1.71 1.42 1.26 4.32 4.56 3.37 3.37
2.92 1.64 1.63 1.75 1.40 0.97 0.96 4.53 4.50 3.49 3.44
2.82 1.76 1.80 1.90 1.55 1.18 1.10 4.47 4.60 3.45 3.42
2.54 2.10 2.24 2.20 1.89 1.70 1.44 4.26 4.71 3.38 3.45
2.88 1.76 1.80 1.96 1.60 1.25 1.12 4.56 4.74 3.48 3.48
2.62 2.08 2.23 2.24 1.93 1.72 1.45 4.35 4.92 3.46 3.60
2.78 1.93 2.03 2.14 1.80 1.52 1.31 4.50 4.91 3.49 3.58
2.65 1.16 1.04 1.01 0.90 1.64 1.39 2.21 2.21 2.00 1.68
3.09 0.69 0.71 1.31 1.29 0.89 0.97 2.03 1.78 2.06 1.56
3.17 2.98 2.72 2.19 2.27 3.04 3.15 3.35 2.66 3.62 3.28
4.54 4.75 4.09 3.02 3.05 4.39 4.96 4.22 3.21 4.72 4.08
3.91 2.31 1.67 1.80 1.55 1.99 1.89 2.00 2.17 1.50 1.18
4.24 4.02 3.37 4.09 3.88 3.43 3.23 2.36 1.47 3.19 3.53
4.13 5.86 5.80 5.47 5.43 5.73 5.63 4.66 3.84 4.55 5.11
4.92 5.61 6.03 5.07 4.88 6.09 5.70 5.37 5.61 5.49 4.80
4.04 8.07 7.67 7.36 7.52 7.43 7.59 6.12 4.97 6.14 7.10
2.51 4.07 3.93 3.66 3.77 4.34 4.07 4.51 3.81 4.62 4.58
Appendix 7.11 Displacement data for the template grip (cont.)
lrtd 2hmi lhmv lbqm lbqn lhni lhnv lklm lrev lrtl lrt2 lrt3 lrt4 lrt5 lrt6 lrt7 lrth lrti ltvr luwb lvrt lvru
1 Val90 CA 2.34 1.70 0.91 4.82 4.57 5.51 5.34 4.81 5.93 5.49 3.47 2.74 6.38 5.95 5.11 5.28 6.49 6.16 6.31 5.50 6.30 6.39
; Val90 C 3.02 2.47 1.62 5.26 5.31 5.41 5.34 4.96 6.12 5.56 3.50 4.01 6.62 6.03 5.03 5.25 7.04 6.29 6.23 5.57 6.19 6.68
! Val90 0 3.74 4.35 3.50 5.95 5.94 6.21 5.94 6.15 7.99 6.37 4.15 5.83 8.17 7.16 5.87 6.10 8.73 8.29 7.24 6.43 6.57 8.21
1 Val90 CB 2.97 2.38 0.94 6.03 5.51 6.78 6.49 6.53 7.40 7.20 4.38 2.95 8.13 7.52 6.88 7.04 8.16 7.95 7.67 7.04 7.79 7.89
! Val90 CGI 3.20 1.23 2.13 5.78 5.03 7.18 6.86 6.66 7.62 7.74 4.03 3.50 8.61 8.06 7.29 7.40 8.89 8.56 8.03 7.34 7.99 8.40
! Val90 CG2 3.21 4.22 3.11 6.50 6.15 6.73 6.75 7.06 7.13 7.28 6.12 2.59 8.24 7.98 7.22 7.36 7.94 8.12 8.40 7.14 8.30 7.62
; Gln91 N 3.22 1.72 0.27 5.30 5.71 4.74 4.95 3.88 4.40 4.87 3.60 3.17 5.40 5.13 4.17 4.45 5.66 4.32 5.37 4.96 5.78 5.29
Gln91 CA 3.87 2.27 0.77 6.00 6.66 4.70 4.97 4.01 4.95 4.93 4.56 4.30 5.55 5.18 4.15 4.45 6.09 4.28 5.27 5.07 5.72 5.38
. Gln91 C 3.44 1.76 0.74 5.12 5.83 4.70 5.22 5.24 5.33 5.84 5.13 4.51 4.89 4.73 5.19 5.41 5.30 5.00 5.37 4.87 6.39 5.62
Gln91 0 3.13 1.30 0.99 4.49 5.28 4.80 5.40 6.22 5.28 6.75 5.54 4.10 4.74 4.65 6.15 6.36 5.10 5.54 5.66 4.74 7.15 6.09
Gln91 CB 4.93 3.67 1.43 7.40 8.17 5.02 5.00 3.39 4.37 4.55 5.62 4.53 6.20 5.58 3.77 4.10 7.06 4.06 5.34 5.78 5.58 5.52
^  Gln91 CG 5.95 5.06 2.65 6.11 4.47 4.25 6.20 4.26 7.82 7.01 6.72 6.78 3.64 4.06 8.45 3.36 5.23 7.56 6.79 6.27
& Gln91 CD 6.76 6.24 3.45 6.59 4.82 6.14 6.93 6.32 9.49 7.63 7.86 9.58 5.77 6.22 11.12 4.38 5.59 10.27 9.79 9.34
Gln91 OE1 7.26 6.09 5.02 6.25 5.17 7.13 9.14 7.85 9.84 9.01 7.78 10.58 7.36 7.79 12.82 5.72 5.68 11.61 10.81 10.66
5 Gln91 NE2 7.54 7.87 2.93 7.48 5.21 7.44 5.35 6.76 10.79 7.31 9.15 11.20 6.32 6.79 11.88 4.93 6.03 11.44 11.49 10.88
i Leu92 N 3.53 1.97 0.63 5.34 5.91 4.98 5.66 5.85 6.62 5.98 6.09 6.24 4.93 4.67 5.64 5.63 5.24 5.82 5.48 5.30 6.57 5.74
Leu92 CA 3.38 1.82 0.63 5.04 5.51 5.35 6.07 7.07 7.35 6.88 6.65 7.28 4.63 4.53 6.69 6.60 4.79 6.61 5.66 5.57 7.37 6.15
Leu92 C 2.56 1.54 0.64 3.97 4.41 4.04 4.61 5.55 5.35 4.93 4.38 5.60 3.40 3.44 4.99 4.85 3.82 4.63 4.20 4.32 5.68 4.48
s Leu92 0 2.61 1.81 0.92 3.99 4.32 4.32 4.62 6.52 5.81 5.30 4.14 6.19 3.34 3.32 5.70 5.55 4.27 4.33 5.12 4.60 6.17 4.88
Leu92 CB 4.05 2.31 0.58 6.13 6.47 6.66 7.60 8.69 9.48 8.85 8.85 9.95 5.57 5.22 8.44 8.29 5.35 8.77 7.08 6.82 9.22 8.08
Leu92 CG 4.81 1.19 0.49 6.98 7.92 6.72 7.58 11.30 10.17 11.43 11.52 11.99 5.83 6.29 11.00 10.87 5.20 11.34 7.35 7.00 11.54 10.32
Lcu92 CD1 7.21 2.58 0.66 8.01 9.38 9.50 9.96 13.45 12.45 13.26 13.35 14.38 6.43 7.32 13.07 12.84 5.72 13.30 9.82 9.56 13.64 12.36
Leu92 CD2 3.39 2.79 0.41 6.28 7.50 5.59 7.06 11.85 9.79 12.21 11.95 12.66 7.61 7.67 11.60 11.57 6.39 11.72 6.83 6.46 12.25 10.81
? Gly93 N 1.94 1.31 0.51 3.42 4.06 2.78 3.61 3.23 3.36 2.89 2.94 3.55 2.71 2.86 2.80 2.66 2.66 3.55 2.76 3.10 3.77 3.24
; Gly93 CA 1.27 1.03 0.43 2.33 2.96 1.80 2.47 1.61 1.78 1.09 1.34 1.78 1.58 1.81 1.19 1.07 1.66 1.69 1.71 2.11 2.25 1.75
1 Gly93 C 0.92 0.90 0.49 2.14 2.70 1.40 1.96 1.17 1.40 0.63 0.75 1.71 1.31 1.44 0.85 0.78 1.29 1.37 1.22 1.61 1.67 1.50
; Gly93 0 1.52 1.06 0.74 3.25 3.90 2.48 1.84 1.09 1.54 0.49 0.90 2.00 1.58 1.60 0.79 0.76 1.33 1.37 2.00 1.58 1.77 2.58
Appendix 7.11 Displacement data for the template grip (cont.)
lrtd 2hmi lhmv lbqm lbqn lhni lhnv lklm lrev lrtl lrt2
I Vall48 N 0.30 0.85 0.24 3.60 3.33 3.12 4.12 2.16 4.83 2.00 2.67
! Val 148 CA 0.21 0.76 0.28 3.43 3.19 2.96 3.86 2.05 4.62 1.91 2.55
| Val 148 C 0.30 0.90 0.24 3.53 3.23 2.97 3.98 2.09 4.59 1.90 2.55
| Val 148 0 0.61 1.35 0.41 3.88 3.36 3.22 4.38 2.16 4.90 1.96 2.68
i Val 148 CB 0.21 0.51 0.41 3.19 3.11 2.90 3.60 1.88 4.56 1.88 2.46
i Vall48 CGI 0.16 3.01 2.69 5.81 5.84 5.55 6.15 4.55 7.25 4.63 5.09
j  Val 148 CG2 0.24 2.23 1.86 2.85 3.31 2.34 3.25 2.12 4.01 2.16 1.87
Leu149 N 0.13 0.70 0.37 3.21 3.19 2.72 3.66 2.02 4.23 1.83 2.39
j Leu 149 CA 0.28 0.71 0.29 3.23 3.20 2.70 3.77 1.99 4.14 1.78 2.31
i  Leu 149 C 0.39 0.70 0.32 3.47 3.29 3.00 4.00 2.11 4.47 1.95 2.55
j  Leu149 0 0.45 0.52 0.51 3.57 3.09 2.93 3.83 2.08 4.64 1.92 2.67
Leu149 CB 
Leu 149 CG
0.36 0.71 0.32 2.96 3.07 2.33 3.45 1.86 3.79 1.67 2.03
1.01 0.80 0.27 2.93 3.25 2.19 3.49 1.31 3.66 1.08 1.83
, Leu 149 CD1 2.67 0.84 0.77 2.77 3.37 2.00 3.43 3.54 3.48 3.35 1.56
| Leu 149 CD2 2.25 0.97 0.68 3.41 3.83 2.33 3.76 2.93 3.76 2.92 1.84
; Pro150 N 0.48 1.01 0.41 3.67 3.64 3.41 4.51 2.36 4.64 2.16 2.72
! Pro 150 CA 0.52 1.03 0.58 3.93 3.80 3.75 4.80 2.53 4.97 2.40 2.98
| Pro150 C 0.76 0.91 0.58 3.84 3.70 3.68 4.73 2.40 4.87 2.30 2.84
j  Pro 150 0 1.08 1.15 0.49 3.73 3.54 3.30 4.37 2.13 4.45 1.98 2.59
| Pro 150 CB 0.61 1.46 0.56 4.30 4.09 3.77 4.89 2.75 5.06 2.63 3.27
! Pro 150 CG 0.67 0.47 0.66 4.16 4.13 3.67 4.91 2.74 4.91 2.50 2.07
| Pro 150 CD 0.76 1.29 0.52 3.75 3.93 3.59 4.93 2.52 4.63 2.20 2.77
1 Gin 151 N 0.58 0.84 0.73 3.94 3.84 4.09 5.12 2.72 5.36 2.72 3.13
! Glnl51 CA 0.75 0.85 0.84 3.94 3.83 4.22 5.23 2.64 5.38 2.64 3.02
; Gin 151 C 1.32 1.58 0.92 4.33 4.23 4.08 5.08 3.11 5.68 3.09 3.43
j Glnl51 O 3.56 3.92 0.89 5.99 5.87 3.77 4.77 5.01 7.17 4.94 5.23
| Gin 151 CB 0.79 1.22 0.96 3.89 3.86 4.69 5.72 3.06 5.96 3.02 3.57
* Glnl51 CG 1.81 2.93 3.20 4.49 3.82 5.05 5.85 3.30 5.74 4.23 5.51
Irt3 lrt4 lrt5 lrt6 lrt7 lrth Irti ltvr luwb lvrt lvru
4.29 3.19 3.22 2.22 1.98 2.85 2.99 4.60 4.13 4.70 4.67
4.11 3.18 3.16 2.15 1.90 2.82 2.88 4.37 3.81 4.48 4.59
4.08 3.16 3.12 2.12 1.88 2.78 2.85 4.25 3.87 4.51 4.64
4.41 3.19 3.16 2.16 2.00 2.83 2.95 4.15 4.18 4.91 5.09
4.04 3.29 3.27 2.10 1.85 2.98 2.89 4.56 3.56 4.32 4.35
6.75 3.40 3.42 4.74 4.58 3.33 3.09 7.41 6.16 6.97 6.93
2.99 3.16 3.06 2.00 2.13 2.61 2.43 4.03 3.39 3.52 3.58
3.68 3.12 3.07 2.06 1.75 2.73 2.75 4.36 3.60 4.13 4.24
3.60 3.06 3.02 1.98 1.69 2.68 2.70 4.25 3.61 4.11 4.21
3.80 3.33 3.32 2.21 1.86 2.90 2.87 4.44 3.94 4.43 4.45
3.82 3.60 3.65 2.40 1.86 3.09 2.98 4.25 3.90 4.59 4.57
3.28 2.91 2.88 1.81 1.59 2.49 2.52 4.02 3.21 3.72 3.95
3.11 2.85 2.82 1.43 1.09 2.48 2.41 3.87 2.98 3.63 3.87
2.89 2.66 2.64 3.79 3.46 2.31 2.35 3.55 2.72 3.48 3.64
3.12 2.98 2.95 3.03 2.93 2.72 2.34 4.14 3.10 3.82 4.07
4.05 3.40 3.34 2.29 2.05 2.90 3.00 4.94 4.39 4.55 4.68
4.28 3.66 3.61 2.54 2.26 3.17 3.17 5.24 4.81 4.83 4.93
4.10 3.54 3.51 2.45 2.16 3.06 3.08 5.12 4.72 4.68 4.78
3.72 3.24 3.19 2.15 1.84 2.74 2.75 4.96 4.38 4.44 4.53
4.56 3.93 3.86 2.72 2.51 3.52 3.30 5.40 5.10 5.08 5.21
4.56 3.71 3.61 2.54 2.35 2.90 3.29 5.44 5.01 4.86 5.01
4.27 3.38 3.29 2.25 2.09 2.65 3.15 5.33 4.59 4.58 4.78
4.51 3.92 3.93 2.80 2.60 3.51 3.47 5.24 5.08 4.91 4.99
4.44 3.86 3.86 2.76 2.55 3.48 3.45 5.24 5.13 4.83 4.88
4.74 4.34 4.33 3.29 3.08 3.91 3.77 5.08 5.15 5.37 5.25
6.25 6.06 6.02 5.18 4.97 5.61 5.37 4.62 4.90 7.11 6.81
4.93 4.27 4.27 3.15 3.02 4.03 3.94 5.53 5.49 5.05 5.04
5.03 4.05 4.06 4.17 3.94 3.88 4.10 5.78 5.64 5.98 6.80
Appendix 7.11 Displacement data for the template grip (cont.)
lrtd 2hmi lhmv lbqm lbqn lhni lhnv lklm lrev lrtl lrt2
Glnl51 CD 0.56 3.44 4.89 3.75 3.58 5.90 6.41 1.36 4.65 2.37 4.29
] Glnl51 OE1 1.63 3.69 5.01 3.81 3.95 6.29 6.61 2.47 3.49 0.42 2.60
j G lnl51 NE2 2.61 4.85 7.02 3.78 3.85 6.70 7.06 1.25 5.80 3.36 5.66
j Glyl52 N 1.11 0.56 1.08 3.49 3.61 4.55 5.50 2.43 5.00 2.47 2.81
j Glyl52 CA 1.10 0.96 1.13 3.63 3.76 4.45 5.35 2.60 5.12 2.56 3.03
! Glyl52 C 1.17 1.17 0.94 3.72 3.93 4.21 5.15 2.56 5.04 2.58 2.95
j  Gly 152 0 1.59 2.23 0.92 4.18 4.49 4.16 5.56 2.77 5.40 2.80 3.25
; Trpl53N 1.04 0.30 0.89 3.57 3.70 4.20 4.66 2.37 4.66 2.43 2.65
; Trpl53 CA 1.08 0.31 0.75 3.66 3.88 3.97 4.45 2.24 4.44 2.33 2.42
! Trpl53 C 1.03 0.44 0.78 3.73 3.98 3.62 4.29 2.16 4.25 2.23 2.33
| Trpl53 0 1.11 1.06 0.95 4.33 4.82 3.85 4.37 2.41 4.30 2.37 2.58
Trpl53 CB 1.19 0.36 0.72 3.60 3.80 3.96 4.50 2.23 4.43 2.27 2.37
i  Trp 153 CG 1.23 0.35 0.56 3.77 3.98 3.80 4.34 2.04 4.18 2.08 2.07
j Trp 153 CD1 1.31 0.40 0.63 4.11 4.52 3.89 4.60 1.93 4.11 1.95 1.89
; Trp 153 CD2 1.16 0.40 0.55 3.64 3.63 3.60 4.02 1.94 3.93 1.98 1.94
! Trp 153 NE1 1.28 0.43 0.78 4.20 4.53 3.80 4.50 1.79 3.81 1.81 1.68
j Trp 153 CE2 1.19 0.42 0.57 3.92 3.98 3.62 4.15 1.79 3.70 1.82 1.71
| Trp 153 CE3 1.11 0.51 0.79 3.33 3.13 3.46 3.69 1.97 3.87 2.03 2.01
Trp 153 CZ2 1.15 0.51 0.59 3.90 3.79 3.51 3.99 1.70 3.44 1.73 1.58
j  Trp 153 CZ3 1.10 0.61 0.74 3.31 2.99 3.33 3.52 1.88 3.63 1.93 1.88
! Trp 153 CH2 1.11 0.59 0.51 3.59 3.28 3.36 3.68 1.74 3.42 1.78 1.67
i  Lysl54N 1.02 0.20 0.71 3.21 3.22 3.31 4.19 1.96 4.14 2.09 2.09
j  Lysl54 CA 1.04 0.34 0.71 3.24 3.23 2.95 4.01 1.89 4.00 2.00 2.01
| Lysl54 C 1.17 0.36 0.58 3.14 3.03 2.92 3.95 1.73 3.79 1.84 1.87
j  Lys 154 0 1.41 0.69 0.43 3.08 2.91 2.89 3.95 1.65 3.68 1.81 1.85
j Lys 154 CB 1.08 0.64 0.68 3.37 3.43 2.53 3.57 1.90 4.05 1.99 2.00
Lys 154 CG 1.12 1.95 0.99 3.90 3.70 2.41 3.34 1.86 3.86 1.98 2.13
i Lys 154 CD 1.32 1.42 1.13 2.49 2.08 1.72 2.67 1.86 3.75 2.00 2.13
■y
i
lrt3 lrt4 lrt5 lrt6 lrt7 lrth Irti ltvr luwb lvrt lvru
4.97 3.55 3.70 2.18 1.75 3.48 3.94 4.97 6.31 6.69 6.50
3.98 3.68 3.77 0.70 0.72 3.61 3.20 4.76 6.58 5.94 4.81
6.72 3.23 3.47 3.06 2.27 3.20 5.47 5.05 7.05 8.33 8.51
4.16 3.62 3.70 2.59 2.44 3.34 3.30 5.71 5.51 4.47 4.51
4.24 3.84 3.92 2.81 2.62 3.50 3.32 5.61 5.56 4.85 4.65
4.19 3.74 3.76 2.81 2.63 3.33 3.24 5.83 5.57 4.85 4.82
4.45 3.86 3.79 2.97 2.76 3.34 3.33 7.39 6.53 5.27 5.51
3.95 3.56 3.60 2.68 2.53 3.19 3.10 4.56 4.66 4.46 4.41
3.81 3.39 3.38 2.57 2.41 2.97 2.90 4.62 4.59 4.29 4.32
3.63 3.33 3.35 2.56 2.43 2.91 2.79 4.66 4.36 4.08 4.14
3.70 3.71 3.84 2.85 2.81 3.19 3.10 5.38 4.59 4.13 4.25
3.83 3.34 3.32 2.55 2.35 2.88 2.83 4.58 4.63 4.27 4.30
3.66 3.12 3.08 2.33 2.11 2.68 2.56 4.72 4.48 4.01 4.05
3.60 2.99 2.95 2.23 1.88 2.55 2.44 5.26 4.48 3.91 3.99
3.51 3.01 2.97 2.15 2.04 2.55 2.39 4.40 4.17 3.83 3.85
3.42 2.83 2.78 2.03 1.69 2.38 2.20 5.31 4.20 3.69 3.77
3.37 2.83 2.79 1.98 1.78 2.37 2.17 4.81 4.02 3.64 3.69
3.49 3.05 3.02 2.14 2.18 2.58 2.40 3.84 4.03 3.82 3.81
3.23 2.71 2.67 1.83 1.67 2.24 1.98 4.68 3.78 3.47 3.52
3.37 2.93 2.90 1.97 2.07 2.44 2.23 3.72 3.77 3.67 3.66
3.24 2.76 2.73 1.83 1.81 2.27 2.02 4.15 3.66 3.49 3.51
3.53 2.96 2.94 2.35 2.20 2.62 2.50 3.90 4.11 3.94 3.91
3.40 2.86 2.85 2.31 2.16 2.53 2.38 3.78 3.90 3.79 3.75
3.24 2.78 2.79 2.18 2.07 2.42 2.24 3.62 3.72 3.58 3.53
3.16 2.78 2.78 2.11 2.01 2.36 2.22 3.56 3.60 3.50 3.38
3.47 2.74 2.73 2.34 2.15 2.46 2.36 3.69 3.78 3.86 3.77
3.50 2.77 2.72 2.31 2.07 2.54 2.40 3.66 3.46 3.57 3.72
3.49 2.65 2.61 2.34 2.11 2.32 2.30 3.03 3.00 3.61 3.54
Appendix 7.11 Displacement data for the template grip (cont.)
lrtd 2hmi lhmv lbqm lbqn lhni lhnv lklm lrev lrtl lrt2 lrt3 lrt4 lrt5 lrt6 lrt7 lrth lrti ltvr luwb lvrt lvru
Lysl54 CE 2.00 1.73 1.97 3.24 3.12 3.64 4.78 1.96 3.64 2.09 2.24 3.54 2.76 2.69 2.43 2.29 2.39 2.36 4.87 5.01 3.39 3.60
Lys 154 NZ 3.53 1.08 1.37 3.63 3.26 2.88 4.02 2.01 3.40 2.18 2.25 3.44 2.61 2.64 2.50 2.53 2.40 2.22 4.24 4.43 3.44 3.49
The measured distances between the unliganded (ldlo) structure and each RT structure for all the atoms of the residues of template grip.
Appendix 7.12 Displacement data for the RNase H active site
lrtd 2hmi lhmv lbqm lbqn lhni lhnv lklm lrev lrtl
| Asp443 N 0.26 0.55 0.35 3.48 3.38 3.76 4.25 2.73 1.56 3.25
j Asp443 CA 0.11 0.43 0.30 3.59 3.49 3.83 4.33 2.81 1.62 3.33
j Asp443 C 0.39 0.48 0.50 3.63 3.61 3.90 4.49 2.89 1.63 3.41
Asp443 0 0.54 0.60 1.01 3.65 3.65 3.89 4.48 3.02 1.51 3.50
j Asp443 CB 0.41 0.41 0.58 3.73 3.65 3.83 4.23 2.83 1.74 3.25
! Asp443 CG 0.78 0.45 0.67 3.79 3.68 3.88 4.23 2.85 2.73 3.36
Asp443 OD1 0.81 1.35 0.74 3.71 3.62 4.21 4.49 2.93 2.96 3.31
1 Asp443 OD2 1.17 2.20 0.85 3.91 3.76 3.68 4.42 2.91 3.75 3.65
; Glu478N 0.84 1.11 0.82 3.63 3.85 4.14 4.65 2.84 2.17 3.31
1 Glu478 CA 0.81 0.77 0.56 3.50 3.80 3.95 4.41 2.62 2.20 3.03
; Glu478 C 0.77 0.78 0.43 3.48 3.56 3.96 4.47 2.58 2.28 2.98
Glu478 O 0.99 0.94 0.40 3.48 3.41 4.04 4.61 2.92 2.45 3.20
Glu478 CB 0.83 0.73 0.49 3.47 3.77 3.90 4.34 2.45 2.24 2.83
, Glu478 CG 0.71 0.91 0.41 3.02 4.44 3.62 3.88 1.79 1.98 2.24
I Glu478 CD 2.20 1.42 1.08 2.54 2.88 2.34 2.46 1.36 2.52 1.15
: Glu478 OE1 3.87 1.58 1.33 3.57 1.67 3.09 2.96 2.19 3.77 3.17
s Glu478 OE2 1.73 1.47 2.87 3.91 2.36 2.49 3.35 3.04 1.96
j Asp498 N 0.58 0.26 0.38 3.42 3.57 3.08 3.40 1.93 1.63 2.21
( Asp498 CA 0.51 0.22 0.53 3.68 3.84 3.10 3.42 1.79 1.57 2.05
; Asp498C 0.47 0.06 0.57 3.43 3.56 3.10 3.44 1.85 1.64 2.26
Asp498 0 0.54 0.53 1.54 3.75 3.73 3.11 3.48 1.81 1.67 2.31
j Asp498 CB 0.53 0.15 0.65 4.68 4.83 3.34 3.72 1.76 1.53 1.99
j Asp498 CG 0.56 0.10 0.64 3.43 3.63 3.78 4.11 2.20 1.87 2.50
! Asp498 OD1 0.68 0.47 0.59 2.91 3.08 4.11 4.27 1.22 1.88 1.49
i Asp498 OD2 0.55 0.37 0.88 4.15 4.33 4.10 4.35 3.93 2.14 4.09
: His539 N 1.11 1.83 1.43 2.18 2.37 3.45 3.81 2.83 3.00 3.16
| His539 CA 1.53 1.97 1.79 1.94 2.55 3.45 3.83 3.17 3.32 3.51
j His539 C 1.50 1.81 1.83 1.78 2.52 2.77 3.28 3.47 3.14 3.79
| His539 0 1.61 1.72 2.06 1.88 3.42 2.70 3.40 3.66 3.76 5.64
1
lrt2 lrt3 lrt4 lrt5 lrt6 lrt7 lrth Irti ltvr luwb lvrt lvru
2.63 1.59 2.70 2.55 2.86 3.07 3.03 2.71 3.46 4.17 1.74 1.82
f
2.73 1.58 2.73 2.57 2.93 3.16 3.07 2.76 3.54 4.24 1.79 1.96 1
2.69 1.58 2.78 2.61 2.99 3.23 3.09 2.88 3.83 4.44 1.71 2.28 1
2.76 1.54 2.90 2.72 3.06 3.35 3.14 3.02 3.93 4.52 1.65 2.43 I
2.83 1.50 2.69 2.51 2.86 3.16 2.98 2.77 3.38 4.17 1.84 1.98 1
2.96 3.18 2.68 2.46 2.98 3.29 2.94 2.75 3.36 4.20 3.55 3.34 Í¡
2.93 5.56 3.03 2.77 2.97 3.22 3.23 2.94 3.50 4.37 4.24 3.88
3.52 2.50 2.56 2.40 3.14 3.50 2.85 2.98 3.28 4.31 4.57 4.37 Í
2.49 1.95 2.74 2.53 2.92 3.25 2.94 2.77 3.80 4.42 2.17 1.93 1
2.15 1.99 2.58 2.37 2.75 3.06 2.83 2.64 3.81 4.34 2.21 1.86 !Ï
2.21 2.11 2.59 2.40 2.69 3.05 2.82 2.58 3.74 4.40 2.40 2.02 !
2.43 2.34 3.00 2.76 2.96 3.32 3.10 2.95 3.53 4.67 2.77 2.27 iI
1.90 2.07 2.45 2.23 2.61 2.90 2.74 2.58 3.85 4.30 2.30 1.89 j
1.38 1.84 1.73 1.58 1.95 2.20 2.07 2.05 3.23 3.72 1.96 1.53 I
1.59 2.81 1.09 1.29 1.10 1.15 0.88 0.67 2.56 2.07 2.60 2.80 1
2.44 4.18 2.58 2.50 3.04 1.83 2.04 2.23 3.30 2.38 3.58 3.79 i
3.11 3.26 1.63 2.09 1.83 3.22 1.63 0.99 3.13 2.31 3.33 3.93
!
1.79 1.59 2.14 1.97 1.79 2.11 2.29 2.11 3.17 3.16 1.81 1.75
j
1.60 1.54 1.99 1.83 1.60 1.93 2.15 1.90 3.33 3.13 1.73 1.69 1
1.79 1.66 2.04 1.88 1.73 2.06 2.25 2.02 3.12 3.23 1.86 1.78 !
1.91 1.76 2.01 1.84 1.70 2.03 2.29 1.99 3.41 3.40 1.89 1.83
1.36 1.47 2.03 1.86 1.50 1.83 2.13 1.82 3.85 3.43 1.63 1.65 \
1.81 1.80 2.34 2.16 1.70 2.21 2.40 2.22 4.13 3.96 2.14 2.11 \
0.72 2.13 2.52 2.34 0.77 1.10 2.23 3.21 4.35 4.07 2.45 2.58 \
3.38 1.92 2.41 2.23 3.34 3.93 2.81 1.97 4.35 4.33 2.27 2.16 \
1.92 2.68 2.95 3.43 3.13 3.06 2.51 3.63 3.01 1.73 2.04
1.97 3.06 3.44 4.17 3.52 3.47 2.81 3.75 3.39 2.69 2.95
j * *3 § s
2.37 2.99 3.46 4.57 3.84 3.26 2.90 2.93 2.91 3.10 3.41 1
2.69 3.14 3.67 6.42 5.72 3.34 3.20 2.74 3.37 3.70 4.13 1
Appendix 7.12 Displacement data for the RNase H active site (cont.).
lrtd 2hmi lhmv lbqm lbqn lhni lhnv lklm lrev lrtl lrt2 lrt3 lrt4 lrt5 lrt6 lrt7 lrth lrti ltvr luwb lvrt lvru
His539 CB 1.94 2.34 1.83 2.24 2.62 4.02 4.16 3.20 3.46 3.58 1.96 3.23 3.65 4.41 3.61 3.69 2.85 4.28 3.75 3.23 3.34
His539 CG 2.24 2.72 1.98 2.29 2.77 4.79 4.80 2.98 4.50 3.32 1.70 3.39 3.81 4.13 3.36 3.81 2.84 4.69 4.26 2.99 2.94
His539 ND1 4.37 3.25 1.88 3.84 4.84 5.88 6.17 4.88 6.21 5.18 3.44 5.42 5.96 5.87 5.19 5.74 4.71 4.89 5.12 3.14 3.26
His539 CD2 1.53 3.94 2.42 1.97 1.76 4.86 4.52 1.89 4.90 2.15 1.68 2.09 2.41 2.93 2.24 2.50 1.79 4.97 4.18 2.92 2.45
His539 CEI 4.06 3.67 2.08 3.56 4.51 6.44 6.49 4.15 6.90 4.41 2.66 5.06 5.58 5.09 4.44 5.28 4.24 5.26 5.38 2.91 2.94
His539 NE2 1.91 3.87 2.46 1.99 2.39 5.85 5.53 2.16 6.23 2.47 1.35 2.93 3.33 3.27 2.53 3.22 2.25 5.30 4.82 2.84 2.35
Asp549 N 1.17 1.32 0.80 3.33 3.25 3.85 4.03 3.15 3.52
Asp549 CA 1.06 1.74 0.97 3.75 3.64 4.09 4.12 3.16 3.62
Asp549 C 1.13 1.73 0.96 3.88 3.88 4.23 4.52 3.47 4.04
Asp549 0 1.04 1.78 0.92 3.65 3.83 4.12 4.63 3.31 4.07
Asp549 CB 1.21 2.20 1.44 3.54 3.46 3.96 4.09 3.13 3.50
o* The measured distances between the unliganded (ldlo) structure and each RT structure for all the atoms of the residues of the RNase H active 
^  site.
Appendix 7.13 Displacement data for the NNIBP
lrtd 2hmi lhmv lbqm lbqn lhni lhnv lklm lrev Irti lrt2
Leu100 N 0.42 0.31 1.16 1.83 1.82 1.20 1.86 1.31 1.48 1.41 1.34
Leu 100 CA 0.39 0.35 1.11 2.09 2.13 1.35 1.95 1.41 1.56 1.48 1.47
LeulOO C 0.30 0.31 1.11 1.98 2.02 1.37 1.89 1.13 1.56 1.28 1.33
Leu100 0 0.60 0.44 1.63 1.82 1.67 1.51 1.70 1.01 1.57 1.20 1.19
LeulOO CB 0.42 0.48 1.10 2.39 2.52 1.70 2.06 1.57 1.69 1.56 1.53
LeulOO CG 0.64 2.49 1.12 2.31 2.62 2.09 2.29 1.56 1.92 1.87 1.69
LeulOO CD1 0.75 4.13 1.13 2.47 2.81 2.34 2.30 1.74 1.91 1.61 1.51
LeulOO CD2 0.73 2.80 1.15 2.16 2.81 2.90 2.81 1.40 2.33 2.31 1.99
LyslOl N 0.12 0.52 0.76 2.19 2.43 1.39 2.08 1.39 1.63 1.43 1.67
LyslOl CA 0.23 0.52 0.73 2.23 2.50 1.59 2.12 1.32 1.64 1.36 1.62
LyslOl C 0.31 0.71 0.73 2.28 2.65 1.89 2.26 1.26 1.70 1.44 1.60
LyslOl 0 0.53 0.67 0.86 2.42 3.04 1.77 2.38 1.11 1.84 1.36 1.50
LyslOl CB 0.41 0.66 0.92 2.36 2.58 1.58 2.08 1.59 1.66 1.61 1.76
LyslOl CG 0.56 1.96 1.14 2.19 2.11 1.40 2.09 1.21 1.71 1.90 1.56
LyslOl CD 1.47 2.31 1.36 1.79 2.13 1.40 1.73 1.36 3.62 1.56 3.15
LyslOl CE 0.94 1.94 1.70 1.51 2.22 1.48 1.90 2.32 3.46 1.86 2.32
LyslOl NZ 1.35 3.13 2.12 1.41 2.02 1.56 1.89 1.97 5.11 1.09 3.35
Lysl03 N 0.63 1.56 0.86 2.52 2.62 2.93 2.64 1.45 2.15 1.69 1.64
Lysl03 CA 0.76 1.86 1.01 2.61 2.70 3.11 2.76 1.38 2.45 1.68 1.65
Lysl03 C 1.05 2.20 1.13 2.78 3.03 3.32 3.02 1.42 2.55 1.64 1.60
Lysl03 0 2.03 3.29 2.07 2.60 3.05 3.71 3.46 1.87 2.99 2.18 2.06
Lysl03 CB 0.93 2.00 1.22 2.43 2.40 3.12 2.77 1.29 2.66 1.74 1.69
Lysl03 CG 0.82 1.74 1.25 1.77 1.73 3.31 2.79 1.22 2.56 2.07 1.69
Lysl03 CD 0.92 1.80 1.26 2.34 2.49 3.21 2.72 1.18 2.58 2.11 1.63
Lysl03 CE 1.03 1.61 1.26 1.32 1.71 3.39 2.69 1.04 2.41 2.42 1.54
Lys 103 NZ 1.56 1.72 1.28 2.59 2.84 3.37 2.69 1.15 4.05 2.47 1.54
Val 106 N 0.22 1.41 0.48 3.20 3.23 3.50 3.41 1.28 2.65 2.14 2.07
Val 106 CA 0.16 1.44 0.53 2.96 2.94 3.13 3.12 1.14 2.45 1.99 1.86
Val 106 C 0.23 1.40 0.53 3.06 3.17 3.35 3.10 1.07 2.56 1.74 1.60
Irt3 lrt4 lrt5 lrt6 lrt7 lrth Irti ltvr luwb lvrt lvru 1
1.28 1.33 1.24 1.37 1.63 1.08 1.46 1.88 2.18 1.26 1.18 1
1.46 1.39 1.30 1.44 1.71 1.12 1.50 1.96 2.26 1.35 1.19 j
1.40 1.18 1.11 1.26 1.52 1.02 1.32 1.90 2.15 1.25 1.18
1.43 0.94 0.97 1.10 1.33 0.91 1.22 2.06 1.97 1.17 1.18 1
1.68 1.50 1.42 1.56 1.79 1.20 1.48 2.15 2.41 1.46 1.23 j
1.92 1.71 1.67 1.86 2.21 1.55 1.72 2.25 2.67 1.75 1.42 i
2.04 1.56 1.47 1.83 1.86 1.47 1.58 2.32 2.51 1.68 1.44 1
2.20 1.99 2.03 2.23 3.10 2.06 2.03 2.55 3.27 2.23 1.91
I
1.47 1.39 1.23 1.37 1.64 1.08 1.45 1.88 2.33 1.42 1.22 f
1.48 1.32 1.17 1.30 1.59 1.09 1.40 1.84 2.32 1.46 1.28 1
1.49 1.37 1.32 1.40 1.60 1.22 1.28 1.98 2.34 1.61 1.55
1.55 1.35 1.51 1.48 1.60 1.17 1.15 2.00 2.30 1.50 1.55 1
1.53 1.46 1.31 1.37 1.68 1.07 1.72 1.77 2.31 1.56 1.57 1
1.38 1.61 0.87 1.30 1.43 1.07 1.99 1.65 2.29 1.33 1.29 i
3.22 1.99 1.54 3.16 3.07 1.06 2.25 1.42 2.03 3.19 2.83 j
2.74 2.48 2.51 2.89 2.70 1.18 2.26 1.21 2.01 2.91 2.08 j
4.31 4.49 4.55 4.81 4.71 2.96 2.19 1.06 1.49 4.65 3.82 j
1.99 1.88 1.84 1.63 1.76 1.83 1.34 2.42 2.67 2.41 2.65 j
2.24 2.05 2.05 1.73 1.88 2.02 1.36 2.38 2.86 2.66 2.97 j
2.43 2.12 2.09 1.63 1.88 2.08 1.56 2.68 3.25 2.78 2.92
3.00 2.63 2.61 2.22 2.60 2.61 2.26 2.91 3.72 3.27 3.27 !
2.41 2.25 2.27 1.99 2.04 2.32 1.40 2.22 2.76 3.01 3.52 j
2.24 2.35 2.33 2.21 2.23 2.31 1.63 2.18 2.87 3.04 3.68 j
2.29 2.29 2.26 2.15 2.24 2.28 1.65 2.12 2.88 3.06 3.58
2.31 2.35 2.25 2.36 2.46 2.19 1.90 2.03 3.06 2.87 3.50
2.52 2.50 2.44 2.64 3.07 2.56 1.70 2.40 3.19 3.10 3.65
2.33 2.19 2.33 1.91 2.06 2.34 1.60 3.52 3.39 3.03 3.01 t
2.10 1.90 2.08 1.72 1.82 2.08 1.30 3.15 3.01 2.73 2.72
2.11 1.93 2.13 1.84 1.84 2.02 1.16 3.40 3.06 2.80 2.75 <SÍ*6*
Appendix 7.13 Displacement data for the NNIBP (cont.)
lrtd 2hmi lhmv lbqm lbqn lhni lhnv lklm lrev lrtl lrt2
! Vail 06 0 0.29 1.42 0.78 3.40 3.92 3.84 3.00 1.17 3.02 1.99 1.77
5 V ail06 CB 0.09 1.46 0.38 2.98 2.81 2.93 3.24 1.30 2.55 2.37 2.38
I Vall06 CGI 0.08 1.57 0.33 2.70 2.78 2.88 3.17 1.32 2.45 2.40 2.43
{ Vail06 CG2 0.20 1.55 0.76 2.76 2.63 2.81 3.18 1.15 2.34 2.48 2.56
1 Vall79 N 0.32 1.06 1.71 2.02 2.72 2.20 2.54 0.49 1.47 0.69 0.57
j V ail79 CA 0.23 1.19 1.41 1.95 2.35 2.16 2.28 0.37 1.34 0.66 0.51
j Vall79 C 0.24 1.13 1.05 1.74 2.04 2.00 2.12 0.46 1.28 0.69 0.54
! Vail 79 0 0.28 1.09 0.83 1.74 1.87 2.08 2.30 0.58 1.38 0.66 0.63
! V ail79 CB 0.72 1.47 1.72 1.82 2.07 2.36 2.18 0.30 1.46 0.62 0.51
: Vail79 CGI 1.61 0.52 2.03 3.29 3.18 3.82 3.67 2.18 1.59 2.85 2.45
; Vall79 CG2 1.99 2.83 2.15 1.67 2.10 0.80 0.86 1.66 2.16 1.92 1.56
Tyrl81 N 0.97 1.18 0.60 1.75 1.79 1.70 1.97 0.83 1.50 1.00 0.78
g  Tyrl81 CA 0.99 1.02 0.56 1.83 1.81 1.76 2.13 0.95 1.66 1.12 0.87
. Tyrl81 C 0.96 1.01 0.74 1.85 1.80 1.78 2.10 0.94 1.67 1.12 0.79
! Tyr 181 0 1.17 1.13 0.90 1.89 1.79 1.80 1.91 0.93 1.59 1.21 0.84
■ Tyrl81 CB 0.94 0.96 0.34 1.81 1.70 1.58 2.19 0.92 1.58 1.04 0.93
i Tyr 181 CG 0.98 1.00 1.02 3.75 3.77 3.58 4.00 2.96 3.59 3.07 2.95
j  Tyrl81 CD1 0.80 1.39 1.71 4.97 6.31 5.05 5.19 4.73 5.09 4.92 4.80
! Tyr 181 CD2 1.25 1.80 2.61 5.09 3.28 4.63 5.04 4.02 4.70 4.00 3.87
; Tyr 181 CEI 0.82 1.33 2.19 6.85 8.31 6.84 6.87 6.53 6.91 6.79 6.61
: Tyr 181 CE2 1.31 1.97 3.18 6.85 5.23 6.35 6.65 5.79 6.50 5.79 5.65
!  Tyrl81 CZ 1.06 1.19 2.48 7.56 7.74 7.27 7.41 6.81 7.40 6.98 6.80
: TyrlSl OH 1.08 1.38 3.23 9.44 9.69 9.08 9.10 8.70 9.28 8.95 8.69
Tyrl88 N 0.92 0.99 0.82 1.86 2.01 2.08 2.38 0.48 1.86 0.55 0.56
i Tyr 188 CA 0.89 0.94 0.80 2.02 2.12 2.27 2.53 0.70 1.89 0.79 0.82
i Tyr 188 C 0.90 1.12 0.79 1.93 2.07 2.14 2.33 0.71 1.60 0.70 0.77
j  Tyr 188 O 1.41 1.22 0.83 2.06 1.80 2.04 2.03 1.32 1.37 1.25 0.96
{ Tyr 188 CB 1.00 0.80 0.69 2.26 2.15 2.50 2.70 1.13 2.09 1.17 1.14
; Tyr 188 CG 1.02 0.87 0.65 4.74 4.94 5.10 3.75 4.40 3.74 3.74
Irt3 lrt4 lrt5 lrt6 lrt7 lrth Irti ltvr luwb lvrt lvru
2.58 2.45 2.78 2.58 2.40 2.58 1.35 4.60 3.01 3.49 3.28
2.26 2.06 2.19 1.83 1.98 2.25 1.65 3.18 3.14 2.79 2.65
2.10 1.87 1.99 1.79 1.93 2.10 1.63 3.09 2.75 2.58 2.12
2.10 1.90 1.99 1.57 1.82 2.15 1.61 2.76 2.97 2.65 2.62
1.63 1.52 1.66 1.04 0.82 1.82 0.35 2.12 1.78 2.18 2.50
1.30 1.40 1.51 0.76 0.72 1.66 0.25 2.05 1.59 1.88 2.22
1.09 1.27 1.38 0.67 0.72 1.52 0.27 1.97 1.54 1.72 2.05
1.13 1.31 1.43 0.83 0.72 1.71 0.23 2.12 1.69 1.77 2.08
1.41 1.53 1.60 0.63 0.68 1.86 0.33 2.04 1.30 1.93 2.43
2.54 2.88 2.96 1.91 2.25 3.15 2.86 3.80 2.80 3.07 3.57
0.83 0.99 0.98 1.72 1.35 0.97 2.41 1.14 1.55 0.97 0.92
0.69 1.29 1.41 1.03 1.03 1.41 0.59 2.14 1.81 1.52 1.76
0.63 1.32 1.45 1.08 1.24 1.44 0.69 2.22 2.01 1.55 1.79
0.55 1.34 1.45 1.07 1.24 1.47 0.60 2.15 1.89 1.56 1.84
0.63 1.28 1.34 1.07 1.29 1.36 0.52 1.97 1.62 1.56 1.80
0.48 1.12 1.25 1.05 1.23 1.18 0.80 2.07 2.03 1.52 1.59
0.83 3.01 3.13 3.09 3.28 3.10 0.74 3.89 3.39 3.41
2.22 4.70 4.64 4.89 4.76 4.72 0.70 6.36 4.70 4.67
2.20 4.08 4.31 4.02 4.46 4.34 1.28 3.29 4.60 4.78
2.39 6.54 6.49 6.70 6.62 6.59 0.64 8.14 6.56 6.62
2.59 5.76 6.04 5.79 6.19 6.10 1.39 4.96 6.27 6.51
1.81 6.79 6.93 6.90 7.08 7.00 0.86 7.39 7.09 7.28
2.33 8.66 8.81 8.78 8.97 8.97 1.00 9.13 8.91 9.27
1.27 1.34 1.50 0.78 0.76 1.58 0.61 1.82 2.03 1.47 1.88
1.46 1.36 1.54 0.95 0.89 1.65 0.72 1.96 2.16 1.76 2.03
1.37 1.13 1.29 0.75 0.74 1.35 0.50 1.83 1.99 1.63 1.95
1.30 1.00 1.15 1.00 1.11 1.16 0.57 1.62 1.69 1.51 1.86
1.69 1.62 1.77 1.35 1.30 1.91 1.10 2.17 2.37 2.05 2.19
4.32 4.05 4.19 3.99 3.93 4.24 3.55 4.70 4.73 4.46 4.36
Appendix 7.13 Displacement data for the NNIBP (cont.)
lrtd 2hmi lhmv lbqm lbqn lhni lhnv Iklm lrev Irti lrt2
I Tyrl88 CD1 1.07 0.80 0.76 7.26 7.38 7.61 6.02 6.75 5.90 5.90
j Tyrl88 CD2 1.02 1.08 0.55 4.63 4.85 4.91 4.01 4.34 4.11 4.14
j Tyrl88 CEI 1.10 0.85 0.69 9.56 9.73 9.87 8.50 9.00 8.39 8.39
j Tyrl88 CE2 1.05 1.21 0.46 6.93 7.21 7.18 6.49 6.53 6.58 6.62
{ Tyrl88 CZ 1.10 1.08 0.49 9.36 9.63 9.65 8.71 8.87 8.71 8.73
j Tyrl88 OH 1.17 1.24 0.35 11.64 11.95 11.95 11.17 11.09 11.18 11.23
! Glyl90 N 0.47 1.37 0.65 2.45 2.36 2.63 2.69 1.14 1.72 1.14 1.00
! Glyl90 CA 0.44 1.46 0.56 2.70 2.35 2.83 2.96 1.17 1.97 1.25 0.98
; Glyl90 C 0.23 1.28 0.73 2.72 2.42 2.90 2.99 1.19 2.00 1.18 0.95
I Glyl90 0 0.40 1.09 1.01 2.59 2.34 2.90 2.83 1.29 1.87 1.03 0.88
J Phe227 N 0.92 1.62 0.75 4.47 4.50 4.32 4.58 2.09 3.51 3.08 2.72
Phe227 CA 0.88 1.50 0.85 4.94 4.85 4.59 4.90 2.70 3.94 3.67 3.20
Ü Phe227 C 0.91 1.45 0.70 4.88 4.80 4.47 4.80 2.73 3.83 3.67 3.10
. Phe227 O 0.76 1.42 0.72 4.67 4.59 4.12 4.55 2.46 3.66 3.32 2.84
j Phe227 CBi 0.84 1.36 0.95 5.10 4.77 4.57 5.05 2.87 4.22 3.90 3.58
j Phe227 CG 0.67 1.55 0.92 5.48 6.26 4.63 5.12 2.93 4.47 4.10 3.70
| Phe227 CD1 0.87 1.78 1.00 6.09 6.01 4.87 5.28 3.12 4.76 4.45 3.70
j Phe227 CD2 0.39 1.56 0.82 5.35 8.36 4.49 5.05 2.91 4.53 4.12 3.87
I Phe227 CEI 0.75 1.96 0.97 6.51 7.60 4.99 5.36 3.19 5.01 4.70 3.80
j Phe227 CE2 0.26 1.80 0.78 5.85 10.12 4.58 5.11 2.98 4.83 4.44 4.02
1 Phe227 CZ 0.42 1.97 0.85 6.39 9.67 4.84 5.26 3.07 5.01 4.67 3.94
j Trp229 N 0.99 1.21 0.81 4.59 4.22 4.71 5.12 4.67 4.44 5.14 3.89
j Trp229 CA 0.97 1.13 0.81 4.65 4.21 4.88 5.36 4.11 4.85 5.71 4.32
! Trp229 C 1.19 1.23 0.80 4.68 4.27 4.73 5.07 4.41 4.82 5.93 4.54
; Trp229 0 1.45 1.35 0.82 4.65 4.44 4.36 4.75 4.23 4.59 5.72 4.38
j Trp229 CB 0.85 1.10 0.77 4.58 4.29 4.77 5.32 4.10 4.80 5.71 4.33
| Trp229 CG 0.99 1.07 0.75 4.77 4.52 4.98 5.44 4.19 5.21 5.25 4.50
j Trp229 CD1 1.01 1.08 0.90 5.53 5.45 5.46 5.63 4.51 5.59 5.36 4.56
| Trp229 CD2 1.20 1.14 0.74 5.14 4.77 4.72 5.45 4.05 5.26 5.06 4.60
Irt3 lrt4 lrt5 lrt6 lrt7 lrth Irti ltvr luwb lvrt lvru
6.50 6.34 6.47 6.23 6.20 6.44 5.78 7.02 7.25 6.61 6.50
5.48 4.19 4.33 4.24 4.20 4.50 3.83 4.80 4.51 4.71 4.59
8.86 8.75 8.87 8.69 8.68 8.86 8.18 9.43 9.49 8.96 8.87
7.92 6.57 6.71 6.68 6.66 6.85 6.18 7.20 6.72 6.99 6.89
9.34 8.84 8.98 8.89 8.89 9.03 8.33 9.51 9.20 9.11 9.05
11.85 11.23 11.38 11.31 11.35 11.43 10.77 11.88 11.40 11.43 11.42
1.57 1.26 1.36 1.32 1.15 1.35 0.85 2.06 2.57 1.91 2.26
1.65 1.34 1.45 1.46 1.26 1.47 0.98 2.31 2.84 2.01 2.45
1.63 1.43 1.50 1.39 1.26 1.55 1.01 2.34 2.89 2.18 2.57
1.49 1.55 1.53 1.27 1.21 1.56 0.91 2.45 2.78 2.15 2.53
2.89 2.62 2.64 2.89 3.06 2.61 2.22 5.50 5.07 3.43 3.35
3.48 3.17 3.30 3.48 3.65 3.08 2.73 5.77 5.32 3.89 3.82
3.42 3.15 3.26 3.48 3.68 2.98 2.77 5.71 5.26 3.72 3.63
3.08 2.79 2.92 3.12 3.34 2.66 2.55 5.47 5.06 3.32 3.23
3.85 3.39 3.59 3.66 3.83 3.35 3.07 5.61 5.27 4.16 4.12
3.98 3.76 3.95 3.95 4.03 3.92 3.26 5.75 5.41 4.38 4.31
4.18 4.24 4.56 4.47 4.53 4.68 3.53 6.23 5.78 4.70 4.67
4.10 3.94 3.90 3.94 3.92 3.93 3.42 5.50 5.22 4.49 4.25
4.32 4.67 4.99 4.81 4.80 5.28 3.76 6.45 5.95 4.95 4.87
4.30 4.52 4.44 4.35 4.25 4.64 3.78 5.70 5.38 4.78 4.52
4.32 4.78 4.92 4.71 4.63 5.23 3.85 6.18 5.73 4.93 4.77
4.06 4.40 4.53 4.56 4.89 3.74 3.68 5.47 5.23 4.34 4.27
4.32 4.85 4.99 5.04 5.43 4.05 4.08 5.75 5.43 4.67 4.62
4.36 5.08 5.21 5.29 5.72 4.20 4.28 5.36 5.30 4.57 4.46
4.16 4.97 5.05 5.12 5.57 4.01 4.17 4.99 5.04 4.39 4.17
4.18 4.89 4.98 5.12 5.55 4.00 4.02 5.87 5.39 4.57 4.55
4.32 5.10 5.10 5.34 5.55 4.15 4.46 5.83 5.59 4.82 4.87
4.24 6.59 6.59 6.91 6.90 4.22 4.78 6.15 5.69 5.01 5.11
4.55 4.51 4.36 4.55 4.81 4.14 4.66 5.49 5.70 4.85 4.97
Appendix 7.13 Displacement data for the NNIBP (cont.)
lrtd 2hmi lhmv lbqm lbqn lhni lhnv lklm lrev lrtl lrt2
} Trp229 NE1 1.17 1.16 1.00 5.54 5.28 5.49 5.76 4.57 5.85 5.26 4.67
{ Trp229 CE2 1.26 1.20 0.88 4.98 4.64 5.06 5.66 4.29 5.67 5.08 4.70
j Trp229 CE3 1.38 1.24 0.73 6.58 6.19 4.24 5.31 3.77 5.00 5.15 4.64
; Trp229 CZ2 1.46 1.33 0.93 5.26 4.98 4.94 5.74 4.29 5.82 5.22 4.85
î Trp229 CZ3 1.58 1.36 0.82 7.48 7.27 4.11 5.38 3.75 5.15 5.26 4.77
) Trp229 CH2 1.61 1.41 0.89 6.50 6.38 4.46 5.60 4.01 5.56 5.30 4.88
Leu234 N 0.96 1.32 1.06 4.03 3.94 3.40 3.63 1.69 2.73 2.17 1.99
Leu234 CA 0.90 1.36 1.08 3.87 3.76 3.32 3.48 1.47 2.70 1.93 1.89
Leu234 C 0.80 1.38 1.07 3.97 3.81 3.34 3.63 1.11 2.70 1.76 1.85
: Leu234 0 0.81 1.11 1.07 4.73 4.68 4.15 4.44 1.38 3.26 2.48 2.32
! Leu234 CB 0.87 1.30 1.08 4.13 3.96 3.71 3.75 1.74 3.19 2.30 2.23
Leu234 CG 0.84 1.67 1.18 3.71 4.03 3.49 3.69 2.04 2.81 2.53 2.17
f è  Leu234 CD1 0.97 1.82 0.86 4.40 5.11 3.85 4.84 3.98 3.97 5.06 4.34
i Leu234 CD2 0.72 2.15 1.37 2.64 3.23 2.83 2.72 0.53 4.44 3.10 3.41
j His235 N 1.01 1.92 1.24 3.20 2.91 2.74 3.10 0.54 2.30 0.95 1.37
; His235 CA 1.16 2.07 1.27 3.25 2.99 2.98 3.33 0.11 2.50 1.10 1.45
; His235 C 0.92 2.11 0.92 3.44 3.16 3.19 3.62 0.39 2.95 1.44 1.73
; His235 0 0.63 2.19 0.80 3.31 2.96 2.94 3.62 0.56 3.01 1.23 1.90
; His235 CB 1.58 2.30 1.43 2.82 2.58 2.67 3.00 0.44 2.13 0.79 1.08
: His235 CG 1.74 2.42 1.38 2.65 2.42 2.46 2.72 0.69 1.58 0.22 0.78
His235 ND1 1.63 2.50 1.34 1.98 1.84 2.46 2.38 2.40 2.65 2.11 1.46
His235 CD2 2.08 2.54 1.35 3.11 2.88 2.18 2.70 1.31 2.02 2.23 0.72
i His235 CEI 1.86 2.71 1.29 2.07 2.06 2.19 2.15 2.23 2.15 1.19 0.93
! His235 NE2 2.17 2.75 1.30 2.74 2.67 2.02 2.35 1.17 0.73 1.62 0.68
i Pro236 N 1.24 2.09 0.91 3.89 3.65 3.62 4.00 0.57 3.33 2.06 1.86
j Pro236 CA 1.29 2.09 0.85 4.15 3.88 3.86 4.30 0.86 3.77 2.44 2.17
j Pro236 C 1.14 2.05 0.57 3.63 3.45 3.22 3.76 0.35 3.44 1.88 1.81
! Pro236 0 1.06 2.23 0.51 3.42 3.32 2.85 3.64 0.66 3.68 1.94 2.06
Irt3 lrt4 lrt5 lrt6 lrt7 lrth Irti ltvr luwb lvrt lvru
4.39 6.14 6.03 6.43 6.29 4.20 5.15 6.04 5.84 5.12 5.23
4.59 4.86 4.66 4.91 4.98 4.16 5.09 5.64 5.85 5.03 5.27
4.74 5.09 4.87 4.89 5.28 4.13 4.52 5.16 5.68 4.75 4.86
4.81 4.89 4.61 4.66 4.83 4.15 5.39 5.45 5.99 5.12 5.44
4.96 6.24 6.00 5.82 6.26 4.12 4.81 4.97 5.82 4.85 5.04
5.00 5.81 5.55 5.30 5.73 4.12 5.24 5.11 5.97 5.03 5.33
2.39 2.12 2.06 2.04 2.05 2.08 2.14 3.99 3.77 2.83 2.63
2.33 1.84 1.80 1.78 1.78 1.98 1.94 3.86 3.64 2.72 2.59
2.30 1.67 1.65 1.52 1.45 1.90 1.93 3.98 3.75 2.71 2.57
2.81 2.36 2.38 2.32 2.12 2.54 2.39 4.70 4.53 3.33 3.11
2.88 2.39 2.34 2.29 2.33 2.60 2.17 4.13 3.94 3.13 3.13
2.60 2.13 2.01 2.60 2.59 2.10 2.03 4.09 4.04 2.78 3.24
4.90 4.75 4.66 5.14 4.85 4.59 3.90 5.00 5.50 4.55 3.60
3.00 2.36 2.30 3.11 3.49 2.85 3.68 3.34 3.37 4.33 3.06
1.82 1.05 1.10 0.97 0.69 1.43 1.05 3.33 3.19 2.15 2.03
2.11 1.47 1.58 1.64 1.36 2.01 0.95 3.38 3.43 2.45 2.32
2.71 1.92 2.07 2.11 1.77 2.53 1.14 3.48 3.69 3.06 2.81
2.60 1.57 1.90 1.49 1.14 2.24 1.24 3.35 3.35 3.19 2.75
1.79 1.42 1.56 1.77 1.66 2.05 0.61 3.00 3.10 2.08 1.99
1.36 1.11 1.22 1.30 1.31 1.62 0.48 2.82 2.78 1.45 1.50
3.50 2.20 1.81 3.01 3.38 2.26 1.00 2.12 2.76 2.94 3.39
0.92 1.06 1.04 1.78 1.20 1.23 1.28 3.22 2.51 1.69 1.21
3.22 2.05 1.86 2.16 2.67 2.18 0.54 2.12 2.44 2.31 2.83
0.86 0.56 0.92 1.22 0.86 1.07 1.18 2.79 2.31 0.39 0.33
3.45 2.78 2.80 3.35 3.03 3.38 1.26 3.72 4.34 3.56 3.34
4.06 3.26 3.31 3.89 2.55 3.96 1.51 3.83 4.64 4.20 3.84
3.54 2.77 2.70 3.15 2.73 3.40 1.18 3.46 3.97 3.73 3.46
3.68 2.79 2.64 3.08 2.64 3.50 1.24 3.11 3.66 3.95 3.65
Appendix 7.13 Displacement data for the NNIBP (cont.)
lrtd 2hmi lhmv lbqm lbqn lhni lhnv lklm lrev Irti lrt2 lrt3 lrt4 lrt5 lrt6 lrt7 lrth Irti ltvr luwb lvrt lvru
Pro236 CB 1.97 2.15 1.30 4.91 4.45 4.57 4.98 1.38 4.28 3.34 2.64 4.97 4.22 4.30 5.30 5.03 5.11 1.94 4.18 5.39 4.98 4.43
Pro236 CG 2.22 2.66 1.35 4.85 4.68 4.42 4.98 1.27 5.21 3.31 2.39 6.06 5.45 5.44 5.41 5.09 6.30 1.62 4.03 5.05 5.78 5.59
Pro236 CD 1.80 2.11 1.05 4.39 4.31 3.87 4.43 0.76 3.52 2.66 2.02 4.12 3.53 3.46 4.42 4.06 4.25 1.28 3.92 4.63 3.85 3.89
Tyr318 N 0.84 1.26 0.72 1.25 1.15 1.28 1.06 0.23 0.55 0.33 0.26 0.41 0.22 0.27 0.37 0.21 0.23 0.67 1.61 1.34 0.42 0.52
Tyr318 CA 0.59 1.02 0.73 1.39 1.31 1.48 1.31 0.25 0.74 0.46 0.70 0.83 0.37 0.26 0.34 0.37 0.43 0.82 1.66 1.51 0.67 0.71
Tyr318 C 0.55 0.79 0.73 1.30 1.27 1.40 1.19 0.30 0.70 0.41 0.74 0.91 0.32 0.26 0.37 0.44 0.39 0.76 1.51 1.42 0.63 0.68
Tyr318 0 0.54 0.77 0.71 1.30 1.17 1.54 1.05 0.35 0.60 0.38 0.83 0.94 0.22 0.21 0.45 0.48 0.27 0.64 1.40 1.38 0.63 0.66
Tyr318 CB 0.50 1.16 0.79 1.54 1.59 1.68 1.71 0.37 1.02 0.67 0.97 1.08 0.75 0.54 0.59 0.62 0.74 0.98 2.03 1.87 1.08 1.06
Tyr318CG 0.51 1.30 0.85 1.77 1.87 1.91 2.05 0.52 1.35 0.87 1.03 1.43 0.95 0.78 0.85 0.80 0.95 1.12 2.39 2.22 1.40 1.32
Tyr318 CD1 0.45 1.31 1.83 2.14 2.08 2.33 2.25 0.69 1.53 1.24 1.08 1.63 1.33 1.29 1.16 1.03 1.15 1.21 2.65 2.41 1.62 1.47
Tyr318 CD2 0.63 1.84 2.28 2.08 2.26 3.24 2.36 0.54 1.69 0.93 1.03 1.76 1.20 1.27 0.99 0.88 1.19 1.21 2.94 2.98 1.82 1.73
Tyr318 CEI 0.52 1.50 1.94 2.37 2.49 2.41 2.55 0.85 1.86 1.37 1.10 1.98 1.50 1.47 1.36 1.16 1.35 1.34 2.99 2.72 1.94 1.77
Tyr318 CE2 0.64 1.93 2.22 2.43 2.63 3.59 2.67 0.68 2.01 1.09 1.06 2.08 1.37 1.42 1.22 1.04 1.41 1.34 3.38 3.31 2.11 1.98
Tyr318 CZ 0.57 1.59 0.89 2.40 2.67 2.51 2.67 0.83 2.03 1.18 1.10 2.13 1.34 1.22 1.31 1.11 1.39 1.39 3.22 2.93 2.06 1.92
Tyr318 OH 0.65 1.74 2.91 2.81 3.17 2.88 2.95 0.98 2.38 1.32 1.16 2.49 1.53 1.44 1.51 1.25 1.64 1.52 3.68 3.32 2.38 2.24
Glul38 N 0.64 0.54 0.74 1.05 1.13 1.37 0.88 1.06 1.09 0.86 1.09 2.00 1.07 1.03 0.84 0.87 1.33 1.22 1.17 1.38 0.93 1.51
G lut38 CA 0.65 0.56 0.94 1.27 1.34 1.43 0.95 1.31 1.20 1.18 1.30 2.10 1.25 1.21 1.06 1.24 1.55 1.32 1.34 1.56 1.03 1.68
Glul38 C 1.14 0.66 0.81 1.39 1.30 1.54 0.67 1.17 1.05 1.06 1.11 1.84 1.20 1.11 1.00 1.14 1.51 1.43 1.04 1.24 0.94 2.02
Glul38 0 1.26 0.98 1.00 2.03 1.81 1.80 0.47 1.21 1.00 1.05 1.30 1.57 1.37 1.28 1.16 1.07 1.51 1.48 1.21 1.05 1.04 2.06
Glul38 CB 0.74 0.76 1.41 1.23 1.42 1.39 1.21 1.81 1.62 1.74 1.81 2.29 1.70 1.73 1.58 1.68 1.94 1.39 1.71 1.87 1.47 1.66
Glul38 CG 1.56 0.70 3.81 3.27 3.32 3.36 3.83 4.24 4.23 4.08 4.25 4.61 3.97 4.12 4.17 4.15 4.39 1.83 4.15 4.33 4.06 2.94
Glul38 CD 0.66 1.40 4.14 4.50 3.98 3.19 4.01 4.52 4.64 4.46 4.67 4.66 4.39 4.50 4.54 4.46 4.71 1.61 4.66 4.62 4.45 2.95
Glul38 OE1 1.65 3.31 2.48 4.48 2.45 1.43 3.49 3.13 2.94 2.79 2.87 3.73 2.51 2.60 2.59 6.50 2.79 1.04 3.08 3.28 2.49 1.58
G lut38 OE2 2.30 0.41 6.11 6.25 6.17 5.22 5.27 6.55 6.73 6.65 6.84 5.84 6.65 6.72 6.81 6.70 6.96 3.55 6.77 6.33 6.74 5.05
The measured distances between the unliganded (ldlo) structure and each RT structure for all the atoms of the residues of NNIBP.
Appendix 7.14 Displacement data between motifs of RT
73Ca:231Ca 91Ca:185Ca 184Ca:498Ca 498Ca:231C(
ldlo 25.23 16.32 60.93 58.37
lhmv 16.27 62.12 60.47
lrtd 23.22 12.57 61.01 58.01
2hmi 27.61 14.16 61.11 59.49
lbqm 28.41 13.14 63.04 55.91
lbqn 28.03 12.66 62.39 56.51
lhni 28.28 12.97 62.41 55.12
lhnv 29.33 12.77 62.86 55.28
lklm 30.54 62.37 56.26
lrev 31.79 16.05 62.45 55.11
Irti 31.65 12.86 62.73 54.81
lrt2 30.43 13.89 62.43 54.98
lrt3 31.28 16.96 61.32 54.95
lrt4 31.69 12.80 63.38 55.74
lrt5 32.11 12.86 63.24 55.42
lrt6 31.47 13.26 62.36 54.96
lrt7 31.59 13.19 62.73 55.20
lrth 30.13 12.95 63.59 56.24
Irti 29.39 13.61 63.04 56.80
ltvr 29.10 13.15 63.43 55.86
luwb 28.93 12.86 62.83 55.43
lvrt 31.15 11.98 62.48 55.26
lvru 31.05 13.01 63.07 55.41
The measured distance between selected motifs in each of the crystal structures.
73 Ca of the fingers segment of the template grip and 231 Ca of the primer grip 
91 Ca of the palm segment of the template grip and 185 Ca of the PAS 
184 Ca of the PAS and 498 Ca of the RNase H active site 
498 Ca of the RNase H active site and 231 Ca of the primer grip
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Appendix 7.15 Hypoedit utility in Catalyst
The Hypoedit file of Catalyst used to manually construct a pharmacophore named 
‘crystalQuery.chm’.
!/bin/csh
#
# Here is an example of how one would use the hypoedit program to make 
a
# Catalyst 3D query named crystalQuery.chm that could be used to 
search a
# Catalyst database. Note that all coordinates and tolerances are in
# picometers.
#
$CATALYST_GOODIES/hypoedit \
-diet $CATALYST__CONF/Dictionary. chm \
-feat HYDROPHOBIC \
-feat HYDROPHOBIC \
-feat HYDROPHOBIC \
-feat "HB DONOR" \
-feat "HB ACCEPTOR" \
-blob 100.0 100.0 100.0 150.0 1 \
-blob 200.0 200.0 200.0 150.0 2 \
-blob 300.0 300.0 300.0 150.0 3 \
-blob 400.0 400.0 400.0 150.0 4 \
-blob 500.0 500.0 500.0 200.0 5 \
-blob 600.0 600.0 600.0 150.0 6 \
-blob 700.0 700.0 700.0 200.0 7 \
-xvol 800.0 800.0 800.0 250.0 \
-xvol 900.0 900.0 900.0 250.0 \
-xvol 1000.0 1000.0 1000.0 250.0 \
-xvol 1100.0 1100.0 1100.0 250.0 \
crystalQuery.chm
Appendix 7.15.1 Hypoedit file of activity ‘weighted’ structural query
Hypoedit file used to generate a Catalyst pharmacophore, named 
weighted_pocket.chm’ of the Unity 3D structural query based on the ‘weight’ binding 
pocket.
-diet $CATALYST_CONF/Dietionary.chm \
-feat " HB ACCEPTOR" \
-feat "HB ACCEPTOR" \
-feat " HB ACCEPTOR" \
-feat " HB ACCEPTOR" \
-feat "HB ACCEPTOR" \
-feat "HB ACCEPTOR" \
-feat "HB ACCEPTOR" \
-feat " HB ACCEPTOR" \
-feat " HB ACCEPTOR" \
-feat "HB ACCEPTOR" \
-feat "HB ACCEPTOR" \
-feat "HB ACCEPTOR" \
-feat " HB ACCEPTOR" \
-feat " HB ACCEPTOR" \
-feat " HB ACCEPTOR" \
-feat "HB ACCEPTOR" \
-feat " HB ACCEPTOR" \
-feat " HB DONOR" \
-feat " HB DONOR" \
-feat "HB DONOR" \
-feat " HB DONOR" \
-feat " HB DONOR" \
-feat "HB DONOR" \
-feat "HB DONOR" \
-feat " HB DONOR" \
-feat "HB DONOR" \
-feat " HB DONOR" \
-feat " HB DONOR" \
-feat "HB DONOR" \
-feat " HB DONOR" \
-feat " HB DONOR" \
-feat " HB DONOR" \
-feat "HB DONOR" \
-feat "HB DONOR" \
-feat "HB DONOR" \
-feat " HB DONOR" \
-feat " HB DONOR" \
-feat "HB DONOR" \
-feat " HB DONOR" \
-feat "HB DONOR" \
-feat HYDROPHOBIC \ 
-feat HYDROPHOBIC \ 
-feat HYDROPHOBIC \ 
-feat HYDROPHOBIC \ 
-feat HYDROPHOBIC \ 
-feat HYDROPHOBIC \ 
-feat HYDROPHOBIC \ 
-feat HYDROPHOBIC \ 
-feat HYDROPHOBIC \ 
-feat HYDROPHOBIC \
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
-blob
- 5 5 2 . 8 7  - 5 1 . 5 7  494 .66  150 .0  1 \  
- 5 3 0 . 8 5  113 .81  743 .99  250 .0  2 \  
930 .99  256 .05  - 1 3 6 . 1 6  150 .0  3 \
858 .95  - 3 5 . 0 9  - 1 4 3 . 2 1  250 .0  4 \
502 .25  - 7 2 8 . 6 6  - 2 9 4 . 8 1  150 .0  5 \
741.95 -632.79 -162.71 250.0 6 \ 
-822.18 -327.38 369.09 150.0 7 \ 
-918.05 -47.89 317.19 250.0 8 \ 
-431.50 -182.48 -31.69 150.0 9 \ 
-480.65 -25.89 -282.81 250.0 10 \ 
-342.70 197.06 288.47 150.0 11 \ 
-176.95 307.11 77.49 250.0 12 \ 
-255.80 148.30 -1190.24 150.0 13 \ 
-222.25 -56.19 -973.31 250.0 14 \ 
-404.50 62.41 -457.82 150.0 15 \ 
-394.15 126.51 -750.71 250.0 16 \ 
-261.76 -44.49 -751.04 150.0 17 \ 
-276.25 -200.99 -495.51 250.0 18 \ 
-285.44 691.11 -73.89 150.0 19 \ 
-12.15 748.61 -152.01 250.0 20 \ 
-9.48 -353.59 843.95 150.0 21 \ 
58.15 -636.69 771.29 250.0 22 \ 
-219.95 -409.75 693.08 150.0 23 \ 
-5.35 -499.49 519.89 250.0 24 \ 
-53.69 -910.81 328.91 150.0 25 \ 
-125.05 -649.29 225.89 250.0 26 \ 
-463.01 -759.44 415.69 150.0 27 \ 
-474.55 -558.99 638.59 250.0 28 \ 
-175.62 -700.51 -409.40 150.0 29 \ 
-168.55 -500.19 -632.61 250.0 30 \ 
-778.61 91.53 562.49 150.0 31 \ 
-682.45 255.91 794.29 250.0 32 \ 
581.62 -295.64 -477.80 150.0 33 \
874.25  - 2 4 7 . 9 9  - 4 3 2 . 01  250.0  34 \  
- 6 2 6 . 6 9  375 .24  501.68 150.0  35 \  
- 4 7 1 . 7 5  425 .11  741.69 250.0  36 \  
- 8 0 7 . 4 1  - 1 1 . 5 2  698.09 150.0  37 \ 
- 6 0 4 . 3 5  181 .51  772.99 250.0  38 \  
138 .65  524 .86  135.02 150.0  39 \
415 .05  461 .71  195.99 250 .0  40 \
634 .05  - 173 . 63  - 4 91 . 93  150.0 41 \
845.95 -203.09 -687.71 250.0 42 \ 
-1030.31 -177.08 -147.21 150.0 43 \ 
-1199.95 -279.39 64.59 250.0 44 \ 
146.87 -433.90 -1008.27 150.0 45 \ 
-66.95 -419.09 -812.91 250.0 46 \ 
-254.33 -688.46 -410.56 150.0 47 \ 
-269.25 -399.29 -394.41 250.0 48 \ 
-458.06 -98.31 15.55 150.0 49 \ 
-522.05 167.41 -81.41 250.0 50 \ 
-159.40 -382.06 -828.64 150.0 51 \ 
-217.55 -106.19 -760.71 250.0 52 \ 
-638.52 223.04 -497.78 150.0 53 \ 
-411.25 43.71 -480.81 250.0 54 \ 
-843.18 -293.65 -163.37 150.0 55 \ 
-979.45 -38.39 -144.11 250.0 56 \ 
-804.77 242.98 122.12 150.0 57 \ 
-871.15 20.81 296.29 250.0 58 \ 
531.74 923.86 -399.01 150.0 59 \ 
368.85 1081.71 -218.31 250.0 60 \ 
-393.76 -402.59 24.39 150.0 61 \
-blob -123.95 -297.89 42.89 250.0 62 \ 
-blob 149.51 -548.03 -14.28 150.0 63 \
-blob 411.25 -423.59 -24.61 250.0 64 \
-blob -12.53 906.82 -797.30 150.0 65 \
-blob -178.65 732.21 -636.01 250.0 66 \ 
-blob -121.49 -96.34 56.92 150.0 67 \ 
-blob -28.45 -81.49 331.19 250.0 68 \ 
-blob -740.21 -455.84 644.86 150.0 69 \ 
-blob -674.05 -730.29 711.19 250.0 70 \ 
-blob -495.77 -268.24 843.93 150.0 71 \ 
-blob -481.35 -493.69 662.09 250.0 72 \ 
-blob -377.26 -342.08 721.87 150.0 73 \ 
-blob -241.65 -403.09 472.89 250.0 74 \ 
-blob -2.35 -349.42 791.82 150.0 75 \ 
-blob 240.65 -451.89 671.19 250.0 76 \
-blob 365.82 -111.68 843.39 150.0 77 \
-blob 109.25 0.31 767.69 250.0 78 \
-blob 723.47 -478.30 -119.87 150.0 79 \ 
-blob 524.85 -302.99 -1.91 250.0 80 \ 
-blob -847.97 -215.56 1397.14 150.0 81 \ 
-blob -908.15 -247.45 1194.43 150.0 82 \ 
-blob -159.35 135.18 -129.94 150 83 \ 
-blob 166.77 693.64 -86.71 150 84 \
-blob 72.89 779.65 -197.75 150 85 \
-blob -405.78 713.76 -21.28 150 86 \ 
-blob 1041.68 216.08 -627.94 150 87 \ 
-blob 146.52 645.41 -1095.73 150 88 \ 
-blob -167.63 461.01 -678.73 150 89 \ 
-blob 758.60 986.79 -3.54 150 90 \ 
weighted_pocket.ehm
